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The clinical effectiveness and cost-effectiveness of cetuximab
(review of technology appraisal no. 176) and panitumumab
(partial review of technology appraisal no. 240) for
previously untreated metastatic colorectal cancer:
a systematic review and economic evaluation
Nicola Huxley,1* Louise Crathorne,1 Jo Varley-Campbell,1
Irina Tikhonova,1 Tristan Snowsill,1 Simon Briscoe,1 Jaime Peters,1
Mary Bond,1 Mark Napier2 and Martin Hoyle1
1Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK
2Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
*Corresponding author nicola.huxley@monash.edu
Background: Colorectal cancer is the fourth most commonly diagnosed cancer in the UK after breast,
lung and prostate cancer. People with metastatic disease who are sufficiently fit are usually treated with
active chemotherapy as first- or second-line therapy. Targeted agents are available, including the
antiepidermal growth factor receptor (EGFR) agents cetuximab (Erbitux®, Merck Serono UK Ltd, Feltham, UK)
and panitumumab (Vecitibix®, Amgen UK Ltd, Cambridge, UK).
Objective: To investigate the clinical effectiveness and cost-effectiveness of panitumumab in combination
with chemotherapy and cetuximab in combination with chemotherapy for rat sarcoma (RAS) wild-type
(WT) patients for the first-line treatment of metastatic colorectal cancer.
Data sources: The assessment included a systematic review of clinical effectiveness and cost-effectiveness
studies, a review and critique of manufacturer submissions, and a de novo cohort-based economic analysis.
For the assessment of effectiveness, a literature search was conducted up to 27 April 2015 in a range of
electronic databases, including MEDLINE, EMBASE and The Cochrane Library.
Review methods: Studies were included if they were randomised controlled trials (RCTs) or systematic
reviews of RCTs of cetuximab or panitumumab in participants with previously untreated metastatic
colorectal cancer with RAS WT status. All steps in the review were performed by one reviewer and
checked independently by a second. Narrative synthesis and network meta-analyses (NMAs) were
conducted for outcomes of interest. An economic model was developed focusing on first-line treatment
and using a 30-year time horizon to capture costs and benefits. Costs and benefits were discounted at
3.5% per annum. Scenario analyses and probabilistic and univariate deterministic sensitivity analyses
were performed.
Results: The searches identified 2811 titles and abstracts, of which five clinical trials were included.
Additional data from these trials were provided by the manufacturers. No data were available for
panitumumab plus irinotecan-based chemotherapy (folinic acid + 5-fluorouracil + irinotecan) (FOLFIRI) in
previously untreated patients. Studies reported results for RAS WT subgroups. First-line treatment with
anti-EGFR therapies in combination with chemotherapy appeared to have statistically significant benefits
for patients who are RAS WT. For the independent economic evaluation, the base-case incremental
cost-effectiveness ratio (ICER) for RAS WT patients for cetuximab plus oxaliplatin-based chemotherapy
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(folinic acid + 5-fluorouracil + oxaliplatin) (FOLFOX) compared with FOLFOX was £104,205 per
quality-adjusted life-year (QALY) gained; for panitumumab plus FOLFOX compared with FOLFOX was
£204,103 per QALY gained; and for cetuximab plus FOLFIRI compared with FOLFIRI was £122,554 per
QALY gained. The ICERs were sensitive to treatment duration, progression-free survival, overall survival
(resected patients only) and resection rates.
Limitations: The trials included RAS WT populations only as subgroups. No evidence was available for
panitumumab plus FOLFIRI. Two networks were used for the NMA and model, based on the different
chemotherapies (FOLFOX and FOLFIRI), as insufficient evidence was available to the assessment group to
connect these networks.
Conclusions: Although cetuximab and panitumumab in combination with chemotherapy appear to be
clinically beneficial for RAS WT patients compared with chemotherapy alone, they are likely to represent
poor value for money when judged by cost-effectiveness criteria currently used in the UK. It would be
useful to conduct a RCT in patients with RAS WT.
Study registration: This study is registered as PROSPERO CRD42015016111.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Epidermal growth factor receptor (EGFR) The protein encoded by the EGFR gene is a transmembrane
glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of
the epidermal growth factor family. The epidermal growth factor receptor is a cell surface protein that
binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerisation and
tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with
lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have
been found for this gene.
Kirsten rat sarcoma (KRAS) The KRAS gene belongs to a class of genes known as oncogenes. When
mutated, oncogenes have the potential to cause normal cells to become cancerous. The proteins encoded
by these genes play important roles in cell division, cell differentiation and the self-destruction of cells
(apoptosis).
Neuroblastoma rat sarcoma (NRAS) The NRAS gene belongs to a class of genes known as oncogenes.
When mutated, oncogenes have the potential to cause normal cells to become cancerous. The proteins
encoded by these genes play important roles in cell division, cell differentiation and the self-destruction of
cells (apoptosis).
Rat sarcoma (RAS) This gene family consists of Harvey rat sarcoma (HRAS), neuroblastoma rat sarcoma
(NRAS) and Kirsten rat sarcoma (KRAS).
Wild type The normal, non-mutated version of a gene that is common in nature.
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Note
This monograph is based on the Technology Assessment Report produced for the National
Institute for Health and Care Excellence (NICE). The full report contained a considerable
number of data that were deemed confidential. The full report was used by the Appraisal
Committee at NICE in their deliberations. The full report with each piece of confidential data
removed and replaced by the statement ‘confidential information (or data) removed’ is
available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
Colorectal cancer is any cancer that affects the large bowel or rectum. Metastatic colorectal canceroccurs when this cancer spreads to other parts of the body. This type of cancer most often spreads first
to the liver, but may also spread to other parts of the body including the lungs, brain and bones.
Metastatic colorectal cancer is often treated with chemotherapy and, when possible, surgery is performed
to remove cancerous tumour tissue.
It has been suggested that targeted therapies such as cetuximab and panitumumab, used in combination
with chemotherapies, may improve health outcomes for some people. These people are selected through
genetic testing; people can receive treatment with these targeted therapies if they do not have
specific mutations.
This study considered the costs and benefits of these targeted therapies when they are added to standard
chemotherapy treatment.
The study found some benefit with regard to health outcomes when using these targeted therapies in
addition to chemotherapy compared with chemotherapy alone. However, the costs of these therapies are
very high.
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Scientific summary
Background
Colorectal cancer (CRC) is the fourth most common cancer in the UK. In 2011, 34,000 people were
diagnosed with CRC in England. Approximately 25% of people with CRC have metastatic disease (mCRC).
Cetuximab (Erbitux®, Merck Serono UK Ltd, Feltham, UK) and panitumumab (Vecitibix®, Amgen UK Ltd,
Cambridge, UK) are inhibitors of epidermal growth factor receptor (EGFR) that can be used in combination
with chemotherapy regimens for the treatment of CRC. The European Medicines Agency marketing
authorisations for cetuximab and panitumumab are licensed for a targeted population based on rat
sarcoma (RAS) wild-type (WT) status.
Objective
The key objectives of this report were to estimate the clinical effectiveness and cost-effectiveness of
cetuximab and panitumumab for the first-line treatment of RAS WT mCRC.
Methods
The assessment included a systematic review of clinical effectiveness and cost-effectiveness studies, a
review of manufacturer submissions and a de novo economic analysis.
Clinical effectiveness systematic review
A systematic review of published research evidence was undertaken following principles published by the
Centre for Reviews and Dissemination (CRD).
The population of interest was defined as adults with RAS WT mCRC. The interventions of interest were
cetuximab in combination with FOLFOX (folinic acid + 5-fluorouracil + oxaliplatin or irinotecan-based
chemotherapy and panitumumab in combination with 5-fluorouracil-containing regimens. Comparators
identified in the scope were FOLFOX, XELOX (capecitabine + oxaliplatin), FOLFIRI (folinic acid +
5-fluorouracil + irinotecan), capecitabine, tegafur (UFToral®, Merck Serono, Feltham, UK; no longer
produced in the UK), folinic acid and 5-fluorouracil, and bevacizumab (Avastin®, Roche Products Ltd),
in combination with oxaliplatin- or irinotecan-based chemotherapy. Evidence on the following outcome
measures was considered: overall survival (OS), progression-free survival (PFS), response rate, adverse
events (AEs) related to treatment and health-related quality of life (HRQoL).
Searches were conducted in January 2015 and updated on 27 April 2015. After the reviewers had
identified studies for inclusion, the quality of the clinical effectiveness data was assessed according to
recommendations provided by the CRD. The bibliographies of included papers were scrutinised for further
potentially relevant studies. Manufacturers’ submissions were assessed for unpublished data.
The extracted data and quality assessment for each study were presented in structured tables and as a
narrative summary. Network meta-analyses (NMAs) were undertaken within a Bayesian framework in
WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK).
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Cost-effectiveness systematic review
The inclusion criteria for the cost-effectiveness systematic review were the same as for the clinical
effectiveness systematic review, except that the relevant study design was full cost-effectiveness studies.
Cost studies were considered only if they were UK based.
Studies were critiqued using summary tables and narrative synthesis, and full papers were quality appraised
using published guidelines.
Peninsula Technology Assessment Group de novo cost–utility model
Two treatment networks were considered, based on the results of the clinical effectiveness review and the
treatments that were considered to be widely used in the NHS:
1. FOLFOX network –
¢ cetuximab plus FOLFOX
¢ panitumumab plus FOLFOX
¢ FOLFOX
2. FOLFIRI network –
¢ cetuximab plus FOLFIRI
¢ FOLFIRI.
Scenario analyses considered bevacizumab and XELOX as comparators.
Other comparators were not considered as patients eligible for combination chemotherapies were unlikely
to receive these treatments.
The patient population considered was first-line patients with RAS WT mCRC. A subgroup analysis was
also presented for patients with metastases confined to the liver.
The Peninsula Technology Assessment Group (PenTAG) cost-effectiveness model, implemented in
Microsoft Excel® (2010; Microsoft Corporation, Redmond, WA, USA), simulated a cohort of people with
RAS WT mCRC starting on first-line treatment. Health states for unresected patients included first-line PFS,
second-line treatment with FOLFOX or FOLFIRI and third-line best supportive care. A post-resection state
was modelled for the proportion of patients who become suitable for resection of liver metastases.
Survival after first-line progression was assumed to be independent of first-line treatment. A scenario
analysis explored OS as a product of the responses to both first-line treatment and subsequent lines of
treatment, as experienced in the randomised controlled trials (RCTs).
Clinical effectiveness data for first-line treatment was taken from the relevant trials. OS and post-resection
PFS were taken from published literature.
The PRIME (Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal
cancer to determine Efficacy) and CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy
for Metastatic Colorectal Cancer) trials were chosen as the baseline RCTs for the two model networks.
Treatment duration was estimated through direct and indirect comparisons and capped to mean PFS.
Difference in test accuracy of RAS mutation testing between trials and clinical practice was not
incorporated into the model because of a lack of evidence.
SCIENTIFIC SUMMARY
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In the absence of RAS WT data, EuroQol 5-Dimensions data from two trials with Kirsten rat sarcoma
(KRAS) WT populations was used to inform first- and second-line utility values (0.767 and 0.762,
respectively). Third-line utility (0.641) was taken from published literature.
Utilities post resection were calculated as an age-related population utility in PFS (0.831) and a disutility
based on a weighted average of second- and third-line utilities (0.142).
In the base case, the monthly costs of drug acquisition were calculated using list prices for cetuximab
(£3859) and panitumumab (£4109).
The monthly costs of drug acquisition for FOLFOX (£86) and FOLFIRI (£128) were estimated using the
Commercial Medicines Unit Electronic Market Information Tool (CMU eMit).
In line with common clinical practice in the NHS, cetuximab was assumed to be administered fortnightly.
Panitumumab was modelled on a fortnightly basis, in line with its marketing authorisation.
Administration costs included the costs of chemotherapy delivery, pharmacy costs and the costs of infusion
pumps and line maintenance. The total monthly drug administration costs were:
l cetuximab/panitumumab plus FOLFOX – £1563
l FOLFOX – £1544
l cetuximab plus FOLFIRI – £849
l FOLFIRI – £830.
Other costs, including the costs of resection surgery, medical management and AE treatment, were based
on NHS reference costs, published literature and previous economic assessments.
Results
Clinical effectiveness systematic review
Five RAS WT subgroup analyses from RCTs met the inclusion criteria for the clinical effectiveness
systematic review.
The risk of bias in the studies was high but was generally similar between studies. Because the analyses
were of subgroup data, all comparisons were made without protection by stratification/randomisation, but
no major differences in baseline characteristics were observed, minimising the potential for selection bias.
Because of the retrospective nature of the RAS analysis, the low number of samples reduced the power of
the studies to show statistically significant differences between the treatments.
All subgroup analyses contributed to NMAs. No studies were identified comparing FOLFOX with FOLFIRI in
the RAS WT population and so two discrete networks were generated, one evaluating FOLFOX-containing
chemotherapy regimens and one evaluating FOLFIRI-containing chemotherapy regimens.
Cetuximab
Two trials [OPUS (Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer) and
CRYSTAL] provided evidence for the effectiveness of cetuximab plus chemotherapy compared with
chemotherapy alone. The evidence consistently suggested a treatment effect in favour of cetuximab plus
chemotherapy compared with chemotherapy alone, including a reduction in the risk of progression
[cetuximab+ FOLFOX vs. FOLFOX: hazard ratio (HR) 0.53, 95% confidence interval (CI) 0.27 to 1.04;
cetuximab+ FOLFIRI vs. FOLFIRI: HR 0.56, 95% CI 0.41 to 0.76] and an improvement in OS (cetuximab+ FOLFIRI
vs. FOLFIRI: HR 0.69, 95% CI 0.54 to 0.88). Tumour response rates in the experimental arm ranged from 58%
to 66% across studies, and in the control arm ranged from 29% to 60% across studies. In people with liver
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metastases at baseline, improvement in OS and PFS was consistent with the results for the whole RASWT
population. Overall, in all of the trials the clinical safety results were consistent with the results for the KRAS
WT population.
One trial [FIRE-3; 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab versus FOLFIRI Plus
Bevacizumab in First Line Treatment of Colorectal Cancer] provided evidence for the effectiveness of
cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI. Cetuximab plus FOLFIRI showed an
improvement in OS compared with bevacizumab plus FOLFIRI (HR 0.70, 95% CI 0.53 to 0.92), but other
results were similar across the arms.
Panitumumab
One trial (PRIME) provided evidence for the effectiveness of panitumumab plus FOLFOX compared with
FOLFOX. No studies were identified that compared panitumumab plus FOLFIRI with FOLFIRI. The evidence
suggested a treatment effect in favour of panitumumab plus FOLFOX compared with FOLFOX. For PFS
the HR was 0.72 (95% CI 0.58 to 0.9) and for OS the HR was 0.77 (95% CI 0.64 to 0.94), favouring
panitumumab + FOLFOX. The clinical safety results were consistent with the results for the KRAS WT
population. The liver metastases subgroup results for OS and PFS were consistent with the results for the
total RAS WT population.
One trial [PEAK; Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of
Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors]
provided evidence for the effectiveness of panitumumab plus FOLFOX compared with bevacizumab plus
FOLFOX. For PFS, panitumumab plus FOLFOX was associated with a 35% reduction in the risk of
progression compared with bevacizumab plus FOLFOX. Little OS benefit with panitumumab plus FOLFOX
was observed (HR 0.63, 95% CI 0.39 to 1.02). Overall response rates were similar in both arms.
Network meta-analysis: FOLFOX network
The NMA provided no statistically significant evidence to suggest that cetuximab plus FOLFOX was any
more effective than FOLFOX, bevacizumab plus FOLFOX or panitumumab plus FOLFOX at increasing PFS
or OS.
Direct evidence suggested that panitumumab plus FOLFOX was more effective at increasing PFS than
FOLFOX and bevacizumab plus FOLFOX. Panitumumab plus FOLFOX was also estimated to be more
effective at increasing survival than FOLFOX.
There was little evidence to suggest that cetuximab plus FOLFOX was more effective at improving the
objective response rate (ORR) or reducing the incidence of AEs than panitumumab plus FOLFOX.
Network meta-analysis: FOLFIRI network
Evidence from the NMA suggested that cetuximab plus FOLFIRI and bevacizumab plus FOLFIRI were more
effective than FOLFIRI at increasing time to progression or death and improving the ORR.
Direct evidence suggested that cetuximab plus FOLFIRI was more effective than FOLFIRI and bevacizumab
plus FOLFIRI at increasing survival.
Cost-effectiveness
Published economic evaluations
Four studies were identified in the cost-effectiveness systematic review, only one of which was a full paper.
No study completely answered the decision problem in this health technology assessment.
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Appraisal of Merck Serono’s economic analysis
Merck Serono’s cost-effectiveness review was generally appropriate but was restricted to cetuximab studies
and not RAS WT populations. This accounted for all of the differences between the PenTAG review and
Merck Serono’s review.
The Merck Serono model was generally poorly reported. The general structure of the model was similar to
that of the PenTAG model.
In the base case, Merck Serono assumed fortnightly administration of cetuximab. The estimated
incremental cost-effectiveness ratios (ICERs) for the two key comparisons were as follows:
1. cetuximab plus FOLFOX compared with FOLFOX – £47,000 per quality-adjusted life-year (QALY)
2. cetuximab plus FOLFIRI compared with FOLFIRI – £56,000 per QALY.
The most important difference between the models was that the Merck Serono model used lower mean
treatment durations. This had the effect that the Merck Serono model estimated far lower ICERs than the
PenTAG model.
Peninsula Technology Assessment Group model
Our base-case results were as follows:
l FOLFOX network:
¢ discounted QALYs – FOLFOX 1.26, panitumumab plus FOLFOX 1.41, cetuximab plus FOLFOX 1.61
¢ discounted total costs – FOLFOX £30,585, panitumumab plus FOLFOX £61,225, cetuximab plus
FOLFOX £67,057
¢ ICERs per QALY gained compared with FOLFOX – cetuximab plus FOLFOX £104,205, panitumumab
plus FOLFOX £204,103.
l FOLFIRI network:
¢ discounted QALYS – FOLFIRI 1.23, cetuximab plus FOLFIRI 1.53
¢ discounted total costs – FOLFIRI £28,250, cetuximab plus FOLFIRI £65,380
¢ ICER per QALY gained compared with FOLFIRI – cetuximab plus FOLFIRI £122,554.
For cetuximab plus FOLFOX compared with FOLFOX, most incremental QALYs came from PFS post
resection. This is largely because of the high expected resection rate for cetuximab plus FOLFOX compared
with FOLFOX. Total incremental QALYs for panitumumab plus FOLFOX compared with FOLFOX were lower
than for cetuximab plus FOLFOX compared with FOLFOX because a lower resection rate was predicted.
For cetuximab plus FOLFIRI compared with FOLFIRI, post-resection QALYs were less important than for
cetuximab plus FOLFOX compared with FOLFOX because of low rates of resection estimated for cetuximab
plus FOLFIRI and FOLFIRI.
First-line drug acquisition costs were the largest cost items.
Probabilistic sensitivity analyses predicted that, at a willingness-to-pay threshold of £30,000 per QALY, the
probability that FOLFOX was most cost-effective was 80% (cetuximab plus FOLFOX 20%, panitumumab
plus FOLFOX 0%) and the probability that FOLFIRI was most cost-effective was 100% (cetuximab plus
FOLFIRI 0%) in the two networks.
For the liver metastases subgroup, the ICERs compared with FOLFOX were £95,514 per QALY gained for
cetuximab plus FOLFOX and £86,875 per QALY gained for panitumumab plus FOLFOX. The ICER for
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cetuximab plus FOLFIRI was £76,298 per QALY gained compared with FOLFIRI. There was greater
uncertainty in the results for this subgroup as estimates for PFS for unresected patients required
additional assumptions.
When OS was modelled directly from the RCTs, with treatment duration uncapped and second-line drug
costs altered to match those in the RCTs, the ICER for cetuximab plus FOLFOX compared with FOLFOX
increased to £219,952 per QALY, the ICER for panitumumab plus FOLFOX compared with FOLFOX
reduced to £92,585 per QALY and the ICER for cetuximab plus FOLFIRI compared with FOLFIRI reduced to
£84,523 per QALY.
Deterministic sensitivity analyses showed that the cost-effectiveness results were very sensitive to resection
rates, PFS and OS post resection, PFS for unresected patients and treatment duration.
Comparison between the Peninsula Technology Assessment Group
cost-effectiveness results and the Merck Serono cost-effectiveness results
Items that differed between the PenTAG and Merck Serono models and had an important impact on
cost-effectiveness included treatment duration, rates of resection, PFS and progressive disease, and costs
of treatment.
Comparison between the current multiple technology appraisal and previous
single technology appraisals (TA176 and TA240)
The current scope specified people with RAS WT mCRC, whereas previous single technology appraisals
specified EGFR-expressing mCRC [technology appraisal (TA) no. 176] and KRAS WT mCRC (TA240).
No comparison can be made between TA240 and the current assessment as TA240 was terminated.
TA176 assessed the clinical effectiveness and cost-effectiveness of first-line cetuximab in combination with
chemotherapy for mCRC patients. When comparisons could be made, effect estimates for cetuximab were
generally similar between the two reviews.
Both TA176 and the current assessment include a de novo economic analysis provided by Merck Serono.
As we do not have the original model for TA176, it is not possible to confirm which parameters differed,
but the main differences appeared to be around first-line treatment costs.
Discussion
The systematic reviews of clinical effectiveness and cost-effectiveness were conducted by an independent,
experienced research team using the latest evidence and working to a prespecified protocol (PROSPERO
CRD42015016111). This technology assessment builds on existing secondary research and economic
evaluations.
Strengths and limitations of the systematic review of effectiveness studies
A strength of this report is the use of a systematic review and a NMA to evaluate the relative efficacy of
cetuximab and panitumumab in people with mCRC with RAS WT tumours.
There are some important sources of uncertainty that may impact on the conclusions, including the use of
subgroup analyses of intention-to-treat trial populations; the lack of evidence to estimate the effectiveness
of panitumumab plus FOLFIRI; the lack of direct evidence to compare cetuximab + FOLFOX with
panitumumab plus FOLFOX or FOLFOX-containing regimens with FOLFIRI-containing regimens; unclear
time points at which ORR was measured in the trials; and the lack of reported HRQoL estimates for the
RAS WT population.
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The study arm populations were younger and fitter than the UK population of people with mCRC and the
extent to which the results can be generalised to the UK NHS mCRC population is unclear.
Strengths and limitations of the de novo economic analysis
A strength of the PenTAG model is that it was independently produced. It uses up-to-date clinical
effectiveness data, acquired through the systematic review. Drug acquisition costs were obtained, when
possible, from the CMU eMit database, reflecting the true cost to the NHS.
Areas of uncertainty were explored through scenario analyses and sensitivity analyses.
The model is subject to the same limitations as the clinical effectiveness review as data from the clinical
effectiveness review were carried through into the modelling. Additional assumptions were also made in
the model when evidence was not available.
Conclusions
Clinical effectiveness evidence in this review suggests that there is some clinical benefit from anti-EGFR
therapies in comparison with standard chemotherapy treatments. Estimates of cost-effectiveness currently
suggest that these therapies are likely to represent poor value for money at willingness-to-pay thresholds
of £20,000 per QALY.
In summary, there is potential for clinical benefit from anti-EGFR therapies, but the cost of administering
these therapies is substantial.
Study registration
This study is registered as PROSPERO CRD42015016111.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Aetiology and pathology
Colorectal cancer (CRC), also referred to as bowel cancer, is any cancer that affects the colon (large bowel)
and rectum. It usually develops slowly over a period of 10–15 years. The tumour typically begins as a
non-cancerous polyp. A polyp is a growth of tissue that develops on the lining of the large intestine (colon
or rectum) that can become cancerous. Metastatic colorectal cancer (mCRC) refers to disease that has
spread beyond the large intestine and nearby lymph nodes.1 This type of cancer most often spreads first to
the liver, but metastases may also occur in other parts of the body including the lungs, brain and bones.1
The pathology of the tumour is usually determined by analysis of tissue taken from a biopsy or surgery.
The extent to which the cancer has spread is described as its stage.2 Staging is essential in determining the
choice of treatment and in assessing prognosis.2 More than one system is used for the staging of cancer.
CRC stage can be described using the modified Dukes’ staging system (based on postoperative findings –
a pathological staging based on resection of the tumour and measuring the depth of invasion through the
mucosa and bowel wall) or the more precise tumour invasion, nodal involvement and metastatic spread
(TNM) staging system, which is based on the depth of tumour invasion (T), nodal involvement (N) and
metastatic spread (M) assessed preoperatively by radiological examination (Table 1).2 Metastatic disease is
classified as stage IV or modified Dukes’ stage D.
TABLE 1 Staging of CRC
Staging
group TNM staging and sites involved
Modified Dukes’
stage
Stage 0 Carcinoma in situ (Tis, N0, M0)
Stage I No nodal involvement, no distant metastases A
Tumour is confined to submucosa (T1, N0, M0)
Tumour has grown into (but not through) muscularis propria (T2, N0, M0)
Stage II No nodal involvement, no distant metastases B
Tumour has grown into (but not through) the serosa (T3, N0, M0)
Tumour penetrates through the serosa and peritoneal surface, directly extends to
other organs or body structures or perforates the bowel (T4a/b, N0, M0)
Stage III Nodal involvement, no distant metastases (any T, N1/N2, M0) C
Stage IV Distant metastases (any T, any N, M1) D
Tis, tumour in situ (abnormal cells present but may spread to neighbouring tissue, sometimes referred to as preinvasive
cancer); T1, T2, T3, T4, stage of cancer; N0, no regional lymph node involvement; M0, no distant metastasis; M1, distant
metastasis present.
National Institute for Health and Care Excellence (2015) NICE Pathways: Staging Colorectal Cancer.2 Available from:
https://pathways.nice.org.uk/pathways/colorectal-cancer. NICE guidance is prepared for the National Health Service in
England, and is subject to regular review and may be updated or withdrawn. NICE has not checked the use of its content
in this article to confirm that it accurately reflects the NICE publication from which it is taken.
DOI: 10.3310/hta21380 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 38
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
Epidemiology
Incidence and prevalence
In terms of incidence, CRC is the fourth most common cancer in the UK behind breast, lung and prostate
cancer, accounting for 13% of all new cancer cases.3 It is the third most common cancer in both men
(14% of the total for men) and women (11% of the total) separately.3 Table 2 summarises the number of
new cases and incidence rates in the UK.
Approximately two-thirds (66%) of cancer cases affect the colon and one-third (34%) affect the rectum,
although this distribution varies by sex.3 The crude incidence rates show that there are 46 and 41 new
colon cancer cases per year for every 100,000 men and women in the UK, respectively, and around 29 and
17 new rectal cancer cases per year for every 100,000 men and women in the UK, respectively.3
Approximately 25% of people present with metastases at initial diagnosis and almost 50% of people with
CRC will develop metastases.4
Prevalence refers to the number of people who have previously received a diagnosis of cancer and who are still
alive at a given time point. Some people will have been cured of their disease and others will not. In the UK,
> 143,000 people were still alive at the end of 2006, up to 10 years after being diagnosed with CRC (Table 3).3
Risk factors
Risk factors for CRC include age and family history. In the UK between 2009 and 2011, an average 43%
of bowel cancer cases were diagnosed in people aged ≥ 75 years and 95% of cases were diagnosed in
those aged ≥ 50 years.3 The lifetime risk of developing bowel cancer in the UK is 1 in 14 for men and 1 in
19 for women.3
TABLE 2 Colorectal cancer (ICD-10 C18–20): numbers of new cases and crude and European age-standardised
incidence rates per 100,000 population (UK, 2011)
Variable England Wales Scotland Northern Ireland UK
Male
Cases, n 18,971 1297 2239 664 23,171
Crude rate 72.6 86.2 87.9 74.7 74.6
AS rate (95% CI) 56.7
(55.9 to 57.5)
60.2
(57.0 to 63.5)
67.4
(64.6 to 70.2)
66.4
(61.3 to 71.4)
58.0
(57.3 to 58.8)
Female
Cases, n 15,073 1046 1756 535 18,410
Crude rate 55.9 67.1 64.9 57.8 57.2
AS rate (95% CI) 36.8
(36.2 to 37.4)
40.6
(38.2 to 43.1)
41.9
(39.9 to 43.9)
42.9
(39.3 to 46.5)
37.6
(37.1 to 38.2)
Total
Cases, n 34,044 2343 3995 1199 41,581
Crude rate 64.1 76.5 76.0 66.1 65.8
AS rate (95% CI) 46.0
(45.5 to 46.5)
49.6
(47.6 to 51.6)
53.3
(51.7 to 55.0)
53.5
(50.5 to 56.5)
47.0
(46.6 to 47.5)
AS, age standardised; CI, confidence interval; ICD-10, International Statistical Classification of Diseases and Related Health
Problems, Tenth Edition.
Note
The ICD-10 codes for cancer incidence and mortality are ICD-10 C18–C20 (which includes cancers of the colon, rectum and
rectosigmoid junction).
Adapted from Cancer Research UK’s 2011 publication entitled Bowel Cancer Incidence Statistics, Cancer Research UK.3
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Mortality
Colorectal cancer is the second most common cause of cancer death in the UK (2012 data), accounting
for 10% of all deaths from cancer.5 In 2012 there were 16,187 deaths from CRC in the UK (Table 4).
The crude mortality rates show that there are 28 CRC deaths per year for every 100,000 men in the UK
and 23 per year for every 100,000 women.5
Around 6 in 10 (61%) CRC deaths are due to cancers of the colon and around 4 in 10 (39%) are due to
cancers of the rectum.5 Almost one-fifth (18%) of CRC deaths occur in people aged 60–69 years.5
TABLE 3 Colorectal cancer (ICD-10 C18–20): 1-, 5- and 10-year prevalence (UK, 2006)
Group
Prevalence
1 year 5 years 10 years
Male 14,635 51,183 78,483
Female 11,415 40,594 65,075
Total 26,050 91,777 143,558
ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Edition.
Note
The ICD codes for cancer incidence and mortality are ICD-10 C18–C20 (which includes cancers of the colon, rectum and
rectosigmoid junction).
Adapted from Cancer Research UK’s 2011 publication entitled Bowel Cancer Incidence Statistics, Cancer Research UK.3
TABLE 4 Colorectal cancer (ICD-10 C18–C20): numbers of deaths and crude and European age-standardised
mortality rates per 100,000 population (UK, 2012)
Group England Wales Scotland Northern Ireland UK
Male
Cases, n 7200 525 837 233 8795
Crude rate 27.3 34.8 32.5 26.0 28.1
AS rate (95% CI) 20.0
(19.5 to 20.4)
23.0
(21.1 to 25.0)
23.3
(21.7 to 24.8)
22.2
(19.3 to 25.0)
20.5
(20.1 to 20.9)
Female
Cases, n 6036 387 784 185 7392
Crude rate 22.2 24.7 28.7 19.9 22.8
AS rate (95% CI) 12.6
(12.3 to 12.9)
13.1
(11.8 to 14.4)
16.2
(15.1 to 17.4)
12.8
(10.9 to 14.6)
13.0
(12.7 to 13.3)
Total
Cases, n 13,236 912 1621 418 16,187
Crude rate 24.7 29.7 30.5 22.9 25.4
AS rate (95% CI) 15.9
(15.7 to 16.2)
17.6
(16.5 to 18.7)
19.2
(18.3 to 20.1)
17.0
(15.3 to 18.6)
16.3
(16.1 to 16.6)
AS, age standardised; CI, confidence interval; ICD-10, International Statistical Classification of Diseases and Related Health
Problems, Tenth Edition.
Note
The ICD codes for cancer incidence and mortality are ICD-10 C18–C20 (which includes cancers of the colon, rectum and
rectosigmoid junction).
Adapted from Cancer Research UK’s 2012 publication entitled Bowel Cancer Mortality Statistics, Cancer Research UK.5
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Survival and prognosis
Approximately 77% of men survive CRC for at least 1 year, which is predicted to fall to 59% at ≥ 5 years,
as shown by age-standardised net survival for people diagnosed with CRC during 2010–11 in England and
Wales.6 Survival for women at 1 and 5 years is slightly lower, with 74% surviving for ≥ 1 year and 58%
predicted to survive for at least 5 years.6
Survival is, however, highly dependent on the stage of disease at diagnosis. Survival by stage is not yet
routinely available for the UK because of inconsistencies in the collecting and recording of staging data in
the past. However, published estimates suggest that approximately 90% of people diagnosed at the
earliest stage will survive for > 5 years, whereas < 10% of people diagnosed with distant metastases will
survive for > 5 years.7 In general, the earlier the diagnosis the higher the chances of survival.7
Impact of the health problem
Colorectal cancer is a significant cause of morbidity and mortality.8 When treating people with mCRC, the
main aims of treatment are to relieve symptoms and to improve health-related quality of life (HRQoL)
and survival.1
Measurement of disease
The outcome end points of CRC can be measured in a variety of ways.
l Overall survival (OS): defined as the time from randomisation to death from any cause.9
l Progression-free survival (PFS): defined as time from randomisation until disease progression or death.9
l Objective response rate (ORR): defined as either a partial response (PR) or a complete response (CR).
The numbers of CRs and PRs are important as the benefits from CRs tend to be greater:
¢ CR – all detectable tumour has disappeared
¢ PR – roughly corresponds to at least a 50% decrease in the total tumour volume but with evidence
of some residual disease still remaining
¢ Stable disease – includes either a small amount of growth (typically < 20% or < 25%) or a small
amount of shrinkage
¢ Progressive disease – means that the tumour has grown significantly or that new tumours have
appeared. The appearance of new tumours is always progressive disease, regardless of the
response of other tumours. Progressive disease normally means that the treatment has failed.
l HRQoL: how a person’s well-being is affected by treatment.
Current service provision
National Institute for Health and Care Excellence (NICE) guidance is available on the diagnosis and
management of mCRC1 and first-line chemotherapeutic treatments for mCRC10–12 [see Current National
Institute for Health and Care Excellence guidelines: biological agents (first line)]. NICE guidance on the use
of second-line or subsequent treatments is also available;13 however, it is not discussed in detail in this
report as it is beyond the scope of this multiple technology appraisal (MTA).14
Management of disease
Treatment of mCRC may involve a combination of surgery, chemotherapy, radiotherapy and supportive
care (Figure 1).
The majority of people with metastatic disease are not initially suitable for potentially curative resection.1,4
Up to 30% of people may be cured if metastases in the liver can be resected. For surgery to be
considered, there must be no evidence of cancer outside the liver and there must be an adequate amount
of normal liver left behind after the resection to sustain life.1 Surgical skill is crucial to outcomes and there
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is evidence of wide variation in survival rates depending on the individual surgeon who operates.15
Chemotherapy may be recommended before surgery in some cases, even if the metastatic disease appears
to be confined to the liver.1,4 This approach may help a person who is a borderline candidate for surgery
(because of the size or location of the tumours) to become suitable for resection, after a response has
been achieved with combination chemotherapy.1,4
For the majority of people, however, surgery with curative intent is not an option because of the widespread
nature of their disease and/or their poor suitability for surgery.1 These people are treated with palliative intent
using a combination of specialist treatments – palliative surgery (e.g. in cases in which the tumour is causing an
obstruction), chemotherapy or radiotherapy – to improve both the duration and the quality of their remaining
life.1 NICE recommends chemotherapy options including 5-fluorouracil and folinic acid in combination with
oxaliplatin (FOLFOX), tegafur (UFToral®, Merck Serono UK Ltd, Feltham, UK; no longer produced in the UK) in
combination with 5-fluorouracil and folinic acid, capecitabine in combination with oxaliplatin (XELOX) and
Patient with advanced
or mCRC
Symptom control
CET + FOLFOX
CET + FOLFIRI
As per recommendations in NICE 
(TA17610)
BEV + FOLFOX or CAP + OX
Not recommended NICE (TA21212)
Available on CDFa
PAN + CTX
Unable to recommend NICE (TA24011)
Information about stomas
Biological agents
First-line agents
Second-line agents
Ongoing care and support
Hepatic metastasisExtrahepatic metastasis
Surgery for metastasesChemotherapy
FIGURE 1 Managing advanced and metastatic CRC (NICE pathways). BEV, bevacizumab; CAP, capecitabine;
CDF, Cancer Drugs Fund; CET, cetuximab; CTX, chemotherapy; FOLFIRI, folinic acid+ 5-fluorouracil + irinotecan;
FOLFOX, folinic acid + 5-fluorouracil + oxaliplatin; OX, oxaliplatin; PAN, panitumumab; TA, technology appraisal.
a, Bevacizumab is not recommended by NICE (TA21212). At the time of scoping bevacizumab was available (subject to
satisfying criteria for access) via the CDF; however, this drug was delisted for the indication under review in this TA in
March 2015. Adapted with permission from the National Institute for Health and Care Excellence’s publication
entitled NICE Pathway: Managing Advanced and Metastatic Colorectal Cancer. Available from http://pathways.nice.
org.uk/pathways/colorectal-cancer13 (accessed 13 March 2017). Content accurate at time of going to press.
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capecitabine alone.1 In practice, 5-fluorouracil and folinic acid may also be used in combination with irinotecan
(FOLFIRI) in some people for whom oxaliplatin is not suitable.1 FOLFOX may be administered in different
regimens, most commonly FOLFOX4 and FOLFOX6. The differences in drug acquisition and administration costs
of all of these regimens are discussed in Chapter 6 (see Model parameters, Costs), but in effectiveness they are
widely considered by the clinical community to be equal. Single-agent fluoropyrimidine regimens (tegafur,
folinic acid and 5-fluorouracil and capecitabine monotherapy) are generally given to patients for whom
combination therapy is not suitable (Dr Mark Napier, Royal Devon & Exeter NHS Foundation Trust, 2015,
personal communication; Merck Serono submission version 2, 15 June 2015, Table 4, p. 22).
Folinic acid is also known as leucovorin (Sodiofolin®; medac GmbH, Stirling, UK) and is given alongside
5-fluorouracil to improve the response rate compared with 5-fluorouracil alone. It is given as calcium
folinate (also known as leucovorin calcium) or less frequently as disodium folinate.16 Folinic acid (and
calcium folinate and disodium folinate), unless otherwise stated, are racemic mixtures (with equal amounts
of left- and right-handed enantiomers), in which only the levoisomer (left-handed form) is pharmacologically
active.17 The levoisomer, levoleucovorin, has marketing authorisation in the UK [as calcium levofolinate
(Isovorin®; Pfizer Limited, Sandwich, UK) and disodium levofolinate (levofolinic acid; medac GmbH, Stirling,
UK)] and is administered at half the dose of standard (racemic) leucovorin. There appears to be no
significant difference between levoleucovorin and leucovorin in terms of efficacy or adverse events (AEs),
but levoleucovorin is significantly more expensive than leucovorin at present.17
Chemotherapy may be combined with biological agents such as cetuximab (Erbitux®, Merck Serono)
(currently recommended for people satisfying criteria specified in NICE technology appraisal (TA) no. 17610),
panitumumab (Vectibix®, Amgen, Cambridge, UK) and bevacizumab (Avastin®, Roche Products Ltd) [see
Current National Institute for Health and Care Excellence guidelines: biological agents (first line)]. Although
bevacizumab is included in the final scope for this TA, it is not recommended by NICE (TA21212). It was
available subject to satisfaction of criteria for access via the Cancer Drugs Fund (CDF), but has recently
(March 2015) been delisted for the indication under review in this TA.18 As of 17 July 2015, bevacizumab
remains delisted for this indication.
Personalised treatment
Normal cell behaviour in multicellular organisms is controlled by a complex network of signalling pathways
that ensures that cells proliferate only when they are required to, for example in wound healing.19 Cancer
occurs when normal growth regulation breaks down, usually because of defects within these signalling
mechanisms.19 The rat sarcoma (RAS) genes play an important role in the epidermal growth factor receptor
(EGFR) pathway, a complex signalling cascade that is involved in the development and progression of
cancer (Figure 2).20 Signals are passed from protein to protein along several different pathways. Disruption
of the signals through mutation of the RAS gene is involved in many tumour types.
The three RAS genes – Kirsten rat sarcoma (KRAS), Harvey rat sarcoma (HRAS) and neuroblastoma rat
sarcoma (NRAS) – are the most common oncogenes in human cancer.19,20 All three are widely expressed,
with KRAS expressed in almost all cell types.19 Published research has demonstrated that mutations in
codons 12 and 13 of exon 2 of the KRAS gene are predictive of a reduced response to anti-EGFR therapies
in mCRC.22–29 For this reason, only people with KRAS exon 2 wild-type (WT) tumours were initially
approved for treatment with this class of agents.30–32
More recently, it has been shown that other mutations in genes of the RAS family (mutations in codon 61
of exon 3 and codons 117 and 146 of exon 4 of KRAS, and mutations in exons 2, 3 and 4 of NRAS) are
also associated with a reduced response to anti-EGFR therapy.4,26,28,29,33,34 These developments led the
European Medicines Agency (EMA) to update the marketing authorisations for cetuximab and
panitumumab in 2013 by restricting the indication in mCRC to the treatment of people with RAS WT
tumours (see Interventions considered in the scope of this assessment).35–40
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Exon 2 mutations in the KRAS gene occur in approximately 40% of mCRC cases and other KRAS and
NRAS mutations occur in approximately 10% of mCRC cases (Figure 3).22,26,33,41–44 Approximately 50% of
people do not have RAS mutations and are classified as RAS WT.
RAS mutation testing
A biomarker test is a simple way of looking at the type and status of particular genes of interest in a
cancer. Biomarkers have been found for many different types of cancer, such as colorectal, breast and lung
cancer, and have an increasingly important role in helping physicians to tailor care and treatment on an
individual basis, known as ‘personalised medicine’. RAS − a predictive biomarker − is a group of genes
that includes KRAS and NRAS and can be used to help select the most appropriate therapy for each
individual mCRC.
Methods for RAS mutation testing, whose use in the UK has been identified in a previous Health
Technology Assessment report45 and by the Peninsula Technology Assessment Group (PenTAG), are
summarised in Table 5. Additional techniques have also been developed and are in use internationally,
Nuclear targets
Tumorigenesis
Proliferation
Metastasis
Chemoresistance
Radioresistance
EGFR
PLC-γ PI-3K RAS STATs
FIGURE 2 Epidermal growth factor receptor signalling pathway. PI-3K, phosphoinositide 3-kinase; PLC-γ,
phospholipase C gamma; STAT, signal transducer and activator of transcription. Adapted by permission from
Macmillan Publishers Ltd on behalf of Cancer Research UK: British Journal of Cancer. Lo HW, Hung MC. Nuclear
EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and
patient survival. British Journal of Cancer 2006;94(2):184–8. Copyright 2006.21
EGFR +
TA176
2009 EGFR –
KRAS exon 2 MT
(≈40%)TA240
2011 KRAS exon 2 WT
(≈60%)
RAS MT
(≈50%)
NICE scope13
2013 RAS WT 
(all loci: KRAS exons 2, 
3 and 4; NRAS exons 2, 
3 and 4) (≈50%)
FIGURE 3 Grouping of molecular characteristics of tumours: research progress. ID, identification; MT, mutant.
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7
including the Randox KRAS, BRAF, PIK3CA* Array (Randox Laboratories Ltd, Crumlin, UK) and the
SNaPshot® Multiplex kit (Applied Biosystems, Foster City, CA, USA).
Many techniques and products reported are assays associated with the polymerase chain reaction (PCR) or
that require use of PCR techniques prior to their implementation. Additionally, some laboratories offer their
own in-house variant of real-time PCR.45
Currently, there are no NICE recommendations for which mutation test should be used in the NHS. A NICE
diagnostics review of KRAS mutation testing for identifying adults with mCRC was suspended in 2013,
following notification of potential changes to clinical practice over who may benefit from first-line
treatment with cetuximab or panitumumab.49 A review by Westwood et al.45 did demonstrate that
evidence linking test accuracy with treatment effects is unavailable for most techniques currently in use. It
concluded that there were ‘no clear differences in the treatment effects . . . regardless of which KRAS
mutation test was used to select patients’.45 Further discussion of the tests available and their impact on
this review is reported in Appendix 1.
Current National Institute for Health and Care Excellence guidelines:
biological agents (first line)
National Institute for Health and Care Excellence TA176: cetuximab for the
first-line treatment of metastatic colorectal cancer
National Institute for Health and Care Excellence TA176 states that:
Cetuximab in combination with 5-fluorouracil (5-FU), folinic acid and oxaliplatin (FOLFOX), within
its licensed indication, is recommended for the first-line treatment of mCRC only when all of the
following criteria are met:
l the primary colorectal tumour has been resected or is potentially operable
l the metastatic disease is confined to the liver and is unresectable
l the person is fit enough to undergo surgery to resect the primary colorectal tumour and to
undergo liver surgery if the metastases become resectable after treatment with cetuximab
TABLE 5 Methods used for RAS mutation testing
Test Limit of detection (%) Source
KRAS and NRAS
Sanger sequencing 10–20 Wong et al.46
Pyrosequencing 5 Wong et al.46
High-resolution melt 1–5 Wong et al.46
StripAssay® (ViennaLab Diagnostics, Vienna, Austria) 1 ViennaLab Diagnostics47
Next-generation sequencing ≈5 Westwood et al.45
KRAS
Cobas® (Roche Diagnostics Limited, Rotkreuz, Switzerland) 5 Wong et al.46
Therascreen® (Qiagen, Venlo, the Netherlands) 1–5 Wong et al.46
Peptide Nucleic Acid Clamp® (Panagene, Daejeon,
Republic of Korea)
1 Panagene48
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l the manufacturer rebates 16% of the amount of cetuximab used on a per patient basis.
Reproduced with permission from National Institute for Health and Clinical Excellence (2009)
TA176 Cetuximab for the first-line treatment of metastatic colorectal cancer. Available from:
www.nice.org.uk/guidance/TA176.10 Content accurate at time of going to press
Cetuximab in combination with 5-FU, folinic acid and irinotecan (FOLFIRI), within its licensed indication,
is recommended for the first-line treatment of mCRC only when all of the following criteria are met:
l the primary colorectal tumour has been resected or is potentially operable
l the metastatic disease is confined to the liver and is unresectable
l the patient is fit enough to undergo surgery to resect the primary colorectal tumour and to
undergo liver surgery if the metastases become resectable after treatment with cetuximab
l the patient is unable to tolerate or has contraindications to oxaliplatin.
Reproduced with permission from National Institute for Health and Clinical Excellence (2009)
TA176 Cetuximab for the first-line treatment of metastatic colorectal cancer. Available from:
www.nice.org.uk/guidance/TA176.10 Content accurate at time of going to press
Patients who meet these criteria should receive treatment with cetuximab for no more than 16 weeks.10
At 16 weeks, treatment with cetuximab should stop and patients should be assessed for resection of
liver metastases.10
National Institute for Health and Care Excellence TA240: panitumumab for the first-line
treatment of metastatic colorectal cancer
The appraisal of panitumumab in combination with chemotherapy for the treatment of mCRC (TA240)
was ended because no evidence submission was received from the manufacturer or sponsor of the
technology.11 Therefore, NICE was unable to make a recommendation about the use in the NHS of
panitumumab in combination with chemotherapy for the treatment of mCRC.11
National Institute for Health and Care Excellence TA212: bevacizumab in combination
with oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine for the
treatment of metastatic colorectal cancer
Bevacizumab in combination with oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine is
not recommended by NICE for the treatment of mCRC.12
Current usage in the NHS
Currently, only cetuximab is recommended by NICE and is available for use on the NHS in England subject
to satisfaction of criteria set out in TA17610 [see Current National Institute for Health and Care Excellence
guidelines: biological agents (first line)]. For people with mCRC not meeting the criteria set out in TA176,
cetuximab is available through the CDF.50
The National Institute for Health and Care Excellence was unable to make a recommendation about the
use in the NHS of panitumumab in combination with chemotherapy for the treatment of mCRC [TA240;11
see Current National Institute for Health and Care Excellence guidelines: biological agents (first line)].
Panitumumab is currently available for the first-line treatment of mCRC through the CDF.51
Bevacizumab was not recommended by NICE for the treatment of mCRC [TA212;12 see Current National
Institute for Health and Care Excellence guidelines: biological agents (first line)]. At the time of scoping,
bevacizumab was available (subject to satisfaction of eligibility criteria) through the CDF; however, it was
delisted in March 2015.18
Almost one-third of patients in the UK receive cetuximab or panitumumab in combination with oxaliplatin-
or irinotecan-based chemotherapy (Table 6).
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Current service cost
Treatment costs can include the following: cost of first-line chemotherapy drugs (cetuximab,
panitumumab, irinotecan or oxaliplatin, folinic acid, 5-fluorouracil), cost of administration in the first line,
cost of curative intent liver surgery, cost of post-resection therapy in those who underwent curative
resection of liver metastases, cost of management of AEs in the first line, cost of treatments in the second
line, cost of treatment in the third line and cost of RAS screening.
Description of technology under assessment
Interventions considered in the scope of this assessment
The scope of this review was to ascertain the clinical effectiveness and cost-effectiveness of two
interventions for previously untreated mCRC. These interventions were cetuximab and panitumumab.
Cetuximab
Cetuximab is a recombinant monoclonal antibody that blocks the human EGFR and therefore inhibits the
proliferation of cells that depend on EGFR activation for growth.35
Previously, cetuximab was indicated for use in people with EGFR-expressing KRAS WT mCRC.30,31,52,53 In
November 2013, in response to new biomarker data, the Committee for Medicinal Products for Human
Use (CHMP) changed the indication to clarify the particular genetic make-up of the cancer that must be
present before treatment with cetuximab is initiated.37,39 Based on this recommendation, cetuximab is now
indicated for the treatment of people with EGFR-expressing RAS WT mCRC:
l in combination with irinotecan-based chemotherapy
l in first line in combination with FOLFOX
l as a single agent in people who have failed oxaliplatin- and irinotecan-based therapy and who are
intolerant to irinotecan.35
In this label change, the combination of cetuximab with oxaliplatin-containing chemotherapy is now
contraindicated for people with RAS mutant mCRC or for whom the RAS status is unknown.35
TABLE 6 Estimated current usage of regimens
Regimen
Estimated current
proportion of first-line
mCRC patients in UK (%)
Estimated proportion of first-line mCRC
patients in UK if CET/PAN/BEV no longer
available through CDF and not recommended
by NICE (%)
FOLFOXa 30 60
FOLFIRIb 10 20
Tegafur, FA + 5-FU, capecitabinec 20 20
BEV +OX- or IRIN-based CTX 10 NA
CET/PAN +OX- or IRIN-based CTX 30 NA
5-FU, 5-fluorouracil; BEV, bevacizumab; CET, cetuximab; CTX, chemotherapy; FA, folinic acid; IRIN, irinotecan; NA, not
applicable; OX, oxaliplatin; PAN, panitumumab.
a 5-FU and capecitabine (XELOX) used interchangeably (capecitabine is an oral pro-drug of 5-FU).
b 5-FU and capecitabine [XELIRI (capecitabine + irinotecan)] used interchangeably (capecitabine is an oral pro-drug of 5-FU).
c Tegafur/uracil was discontinued in 2013 (Merck Serono submission version 2, 15 June 2015, section 1.2, p. 19).
Source: Dr Mark Napier (2015, personal communication).
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Premedication with an antihistamine and a corticosteroid at least 1 hour prior to the administration of
cetuximab should be given. This premedication is recommended before the initial and subsequent
infusions. Cetuximab is administered once a week; the initial dose is 400 mg/m2 of body surface area, with
subsequent weekly doses of 250 mg/m2 of body surface area.35
One common AE related to cetuximab treatment is the development of skin reactions, which occurs in
> 80% of people and mainly presents as an acne-like rash or, less frequently, as pruritus, dry skin,
desquamation, hypertrichosis or nail disorders (e.g. paronychia).35 The majority of skin reactions develop
within the first 3 weeks of treatment.35 The Summary of Product Characteristics (SPC) notes that, if a
person experiences a grade 3 or 4 skin reaction, cetuximab treatment must be stopped, with treatment
being resumed only if the reaction resolves to grade 2.35 Other common AEs of cetuximab include mild or
moderate infusion-related reactions such as fever, chills, nausea, vomiting, headache, dizziness or dyspnoea
that occur soon after the first cetuximab infusion.35
Panitumumab
Panitumumab is a recombinant monoclonal antibody that targets the EGFR, thereby inhibiting the growth
of EGFR-expressing tumours.36
In June 2013, the CHMP changed the indication for the use of panitumumab for the treatment of
mCRC,38,40 restricting use to the treatment of adults with RAS WT mCRC:
l in first line in combination with FOLFOX or FOLFIRI
l in second line in combination with FOLFIRI for people who have received first-line fluoropyrimidine-
based chemotherapy (excluding irinotecan)
l as monotherapy after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing
chemotherapy regimens.36
In this label change, the combination of panitumumab with oxaliplatin-containing chemotherapy is now
contraindicated for people with RAS mutant mCRC or for whom the RAS mCRC status is unknown.36
The recommended dose of panitumumab is 6 mg/kg of bodyweight given once every 2 weeks.36 Before
infusion, panitumumab should be diluted in 0.9% sodium chloride to a final concentration not exceeding
10 mg/ml.36
Panitumumab is contraindicated in people with a history of severe or life-threatening hypersensitivity
reactions to the active substance or to any of the excipients.36 The most common AEs observed (incidence
≥ 20%) are skin toxicities (i.e. erythema, dermatitis acneiform, pruritus, exfoliation, rash and fissures),
paronychia, hypomagnesaemia, fatigue, abdominal pain, nausea, diarrhoea and constipation.36
As noted, recent research (see Personalised treatment) has resulted in the CHMP adopting a change to the
licensed indication for both cetuximab and panitumumab, restricting use to people with RAS WT mCRC.
These developments and changes to the licensed indications provide the rationale for this MTA.
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
(review of TA176 and partial review of TA240) (ID794)
Although this MTA seeks to update previous guidance (TA17610 and TA24011), it is important to note the
differences between the scope for the previous single technology appraisals (STAs) and the scope for this
current MTA review (ID794).14 The main difference is in the population criterion. The current scope
specifies people with RAS WT mCRC, whereas previous STA reviews specified EGFR-expressing mCRC
(TA176)54 and KRAS WT mCRC (TA240).11 A summary of the differences between the scopes for the
reviews and how the product licences have changed is provided in Table 7.
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Chapter 2 Definition of the decision problem
Decision problem
Cetuximab and panitumumab (interventions of interest to this appraisal) were evaluated separately in 2009
(TA17610) and 2011 (TA24011) [see Chapter 1, Current National Institute for Health and Care Excellence
guidelines: biological agents (first line)].
At the time of TA176 (2009), RAS WT status was defined based on a single part (‘exon’) of the KRAS gene
and testing typically focused on KRAS codons 12 and 13.56 However, subsequent research has suggested
that mutations in other KRAS codons and other genes downstream of the EGFR may also confer drug
resistance, explaining why some individuals with KRAS codon 12 and 13 WT tumours did not respond to
therapy.56 The absence of mutations in the NRAS gene and in two further exons (3 and 4) of KRAS was
found to improve the effectiveness of cetuximab and panitumumab.56 These developments led the EMA to
update the marketing authorisations for cetuximab39 and panitumumab40 in 2013 by restricting the
indication in CRC to the treatment of people with RAS WT tumours. It is this change to the licensed
indications for these products that provides the rationale for this appraisal.14
Population, including subgroups
The population specified in the final scope issued by NICE was people with previously untreated RAS
WT mCRC.14
The subgroup of interest was based on the location of metastases, specifically liver- and non-liver-limited
disease.14
Interventions
This MTA considered two interventions.
1. Cetuximab is a recombinant monoclonal antibody that blocks the human EGFR, inhibiting the growth of
tumours expressing EGFR.35 Cetuximab has a UK marketing authorisation for the treatment of people
with EGFR-expressing RAS WT mCRC, in combination with either FOLFOX or irinotecan-based
chemotherapy.10
2. Panitumumab is a recombinant, fully human immunoglobulin G2 monoclonal antibody that binds to
the EGFR, blocking its signalling pathway and inhibiting the growth of tumours.36 It has a UK marketing
authorisation for use in combination with FOLFOX for treating previously untreated RAS WT mCRC.36
Panitumumab is also licensed for use second line in combination with FOLFIRI for people who have
received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan), although clinical trials
have also measured the effectiveness of panitumumab in combination with FOLFIRI for previously
untreated mCRC.36
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Comparators
The scope issued by NICE14 specified that the interventions should be compared with each other and with:
l FOLFOX
l XELOX
l FOLFIRI
l capecitabine
l tegafur, folinic acid and 5-fluorouracil
l bevacizumab, in combination with oxaliplatin- or irinotecan-based chemotherapy.
The Assessment Group noted that tegafur/uracil was discontinued in 2013 (Merck Serono submission
version 2, 15 June 2015, section 1.2, p. 19). Capecitabine and folinic acid plus 5-fluorouracil are typically
preferred for patients with poor performance status (Dr Mark Napier, 2015, personal communication, and
Merck Serono submission version 2, 15 June 2015).
Outcomes
The outcomes of interest considered in this review included:
l OS
l PFS
l response rate (including ORR, CR, PR, progressive disease, stable disease)
l rate of resection of metastases
l adverse effects of treatment
l HRQoL.14
Overall aims and objectives of the assessment
The aim of this project was to review the clinical effectiveness and cost-effectiveness of cetuximab and
panitumumab in a MTA. This included a review of TA17610 (cetuximab) and a partial review of TA24011
(panitumumab) for adults with previously untreated mCRC with RAS WT status. The medical benefits and
risks associated with these treatments were assessed and compared across the treatments and against
available standard drug treatments. The review also assessed whether or not these drugs are likely to be
considered good value for money for the NHS.
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing effectiveness
Evidence for the clinical effectiveness of cetuximab and panitumumab for people with previously untreated
RAS WT mCRC was assessed by conducting a systematic review of published research evidence. The
review was undertaken following the general principles published by the Centre for Reviews and
Dissemination (CRD).57 The project was undertaken in accordance with a protocol (PROSPERO number
CRD42015016111). There were no major departures from this protocol.
Individuals respond differently to some drugs.58,59 Genotype is an important determinant of both the
response to treatment and the susceptibility to adverse reactions for a wide range of drugs,60,61 for
example response to EGFR inhibitors has been shown to be dependent on gene expression in colon
cancer, with studies demonstrating a treatment interaction between RAS status and the effectiveness of
EGFR inhibitors.62–64 In line with research evaluating the negative impact of RAS mutations on the
effectiveness of EGFR inhibitors, approval for the use of anti-EGFR antibodies has now been limited to
people with mCRC with RAS WT tumours.44,65 Tumour samples from trial populations supporting the
original licensed indications were evaluated retrospectively for RAS status. Importantly, therefore, data
supporting this recent licence change and this NICE assessment are not from the intention-to-treat (ITT)
population for any of the included studies but from a subgroup of people contained within the original
randomised controlled trials (RCTs), and the results are therefore subject to uncertainty. However, no RCTs
with an ITT population by RAS WT status were identified.
Previously, NICE has appraised cetuximab (TA17610) for the treatment of people with EGFR-expressing
mCRC, in line with the licensed indication at the time. Two of the identified cetuximab trials were included
in the last appraisal; however, only data from the subgroup of people evaluated as RAS WT from those
trials are relevant to the scope of this review, as set out in the final scope from NICE (see Chapter 2,
Population, including subgroups). The appraisal of panitumumab in combination with chemotherapy for
the treatment of mCRC (NICE TA24011) ended because no evidence submission was received from the
manufacturer or sponsor of the technology. As such, NICE was unable to make recommendations relating
to the use of panitumumab in the NHS. All data included in this update review for both cetuximab and
panitumumab have been identified by the Assessment Group’s searches.
Identification of studies
The search strategy for clinical effectiveness studies included the following search methods:
l searching of bibliographic and ongoing trials databases
l searching of conference proceedings
l contact with experts in the field
l scrutiny of bibliographies of retrieved papers and company submissions.
The following bibliographic and ongoing trials databases were searched for clinical effectiveness studies:
MEDLINE (Ovid), MEDLINE In-Process & Other Non-Indexed Citations (Ovid), EMBASE (Ovid), The Cochrane
Library including the Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled
Trials (CENTRAL), Database of Abstracts of Reviews of Effects and Health Technology Assessment
database, Web of Science (Thomson Reuters), ClinicalTrials.gov, the UK Clinical Research Network’s
(UKCRN) portfolio, the International Standard Randomised Controlled Trials Number (ISRCTN) registry and
the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP).
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The bibliographic database searches were developed and run by an information specialist (SB) in January
2015. Search filters were used to limit the searches to RCTs, when appropriate, and all searches were
limited to English-language studies when possible. No date limits were used. An update search was carried
out on 27 April 2015. No papers or abstracts published after this date were included in the review. The
ongoing trials databases were searched by a reviewer in March 2015. The search strategies for each
database are detailed in Appendix 1.
In addition to the clinical effectiveness searches, the Health Management Information Consortium Ovid)
database was searched for grey literature; this produced no new studies.
The following websites were searched for conference proceedings:
l National Cancer Research Institute [http://conference.ncri.org.uk/ (accessed 7 March 2017)]
l American Association for Cancer Research [http://aacrmeetingabstracts.org/ (accessed 7 March 2017)]
l American Society of Clinical Oncology (ASCO) [http://meetinglibrary.asco.org/abstracts (accessed
7 March 2017)].
The bibliographic search results were exported to, and deduplicated using, EndNote X7 (Thomson Reuters,
CA, USA). Deduplication was also performed using manual checking. Titles and abstracts returned by the
search strategy were examined independently by two researchers (LC and MB) and screened for possible
inclusion. Disagreements were resolved by discussion. Full texts of potentially relevant studies were
ordered. Full publications were assessed independently by two reviewers (LC and MB) for inclusion or
exclusion against prespecified criteria, with disagreements resolved by discussion.
After the reviewers had completed the screening process, the bibliographies of included papers were
scrutinised for further potentially relevant studies. The manufacturers’ submissions were assessed for
unpublished data.
Eligibility criteria
Inclusion and exclusion criteria for the selection of clinical effectiveness and safety evidence were defined
according to the decision problem outlined in the NICE scope;14 inclusion criteria are summarised in Table 8.
The systematic review of clinical effectiveness was based on RCT evidence. Studies published as abstracts
or conference presentations were included only if sufficient details were presented to allow both an
appraisal of the methodology and an assessment of the results to be undertaken. Systematic reviews of
RCTs (although not formally included in the systematic review) were used as potential sources of additional
efficacy evidence. A systematic review was defined as including:
l a focused research question
l explicit search criteria that were available to review, either in the document or on application, and
explicit inclusion/exclusion criteria defining the population(s), intervention(s), comparator(s) and
outcome(s) of interest
l a critical appraisal of included studies, including consideration of internal and external validity of
the research
l a synthesis of the included evidence, whether narrative or quantitative.
The following study types were excluded: animal models, preclinical and biological studies, narrative
reviews, editorials, opinions and non-English-language papers.
Data extraction and management
Included papers were split between two reviewers for the purposes of data extraction, which was carried
out using a standardised data specification form. Data extraction was checked independently by another
reviewer. Information extracted and tabulated included details of the study design and methodology,
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baseline characteristics of participants and results, including any AEs if reported. When information on key
data was incomplete, we attempted to contact the study’s authors to gain further details. Discrepancies
were resolved by discussion. When multiple publications of the same study were identified, data were
extracted and reported as a single study. In addition, the companies (Merck Serono and Amgen) were
approached through NICE to provide missing data for the RAS WT population; this information was
provided as commercial-in-confidence (CiC).
Assessment of risk of bias
The methodological quality of each included study was assessed by one reviewer and checked by a second
reviewer, using criteria based on those proposed by the NHS CRD for RCTs (Table 9).57 The potential
generalisability of the studies was also assessed, as well as the judged applicability to the current
organisation, clinical pathways and practices of the NHS in England.
Methods of data analysis/synthesis
The results of the clinical effectiveness and quality assessment for each included study are presented in
structured tables and as a narrative summary. The possible effects of study quality on the clinical
effectiveness data and review findings are discussed.
Network meta-analysis
Network meta-analyses (NMAs) were undertaken within a Bayesian framework in WinBUGS (version 1.4.3;
MRC Biostatistics Unit, Cambridge, UK). When prior distributions were used these were defined to be as
vague as possible. The NMAs could have been conducted outside of WinBUGS (especially because of the
low number of RCTs); however, the approach taken here allowed calculation of the probability that each
treatment was the most effective compared with all others within the network.
TABLE 8 Inclusion criteria (based on the decision problem) for studies evaluating clinical effectiveness
Study characteristic Inclusion criteria
Population Adults with previously untreated, RAS WTa mCRC
Intervention Cetuximab, in combination with FOLFOX or irinotecan-based chemotherapy
Panitumumab, in combination with 5-fluorouracil-containing regimens
Comparator FOLFOX
XELOX
FOLFIRI
Capecitabine
Tegafur, folinic acid and 5-fluorouracil
Bevacizumab, in combination with oxaliplatin- or irinotecan-based chemotherapy
Outcomes OS
PFS
Response rate
Rate of resection of metastases
AEs
HRQoL
Study design RCTs
Systematic reviews of RCTsb
a RAS WT = KRAS WT and NRAS WT exons 2, 3 and 4.
b Systematic reviews of RCTs were used as potential sources of additional studies including efficacy evidence (they were
not formally included in the review).
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Two networks were analysed: those using FOLFOX regimens and those using FOLFIRI regimens. The
treatment FOLFOX was the baseline treatment in the FOLFOX regimens network, whereas FOLFIRI was the
baseline treatment in the FOLFIRI regimens network.
For the analysis of PFS, OS and ORR, models with a normal likelihood and identify link were used.66
Analysis of AEs used a model with a binomial likelihood and logit link.66 For the analysis of AEs, when no
events were reported in a study arm, a continuity correction of 0.5 was added to every cell for that
particular study to allow analysis to be conducted.66
Analyses were run with three chains and an initial burn-in of 50,000 iterations, followed by an additional
100,000 iterations, on which the results were based. Because of the small number of RCTs contributing to
each network, only fixed-effects models were used. Convergence of the models was assessed visually
using the autocorrelation, density and trace plots for all monitored variables, and checking that each chain
was sampling from the same posterior distribution. The posterior means and 95% credible intervals (CrIs)
from these analyses are reported. The probability that each treatment in the network was ranked as the
most effective (rank 1) down to the least effective (rank 4) was also calculated.
Results
The results of the included studies are discussed in the following sections. Results relating to the patient
population of interest (RAS WT) are subgroup analyses of the original studies. Initially, a summary of the
quantity and quality of the evidence is provided, together with a table presenting an overview of the
included trials. This is followed by a more detailed narrative description, together with an overview of trial
quality, for each included trial. A narrative description of population baseline characteristics and potential
imbalances is provided for each trial. The clinical effectiveness results are reported by outcome (OS, PFS,
ORR, resection rate, HRQoL and AEs). For the efficacy outcomes of OS, PFS and ORR, the results are
presented separately for cetuximab and panitumumab.
Studies identified
We screened the titles and abstracts of 2636 unique references identified by the PenTAG searches and
additional sources and retrieved 52 papers for detailed consideration. Of these, 45 were excluded (a list of
these items with reasons for their exclusion can be found in Appendix 2). Of the excluded items, four
TABLE 9 Quality assessment
Study characteristic Assessment criteria
Treatment allocation 1. Was the assignment to the treatment groups really random?
2. Was treatment allocation concealed?
Similarity of groups 3. Were the groups similar at baseline in terms of prognostic factors?
Implementation of masking 4. Were the care providers blinded to the treatment allocation?
5. Were the outcome assessors blinded to the treatment allocation?
6. Were the participants blinded to the treatment allocation?
Completeness of trial 7. Were all a priori outcomes reported?
8. Were complete data reported [e.g. was attrition and exclusion (including reasons)
reported for all outcomes]?
9. Did the analyses include an ITT analysis?
Generalisability 10. Are there any specific limitations that might limit the applicability of this study’s findings
to the current NHS in England?
Source: CRD.57
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abstracts were identified as relevant to the review33,34,67,68 (see Appendix 3) but were excluded as not
enough information was available to adequately appraise their quality. The authors of the abstracts were
contacted, which led to the identification of an additional two full papers.43,65 In total, post hoc analyses
from five RCTs28,29,43,44,65 met the inclusion criteria. In assessing titles and abstracts, agreement between the
two reviewers was substantial (κ = 0.801). At the full-text stage, agreement was good (κ = 0.636). At both
stages, initial disagreements were easily resolved by consensus.
Update searches were conducted on 27 April 2015 using the same methodology as described earlier. A
total of 175 records were screened by two reviewers (LC and JVC) and four records were selected for full-
text retrieval. Of these, none was formally included in the review; although three were considered to meet
the eligibility criteria for the review,69–71 they were available only in abstract form and, as such, could not
be quality appraised (see Appendix 3).
No studies comparing either cetuximab or panitumumab with the following comparators met the eligibility
criteria for the review: XELOX, capecitabine monotherapy and tegafur plus folinic acid + 5-fluorouracil
(specified in the NICE scope14). In addition, no studies evaluating panitumumab plus FOLFIRI met the
eligibility criteria for the review.
The study selection process is outlined in Figure 4.
Records identified through
database searching
(n = 3841)
Records identified after
duplicates removed
(n = 2636)
Records screened
(n = 2811)
Eligible publications
(n = 5)
Full-text articles assessed
for eligibility
(n = 52)
Records excluded
(n = 2755)
Full-text articles excluded
with reasons
(n = 45)
• Population, n = 27
• Intervention, n = 5
• Comparator, n = 2
• Outcomes, n = 0
• Study design, n = 2
• Duplicate, n = 0
• Language, n = 0
• Unobtainable, n = 0
• Abstract, n = 7a
• No usable data, n = 0
Records identified through
update searching
(n = 175)
Full-text articles identified
via conference abstracts
(n = 2)a
FIGURE 4 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart for studies included and
excluded from the clinical effectiveness review. a, Authors of the abstracts were contacted leading to the
identification of an additional two papers.43,65
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Cetuximab
Study characteristics
The 2009 STA (TA17610) identified two RCTs investigating the effectiveness of the addition of cetuximab
to either oxaliplatin- (FOLFOX) or irinotecan-based (FOLFIRI) chemotherapy [CRYSTAL (Cetuximab
Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer)24 and OPUS (Oxaliplatin
and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer)23]. As research into the impact of
KRAS and NRAS tumour mutations on the effectiveness of EGFR inhibitors developed, the ITT populations
from the pivotal trials were re-evaluated, forming the basis for the revision of the licensed population.
In total, three subgroup analyses from three randomised, open-label trials {OPUS,65 CRYSTAL43 and FIRE-3
[5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab versus FOLFIRI Plus Bevacizumab in First Line
Treatment of Colorectal Cancer]28} were included in the update review. Of note, in the FIRE-328 trial a
protocol amendment was made, restricting eligibility for the ITT population to those with KRAS WT exon 2
tumours, because of the emerging evidence on the negative predictive value of KRAS exon 2 mutations
and the subsequent changes to the licence for cetuximab. However, in all of the included trials the
extended RAS subgroup analysis of interest to this review was conducted retrospectively.
Of the included trials, two evaluated the addition of cetuximab to background chemotherapy (FOLFOX65
or FOLFIRI43) and one evaluated the addition of cetuximab or bevacizumab to background chemotherapy
(FOLFIRI)28 (Table 10). All of the trials evaluated the same dose of cetuximab and administration method.
All of the included trials measured the following outcomes: ORR, PFS, OS, secondary resection of liver
metastases with curative intent and safety and tolerability (including the incidence and type of AEs).28,43,65
In two of the included trials the primary end point was the proportion of participants who had an ORR.28,65
In the OPUS trial65 tumour response was assessed by an independent review committee according to
modified WHO criteria, whereas in the FIRE-3 trial28 tumour response was measured according to the
Response Evaluation Criteria in Solid Tumours (RECIST) version 1.0, as assessed by the study investigators.
The independent review committee conducted a blinded review of images and clinical data. In the
CRYSTAL trial,43 the primary end point, PFS time, was defined as the time from randomisation to disease
progression or death from any cause (within 60 days following randomisation or the last tumour
assessment). No data were identified for HRQoL for the RAS WT population from any of the included trials.
Median follow-up was not reported in the OPUS trial65 or the CRYSTAL trial.43 In the FIRE-3 trial28 the
median follow-up was 33.0 months [interquartile range (IQR) 19.0–55.4 months] in the cetuximab plus
FOLFIRI arm and 39.0 months (IQR 22.5–56.9 months) in the bevacizumab plus FOLFIRI arm.
Population characteristics
The baseline demographic and disease characteristics for the RAS WT subgroup are reported in Table 11.
For the ITT population, for each of the included trials the baseline demographic and disease characteristics
were well matched between the groups. In all studies, existing deoxyribonucleic acid samples from KRAS
exon 2 WT tumours were reanalysed for other RAS mutations in four additional KRAS codons (exons 3 and
4) and six NRAS codons (exons 2, 3 and 4). Mutation status was evaluable in 796 (73.0%) of 1090 trial
participants with KRAS exon 2 WT tumours (see Table 10). The proportions of study participants evaluated
to be RAS WT in the different trials are summarised in Table 10. In all trials, the baseline and disease
characteristics were comparable with those seen for the KRAS WT population (see Appendix 4 for baseline
and disease characteristics for the KRASWT population).
Participants were similar in terms of age, sex distribution and site of primary cancer (see Table 11).
However, as is usually the case with cancer trials, the study populations were significantly younger than
the general population presenting with mCRC, with a median age of 59–65 years for the study
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populations (see Table 11) compared with a peak in number of cases in the UK at between 70 and
79 years of age for men and 75 and 85 years for women.
Panitumumab
Study characteristics
The appraisal of panitumumab in combination with chemotherapy for the treatment of mCRC (TA24011)
was suspended as no evidence submission was received from the manufacturer or sponsor of the
technology. As such, all data included in this update review for panitumumab were identified by the
Assessment Group’s searches. It is also important to consider that, as for cetuximab, the ITT population
from the pivotal trials for panitumumab were re-evaluated in line with research developments on the
impact of RAS mutations on the effectiveness of EGFR inhibitors.
For this MTA review, a total of two subgroup analyses of the RAS WT population from two RCTs29,44
evaluating panitumumab were eligible for inclusion. In the PEAK [Panitumumab Plus mFOLFOX6 vs.
Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients
With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors] study29 the extended RAS subgroup analysis
was prespecified. In the PRIME (Panitumumab Randomized trial In combination with chemotherapy for
Metastatic colorectal cancer to determine Efficacy) study44 the extended RAS subgroup analysis was noted
alongside a protocol amendment restricting the analysis of the ITT population to compare PFS and OS
according to KRAS status.
Of the two included trials, one evaluated the addition of panitumumab to background chemotherapy
(FOLFOX4)44 and one evaluated the addition of panitumumab or bevacizumab to background
chemotherapy [modified FOLFOX6 (mFOLFOX6)].29 All trials evaluated the same dose of panitumumab and
administration method (Table 12). No clinical evidence assessing the effectiveness of panitumumab in
conjunction with FOLFIRI was identified.
Both of the included trials measured the following outcomes: ORR, PFS, OS, secondary resection of liver
metastases with curative intent, and safety and tolerability (including the incidence and type of AEs).29,44
The primary end point in both trials was PFS, defined as the time from randomisation to disease
progression or death from any cause within 60 days after the last tumour assessment or after
randomisation. No data were identified for HRQoL for the RAS WT population from the included trials.
Median follow-up in the PRIME trial was 22.31 months (IQR 10.12–35.65 months) for the panitumumab
plus FOLFOX4 treatment group and 17.71 months (IQR 8.74–32.20 months) for the FOLFOX4 alone
treatment group.44 In the PEAK trial, median follow-up was 14.97 months (IQR 8.83–22.81 months) in
the cetuximab plus mFOLFOX6 treatment group and 14.93 months (IQR 8.76–21.39 months) in the
bevacizumab plus mFOLFOX6 treatment group.29
Population characteristics
Baseline demographic and disease characteristics for the RAS WT subgroup are reported in Table 13.
In all studies, existing deoxyribonucleic acid samples from KRAS exon 2 WT tumours were reanalysed for
other RAS mutations in four additional KRAS codons (exons 3 and 4) and six NRAS codons (exons 2, 3 and
4). Mutation status was evaluable in 682 (65.6%) out of 1345 trial participants with KRAS exon 2 WT
tumours (see Table 12). The proportions of study participants evaluated to be RAS WT for the different
studies are summarised in Table 12. In all trials, the baseline demographic and disease characteristics were
comparable to those seen for the KRAS WT population (see Appendix 4 for baseline and disease
characteristics for the KRAS WT population).
Participants were similar between the arms in terms of age, sex distribution and site of primary cancer
(see Table 13). However, as is usually the case with cancer trials, the study populations were significantly
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younger than the general population presenting with mCRC, with a median age of 60–62 years for the
study populations (see Table 13) compared with a peak in the number of cases in the UK at between
70 and 79 years of age for men and 75 and 85 years for women.
Quality appraisal
We appraised the five identified subgroup analyses. On occasion, however, we referred to the original
trials to clarify issues relating to study design or methods. The reason for this was to put identified
limitations associated with subgroup analyses into context for this appraisal. Quality assessments of the
included trials are presented in Table 14.
Overall, the risk of bias was similar between studies with regard to treatment allocation, allocation
concealment, blinding, outcome reporting and loss to follow-up.
Treatment allocation
The method of random allocation, including the method of sequence generation, was clearly stated and
adequate for all of the included trials. All trials used a stratified permuted block procedure. Stratification
factors varied between the studies but were predominantly based on Eastern Cooperative Oncology Group
(ECOG) performance status (0 or 1 vs. 2) and region (Eastern or Western Europe vs. outside of Europe and
Western Europe, Canada and Australia vs. rest of the world).
However, data for those with RAS WT mCRC were available only from subgroup analyses and not from
the ITT trial population for any of the included trials. In response to research developments demonstrating
a treatment interaction of RAS and EGFR inhibitors (specifically the negative impact of RAS mutations
on the effectiveness of EGFR inhibitors), tumour samples from participants of the original RCTs were
re-evaluated for RAS status. None of the included studies stratified randomisation by RAS status; this
was because the impact of RAS mutations on the effectiveness of EGFR inhibitors was not known at the
protocol development phase. For four of the trials (OPUS,65 CRYSTAL,43 FIRE-328 and PRIME44) the subgroup
analyses were retrospective. However, for two of these trials (PRIME and FIRE-3) protocol amendments
were made in line with research developments. The only trial in which the extended RAS WT subgroup
analysis was prespecified was the PEAK trial.29
Tumour samples from participants in the ITT population identified as KRAS exon 2 WT were re-evaluated
for RAS mutations and allocated to either the RAS WT subgroup or the RAS mutant subgroup. The
methods used to detect RAS mutations varied between studies, minimising the potential for ascertainment
bias. The ascertainment rate for RAS testing of participants with KRAS WT status was 78% [excluding the
PRIME trial in which all participants were tested (n = 512/1060)] and the missing data largely resulted from
unavailable tumour samples or inconclusive RAS test results. Of note, none of the included subgroup
analyses reported the results of a test for treatment interaction.
Similarity of the groups
Three of the included trials fully reported baseline characteristics for the RAS WT population (OPUS,65
CRYSTAL43 and PEAK29). Although the other two trials (PRIME44 and FIRE-328) did not report baseline
characteristics for the subgroup of interest in the trial publication, we were able to confirm these through
Merck Serono and Amgen [19 March 2015, personal communication (via NICE)]. Of note, however,
baseline characteristics provided by the manufacturer for the PRIME study were for a total of 505
participants, whereas the study publication44 reports a total of 512 participants in the RAS WT subgroup.
Given the use of subgroup data, all comparisons were made without protection by stratification/
randomisation, increasing the risk of selection bias. However, from the evidence provided (published and
unpublished) we were able to confirm that the treatment groups were similar at baseline on a range of
prognostic factors for the RAS WT population. Moreover, the characteristics were similar to those for both
the ITT population and the KRAS WT population, suggesting a low risk of selection bias in the RAS-tested
trial population.
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Implementation of masking
The trials had an open-label design and, as such, participants and outcomes assessors were not blinded.
However, a blinded retrospective review of radiological assessment and clinical data was carried out for
progression and best ORR in two of the studies43,65 and for ORR in one study.44 In addition, in one study44
an Independent Data Monitoring Committee reviewed interim analyses of safety and one descriptive
interim analysis of PFS. No independent assessment was performed in either the PEAK trial29 or the
FIRE-3 trial.28
Completeness of trial data
With regard to the reporting of a priori outcomes, all included trials were rated as unclear. This was
because the original trial reports for the ITT population failed to explicitly state if all outcomes defined
in the study protocol were reported. Therefore, we were by default unable to assess if all a priori
outcomes had been reported for the RAS WT population. Summary data, including event numbers and
denominators, were reported for the majority of expected outcomes for the RAS WT population and,
when not reported, we were able to confirm data (predominantly ORRs and resection rates) using
secondary sources, for example EMA documents30–32,38–40,52,53 or through the manufacturers [Merck Serono
and Amgen, 19 March 2015, personal communication (via NICE)].
Withdrawals and dropouts were adequately reported in all of the original trial publications (by providing
numbers and reasons by treatment group in the form of a Consolidated Standards of Reporting Trials flow
diagram) for the ITT population. Loss to follow-up was, however, unclear. With respect to the RAS WT
population, missing data largely resulted from unavailable tumour samples or inconclusive RAS test results.
Currently, available data on the effectiveness of both cetuximab and panitumumab in the RAS WT
population are from subgroup analyses and not from the ITT trial population and, as such, ITT analysis was
not conducted. Because of the retrospective nature of the RAS analysis, a low number of samples was
available for analysis, reducing the power of the studies to show statistical significance.
Applicability to the NHS in England
The population evaluated is in line with that specified in the licensed indication and the NICE final scope.14
The study arm populations had median/mean ages of between 59 and 65 years and the majority of
participants had an ECOG performance status of < 2, meaning that participants were younger and fitter than
the UK population of people with mCRC. This is a recurrent problem, however, in the findings of trials of
therapies for mCRC in the UK population. All of the included studies were multicentre studies (including
European centres) and evaluated the study drugs in line with their licensed indications. Importantly, however,
data for the RASWT population were available only from subgroup analyses rather than ITT analyses and,
as such, sample sizes were often small and the results are subject to a high degree of uncertainty.
The rationale for the use of subgroup data is based on research developments that demonstrated that
genotype is an important determinant of both the response to treatment and the susceptibility to adverse
reactions for a wide range of drugs.60,61 In CRC response to EGFR inhibitors has been shown to be
dependent on gene expression; studies have demonstrated a treatment interaction between RAS status
and the effectiveness of EGFR inhibitors.62–64 It was in line with these research developments evaluating the
negative impact of RAS mutations on the effectiveness of EGFR inhibitors that tumour samples from trial
populations supporting the original licensed indications were evaluated retrospectively for RAS status.
Therefore, data are not from the ITT population for any of the included studies, but are from a subgroup
of people contained within the original RCTs.
Although subject to the uncertainties outlined above, these subgroup data are currently the only available
data for the RAS WT subpopulation. The Assessment Group did not identify any RCTs with an ITT
population by RAS WT status and only one of the included trials29 prespecified the extended RAS analysis.
Of note, the EMA’s recent change to the licensed indication was based on subgroup data from trials that
inform this current assessment and, although subgroup analyses were defined post hoc, the rationale was
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based on research developments into tumour biology and results were in line with the expected direction
of effect and consistent across included studies. Hence, the extent to which the results of the included
trials can provide a reasonable basis for generalisation to the UK NHS population of people with mCRC
is unclear.
Assessment of effectiveness
The following outcomes were assessed:
l PFS
l OS
l ORR
l resection rate.
We also sought HRQoL outcome data from included RCTs; however, no data on HRQoL were reported.
Because of an insufficient number of RCTs, meta-analysis was not undertaken and publication bias was
not investigated using funnel plots.
Cetuximab
Progression-free survival
All of the included cetuximab trials reported PFS.28,43,65 Of these, one trial reported PFS as a primary
outcome.43 The definition of disease progression was relatively consistent across the three trials. In each
case PFS was defined as the interval from random assignment of treatment to radiological evidence of
disease progression or death from any cause. Disease progression was radiologically assessed according to
either RECIST criteria28 or modified WHO criteria.43,65 The time-to-event data were summarised by stratified
hazard ratio (HR). A HR of < 1 indicates an improvement in PFS for treatment (cetuximab) compared
with control.
Cetuximab plus FOLFOX4 compared with FOLFOX4 Bokemeyer et al.65 reported median PFS as
12 months [95% confidence interval (CI) 5.8 months to not reported] and 5.8 months (95% CI 4.7 to
7.9 months) for the cetuximab plus FOLFOX4 and FOLFOX4 arms, respectively (Table 15). The addition of
cetuximab to FOLFOX4 was associated with a 47% reduction in the risk of progression in people with RAS
WT tumours (HR 0.53, 95% CI 0.27 to 1.04) (see Table 15).
TABLE 15 Progression-free survival [RAS WT (all loci)]: cetuximab trials
First author
(trial)
Experimental
(n/Na)
PFS (months),
median (95% CI) Control (n/Na)
PFS (months),
median (95% CI) HRb (95% CI)
Bokemeyer
201565 (OPUS)
CET+ FOLFOX4
(13/38)
12 (5.8 to NR) FOLFOX4 (29/49) 5.8 (4.7 to 7.9) 0.53
(0.27 to 1.04)
Van Cutsem
201543 (CRYSTAL)
CET+ FOLFIRI
(73/178)
11.4 (10 to 14.6) FOLFIRI (99/189) 8.4 (7.4 to 9.4) 0.56
(0.41 to 0.76)
Heinemann
201428 (FIRE-3)
CET+ FOLFIRI
(144/171)
10.4 (9.5 to 12.2) BEV + FOLFIRI
(143/171)
10.2 (9.3 to 11.5) 0.93
(0.74 to 1.17)
BEV, bevacizumab; CET, cetuximab; NR, not reported.
a Number of events/number of patients.
b Stratified HR. Random assignment was stratified by (1) ECOG performance status (0 or 1 vs. 2) (OPUS65); (2) ECOG
performance status (0 or 1 vs. 2) and region (sites in Western Europe vs. Eastern Europe vs. outside Europe) (CRYSTAL43);
or (3) ECOG performance status (0 or 1 vs. 2), number of metastatic sites (one or more than one), white blood cell count
(< 8 × 109 cells/l or ≥ 8 × 109 cells/l) and alkaline phosphatase concentration (< 300 units/l or ≥ 300 units/l) (FIRE-328).
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Cetuximab plus FOLFIRI compared with FOLFIRI Van Cutsem et al.43 reported median PFS as
11.4 months (95% CI 10 to 14.6 months) and 8.4 months (95% CI 7.4 to 9.4 months) for the cetuximab
plus FOLFIRI and FOLFIRI arms, respectively (see Table 15).43 The addition of cetuximab to FOLFIRI was
associated with a 44% reduction in the risk of progression in those with RAS WT tumours (HR 0.56,
95% CI 0.41 to 0.76).
Cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI In the FIRE-3 trial,28 median PFS
was similar between the treatment groups: 10.4 months (95% CI 9.5 to 12.2 months) in the cetuximab
plus FOLFIRI arm and 10.2 months (95% CI 9.3 to 11.5 months) in the bevacizumab plus FOLFIRI arm
(HR 0.93, 95% CI 0.74 to 1.17) (see Table 15).
Overall survival
All of the included cetuximab trials reported OS.28,43,65 In each of the trials OS was defined as the interval
from random assignment of treatment to death. The time-to-event data were summarised by stratified HR.
A HR of < 1 indicates an improvement in OS for treatment compared with control.
Cetuximab plus FOLFOX4 compared with FOLFOX4 In the OPUS trial,65 median OS was 19.8 months
(95% CI 16.6 to 25.4 months) in the cetuximab plus FOLFOX4 group compared with 17.8 months
(95% CI 13.8 to 23.9 months) in the FOLFOX4 group (HR 0.94, 95% CI 0.56 to 1.56) (Table 16).
Cetuximab plus FOLFIRI compared with FOLFIRI In the CRYSTAL trial,43 median OS was 28.4 months
(95% CI 24.7 to 31.6 months) in the cetuximab plus FOLFIRI group compared with 20.2 months (95% CI
17 to 24.5 months) in the FOLFIRI group (HR 0.69, 95% CI 0.54 to 0.88) (see Table 16).
Cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI In the FIRE-3 trial,28 median OS
was 33.1 months (95% CI 24.5 to 39.4 months) in the cetuximab plus FOLFIRI group compared with
25.6 months (95% CI 22.7 to 28.7 months) in the bevacizumab plus FOLFIRI group (HR 0.7, 95% CI 0.53
to 0.92) (see Table 16).
Objective response rate
Data for ORR were available from all three of the included cetuximab studies.28,43,65 In all of the trials
response rate was defined as the percentage of study participants who achieved a PR or CR as the best
ORR according to radiological assessment.
In two of the analyses28,65 ORR was evaluated using RECIST; no independent review was performed.
Tumour response evaluation was performed every 6 weeks (±7 days) in the OPUS trial65 and every 8 weeks
TABLE 16 Overall survival [RAS WT (all loci)]: cetuximab trials
First author
(trial)
Experimental
(n/Na)
OS (months),
median (95% CI) Control (n/Na)
OS (months),
median (95% CI) HRb (95% CI)
Bokemeyer
201565 (OPUS)
CET+ FOLFOX4
(27/38)
19.8
(16.6 to 25.4)
FOLFOX4 (36/49) 17.8 (13.8 to 23.9) 0.94
(0.56 to 1.56)
Van Cutsem
201543 (CRYSTAL)
CET+ FOLFIRI
(130/178)
28.4
(24.7 to 31.6)
FOLFIRI (154/189) 20.2 (17 to 24.5) 0.69
(0.54 to 0.88)
Heinemann
201428 (FIRE-3)
CET+ FOLFIRI
(91/171)
33.1
(24.5 to 39.4)
BEV + FOLFIRI
(110/171)
25.6 (22.7 to 28.7) 0.7
(0.53 to 0.92)
BEV, bevacizumab; CET, cetuximab.
a Number of events/number of patients.
b Stratified HR. Random assignment was stratified by (1) ECOG performance status (0 or 1 vs. 2) (OPUS65); (2) ECOG
performance status (0 or 1 vs. 2) and region (sites in Western Europe vs. Eastern Europe vs. outside Europe) (CRYSTAL43);
or (3) ECOG performance status (0–1 or 2), number of metastatic sites (one or more than one), white blood cell count
(< 8 × 109 cells/l or ≥ 8 × 109 cells/l) and alkaline phosphatase concentration (< 300 units/l or ≥ 300 units/l) (FIRE-328).
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(±7 days) in the FIRE-3 trial,28 and treatment was continued until disease progression, unacceptable
toxicities, death, withdrawal of consent or investigator decision, whichever was earlier. In the CRYSTAL
analysis,43 tumour response, including disease progression, was assessed by an independent review
committee according to modified WHO criteria. The independent review committee conducted a blinded
review of images and clinical data using a common set of prespecified criteria.43
The WHO criteria for response rate72 are older than the current standard RECIST criteria.73 It can be seen that
the two sets of criteria do not fully match: WHO criteria are multidimensional, whereas the RECIST criteria are
unidimensional. This is not necessarily important when considering a single trial but, when there are several
trials and some use one set of criteria and some use another, the results cannot easily be compared.
The effect of treatment on response was measured as an odds ratio (OR) (i.e. odds of a response with
cetuximab vs. odds of a response without cetuximab). The best-available response rate (i.e. CR, PR, stable
disease, progressive disease) is reported in Appendix 5.
Cetuximab plus FOLFOX4 compared with FOLFOX4 Bokemeyer et al.65 reported confirmed CRs or PRs
in 22 people (58%) receiving cetuximab plus FOLFOX4 and in 14 people (29%) receiving FOLFOX4 alone
(Table 17). The adjusted OR for a tumour response with cetuximab plus FOLFOX4 compared with FOLFOX4
alone was 3.33 (95% CI 1.36 to 8.17), favouring the cetuximab plus FOLFOX4 arm.
Cetuximab plus FOLFIRI compared with FOLFIRI Van Cutsem et al.43 reported confirmed CRs or PRs in
118 people (66%) receiving cetuximab plus FOLFIRI and in 73 people (39%) receiving FOLFIRI alone (see
Table 17). The adjusted OR for a tumour response with cetuximab plus FOLFIRI compared with FOLFIRI
alone was 3.11 (95% CI 2.03 to 4.78), favouring the cetuximab plus FOLFIRI arm (see Table 17).
Cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI Heinemann et al.28 reported
confirmed CRs or PRs in 112 people (65%) receiving cetuximab plus FOLFIRI and in 102 people (60%)
receiving bevacizumab plus FOLFIRI (see Table 17). The adjusted OR for a tumour response with cetuximab
plus FOLFIRI compared with bevacizumab plus FOLFIRI was 1.28 (95% CI 0.83 to 1.99), favouring the
cetuximab plus FOLFIRI arm.
Rate of complete resection
Data for rate of complete resection with curative intent before disease progression were available from one
of the included cetuximab trials.43
TABLE 17 Response rate [RAS WT (all loci)]: cetuximab trials
First author (trial) Experimental
ORR, n/N
[% (95% CI)] Control
ORR, n/N
[% (95% CI)] ORa (95% CI)
Bokemeyer
201565 (OPUS)b
CET+ FOLFOX4 22/38
[58 (41 to 74)]
FOLFOX4 14/49
[29 (17 to 43)]
3.33
(1.36 to 8.17)
Van Cutsem
201543 (CRYSTAL)b
CET+ FOLFIRI 118/178
[66 (59 to 73)]
FOLFIRI 73/189
[39 (32 to 46)]
3.11
(2.03 to 4.78)
Heinemann
201428 (FIRE-3)c
CET+ FOLFIRI 112/171
[65.5 (58 to 73)]
BEV + FOLFIRI 102/171
[60 (52 to 67)]
1.28
(0.83 to 1.99)
BEV, bevacizumab; CET, cetuximab.
a Stratified OR. Random assignment was stratified by (1) ECOG performance status (0 or 1 vs. 2) (OPUS65); (2) ECOG
performance status (0 or 1 vs. 2) and region (sites in Western Europe vs. Eastern Europe vs. outside Europe) (CRYSTAL43);
or (3) ECOG performance status (0 or 1 vs. 2), number of metastatic sites (one or more than one), white blood cell count
(< 8 × 109 cells/l or ≥ 8 × 109 cells/l) and alkaline phosphatase concentration (< 300 units/l or ≥ 300 units/l) (FIRE-328).
b Assessed every 8 weeks; median follow-up not reported.
c Assessed 28 days from last treatment cycle (tumour evaluations had to be performed at least 6 weeks after the first
administration of therapy).
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Rate of surgery with curative intent [with complete resection of all lesions (R0)] was defined as the number
of subjects with any resection of metastasis of curative intent and all lesions completely resected to R0
divided by all subjects qualifying for the ITT population. The effect of treatment on the likelihood of
complete resection was measured as an OR.
Cetuximab plus FOLFOX4 compared with FOLFOX4 No data were reported from the OPUS trial65 for
the rate of complete resection for this comparison for the RAS WT population.
Cetuximab plus FOLFIRI compared with FOLFIRI No data were reported for the rate of complete
resection in the CRYSTAL trial publication;43 however, data were provided by Merck Serono [19 March
2015, personal communication (via NICE)]. The rate of complete resection with curative intent before
disease progression was higher in the cetuximab plus FOLFIRI group than in the FOLFIRI group (7.3% vs.
2.1%; OR 3.11, 95% CI 2.03 to 4.78; p-value not reported) (Table 18).
Cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI No data were available from the
FIRE-3 trial28 for the rate of complete resection for this comparison for the RAS WT population.
Subgroup analyses: liver metastasis at baseline
There were no planned subgroup analyses in the RAS WT population as the data for this population were
obtained retrospectively. However, data for people with liver metastasis at baseline were available from
two of the included cetuximab trials43,65 [provided by Merck Serono, 19 March 2015, personal
communication (via NICE)].
Cetuximab plus FOLFOX4 compared with FOLFOX4 In the OPUS trial, among the RAS WT subgroup a
total of 27 (31.0%) participants had metastasis to the liver at baseline. The results for this subgroup are
summarised in Table 19.
Complete resection was performed in two of 15 (13.3%) participants in the cetuximab plus FOLFOX4 arm
and no (0/12; 0%) participants in the FOLFOX4 alone arm.
Cetuximab plus FOLFIRI compared with FOLFIRI Among the RAS WT subgroup a total of 89 (24.3%)
participants in the CRYSTAL trial had metastasis to the liver at baseline. The results of this subgroup are
summarised in Table 19.
Complete resection was performed in seven of 43 (16.3%) participants in the cetuximab plus FOLFOX arm
and three of 46 (6.5%) participants in the FOLFOX alone arm (OR 2.68, 95% CI 0.63 to 11.43).
TABLE 18 Rate of complete resection [RAS WT (all loci)]: cetuximab trials
First author (trial) Experimental n/N (%) Control n/N (%) ORa (95% CI)
Bokemeyer 201565 (OPUS) CET+ FOLFOX4 NR FOLFOX4 NR NR
Data on file [Merck Serono,
19 March 2015,
personal communication
(via NICE)] (CRYSTAL)b
CET+ FOLFIRI 13/178 (7.3) FOLFIRI 4/189 (2.1) 3.11 (2.03 to 4.78)
Heinemann 201428 (FIRE-3) CET+ FOLFIRI NR BEV + FOLFIRI NR NR
BEV, bevacizumab; CET, cetuximab; NR, not reported.
a Stratified OR. Random assignment was stratified by (1) ECOG performance status (0 or 1 vs. 2) (OPUS65); (2) ECOG
performance status (0 or 1 vs. 2) and region (sites in Western Europe vs. Eastern Europe vs. outside Europe) (CRYSTAL43);
or (3) ECOG performance status (0 or 1 vs. 2), number of metastatic sites (one or more than one), white blood cell count
(< 8 × 109 cells/l or ≥ 8 × 109 cells/l) and alkaline phosphatase concentration (< 300 units/l or ≥ 300 units/l) (FIRE-328).
b Median follow-up not reported.
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Cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI No data were available for people
with liver metastasis at baseline from the FIRE-3 trial.28
Panitumumab
Progression-free survival
Both of the included panitumumab trials reported PFS in the RAS WT subgroup.29,44 The definition of
disease progression was relatively consistent in both trials. In each case PFS was defined as the interval
from random assignment of treatment to radiological evidence of disease progression or death from any
cause. Disease progression was radiologically assessed according to RECIST criteria. The time-to-event data
TABLE 19 Subgroup analyses by liver metastases [RAS WT (all loci)]: cetuximab trials
Outcome
Trial
OPUSa CRYSTALa FIRE-328
CET+ FOLFOX4
(n= 15)
FOLFOX4
(n= 12)
CET+ FOLFIRI
(n= 43)
FOLFIRI
(n= 46)
CET+ FOLFIRI
(n=NR)
BEV+ FOLFIRI
(n=NR)
PFS
Progression/death
events, n/N (%)
NR NR NR NR NR NR
PFS (months),
median (95% CI)
NR 7.4 (NR) 14.0 (NR) 8.1 (NR) NR NR
Stratified HRb
(95% CI)
0.35 (0.06 to 1.91) 0.21 (0.09 to 0.49) NR
OS
Deaths, n/N (%) NR NR NR NR NR NR
OS (months),
median (95% CI)
23.9 (NR) 24.8 (NR) 29.8 (NR) 29.5 (NR) NR NR
Stratified HRb
(95% CI)
0.90 (0.33 to 2.42) 0.65 (0.38 to 1.10) NR
ORR
n/N, (%) 11/15c (73.3) 5/12c
(41.7)
36/43c (83.7) 17/46c
(37.0)
NR NR
Stratified ORb
(95% CI)
3.30 (0.63 to 17.16) 8.99 (3.17 to 25.52) NR
Resection rate
Surgical resection
rate, n/N (%)
NR NR NR NR NR NR
Stratified ORb
(95% CI)
NR NR NR
Complete R0
resection rate,
n/N (%)
2/15 (13.3) 0/12 (0) 7/43 (16.3) 3/46 (6.5) NR NR
Stratified ORb
(95% CI)
NE 2.68 (0.63 to 11.43) NR
BEV, bevacizumab; CET, cetuximab; NE, not evaluable; NR, not reported.
a Data on file [Merck Serono, 19 March 2015, personal communication (via NICE)].
b Stratified HR/OR. Random assignment was stratified by (1) ECOG performance status (0 or 1 vs. 2) (OPUS); (2) ECOG
performance status (0 or 1 vs. 2) and region (sites in Western Europe vs. Eastern Europe vs. outside Europe) (CRYSTAL);
or (3) ECOG performance status (0 or 1 vs. 2), number of metastatic sites (one or more than one), white blood cell count
(< 8 × 109 cells/l or ≥ 8 × 109 cells/l) and alkaline phosphatase concentration (< 300 units/l or ≥ 300 units/l) (FIRE-328).
c Assumption made that total n was total population with liver metastasis at baseline.
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were summarised by stratified HR. A HR of < 1 indicates an improvement in PFS for treatment compared
with control.
Panitumumab plus FOLFOX4 compared with FOLFOX4 Douillard et al.44 reported median PFS as
10.1 months (95% CI 9.3 to 12 months) and 7.9 months (95% CI 7.2 to 9.3 months) for the
panitumumab plus FOLFOX4 and FOLFOX4 arms, respectively. The addition of panitumumab to FOLFOX4
was associated with a reduction in risk of progression of 28% (HR 0.72, 95% CI 0.58 to 0.9) (Table 20).
Panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 Schwartzberg et al.29
reported median PFS as 13 months (95% CI 10.9 to 15.1 months) and 9.5 months (95% CI 9 to
12.7 months) for the panitumumab plus mFOLFOX6 and bevacizumab plus FOLFOX4 arms, respectively.
The addition of panitumumab to mFOLFOX6 was associated with a reduction in risk of progression of 35%
(HR 0.65, 95% CI 0.44 to 0.96) (see Table 20).
Overall survival
Both of the included panitumumab trials reported OS for the RAS WT subgroup.29,44 In each case OS was
defined as the interval from random assignment of treatment to death. The time-to-event data were
summarised by stratified HR. A HR of < 1 indicates an improvement in OS for treatment compared
with control.
Panitumumab plus FOLFOX4 compared with FOLFOX4 Douillard et al.44 reported median OS of
25.8 months (95% CI 21.7 to 29.7 months) and 20.2 months (95% CI 17.6 to 23.6 months) for the
panitumumab plus FOLFOX4 and FOLFOX4 arms, respectively (HR 0.77, 95% CI 0.64 to 0.94), favouring
the panitumumab plus FOLFOX4 treatment group (Table 21).
TABLE 20 Progression-free survival [RAS WT (all loci)]: panitumumab trials
First author
(trial) Experimental (n/N)
PFS (months),
median (95% CI) Control (n/N)
PFS (months),
median (95% CI) HRa (95% CI)
Douillard 201344
(PRIME)b
PAN+ FOLFOX4
(156/259)
10.1 (9.3 to 12) FOLFOX4 (170/253) 7.9 (7.2 to 9.3) 0.72 (0.58 to 0.9)
Schwartzberg
201429 (PEAK)
PAN+mFOLFOX6
(50/88)
13 (10.9 to 15.1) BEV +mFOLFOX6
(60/82)
9.5 (9 to 12.7) 0.65 (0.44 to 0.96)
BEV, bevacizumab; PAN, panitumumab.
a Stratified HR. Random assignment was stratified by (1) ECOG performance status (0 or 1 vs. 2) and region (sites in
Western Europe, Canada and Australia vs. rest of the world (PRIME44) or (2) prior adjuvant oxaliplatin therapy (PEAK29).
b Data cut-off date (primary analysis): 30 September 2008.
TABLE 21 Overall survival [RAS WT (all loci)]: panitumumab trials
First author
(trial) Experimental (n/N)
OS (months),
median (95% CI) Control (n/N)
OS (months),
median (95% CI) HRa (95% CI)
Douillard 201344
(PRIME)b
PAN+ FOLFOX4
(204/259)
25.8 (21.7 to 29.7) FOLFOX4 (218/253) 20.2 (17.6 to 23.6) 0.77 (0.64 to 0.94)
Schwartzberg
201429 (PEAK)
PAN+mFOLFOX6
(30/88)
41.3 (28.8 to 41.3) BEV +mFOLFOX6
(40/82)
28.9 (23.9 to 31.3) 0.63 (0.39 to 1.02)
BEV, bevacizumab; PAN, panitumumab.
a Stratified HR. Random assignment was stratified by (1) ECOG performance status (0 or 1 vs. 2) and region (sites in
Western Europe, Canada and Australia vs. rest of world (PRIME44) or (2) prior adjuvant oxaliplatin therapy (PEAK29).
b OS update analysis (descriptive), data cut-off date: 24 January 2013.
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Panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 Schwartzberg et al.29
reported median OS of 41.3 months (95% CI 28.8 to 41.3 months) and 28.9 months (95% CI 23.9 to
13.1 months) for the panitumumab plus mFOLFOX6 and bevacizumab plus mFOLFOX6 arms, respectively
(HR 0.63, 95% CI 0.39 to 1.02), favouring the panitumumab plus mFOLFOX6 treatment group (see
Table 21).
Objective response rate
Data for ORR were available from both included panitumumab studies.29,44
Overall response rate was defined as the percentage of participants who achieved a PR or CR as the best
overall response according to radiological assessments. In both trials29,44 ORR was evaluated using RECIST;
no independent review was performed. Tumour response evaluation was performed every 8 weeks
(±7 days) and treatment was continued until disease progression, unacceptable toxicities, death,
withdrawal of consent or investigator decision, whichever was earlier.
The effect of treatment on response was measured as an OR.
The best-available response rate (i.e. CR, PR, stable disease, progressive disease) is reported in Appendix 5.
Panitumumab plus FOLFOX4 compared with FOLFOX4 Douillard et al.44 reported confirmed CRs or
PRs, and Amgen also reported results in the company submission as academic-in-confidence (AiC)
[19 March 2015, personal communication (via NICE)].
Panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 Schwartzberg et al.29
reported confirmed CRs and PRs in 56 people (64%) receiving panitumumab plus mFOLFOX6 and in
49 people (61%) receiving FOLFOX alone (Table 22). The adjusted OR for a tumour response with
panitumumab plus FOLFOX compared with mFOLFOX6 alone was 1.08 (95% CI 0.55 to 2.12).
Rate of complete resection
Data for rate of complete resection with curative intent before disease progression were available from
both of the included panitumumab trials.29,44
The rate of surgery with curative intent [with complete resection of all lesions (R0)] was defined as the
number of subjects with any resection of metastasis of curative intent and all lesions completely resected
to R0 divided by all subjects qualifying for the ITT population.
TABLE 22 Response rate [RAS WT (all loci)]: panitumumab trials
First author (trial) Experimental
n/N
[% (95% CI)] Control
n/N
[% (95% CI)] ORa (95% CI)
Data on file [Amgen,
19 March 2015,
personal communication
(via NICE)] (PRIME)b
PAN+ FOLFOX4 (Confidential
information has
been removed)c
FOLFOX4 (Confidential
information has
been removed)c
(Confidential
information has
been removed)c
Schwartzberg 201429
(PEAK)b
PAN+mFOLFOX6 56/88
[64 (53 to 74)]
BEV +mFOLFOX6 49/81
[60 (49 to 71)]
1.08
(0.55 to 2.12)
BEV, bevacizumab; PAN, panitumumab.
a Stratified HR. Random assignment was stratified by (1) geographical region (Western Europe, Canada and Australia vs.
rest of the world) and ECOG performance status (0 or 1 vs. 2) (PRIME) or (2) prior adjuvant oxaliplatin therapy (PEAK29).
b Time point measured not reported. Median duration of follow-up was 22.31 months (95% CI 10.12 to 35.65 months)
and 17.71 months (95% CI 8.74 to 32.20 months) for PAN + FOLFOX4 and FOLFOX4, respectively (PRIME), and
14.97 months (95% CI 8.83 to 22.81 months) and 14.93 months (95% CI 8.76 to 21.39 months) for PAN+mFOLFOX6
and BEV +mFOLFOX6, respectively (PEAK29).
c AiC information.
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The effect of treatment on the likelihood of complete resection was measured as an OR.
Panitumumab plus FOLFOX4 compared with FOLFOX4 No data were reported for the rate of
complete resection in the PRIME trial publication;44 however, data were provided as AiC by the
manufacturer [19 March 2015, personal communication (via NICE)] (Table 23). The rate of R0 resection
with curative intent before disease progression for metastases was higher in the panitumumab plus
FOLFOX4 group than in the FOLFOX4 group.
Panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 No data were
reported for the rate of complete resection in the PEAK trial publication;29 however, data were provided by
the manufacturer [19 March 2015, personal communication (via NICE)] (see Table 23). The rate of R0
resection with curative intent before disease progression for metastases was higher in the panitumumab
plus mFOLFOX6 group (13%) than in the mFOLFOX6 group (11%) (OR 1.61, 95% CI 0.45 to 2.96; p-value
not reported).
Subgroup analyses: liver metastases at baseline
There were no planned subgroup analyses in the RAS WT population as the data for this population were
obtained retrospectively. However, data for people with liver metastases at baseline were available from
both of the included panitumumab trials [from Peeters et al.67 and data provided by Amgen, 19 March
2015, personal communication (via NICE)].
Panitumumab plus FOLFOX4 compared with FOLFOX4 Among the RAS WT subgroup a total of
89 (17.6%) participants in the PRIME trial44 had metastasis to the liver at baseline. The results for this
subgroup are summarised in Table 24. Complete resection was performed in 15 out of 48 (31%)
participants in the panitumumab plus FOLFOX4 arm and seven out of 41 (17%) participants in the
FOLFOX4 alone arm, with an OR for panitumumab plus FOLFOX4 compared with FOLFOX4 of 2.2 (95% CI
0.80 to 6.10), favouring panitumumab plus FOLFOX4.
Panitumumab plus FOLFOX4 compared with bevacizumab plus FOLFOX4 Among the RAS WT
subgroup, a total of 45 (26.5%) participants in the PEAK trial29 had metastasis to the liver at baseline.
The results are summarised in Table 24. AiC data provided by Amgen have been removed.
TABLE 23 Rate of complete resection [RAS WT (all loci)]: panitumumab trials
First author (trial) Experimental
n/N
[% (95% CI)] Control
n/N
[% (95% CI)] ORa (95% CI)
Data on file [Amgen,
19 March 2015,
personal communication
(via NICE)] (PRIME)b
PAN+ FOLFOX4 (Confidential
information has
been removed)c
FOLFOX4 (Confidential
information has
been removed)c
(Confidential
information has
been removed)c
Data on file [Amgen,
19 March 2015,
personal communication
(via NICE)] (PEAK)]b
PAN+mFOLFOX6 11/88
[13 (6 to 21)]
BEV +mFOLFOX6 9/82
[11 (5 to 20)]
1.16
(0.45 to 2.96)
BEV, bevacizumab; PAN, panitumumab.
a Stratified HR. Random assignment was stratified by (1) geographical region (Western Europe, Canada and Australia vs.
rest of the world) and ECOG performance status (0 or 1 vs. 2) (PRIME) or (2) prior adjuvant oxaliplatin therapy (PEAK).
b Time point measured not reported. Median duration of follow-up was 22.31 months (95% CI 10.12 to 35.65 months)
and 17.71 months (95% CI 8.74 to 32.20 months) for PAN + FOLFOX4 and FOLFOX4, respectively (PRIME), and
14.97 months (95% CI 8.83 to 22.81 months) and 14.93 months (95% CI 8.76 to 21.39 months) for PAN+mFOLFOX6
and BEV +mFOLFOX6, respectively (PEAK).
c AiC information.
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Adverse events
Data for AEs from the RAS WT subgroup from the individual trials are reported in the following sections.
Within each trial, the safety population consisted of study participants who had received at least one dose
of the study drug. The most frequently reported AEs were as expected for the individual treatments based
on the SPCs for the interventions of interest for this review (cetuximab and panitumumab).
Adverse events in the included trials were coded using versions of the Medical Dictionary for Regulatory
Activities (MedDRA). For all of the included cetuximab and panitumumab trials, the National Cancer
Institute Common Terminology Criteria (NCI-CTC) version 374 (Table 25), frequently used by trials to report
drug toxicities, were used to grade AE severity. For each AE, a grade was assigned using a scale from
TABLE 24 Subgroup analyses by liver metastases [RAS WT (all loci)]: panitumumab trials
Outcome
Trial
aPRIME67 PEAKa,b
PAN+ FOLFOX4
(n= 48)
FOLFOX4
(n= 41)
PAN+mFOLFOX6
(Confidential
information
has been removed)
BEV+mFOLFOX6
(Confidential
information
has been removed)
PFS
Progression/death events,
n/N (%)
38/48 (79) 37/41 (90) (Confidential information
has been removed)
(Confidential information
has been removed)
PFS (months), median
(95% CI)
11.3 (9.4 to 21.3) 9.9 (7.2 to 12.9) (Confidential information
has been removed)
(Confidential information
has been removed)
Stratified HR (95% CI)c,d 0.75 (0.48 to 1.19) (Confidential information has been removed)
OS
Deaths, n/N (%) 32/48 (67) 31/41 (76) (Confidential information
has been removed)
(Confidential information
has been removed)
OS (months), median
(95% CI)
40.7 (26.6 to 51.7) 33.4 (19.4 to 46.8) (Confidential information
has been removed)
(Confidential information
has been removed)
Stratified HR (95% CI)c,d 0.71 (0.43 to 1.16) (Confidential information has been removed)
ORR
n/N (%) 38/47 (81) 27/41 (66) (Confidential information
has been removed)
(Confidential information
has been removed)
Stratified OR (95% CI)c,d 2.18 (0.75 to 6.41) (Confidential information has been removed)
Resection rate
Surgical resection rate,
n/N (%)
16/48 (33) 10/41 (24) (Confidential information
has been removed)
(Confidential information
has been removed)
Stratified OR (95% CI)c,d 1.55 (0.61 to 3.94) (Confidential information has been removed)
Complete resection rate,
n/N (%)
15/48 (31) 7/41 (17) (Confidential information
has been removed)
(Confidential information
has been removed)
Stratified OR (95% CI)c,d 2.2 (0.80 to 6.10) (Confidential information has been removed)
BEV, bevacizumab; PAN, panitumumab.
a Data also provided by Amgen [19 March 2015, personal communication (via NICE)].
b AiC information.
c Stratified HR/OR. Random assignment was stratified by (1) geographical region (Western Europe, Canada and Australia
vs. rest of the world) and ECOG performance status (0 or 1 v 2), (2) prior adjuvant oxaliplatin therapy.
d Time point measured not reported. Median duration of follow-up was 22.31 months (95% CI 10.12 to 35.65 months)
and 17.71 months (95% CI 8.74 to 32.20 months) for PAN + FOLFOX4 and FOLFOX4, respectively (PRIME67), and
14.97 months (95% CI 8.83 to 22.81 months) and 14.93 months (95% CI 8.76 to 21.39 months) for PAN+mFOLFOX6
and BEV +mFOLFOX6, respectively (PEAK).
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0 to 5. Grade 0 is defined as absence of an AE or values within normal limits and grade 5 is defined as
death associated with an AE.
Cetuximab
All of the included cetuximab trials reported AEs.28,43,65 All trials reported grade 3 or 4 events,28,43,65 with
one trial also reporting grade 1 or 2 events.43 Two trials also reported summary AE information (any AEs or
any serious AEs).43,65
As RAS mutation status refers to the tumour only, the EMA concluded in its report that there were no
good reasons to postulate differences in safety profiles related to RAS status other than from the
perspective that people with RAS WT tumours would be treated for longer periods of time. Taking small
sample sizes into account, the assumption that safety is independent of tumour RAS status was considered
to be in line with reported data.39
Cetuximab plus FOLFOX4 compared with FOLFOX4
In the OPUS trial,65 all AEs were recorded between the onset of or after the first day of study medication
up to 6 weeks after the end of the last administration of study treatment. AEs were coded using the
MedDRA version 10.0 and summarised by worst severity per patient according to the NCI-CTC for AEs
version 3.0. Only AEs with a frequency of ≥ 5% in either treatment group were reported.
The incidence of any AE was the same in both treatment arms (100% in each arm) (Table 26). However,
both grade 3 or 4 AEs and serious AEs were more commonly reported in the cetuximab plus FOLFOX4 arm
(78.9% and 39.5%, respectively) than in the FOLFOX4 arm (63.3% and 16.3%, respectively). More
specifically, commonly reported grade 3 and 4 AEs included diarrhoea, leukopenia, neutropenia,
paraesthesia, peripheral sensory neuropathy, rash, any skin reactions and acne-like rash skin reaction. The
incidences of these AEs were similar between treatment arms, except for the skin reactions (any and acne-
like), for which the incidence was higher in the cetuximab plus FOLFOX4 arm (skin reaction any: 13% vs.
0%; skin reaction acne-like: 8% vs. 0%), and paraesthesia, for which the incidence was higher in the
FOLFOX4 arm (0% vs. 6%) (Table 27).
All AEs reported were noted as likely to occur in the SPC and were consistent with the known safety
profile of cetuximab.
Cetuximab plus FOLFIRI compared with FOLFIRI
In the CRYSTAL trial,43 AEs were recorded continuously and categorised according to the MedDRA version 12.0,
except for composite categories, which were categorised according to the MeDRA version 10.0. The severity of
AEs was assessed according to the NCI-CTC for AEs (version 3.0). Only AEs with a frequency of ≥ 5% in either
treatment group were reported.
TABLE 25 The National Cancer Institute’s Common Terminology Criteria for AEs
Grade Description
0 No AE or within normal limits
1 Mild AE
2 Moderate AE
3 Severe AE
4 Life-threatening or disabling AE
5 Death related to an AE
Source: Cancer Therapy Evaluation Program.74
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
TABLE 26 Adverse events (reported at a frequency of ≥ 5% in either treatment group) [RAS WT (all loci)]:
cetuximab trials
AE
Trial
a,b,cOPUS,65 n/N (%) a,b,dCRYSTAL,43 n/N (%) e,fFIRE-3,28 n/N (%)
CET+ FOLFOX4
(n= 38)
FOLFOX4
(n= 49)
CET+ FOLFIRI
(n= 178)
FOLFIRI
(n= 189)
CET+ FOLFIRI
(n= 171)
BEV+ FOLFIRI
(n= 171)
Any AE 38/38 (100) 49/49 (100) 178/178 (100) 187/189 (98.9) NR NR
Worst grade of 3 NR NR NR NR NR NR
Worst grade of 4 NR NR NR NR NR NR
Worst grade of 5 NR NR NR NR NR NR
Any grade 1 or
grade 2 event
NR NR 34/178 (19.1) 79/189 (41.8) NR NR
Any grade 3 or
grade 4 event
30/38 (79) 31/49 (63) 144/178 (80.9) 110/189 (58.2) 118/171 (69.0) 115/171 (67.3)
Any serious AE 15/38 (40) 8/49 (16) 69/178 (38.8) 62/189 (32.8) NR NR
BEV, bevacizumab; CET, cetuximab; NR, not reported.
a Data also provided by Merck Serono [19 March 2015, personal communication (via NICE)].
b Participants were observed for safety 30 days after the last study drug administration.
c AEs were coded using MedDRA version 10.0 terms, with special emphasis on grade 3 and 4 toxic effects according to
the NCI-CTC for AEs version 3.0.
d AEs were coded using MedDRA version 12.0 terms (except composite categories, which used MedDRA version 10.0
terms), with special emphasis on grade 3 and 4 toxic effects according to the NCI-CTC for AEs version 3.0.
e Participants were observed for safety approximately 6 months after randomisation.
f AEs were coded using MedDRA version 13.1 preferred terms, with special emphasis on grade 3 and 4 toxic effects
according to the NCI-CTC for AEs version 3.0.
TABLE 27 Incidence of grade 3 or 4 AEs (reported at a frequency of ≥ 5% in either treatment group) [RAS WT
(all loci)]: cetuximab trialsa
AE
Trial
b,cOPUS65 n/N (%) b,dCRYSTAL,43 n/N (%) b,eFIRE-3,28 n/N (%)
CET+ FOLFOX4
(n= 38)
FOLFOX4
(n= 49)
CET+ FOLFIRI
(n= 178)
FOLFIRI
(n= 189)
CET+ FOLFIRI
(n= 171)
BEV+ FOLFIRI
(n= 171)
Acneiform/
exanthema
NR NR NR NR 33/171 (19.3) 0/171 (0)
Deep-vein
thrombosis
NR NR 11/178 (6.2) 1/189 (0.5) NR NR
Dermatitis
acneiform
NR NR 9/178 (5.1) 0/189 (0) NR NR
Desquamation NR NR NR NR 12/171 (7.0) 1/171 (0.6)
Diarrhoea 1/38 (3) 2/49 (4) 26/178 (14.6) 18/189 (9.5) 18/171 (10.5) 24/171 (14.0)
Fatigue NR NR 12/178 (6.7) 9/189 (4.8) NR NR
Haematotoxicity NR NR NR NR 47/171 (27.5) 37/171 (21.6)
Hepatotoxicity NR NR NR NR 9/171 (5.3) 9/171 (5.3)
Hypertension NR NR NR NR 11/171(6.4) 12/171 (7.0)
Hypokalaemia NR NR NR NR 17/171 (9.9) 7/171 (4.1)
Infection NR NR NR NR 16/171 (9.4) 15/171 (8.8)
Leukopenia 1/38 (3) 3/49 (6) 15/178 (8.4) 7/189 (3.7) NR NR
continued
DOI: 10.3310/hta21380 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 38
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
The incidence of any AE was slightly higher in the cetuximab plus FOLFIRI arm (100%) than in the FOLFIRI
arm (98.9%; see Table 26). Any grade 1 or 2 AEs were more frequently reported in the FOLFIRI arm
(41.8%) than in the cetuximab plus FOLFIRI arm (19.1%), whereas both grade 3 or 4 AEs and serious AEs
were more commonly reported in the cetuximab plus FOLFIRI arm (80.9% and 38.8%, respectively) than in
the FOLFIRI arm (58.2% and 32.8%, respectively). More specifically, commonly reported grade 3 and 4
AEs included deep-vein thrombosis, dermatitis acneiform, diarrhoea, fatigue, leukopenia, neutropenia,
infusion-related reaction, any skin reactions and acne-like rash skin reaction (see Table 27), which all
occurred with a greater incidence in the cetuximab plus FOLFIRI arm than in the FOLFIRI arm. Incidences
were notably higher in the cetuximab plus FOLFIRI arm for any skin reactions (20.8% vs. 0.5%), acne-like
skin reactions (16.9% vs. 0%), neutropenia (30.9% vs. 20.1%) and rash (9.0% vs. 0%).
TABLE 27 Incidence of grade 3 or 4 AEs (reported at a frequency of ≥ 5% in either treatment group) [RAS WT
(all loci)]: cetuximab trialsa (continued )
AE
Trial
b,cOPUS65 n/N (%) b,dCRYSTAL,43 n/N (%) b,eFIRE-3,28 n/N (%)
CET+ FOLFOX4
(n= 38)
FOLFOX4
(n= 49)
CET+ FOLFIRI
(n= 178)
FOLFIRI
(n= 189)
CET+ FOLFIRI
(n= 171)
BEV+ FOLFIRI
(n= 171)
Mucositis/
stomatitis
NR NR NR NR 8/171 (4.7) 6/171 (3.5)
Nail changes/
paronychia
NR NR NR NR 12/171 (7.0) 0/171 (0)
Nausea NR NR NR NR 6/171 (3.5) 9/171 (5.3)
Neurotoxicity 2/38 (5) 5/49 (10) NR NR NR NR
Neutropenia 12/38 (32) 14/49 (29) 55/178 (30.9) 38/189 (20.1) NR NR
Pain NR NR NR NR 6/171 (3.5) 10/171 (5.8)
Paraesthesia 0/38 (0) 3/49 (6.1) NR NR NR NR
Rash 2/38 (5) 0/49 (0) 16/178 (9.0) 0/189 (0) NR NR
Skin reactions NR NR NR NR 49/171 (28.7) 5/171 (2.9)
Thromboembolic
event
NR NR NR NR 8/171 (4.7) 12/171 (7.0)
Thrombosis (any) NR NR NR NR 10/171 (5.8) 13/171 (7.6)
Composite categories
Infusion-related
reaction
NR NR 4/178 (2.2) 0/189 (0) NR NR
Skin reactions
Any 5/38 (13) 0/49 (0) 37/178 (20.8) 1/189 (0.5) NR NR
Acne-like
rash
3/38 (8) 0/49 (0) 30/178 (16.9) 0/189 (0) NR NR
BEV, bevacizumab; CET, cetuximab; NR, not reported.
a For the OPUS and CRYSTAL trials, data were provided for the most common grade 3 or 4 AEs reported at a frequency of
≥ 5% in either treatment group according to composite categories of special interest; for the FIRE-3 trial, data were
provided for grade 3 or 4 AEs reported at a frequency of ≥ 5% in either treatment group.
b Data also provided by Merck Serono [19 March 2015, personal communication (via NICE)].
c AEs were coded using MedDRA version 10.0 terms, with special emphasis on grade 3 and 4 toxic effects according to
the NCI-CTC version 3.0.
d AEs were coded using MedDRA version 12.0 terms (except composite categories, which use MedDRA version 10.0
terms), with special emphasis on grade 3 and 4 toxic effects according to the NCI CTC version 3.0.
e AEs were coded using MedDRA version 13.1 preferred terms, with special emphasis on grade 3 and 4 toxic effects
according to the NCI-CTC version 3.0.
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All AEs reported were noted as likely to occur in the SPC and were consistent with the known safety
profile of cetuximab.
Cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI
In the FIRE-3 trial,28 AEs were recorded continuously from enrolment to the end of the final study visit and
were coded by the MedDRA version 13.1 and classified and graded according to the NCI-CTC for AEs
version 3.0. Only AEs with a frequency of ≥ 5% in either treatment group were reported. Information on
the safety population definition was not available.
The incidence of any grade 3 or 4 AE was similar between the cetuximab plus FOLFIRI arm (69.0%) and
the bevacizumab plus FOLFIRI arm (67.3%); other subcategories of AEs were not reported (see Table 26).
More specifically, commonly reported grade 3 and 4 AEs included acneiform/exanthema, desquamation,
diarrhoea, haematotoxicity, hepatotoxicity, hypertension, hypokalaemia, infection, mucositis/stomatitis, nail
changes/paronychia, nausea, pain, skin reactions, thromboembolic events and thrombosis (any) (see Table 27).
The incidences of these AEs were all comparable between the two arms except for the following, which
occurred with a greater incidence in the cetuximab plus FOLFIRI arm than in the bevacizumab plus FOLFIRI
arm: skin reactions (28.7% vs. 2.9%), nail changes/paronychia (7.0% vs. 0%), desquamation (7% vs. 0.6%)
and acneiform/exanthema (19.3% vs. 0%).
Data on specific AEs that were classified as grade 1 or 2 in severity were also reported by Heinemann
et al.,28 a summary of which is provided in Appendix 5.
Panitumumab
Data were available for AEs from both the PRIME trial44 and the PEAK29 trial. Both trials reported any AEs,
AEs with a worst grade of 3, AEs with a worst grade of 4, AEs with a worst grade of 5, any grade 1 or 2
AEs, any grade 3 or 4 AEs and any serious AEs. AEs with a worst grade of 1 or 2 and AEs with a worst
grade of 3 or 4 were available from the PEAK trial29 but not the PRIME trial.44
The EMA concluded that no new safety concerns were identified for the safety profile of panitumumab in
patients with RAS WT tumour status as these patients were indistinguishable from patients with KRAS WT
tumour status.
Panitumumab plus FOLFOX4 compared with FOLFOX4
In the PRIME trial44 patients were followed for safety 30 days after the last study drug administration. AEs
were coded using the MedDRA (version 15.0) and were graded for severity using the NCI-CTC for AEs
version 3.0, with modifications for specific skin- and nail-related toxicities. The safety population consisted
of those who received at least one dose of the protocol therapy. Only AEs with a frequency of ≥ 5% in
either treatment group were reported.
Similar incidences were found in the panitumumab plus FOLFOX4 arm and the FOLFOX4 arm for any AE
(100% vs. 99%), AEs with a worst grade of 3 (57% vs. 50%), AEs with a worst grade of 4 (28% vs.
20%), AEs with a worst grade of 5 (5% vs. 6%), any grade 1 or 2 AE (10% vs. 22%), any grade 3 or 4 AE
(85% vs. 70%) and any serious AE (43% vs. 37%) (Table 28). More specifically, commonly reported grade
3 and 4 AEs included abdominal pain, anaemia, asthenia, dermatitis acneiform, diarrhoea, fatigue,
hypokalaemia, hypomagnesaemia, mucosal inflammation, peripheral neuropathy, neutropenia,
paraesthesia, rash and stomatitis (Table 29). The incidences of these AEs were similar between the
treatment arms except for the following AEs, which occurred with a greater incidence in the panitumumab
plus FOLFOX4 arm than in the FOLFOX4 arm: dermatitis acneiform (10% vs. 0%), diarrhoea (19% vs. 9%)
and rash (17% vs. 0%).
Data on specific grade 1 or 2 AEs were also provided by Douillard et al.,44 a summary of which is provided
in Appendix 5.
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TABLE 28 Adverse events (reported at a frequency of ≥ 5% in either treatment group) [RAS WT (all loci)]:
panitumumab trials
AE
Trial
a,b,cPRIME,26,44 n/N (%) a,bPEAK,29 n/N (%)
PAN+ FOLFOX4
(n= 250)
FOLFOX4
(n= 249)
PAN+mFOLFOX6
(n= 86)
BEV+mFOLFOX6
(n= 80)
Any AE 250/250 (100) 247/249 (99) 86/86 (100) 80/80 (100)
Worst grade of 3 142/250 (57) 125/249 (50) 60/86 (70) 43/80 (54)
Worst grade of 4 70/250 (28) 50/249 (20) 17/86 (20) 15/80 (19)
Worst grade of 5 13/250 (5) 16/249 (6) 4/86 (5) 7/80 (9)
Worst grade 1 or
grade 2 event
NR NR 5/86 (6) 15/80 (19)
Worst grade 3 or
grade 4 event
NR NR 77/86 (90) 58/80 (73)
Any grade 1 or
grade 2 event
25/250 (10) 56/249 (22) 86/86 (100) 80/80 (100)
Any grade 3 or
grade 4 event
212/250 (85) 175/249 (70) 80/86 (93) 65/80 (81)
Any serious AE 108/250 (43) 92/249 (37) 37/86 (43) 31/80 (39)
BEV, bevacizumab; NR, not reported; PAN, panitumumab.
a Participants were observed for safety 30 days after the last study drug administration.
b AEs were coded using MedDRA version 15.0, with severity graded according to the NCI-CTC for AEs version 3.0, with
modifications for specific skin- and nail-related toxicities. Fatal AEs were classified as grade 5.
c Data cut-off date: 24 January 2013.
TABLE 29 Incidence of grade 3 or 4 AEs (reported at a frequency of ≥ 5% in either treatment group) [RAS WT
(all loci)]: panitumumab trials
AE
Trial
a,b,cPRIME,26 n/N (%) a,b,cPEAK,29 n/N (%)
PAN+ FOLFOX4
(n= 250)
FOLFOX4
(n= 249)
PAN+ FOLFOX6
(n= 86)
BEV+ FOLFOX6
(n= 80)
Abdominal pain 12/250 (5) 13/249 (5) NR NR
Anaemia 13/250 (5) 6/249 (2) NR NR
Asthenia 13/250 (5) 9/249 (4) 3/86 (3) 4/80 (5)
Decreased appetite NR NR 5/86 (6) 0/80 (0)
Deep-vein thrombosis NR NR 2/86 (2) 6/80 (8)
Dehydration NR NR 5/86 (6) 1/80 (1)
Dermatitis acneiform 26/250 (10) 0/249 (0) NR NR
Diarrhoea 47/250 (19) 22/249 (9) 7/86 (8) 8/80 (10)
Fatigue 27/250 (11) 7/249 (3) 10/86 (12) 8/80 (10)
Hypertension NR NR 0/86 (0) 6/80 (8)
Hypokalaemia 25/250 (10) 12/249 (5) 7/86 (8) 6/80 (8)
Hypomagnesaemia 19/250 (8) 0/249 (0) 7/86 (8) 0/80 (0)
Mucosal inflammation 13/250 (5) 1/249 (0) 6/86 (7) 2/80 (3)
Neuropathy peripheral 16/250 (6) 17/249 (7) 8/86 (9) 8/80 (10)
Neutropenia 103/250 (41) 98/249 (39) 27/86 (31) 25/80 (31)
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Panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6
In the PEAK trial29 patients were followed for safety 30 days after the last study drug administration. AEs
were coded using the MedDRA (version 15.0) and were graded for severity using the NCI-CTC for AEs
(version 3.0), with modifications for specific skin- and nail-related toxicities. The safety population consisted
of those who received at least one dose of the protocol therapy. Only AEs with a frequency of ≥ 5% in
either treatment group were reported.29
The incidences of any AE and any grade 1 and 2 AE were the same in both treatment arms (100% in
each). Similar incidences were also found between the arms for AEs with a worst grade of 3 (70% vs.
54%), AEs with a worst grade of 4 (20% vs. 19%), AEs with a worst grade of 5 (5% vs. 9%), the worst
grade 1 or 2 AEs (6% vs. 19%), the worst grade 3 or 4 AEs (90% vs. 73%), any grade 3 or 4 AE (93% vs.
81%) and any serious AE (43% vs. 39%) (see Table 28). More specifically, commonly reported grade 3
and 4 AEs included asthenia, decreased appetite, deep-vein thrombosis, dehydration, diarrhoea, fatigue,
hypertension, hypokalaemia, hypomagnesaemia, mucosal inflammation, peripheral neuropathy, neutropenia,
paraesthesia, peripheral sensory neuropathy, polyneuropathy, pulmonary embolism, rash, skin disorders and
stomatitis (see Table 29). The incidences of these AEs were similar between the treatment arms, except for
the following, which occurred with a greater incidence in the panitumumab plus mFOLFOX6 arm than in the
bevacizumab plus mFOLFOX6 arm: rash (14% vs. 0%) and skin disorders (34% vs. 1%).
Data on specific grade 1 or 2 AEs were also provided by Schwartzberg et al.,29 a summary of which is
provided in Appendix 5.
Network meta-analysis
To inform the decision problem, a NMA was carried out. Based on the trials identified, it was not possible to
construct a complete network. Two discrete networks were generated, one evaluating FOLFOX-containing
chemotherapy regimens and the second comparing FOLFIRI-containing chemotherapy regimens. It should be
stressed that the results from the two discrete networks are not directly comparable.
TABLE 29 Incidence of grade 3 or 4 AEs (reported at a frequency of ≥ 5% in either treatment group) [RAS WT
(all loci)]: panitumumab trials (continued )
AE
Trial
a,b,cPRIME,26 n/N (%) a,b,cPEAK,29 n/N (%)
PAN+ FOLFOX4
(n= 250)
FOLFOX4
(n= 249)
PAN+ FOLFOX6
(n= 86)
BEV+ FOLFOX6
(n= 80)
Paraesthesia 21/250 (8) 15/249 (6) 5/86 (6) 4/80 (5)
Peripheral sensory
neuropathy
NR NR 5/86(6) 3/80 (4)
Polyneuropathy NR NR 9/86 (10) 7/80 (9)
Pulmonary embolism NR NR 8/86 (9) 7/80 (9)
Rash 43/250 (17) 1/249 (0) 12/86 (14) 0/80 (0)
Skin disordersd NR NR 29/86 (34) 1/80 (1)
Stomatitis 14/250 (6) 1/249 (0) 6/86 (7) 0/80 (0)
BEV, bevacizumab; NR, not reported; PAN, panitumumab.
a Data also provided by Amgen [19 March 2015, personal communication (via NICE)].
b Participants were observed for safety 30 days after the last study drug administration.
c AEs were coded using MedDRA version 15.0, with severity graded according to the NCI-CTC for AEs version 3.0, with
modifications for specific skin- and nail-related toxicities. Fatal AEs were classified as grade 5.
d Skin disorders includes multiple terms from the skin and subcutaneous tissue disorders system organ class (MedDRA
version 15.0).
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Convergence of analyses was confirmed using diagnostic plots and by checking that all chains were
sampling from the same posterior distribution.
FOLFOX regimens
Three RCTs26,29,33 contributed to estimating the effectiveness of four treatments: FOLFOX, bevacizumab plus
FOLFOX, panitumumab plus FOLFOX and cetuximab plus FOLFOX. As there was no direct evidence for
cetuximab plus FOLFOX compared with panitumumab plus FOLFOX, the NMA allowed indirect estimation
of this comparison. The network diagram, including which trials informed the NMA for each outcome of
interest, is shown in Figure 5.
Progression-free survival
All three RCTs contributed to the estimation of PFS. The NMA found no evidence to suggest that
cetuximab plus FOLFOX is any more effective than panitumumab plus FOLFOX at increasing the time to
progression (TTP) or death (HR 0.74, 95% Crl 0.36 to 1.49) (Table 30). Nevertheless, as the upper 95% CrI
for cetuximab plus FOLFOX compared with all of the other treatments is > 1, it is possible that cetuximab
plus FOLFOX could be associated with greater progression or death than FOLFOX, bevacizumab plus
FOLFOX or panitumumab plus FOLFOX.
FOLFOX
1 (OPUS)
CET + FOLFOX
1 (PEAK)
BEV + FOLFOX
PAN + FOLFOX
1 (PRIME)
PFS OS ORR
Resection
rate
Any
grade 1/2
AEa
Any
grade 3/4
AEa SAEa
AE by
typea
RAS WT
OPUS
PRIME
PEAK
       b
       b
       b
RAS WT + liver metastasis at baseline
OPUS
PRIME
PEAK
       
   c    
   c    
FIGURE 5 Network diagram for the FOLFOX network. BEV, bevacizumab; CET, cetuximab; PAN, panitumumab;
SAE, serious adverse event. a, AEs based on incidence rates reported in the trials (occurring in ≥ 5% participants in
either treatment arm). b, All trials informed the NMA for grade 3/4 neutropenia, paraesthesia, rash and skin
conditions occurring in ≥ 5% participants in either treatment arm and two trials26,29 informed the NMA for grade
3/4 diarrhoea, hypokalaemia, hypomagnesaemia, mucositis/stomatitis, mucosal inflammation, fatigue, neuropathy
and asthenia occurring in ≥ 5% participants in either treatment arm. c, Data were available to inform the NMA for
both surgical resection rate (partial and complete resection) and complete resection rate. Notes: for the purposes
of the NMA, skin conditions included acneiform exanthema, dermatitis acneiform, desquamation, nail changes/
paronychia, skin reactions and skin disorders; rash was treated separately. As composite reactions appeared to
include conditions also reported by specialist preferred terms, these were excluded from the analysis. Incidence
rates are reported in Adverse events. Figure based on information from the available from the OPUS,33 PRIME26
and PEAK29 trials.
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The direct evidence from the PRIME26 and PEAK29 trials suggests that panitumumab plus FOLFOX is more
effective than FOLFOX (HR 0.72, 95% CrI 0.58 to 0.90) and bevacizumab plus FOLFOX (HR 0.65, 95% CrI
0.44 to 0.96).
Overall survival
All three RCTs contributed to the estimation of OS. The analysis suggests that there is no evidence that
panitumumab plus FOLFOX is more effective than cetuximab plus FOLFOX (HR 1.22, 95% CrI 0.71 to
2.11), as the upper 95% CrI is > 1 (Table 31).
The direct evidence from the PRIME trial26 suggests that panitumumab plus FOLFOX is more effective than
FOLFOX (HR 0.77, 95% CrI 0.64 to 0.93).
Objective response rate
All three RCTs contributed to the estimation of ORR. The ORR was measured at either 6- or 8-week
intervals (according to methods reported in the primary publications). However, because of differences in
the reporting of the timing of the ORR in each study, it is unclear whether or not the timings are entirely
TABLE 30 Hazard ratiosa (95% CrIs) for progression or death from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatmenta Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX < 1 2 66 32
BEV + FOLFOX 1.11
(0.71 to 1.73)
< 1 4 29 67
PAN+ FOLFOX 0.72
(0.58 to 0.90)b
0.65
(0.44 to 0.96)c
20 79 1 < 1
CET+ FOLFOX 0.53
(0.27 to 1.04)d
0.48
(0.21 to 1.07)
0.74
(0.36 to 1.49)
80 15 3 2
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a HR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.44
c Direct evidence from the PEAK trial.29
d Direct evidence from the OPUS trial.65
TABLE 31 Hazard ratiosa (95% CrIs) for OS from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX < 1 32 55 13
BEV + FOLFOX 1.22
(0.73 to 2.05)
2 12 18 67
PAN+ FOLFOX 0.77
(0.64 to 0.93)b
0.63
(0.39 to 1.02)c
74 25 < 1 < 1
CET+ FOLFOX 0.94
(0.56 to 1.57)d
0.77
(0.37 to 1.59)
1.22
(0.71 to 2.11)
24 31 26 19
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a HR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.44
c Direct evidence from the PEAK trial.29
d Direct evidence from the OPUS trial.65
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comparable across studies. Given this uncertainty, results reported for the RAS WT population for this
outcome should be treated with caution.
The NMA suggests that there is little evidence that cetuximab plus FOLFOX is any more effective than
panitumumab plus FOLFOX for ORR (OR 1.90, 95% CrI 0.72 to 5.02) (Table 32).
Resection rates
Only data from the PRIME and PEAK trials were available to analyse resection rates; therefore, a
comparison with cetuximab plus FOLFOX could not be made. The data suggest that there is little
difference in resection rates between the treatments, as the 95% CrIs all include a value of 1 (Table 33).
Adverse events
The indirect evidence suggests that there is no difference in the ORs for any grade 3/4 AEs or any serious
AEs between cetuximab plus FOLFOX and panitumumab plus FOLFOX (Tables 34 and 35). However,
panitumumab plus FOLFOX is estimated (from direct evidence) to be associated with more grade 3/4 AEs
than FOLFOX or bevacizumab plus FOLFOX. The evidence is less clear for cetuximab plus FOLFOX
compared with FOLFOX or bevacizumab plus FOLFOX as the 95% CrIs include a value of 1 (see Table 34).
TABLE 32 Odds ratiosa (95% CrIs) for ORR from a fixed-effects NMA model: FOLFOX network
Intervention
treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX < 1 < 1 11 88
BEV + FOLFOX 1.62 (0.75 to 3.51) 9 34 46 11
PAN+ FOLFOX (Confidential information
has been removed)b
1.08
(0.55 to 2.12)c
6 57 37 < 1
CET+ FOLFOX 3.33 (1.36 to 8.12)d 2.05
(0.63 to 6.70)
1.90
(0.72 to 5.02)
85 9 6 < 1
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR > 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)];
AiC information.
c Direct evidence from the PEAK trial.29
d Direct evidence from the OPUS trial.65
TABLE 33 Odds ratiosa (95% CrIs) for resection rate calculated from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 18 35 46
BEV + FOLFOX 1.04 (0.35 to 3.10) 35 21 44
PAN+ FOLFOX (Confidential information
has been removed)b
1.61 (0.45 to 2.98)c 47 44 9
BEV, bevacizumab; PAN, panitumumab.
a OR > 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)];
AiC information.
c Direct evidence from the PEAK trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)].
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The results of analyses of specific grade 3/4 AEs are shown in Tables 36–39. The available information
allows estimation of the ORs for cetuximab plus FOLFOX compared with panitumumab plus FOLFOX for
neutropenia (see Table 36), paraesthesia (see Table 37), rash (see Table 38) and skin conditions (see Table 39).
The estimated ORs (and 95% CrIs) suggest that there is little difference in the number of individuals
experiencing these AEs between cetuximab plus FOLFOX and panitumumab plus FOLFOX. Note that for
the outcomes of rash and skin conditions, the 95% CrIs are very wide because of the low number of
events reported in all three RCTs.
For the remaining AEs, the OPUS trial33 did not provide the required information and so no comparisons
could be made between cetuximab plus FOLFOX and panitumumab plus FOLFOX for diarrhoea,
hypokalaemia, hypomagnesaemia, mucositis/stomatitis, mucosal inflammation, fatigue, peripheral
neuropathy or asthenia. Instead, analyses are reported to allow an indirect comparison to be made
between bevacizumab plus FOLFOX and FOLFOX (see Appendix 5). Note that, because of the small
numbers of events for hypomagnesaemia, mucositis/stomatitis and mucosal inflammation, the 95% CrIs
are wide.
TABLE 34 Odds ratiosa (95% CrIs) for any grade 3/4 AEsb from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX 34 63 3 0
BEV + FOLFOX 0.81
(0.24 to 2.43)
64 28 8 < 1
PAN+ FOLFOX 2.58
(1.59 to 4.30)c
3.20
(1.21 to 9.56)d
0 < 1 40 60
CET+ FOLFOX 2.24
(0.85 to 6.24)e
2.80
(0.64 to 13.34)
0.86
(0.29 to 2.69)
2 9 49 40
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c OR calculated from study arm data from the PRIME trial.44
d OR calculated from study arm data from the PEAK trial.29
e OR calculated from study arm data from the OPUS trial.65
TABLE 35 Odds ratiosa (95% CrIs) for any serious AEsb from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX 57 37 6 < 1
BEV + FOLFOX 1.09
(0.53 to 2.23)
40 31 26 2
PAN+ FOLFOX 1.30
(0.91 to 1.86)c
1.19
(0.64 to 2.24)d
2 31 64 2
CET+ FOLFOX 3.45
(1.28 to 9.88)e
3.18
(0.94 to 11.33)
2.66
(0.93 to 8.05)
< 1 1 3 95
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c OR calculated from study arm data from the PRIME trial.44
d OR calculated from study arm data from the PEAK trial.29
e OR calculated from study arm data from the OPUS trial.65
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TABLE 36 Odds ratiosa (95% CrIs) for grade 3/4 neutropeniab from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX 28 38 26 8
BEV + FOLFOX 1.07
(0.50 to 2.26)
31 17 22 30
PAN+ FOLFOX 1.08
(0.75 to 1.54)c
1.01
(0.52 to 1.95)d
12 32 38 18
CET+ FOLFOX 1.15
(0.45 to 2.94)e
1.08
(0.32 to 3.57)
1.07
(0.39 to 2.90)
30 13 14 44
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c OR calculated from study arm data from the PRIME trial.44
d OR calculated from study arm data from the PEAK trial.29
e OR calculated from study arm data from the OPUS trial.65
TABLE 37 Odds ratiosa (95% CrIs) for grade 3/4 paresthesiab from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX 3 54 34 10
BEV + FOLFOX 1.21
(0.24 to 5.76)
5 35 22 38
PAN+ FOLFOX 1.44
(0.73 to 2.94)c
1.19
(0.29 to 5.21)d
< 1 7 43 50
CET+ FOLFOX 0.09
(0.01 to 1.45)e
0.07
(0.01 to 1.92)
0.06
(0.01 to 1.10)
92 4 2 2
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c OR calculated from study arm data from the PRIME trial.44
d OR calculated from study arm data from the PEAK trial.29
e OR calculated from study arm data from the OPUS trial.65
TABLE 38 Odds ratiosa (95% CrIs) for grade 3/4 rashb from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX 53 45 2 0
BEV + FOLFOX 1.34
(0.01 to 82.99)
44 38 18 < 1
PAN+ FOLFOX 74.61
(13.2 to 1958)c
56.33
(4.71 to 16,540)d
0 < 1 24 76
CET+ FOLFOX 13.06
(0.67 to 5480)e
13.12
(0.06 to 36,870)
0.17
(0.01 to 86.72)
3 17 56 24
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c OR calculated from study arm data from the PRIME trial.44
d OR calculated from study arm data from the PEAK trial.29
e OR calculated from study arm data from the OPUS trial.65
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Subgroup analysis by liver metastases at baseline
Restricting the evidence to the subgroup of people with liver metastases at baseline has little impact on the
overall conclusions: there is limited evidence to suggest any difference between cetuximab plus FOLFOX
and panitumumab plus FOLFOX for PFS (Table 40), OS (Table 41) and ORR (Table 42) as the 95% CrIs all
include a value of 1.
Only data from two RCTs were available for the analysis of surgical resection rates for the liver metastases
subgroup (Table 43). As the OPUS trial did not report this outcome, no comparison could be made
between cetuximab plus FOLFOX and panitumumab plus FOLFOX. The available data suggest that there is
little evidence of a difference in surgical resection rates between FOLFOX, bevacizumab plus FOLFOX and
panitumumab plus FOLFOX.
TABLE 39 Odds ratiosa (95% CrIs) for grade 3/4 skin conditionsb,c from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX 54 44 2 0
BEV + FOLFOX 1.32
(0.03 to 43.18)
43 42 15 0
PAN+ FOLFOX 135.90
(24.97 to 2660)d
103.1
(18.17 to 2906)e
0 0 18 82
CET+ FOLFOX 13.22
(0.66 to 69.02)f
11.93
(0.10 to 13,540)
0.09
(0.01 to 60.23)
3 14 64 18
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR < 1 favours ‘Intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c For the purposes of the NMA skin conditions included acneiform exanthema, dermatitis acneiform, desquamation, nail
changes/paronychia, skin reactions and skin disorders based on rates reported in the included trials. Rash was treated
separately. As composite reactions appeared to include conditions also reported by specialist preferred terms, these were
excluded from the analysis. Incidence rates are reported in Adverse events.
d OR calculated from study arm data from the PRIME trial.44
e OR calculated from study arm data from the PEAK trial.29
f OR calculated from study arm data from the OPUS trial.65
TABLE 40 Hazard ratiosa (95% CrIs) for progression or death (liver metastases subgroup) from a fixed-effects NMA
model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX 2 17 42 39
BEV + FOLFOX 1.04
(0.42 to 2.59)
6 21 24 49
PAN+ FOLFOX 0.79
(0.49 to 1.27)b
(Confidential
information has
been removed)c
13 56 28 4
CET+ FOLFOX 0.35
(0.06 to 1.96)d
0.34
(0.05 to 2.37)
0.44
(0.07 to 2.66)
79 6 6 8
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a HR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)].
c Direct evidence from the PEAK trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)];
AiC information.
d Direct evidence from the OPUS trial [data on file from Merck Serono, 19 March 2015, personal communication (via NICE)].
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TABLE 41 Hazard ratiosa (95% CrIs) for OS (liver metastases subgroup) from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX 3 41 53 2
BEV + FOLFOX 1.95
(0.35 to 10.79)
< 1 2 10 88
PAN+ FOLFOX 0.69
(0.42 to 1.15)b
(Confidential
information has
been removed)c
65 30 5 0
CET+ FOLFOX 0.90
(0.33 to 2.43)d
0.46
(0.06 to 3.39)
1.29
(0.42 to 3.94)
32 27 31 10
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a HR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)].
c Direct evidence from the PEAK trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)];
AiC information.
d Direct evidence from the OPUS trial [data on file from Merck Serono, 19 March 2015, personal communication (via NICE)].
TABLE 42 Odds ratiosa (95% CrIs) for ORR (liver metastases subgroup) from a fixed-effects NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX < 1 10 45 45
BEV + FOLFOX 0.98
(0.16 to 5.80)
6 15 29 49
PAN+ FOLFOX 2.18
(0.74 to 6.36)b
(Confidential
information has
been removed)c
29 55 14 < 1
CET+ FOLFOX 3.30
(0.63 to 17.10)d
3.35
(0.30 to 38.24)
1.51
(0.21 to 10.80)
64 19 12 5
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR > 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)].
c Direct evidence from the PEAK trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)];
AiC information.
d Direct evidence from the OPUS trial [data on file from Merck Serono, 19 March 2015, personal communication (via NICE)].
TABLE 43 Odds ratiosa (95% CrIs) for surgical resection rate (liver metastases subgroup) calculated from a fixed-effects
NMA model: FOLFOX network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 8 19 72
BEV + FOLFOX 2.18
(0.42 to 11.43)
66 18 36
PAN+ FOLFOX 1.55
(0.61 to 3.93)b
(Confidential
information has
been removed)c
26 62 33
BEV, bevacizumab; PAN, panitumumab.
a OR > 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)].
c Direct evidence from the PEAK trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)];
AiC information.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
For complete resection, all three RCTs reported relevant evidence and so a comparison could be made
between panitumumab plus FOLFOX and cetuximab plus FOLFOX (Table 44). However, there was very little
evidence to say that any one treatment was associated with a greater number of complete resections than
any other, although these analyses were based on a small number of participants.
FOLFIRI regimens
Two RCTs28,43 contributed to the estimation of the effectiveness of three treatments: FOLFIRI, bevacizumab
plus FOLFIRI and cetuximab plus FOLFIRI. Even though there was no evidence on the effectiveness of
panitumumab plus FOLFIRI in this network, the NMA was conducted for the evidence that was available,
that is, to inform the indirect comparison between bevacizumab plus FOLFIRI and FOLFIRI. The network
diagram, including which trials informed the NMA for each outcome of interest, is shown in Figure 6.
Progression-free survival
The NMA suggests that bevacizumab plus FOLFIRI is more effective than FOLFIRI at increasing TTP or death
(HR 0.60, 0.41 to 0.88) and cetuximab plus FOLFIRI is more effective than FOLFIRI at increasing TTP or
death (HR 0.56, 0.41 to 0.76) (Table 45). Evidence from the FIRE-3 RCT suggests that cetuximab plus
FOLFIRI is no more effective than bevacizumab plus FOLFIRI at increasing TTP or death (see Table 45).
Overall survival
The NMA suggests that there is no evidence that bevacizumab plus FOLFIRI is more effective than FOLFIRI
at increasing OS; however, the evidence indicates that cetuximab plus FOLFIRI is more effective than both
FOLFIRI and bevacizumab plus FOLFIRI at increasing OS (Table 46).
Objective response rate
Two RCTs contributed to the estimation of ORR in the FOLFIRI network.28,43 However, because of
differences in the reporting of the timing of ORR in each study, it is unclear whether or not the timings are
entirely comparable across studies. Given this uncertainty, the results reported for the RAS WT population
for this outcome should be treated with caution.
The NMA suggests that bevacizumab plus FOLFIRI and cetuximab plus FOLFIRI are both more effective than
FOLFIRI for the outcome of ORR; however, the evidence that cetuximab plus FOLFIRI is any more effective
than bevacizumab plus FOLFIRI for ORR is uncertain because of the wide 95% CrI (OR 1.28, 95% CrI 0.83
to 1.99) (Table 47).
TABLE 44 Odds ratiosa (95% CrIs) for complete resection rate (liver metastases subgroup) calculated from a
fixed-effects NMA model: FOLFOX network
Intervention
treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX PAN+ FOLFOX First Second Third Fourth
FOLFOX < 1 3 23 73
BEV + FOLFOX 4.22
(0.58 to 30.68)
43 39 12 6
PAN+ FOLFOX 2.20
(0.80 to 6.07)b
(Confidential
information has
been removed)c
7 39 49 4
CET+ FOLFOX 4.63
(0.20 to 104.60)d
1.09
(0.03 to 44.34)
2.09
(0.08 to 56.28)
50 19 15 16
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a OR > 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)].
c Direct evidence from the PEAK trial [data on file from Amgen, 19 March 2015, personal communication (via NICE)];
AiC information.
d Direct evidence from the OPUS trial [data on file from Merck Serono, 19 March 2015, personal communication (via NICE)].
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FIGURE 6 Network diagram for the FOLFIRI network. BEV, bevacizumab; CET, cetuximab; SAE, serious adverse event.
a, AEs based on incidence rates reported in the trials (occurring in ≥ 5% participants in either treatment arm). b, The
CRYSTAL trial used WHO criteria and the FIRE-3 trial used RECIST criteria to assess response. c, Grade 3/4 skin conditions
occurring in ≥ 5% participants in either treatment arm and grade 3/4 diarrhoea occurring in ≥ 5% participants in
either treatment arm. d, Surgical resection rate (partial and complete resection). Notes: for the purposes of the NMA,
skin conditions included acneiform exanthema, dermatitis acneiform, desquamation, nail changes/paronychia, skin
reactions and skin disorders based on rates reported in the included trials. Rash was treated separately. As composite
reactions appeared to include conditions also reported by specialist preferred terms, these were excluded from the
analysis. Incidence rates are reported in Adverse events. Figure based on information available from the CRYSTAL43 and
FIRE-328 trials.
TABLE 45 Hazard ratiosa (95% CrIs) for progression or death from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI < 1 < 1 99
BEV + FOLFIRI 0.60 (0.41 to 0.88) 27 73 < 1
CET+ FOLFIRI 0.56 (0.41 to 0.76)b 0.93 (0.74 to 1.17)c 73 27 < 1
BEV, bevacizumab; CET, cetuximab.
a HR < 1 favours ‘intervention’ treatment.
b Direct evidence from the CRYSTAL trial.43
c Direct evidence from the FIRE-3 trial.28
TABLE 46 Hazard ratiosa (95% CrIs) for OS from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI < 1 47 53
BEV + FOLFIRI 0.99 (0.68 to 1.42) < 1 53 47
CET+ FOLFIRI 0.69 (0.54 to 0.88)b 0.70 (0.53 to 0.92)c 99 < 1 < 1
BEV, bevacizumab; CET, cetuximab.
a HR < 1 favours ‘intervention’ treatment.
b Direct evidence from the CRYSTAL trial.43
c Direct evidence from the FIRE-3 trial.28
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Adverse events
The NMA suggests that bevacizumab plus FOLFIRI and cetuximab plus FOLFIRI are associated with more
grade 3/4 AEs than FOLFIRI (Table 48) and that cetuximab plus FOLFIRI is associated with more skin
conditions than FOLFIRI or bevacizumab plus FOLFIRI (Table 49). For diarrhoea, the evidence is unclear
regarding whether or not one treatment is associated with more cases than any other treatment (Table 50).
TABLE 47 Odds ratioa (and 95% CrI) for ORR from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI 0 13 87
BEV + FOLFIRI 2.43 (1.32 to 4.48) < 1 87 13
CET+ FOLFIRI 3.11 (2.03 to 4.77)b 1.28 (0.83 to 1.99)c 100 < 1 0
BEV, bevacizumab; CET, cetuximab.
a OR > 1 favours ‘intervention’ treatment.
b Direct evidence from the CRYSTAL trial.43
c Direct evidence from the FIRE-3 trial.28
TABLE 48 Odds ratiosa (95% CrIs) for any grade 3/4 AEsb from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI 99 < 1 0
BEV + FOLFIRI 2.82 (1.46 to 5.49) < 1 64 36
CET+ FOLFIRI 3.06 (1.91 to 4.95)c 1.09 (0.69 to 1.72)d 0 36 64
BEV, bevacizumab; CET, cetuximab.
a OR < 1 favours ‘intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c OR calculated from study arm data from the CRYSTAL trial.43
d OR calculated from study arm data from the FIRE-3 trial.28
TABLE 49 Odds ratiosa (95% CrIs) for grade 3/4 skin conditionsb,c from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI 72 28 0
BEV + FOLFIRI 2.67 (0.18 to 1177) 28 72 0
CET+ FOLFIRI 127.60 (11.12 to 53,970)d 47.60 (21.30 to 129.40)e 0 0 100
BEV, bevacizumab; CET, cetuximab.
a OR < 1 favours ‘intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c For the purposes of the NMA skin conditions included acneiform exanthema, dermatitis acneiform, desquamation, nail
changes/paronychia, skin reactions and skin disorders based on rates reported in the included trials. Rash was treated
separately. As composite reactions appeared to include conditions also reported by specialist preferred terms, these were
excluded from the analysis. Incidence rates are reported in Adverse events.
d OR calculated from study arm data from the CRYSTAL trial.43
e OR calculated from study arm data from the FIRE-3 trial.28
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Sensitivity analyses
Addition of FIRE-3 data from the manufacturer’s submission (15 June 2015, version 2; see also Appendix 5)
to the analysis of HRs for progression or death (Table 51), HRs for OS (Table 52) and ORs for ORR (Table 53)
had very little effect on the overall conclusions for the FOLFIRI network.
TABLE 50 Odds ratiosa (95% CrIs) for grade 3/4 diarrhoeab from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI 85 11 4
BEV + FOLFIRI 2.04 (0.82 to 5.20) 4 13 82
CET+ FOLFIRI 1.46 (0.77 to 2.82)c 0.72 (0.37 to 1.38)d 10 76 14
BEV, bevacizumab; CET, cetuximab.
a OR < 1 favours ‘intervention’ treatment.
b Reported in ≥ 5% of participants in either treatment arm.
c OR calculated from study arm data from the CRYSTAL trial.43
d OR calculated from study arm data from the FIRE-3 trial.28
TABLE 51 Hazard ratiosa (95% CrIs) for progression or death from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI < 1 < 1 100
BEV + FOLFIRI 0.58 (0.40 to 0.84) 39 61 < 1
CET+ FOLFIRI 0.56 (0.41 to 0.76)b 0.97 (0.78 to 1.20)c 61 39 < 1
BEV, bevacizumab; CET, cetuximab.
a HR < 1 favours ‘intervention’ treatment.
b Direct evidence from the CRYSTAL trial.43
c Direct evidence from the FIRE-3 trial.28
TABLE 52 Hazard ratiosa (95% CrIs) for OS from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI < 1 47 53
BEV + FOLFIRI 0.99 (0.69 to 1.40) < 1 53 47
CET+ FOLFIRI 0.69 (0.54 to 0.88)b 0.70 (0.54 to 0.90)c 100 < 1 < 1
BEV, bevacizumab; CET, cetuximab.
a HR < 1 favours ‘intervention’ treatment.
b Direct evidence from the CRYSTAL trial.43
c Direct evidence from the FIRE-3 trial.28
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Summary
Summary of the clinical effectiveness systematic review
l Of 2811 titles/abstracts screened, five RAS WT subgroup analyses from RCTs met the inclusion criteria
for the clinical effectiveness systematic review.
l Research has demonstrated a treatment interaction between RAS and EGFR inhibitors. Tumour samples
from trial populations were therefore re-evaluated for RAS status. In response to these research
developments, the EMA has recently amended the licence for cetuximab and panitumumab to restrict
use to people with RAS WT mCRC. Importantly, currently available data for the effectiveness of EGFR
inhibitors in people with RAS WT mCRC are from a subgroup of the ITT trial populations for both
cetuximab and panitumumab. Reported data were in line with the expected direction of effect across
all of the include studies. No RCTs with an ITT population by RAS status were identified in the
Assessment Group’s searches.
l The risk of bias was high but generally similar between studies with regard to randomisation, allocation
concealment, blinding, outcome reporting and loss to follow-up. The main limitation in terms of
interpretation and validity was that all of the included studies were subgroup analyses of ITT trial
populations. Allocation to subgroups was based on re-evaluating tumour samples from the KRAS WT
exon 2 population for RAS status. Although this minimised the potential for ascertainment bias, there
were missing data for some of the trials (either tumours were not evaluable for RAS status or the
results were inconclusive). No significant imbalances between the trial populations were observed,
minimising the potential for selection bias. Because of the retrospective nature of the RAS analysis, for
some studies a low number of samples was available for analysis, reducing the power of the studies to
show statistical significance. Despite these limitations, these are currently the only data available that
have evaluated the effectiveness of cetuximab and panitumumab in people with mCRC with RAS WT
tumour status in line with the recently revised licensed indication and the NICE final scope.
Cetuximab
l Two trials provided evidence for the effectiveness of cetuximab in combination with chemotherapy
(FOLFOX or FOLFIRI) compared with chemotherapy alone (FOLFOX or FOLFIRI).43,65 The evidence
consistently suggested a treatment effect in favour of the addition of cetuximab to chemotherapy
compared with chemotherapy alone.
¢ Median PFS ranged from 11.4 months in the CRYSTAL study to 12 months in the OPUS study for
the experimental arms, and from 5.8 months in the CRYSTAL study to 8.4 months in the OPUS
study for the control arms.
TABLE 53 Odds ratiosa (95% CrIs) for ORR from a fixed-effects NMA model: FOLFIRI network
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFIRI BEV+ FOLFIRI First Second Third
FOLFIRI 0 8 92
BEV + FOLFIRI 2.34 (1.29 to 4.22) < 1 91 8
CET+ FOLFIRI 3.11 (2.03 to 4.76)b 1.33 (0.89 to 2.00)c > 99 < 1 0
BEV, bevacizumab; CET, cetuximab.
a OR > 1 favours ‘intervention’ treatment.
b OR calculated from study arm data from the CRYSTAL trial.43
c OR calculated from study arm data from the FIRE-3 trial.28
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¢ Median OS ranged from 19.8 months in the CRYSTAL study to 20.4 months in the OPUS study for
the experimental arms, and from 17.8 months in the CRYSTAL study to 20.2 months in the OPUS
study for the control arms.
¢ Tumour response rates ranged from 58% in the OPUS study to 66% in the CRYSTAL study in the
experimental arms, and from 29% in the OPUS study to 60% in the CRYSTAL study in the
control arms.
¢ In people with liver metastases at baseline, the results in terms of improvement in OS and PFS were
consistent with the results for the overall RAS WT population. Of people with liver metastases at
baseline, 13.3% in the OPUS study and 16.3% in the CRYSTAL study had complete resection in
the experimental arms.
¢ Overall, clinical safety data for the RAS WT population were consistent with the results for the
KRAS WT population in both of the trials. The most common AEs were diarrhoea, haematotoxicity,
neutropenia and skin reactions.
l One trial provided evidence for the effectiveness of cetuximab in combination with chemotherapy
(FOLFIRI) compared with bevacizumab in combination with chemotherapy (FOLFIRI).28
¢ The proportion of people who achieved an objective response was similar between the cetuximab
plus FOLFIRI arm and the bevacizumab plus FOLFIRI arm. However, the association with longer OS
suggests a benefit for cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI (HR 0.70,
95% CI 0.53 to 0.92).
Panitumumab
l One trial provided evidence for the effectiveness of panitumumab in combination with chemotherapy
(FOLFOX4) compared with chemotherapy alone (FOLFOX4). No evidence was identified comparing
panitumumab plus FOLFIRI with FOLFIRI. The evidence consistently suggested a treatment effect in
favour of the addition of panitumumab to FOLFOX4 compared with FOLFOX4.
¢ Median PFS was 10.1 months in the experimental arm and 7.9 months in the control arm.
¢ Median OS was 25.8 months in the experimental arm and 20.2 months in the control arm.
¢ In people with liver metastases at baseline, the results in terms of improvement in OS and PFS were
consistent with the results for the overall RAS WT population.
¢ Overall, clinical safety data for the RAS WT population were consistent with results for the KRAS
WT population in all of the trials. The most common AEs were diarrhoea, haematotoxicity,
neutropenia and skin reactions.
l One trial provided evidence for the effectiveness of panitumumab in combination with chemotherapy
(mFOLFOX6) compared with bevacizumab in combination with chemotherapy (mFOLFOX6).
¢ The proportion of people who achieved an objective response was similar between the
panitumumab plus mFOLFOX6 arm and the bevacizumab plus mFOLFOX6 arm. For PFS, the
addition of panitumumab to mFOLFOX6 was associated with a 35% reduction in the risk of
progression compared with bevacizumab plus mFOLFOX6. In addition, a trend towards an OS
benefit with panitumumab plus mFOLFOX6 was observed (HR 0.63, 95% CI 0.39 to 1.02).
Summary of the network meta-analysis
l A NMA was also conducted based on the trials identified. It was not possible to construct a complete
network and so two discrete networks were generated, one evaluating FOLFOX-containing
chemotherapy regimens and the other comparing FOLFIRI-containing chemotherapy regimens.
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FOLFOX network
l Three RCTs contributed to the estimation of the effectiveness of four treatments (FOLFOX,
bevacizumab plus FOLFOX, panitumumab plus FOLFOX and cetuximab plus FOLFOX).
l There was no evidence to suggest that cetuximab plus FOLFOX was any more effective than FOLFOX,
bevacizumab plus FOLFOX or panitumumab plus FOLFOX in terms of increasing the time to death or
increasing the TTP or death.
l Direct evidence suggested that panitumumab plus FOLFOX was more effective at increasing the TTP or
death than FOLFOX and bevacizumab plus FOLFOX. Panitumumab plus FOLFOX was also estimated to
be more effective at increasing the time to death than FOLFOX.
l There was limited evidence to suggest that cetuximab plus FOLFOX was more effective at improving
the ORR than panitumumab plus FOLFOX.
l There was little evidence that cetuximab plus FOLFOX was associated with fewer AEs than
panitumumab plus FOLFOX; however, some of these analyses were limited by the small number of
events recorded in the treatment arms.
FOLFIRI network
l No evidence was identified comparing panitumumab plus FOLFIRI with FOLFIRI.
l Two RCTs contributed to the estimation of the effectiveness of three treatments (FOLFIRI, bevacizumab
plus FOLFIRI and cetuximab plus FOLFIRI).
l The evidence suggested that cetuximab plus FOLFIRI and bevacizumab plus FOLFIRI were more effective
than FOLFIRI at increasing the TTP or death and the ORR.
l Direct evidence suggested that cetuximab plus FOLFIRI was more effective than FOLFIRI and
bevacizumab plus FOLFIRI at increasing the time to death.
Summary results tables: clinical effectiveness
Summaries of the results (direct and indirect evidence) for cetuximab plus FOLFOX, cetuximab plus FOLFIRI
and panitumumab plus FOLFOX compared with the interventions of interest are provided for efficacy (PFS,
OS, ORR and complete resection rate) and safety outcomes in Tables 54 and 55, respectively. Note that for
grade 3 or 4 AEs by type (reported in ≥ 5% of participants in either treatment arm), only those analyses in
the NMA are included in the summary results tables. A more complete summary of grade 3 or 4 AEs by
type is provided in Adverse events.
Ongoing trials
Searches of ClinicalTrials.gov, the WHO ICTRP, the UKCRN and the ISRCTN registry were conducted (see
Appendix 1 for the search strategy used) in March 2015. Ten trials were considered as being relevant to
this review (see Appendix 6 for trial details) and were investigated further. Seven trials were identified as
ongoing (ongoing, n = 2; ongoing not recruiting, n = 2; active, not recruiting, n = 1; recruiting, n = 2).
Three trials were completed and included in this review (OPUS,65 CRYSTAL43 and PRIME44).
Manufacturers’ reviews of clinical effectiveness
Both manufacturers, Amgen (panitumumab; 30 April 2015) and Merck Serono (cetuximab; 15 June 2015,
version 2), submitted clinical evidence for consideration for this MTA.
Amgen
Amgen carried out literature searches for clinical evidence in MEDLINE, MEDLINE In-Process & Other
Non-Indexed Citations and EMBASE through Ovid and CENTRAL through The Cochrane Library (Amgen
submission, section 1.2, pp. 11–12). It also carried out a rapid appraisal search in The Cochrane Library to
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identify existing systematic reviews and protocols in the topic area. The search strategies combine free-text
and index terms for relevant cancers with free-text and index terms for relevant interventions (Amgen
submission, appendix 2, pp. 86–114). The Cochrane RCT publication filter was used to limit the search
results to RCTs. No language or date limits were applied.
Amgen also searched grey literature resources, including trials registries, online conference proceedings and
the websites of national guideline and regulatory agencies (Amgen submission, section 1.2, pp. 12–13).
The Amgen literature searches used an appropriate range of databases and grey literature resources for
the topic. The choice of free-text and index terms was also appropriate and the searches had an
appropriate balance of sensitivity and specificity. The search strategies were reproduced in appendix 2,
including the number of hits retrieved per search and the dates that the searches were carried out
(Amgen submission, appendix 2, pp. 86–114).
The submission set out to identify the evidence available from RCTs evaluating the efficacy and safety of
panitumumab and other therapies for the treatment of people with previously untreated mCRC. The
review identified two panitumumab trials (PRIME44 and PEAK29), of which one44 was considered to meet
the criteria set out in the decision problem specified in the final scope14 (Table 56). The PRIME trial44 was
also included in the PenTAG systematic review. In addition, the PenTAG review included the PEAK trial,29
which evaluated the efficacy of panitumumab in combination with mFOLFOX6 compared with
bevacizumab in combination with mFOLFOX6. This trial was excluded from the Amgen submission as
bevacizumab is no longer available through the CDF, but information from the trial was provided as
supporting evidence (Amgen submission, section 4.6, p. 44).
Health-related quality-of-life data from the PRIME trial69 [EuroQol 5-Dimensions (EQ-5D) health state index
and overall health rating] were included in the Amgen submission (section 4.4, p. 31). An analysis of
quality-adjusted survival in participants with RAS WT tumours using the quality-adjusted time without
symptoms of disease or toxicity (Q-TWiST) method was also completed (Amgen submission, section 4.4,
p. 31). No HRQoL data were identified for inclusion in the PenTAG review; however, two abstracts were
identified69,70 (listed in Appendix 3; not formally included as not enough information was provided to
conduct a quality appraisal). Amgen reported a summary of AEs, patient incidence of AEs of interest,
AEs occurring in ≥ 10% of participants in either treatment arm and AEs with a > 5% difference in
incidence between treatment arms (Amgen submission, section 4.7, pp. 49–51; appendix 6, tables 1
and 2). For AEs, the Assessment Group reported a summary of AEs and grade 3/4 AEs occurring in ≥ 5%
of participants in either treatment arm.
In section 4.6 of the Amgen submission (pp. 44–5), the company presented supporting evidence for
panitumumab in combination with FOLFIRI and noted the data used to obtain regulatory approval.
These are included for information in Table 57.
TABLE 56 Amgen’s submission: included panitumumab studies
Trial First author, year
Included in
PenTAG review
Reason for exclusion from PenTAG
review
PRIME
(PAN + FOLFOX4 vs.
FOLFOX4)
Douillard 201344 Yes NA
Reference also made in section 4.4
of the Amgen submission to
Siena et al.69 and Wang et al.70
No Identified and listed in Appendix 3. Both
available only in abstract format; not
enough information to quality appraise
NA, not applicable; PAN, panitumumab.
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Network meta-analysis
Amgen performed a NMA to compare panitumumab in combination with FOLFOX with other identified
comparators in the scope (Amgen submission, section 2.1, p. 51).
The company conducted a systematic review: the search strategy combined ‘drug names’ with ‘disease
terms’ and ‘study design terms’ (the search strategy was provided as an appendix). Inclusion criteria for the
NMA were in line with the PICO (population, intervention, comparator, outcome) criteria specified in the
NICE scope14 (Amgen submission, section 2.1, p. 51).
Evidence informing the NMA came from a total of 21 RCTs [reported in 22 publications28,29,33,34,44,78–94
and one unpublished article (Amgen Ltd. Data on File: Supplemental CSR 20050203 RAS/BRAF Analysis.
15 April 2013)]. Four trials84,87,88,92 were excluded from the primary analysis because of population
differences or differences in the treatment regimen administered. Based on the 17 RCTs, Amgen built one
network. Studies excluded from the company’s primary analysis were included in a sensitivity analysis.
The sensitivity analysis included clinically similar chemotherapy regimens [FOLFOX/XELOX and FOLFIRI/XELIRI
(capecitabine + irinotecan)] and relevant comparators (FOLFOX, XELOX, XELIRI and cetuximab plus FOLFOX/
FOLFIRI). There were too few data to perform a NMA comparing panitumumab plus FOLFOX or FOLFIRI
with the comparators of interest in the subgroup of people with liver metastases.
The study designs of the included studies were comparable; however, not all studies reported all outcomes
of interest (OS, PFS or ORR) and, hence, not all studies contributed to the analysis for each outcome (see
Amgen submission, appendix 8, pp. 27–35). In addition, disease progression and response rate were not
assessed using the same method in all of the included studies; however, it was assumed that this had no
impact on the comparative treatment effect on the PFS or ORR end points. Population characteristics were
assumed to be the same between the studies; however, the studies evaluating a non-EGFR inhibitor
included those with mixed or unknown RAS status.
The company used meta-analysis techniques (random effects with fixed effects examined in sensitivity
analysis) to pool direct comparisons using SAS version 9.2 software (SAS Institute Inc., Cary, NC, USA).
For indirect comparisons, the company used the method of Bucher et al.95 The indirect estimate of
panitumumab compared with the comparator was calculated using the results of the direct comparisons
with a common control. Both fixed- and random-effects meta-analyses were used. Each indirect
comparison was estimated separately within the indirect comparison framework. Within the indirect
TABLE 57 Amgen’s submission: supporting evidence referenced for panitumumab plus FOLFIRI
Trial First author, year
Included in
PenTAG review Reason for exclusion from PenTAG review
PLANET (PAN + FOLFIRI vs.
FOLFIRI)
Abad 201475 No Published as abstract only (see Appendix 3;
not enough information to conduct a quality
appraisal); reports data predominantly for the
KRAS WT population (response rate only is
reported for the RAS WT population)
Study 20060314
(PAN + FOLFIRI)
Data on file from
Amgen (CSR RAS
analysis), October 2014
No Not identified in searches as unpublished
information; study design single arm
Study 20050181
(PAN + FOLFIRI vs. FOLFIRI)
Peeters 201476 No Population previously treated; not first line
Study 20080763
(ASPECCT) (PAN vs. CET)
Price 201477 No Population previously treated; not first line;
not RAS WT. Intervention PAN or CET as
monotherapy
CET, cetuximab; CSR, clinical study report; PAN, panitumumab; PLANET, Safety and Efficacy Study of FOLFOX4+ Panitumumab
vs. FOLFIRI+ Panitumumab in Subjects with WT KRAS Colorectal Cancer and Liver-only Metastases.
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comparison, the underlying assumptions of homogeneity, similarity and consistency were reviewed
according to guidelines by Song et al.96 Details of the implementation of the meta-analysis and indirect
comparison were provided in the Amgen submission (appendix 8).
For the NMA, a Bayesian framework with Markov chain Monte Carlo simulation was used, using
methodology outlined by Ades et al.97 Analyses were performed using SAS version 9.3. Non-informative
priors were used. Analyses were run with an initial burn-in of 10,000 iterations followed by an additional
50,000 iterations. To address the potential for autocorrelation, it was necessary to thin the samples
generated through SAS (a thinning factor of 40 was used). The posterior mean/median and 95% CrI were
reported together with the probability that each treatment was better (more effective) than the others.
Within the indirect comparison, the underlying assumptions of homogeneity, similarity and consistency
were reviewed according to guidelines by Song et al.96 Convergence of the models was examined and
Amgen noted that, in some cases, the models for the treatment arm-level analyses did not converge to a
stationary distribution, showing a high level of autocorrelation between draws of the Markov chain, even
with thinning factors of ≥ 100 and a burn-in period of > 1,000,000 iterations attempted. The results for
these models were not shown; the company note that this was because of their unsuitability. Details of the
implementation of the mixed-treatment comparison are provided in the Amgen submission (appendix 8).
Point estimates for relative effectiveness (including 95% CrIs and the probability of each treatment being
the better treatment) were reported in full in the Amgen submission (appendix 8, pp. 41–2 and
pp. 87–97) and full results (including the results of the sensitivity analyses conducted) were reported
(appendix 8, pp. 87–97). Amgen’s NMA was not used to analyse liver resection rates or AEs.
The following limitations of the NMA were acknowledged: (1) data for non-EGFR inhibitors were from
populations with mixed or unspecified RAS status and (2) data for the RAS WT population were not from
the protocol-defined population for any of the EGFR inhibitor studies and the results were not for the ITT
population but a retrospective subgroup.
Comparison with the Assessment Group’s network-meta-analysis
Of the studies included in Amgen’s NMA [n = 21, reported in 22 publications28,29,33,34,44,78–94 and one
unpublished article (Amgen Ltd. Data on File: Supplemental CSR 20050203 RAS/BRAF Analysis.
15 April 2013)], 18 (including the unpublished article) were not included in the Assessment Group’s NMA.78–94
The reason for their exclusion was that they did not evaluate the effectiveness of the interventions in the RAS
WT population. In addition to the abstracts for the OPUS33 and CRYSTAL34 trials included in the Amgen NMA,
the Assessment Group identified the full publications.43,65
Evidence from the included studies enabled the company to construct a complete network. The study by
Badulescu et al.78 compared FOLFOX and FOLFIRI and enabled the complete network approach based on
the assumption that there was little difference between FOLFOX and FOLFIRI in terms of effectiveness.
The NMA conducted by the Assessment Group included two separate networks (FOLFOX and FOLFIRI) as
none of the included studies provided evidence to link the two networks for the RAS WT population.
Assumptions regarding the similarity between the included trials in terms of study design were considered
by the Assessment Group to be appropriate. However, in terms of population characteristics, although
data included in the NMA for panitumumab and cetuximab were restricted to the RAS WT population in
line with the population specified in the NICE scope,14 data for non-EGFR inhibitors were not available for
the RAS WT population, given that efficacy is not contingent on the expression of the RAS genotype.
Although the Assessment Group consider this to be a logical approach, it should be noted that data
included in the NMA for non-EGFR inhibitor treatments came from study populations with mixed or
unspecified RAS status, the likely impact of which would be to increase the uncertainty surrounding the
effect estimates.
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Analyses were conducted for the following outcomes: PFS, OS, ORR, CR and PR. Time-to-event data were
analysed using study-level data (HR) and response rate data were analysed using study-level data (relative
risk). The company noted that there were too few data to perform a NMA for panitumumab plus FOLFOX
compared with cetuximab plus FOLFOX or cetuximab plus FOLFIRI in the subgroup of people with liver
metastases.
The methods used in Amgen’s NMA were in line with guidance set out in the publication by Ades et al.97
Despite the broader approach taken, the results for panitumumab plus FOLFOX compared with FOLFOX
were similar to those of the Assessment Group’s NMA for OS and PFS. The effect estimates for this
comparison for all outcomes showed a greater effect of panitumumab plus FOLFOX than FOLFOX, but
the 95% CrIs were wider in the Assessment Group’s results. There was no evidence to suggest that
panitumumab plus FOLFOX was any more or less effective than cetuximab plus FOLFOX in terms of TTP
or death or time to death. All of the results, however, are subject to uncertainty as a result of the
acknowledged limitations. As the Assessment Group’s NMA focused entirely on the RAS WT population,
no comparison could be made with Amgen’s analysis of panitumumab plus FOLFOX compared with
XELOX. Also, given that the Assessment Group’s approach to the NMA resulted in two networks, the
results could not be compared with Amgen’s NMA for panitumumab plus FOLFOX compared with either
FOLFIRI or cetuximab plus FOLFIRI.
Merck Serono
Merck Serono also carried out literature searches for clinical evidence in MEDLINE, MEDLINE In-Process &
Other Non-Indexed Citations and EMBASE through Ovid, and CENTRAL through The Cochrane Library
(Merck Serono submission, section 3.1.2.1, p. 11). As per the Amgen review, the searches combined
free-text and index terms for relevant cancers with free-text and index terms for relevant interventions;
however, unlike the Amgen review, the cancer search terms were combined with RAS search terms to
further refine the results (Merck Serono submission, appendix A, pp. 44–9). A publication filter was used
to limit the results to RCTs and observational studies. No language or date limits were applied.
Merck Serono also searched grey literature resources, including an online trials registry (ClinicalTrials.gov)
and several online conference proceedings (Merck Serono submission, section 3.1.2.1, p. 12).
The Merck Serono literature searches used an appropriate range of bibliographic databases and grey
literature resources for the topic, albeit fewer grey literature resources were searched than in the Amgen
review. The choice of free-text and index terms was also appropriate and there was no evidence that the
balance of sensitivity and specificity was compromised by the inclusion of RAS search terms. The database
search strategies are reproduced in appendix A, including the number of hits retrieved per search
(Merck Serono submission, appendix A, pp. 44–9). The dates that the searches were carried out are
reported elsewhere in the submission (Merck Serono submission, section 3.1.2.1, p. 11). The grey literature
search strategies are not reproduced in the appendices, but the numbers of articles retrieved are reported
in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagrams (Merck Serono
submission, section 4.1, pp. 22–5).
The submission set out to identify the relevant efficacy and safety evidence for the interventions of interest in
first-line treatment of people with RASWT mCRC. Seven studies were identified that evaluated cetuximab.
Of these, four were included in the systematic review presented by Merck Serono (Table 58). Three of the
studies were included in the PenTAG systematic review; however, only the studies reporting results for the
RASWT population were considered relevant to the scope for this review and, as such, the other related
publications were excluded on population. The CALGB-80405 study101 was not identified in the PenTAG
searches. This was because we did not search the European Society of Medical Oncology (ESMO) conference
database, instead checking the American Society of Clinical Oncology database, in line with published
recommendations on searching for health technology assessment (HTA) reviews.102 This study would have
been excluded from our review because, although the CALGB-80405 trial randomised participants to
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cetuximab or bevacizumab, participants were not randomised to the background chemotherapy (FOLFOX or
FOLFIRI), which could introduce bias into the analysis. In addition, the data are published only in abstract
form and not in a full paper and, as such, not enough information is provided to conduct a quality appraisal.
Health-related quality-of-life data from the OPUS trial [European Organisation for Research and Treatment
of Cancer (EORTC) QLQ-C30 global health status; unpublished data] and the CALGB-80405 trial101 (EORTC
QLQ-C30 and Dermatology-Specific Quality of Life Questionnaire) were also included in the Merck Serono
submission (section 2.1.3.3, pp. 34–5). No HRQoL data were identified for inclusion in the Assessment
Group’s review. Merck Serono reported a summary of AEs, grade 3/4 AEs by special AE category and a
comparison of the frequency of grade 3/4 AEs (number of subjects) known for cetuximab (section 2.1.4,
pp. 36–40). For AEs, the Assessment Group reported a summary of AEs and grade 3/4 AEs occurring in
≥ 5% participants in either treatment arm.
Data reported for the FIRE-3 trial in the Merck Serono submission are different from those in the analysis
conducted by the Assessment Group (values as reported by Heinemann et al.28). It is possible that the data
reported in the Merck Serono submission are from a more recent data cut-off point, as the number of
participants evaluated as RAS WT in the Merck Serono submission was 199 in the cetuximab plus FOLFIRI
treatment group and 201 in the bevacizumab plus FOLFIRI treatment group; this compares with 171
participants in each treatment group in the published paper.28 These unpublished data were subjected to
sensitivity analysis in the NMA (Merck Serono submission, p. 118). Although the results change slightly, this
difference does not impact on the direction of effect.
Network meta-analysis
Merck Serono performed a NMA to compare cetuximab plus chemotherapy (FOLFOX or FOLFIRI) for the
treatment of RAS WT mCRC with other comparators specified in the NICE scope14 (Merck Serono
submission, section 2, p. 51).
The company conducted a systematic review, with the search strategy combining ‘drug names’ with
‘disease terms’ and ‘study design terms’ (the search strategy was provided as an appendix). Inclusion criteria
for the NMA were in line with the PICO criteria specified in the NICE scope14 (see section 2.1, p. 51).
TABLE 58 Merck Serono’s submission: included cetuximab studies
Trial acronym First author, year
Included in
PenTAG’s review Reason for exclusion from PenTAG’s review
CRYSTAL
(CET + FOLFIRI vs.
FOLFIRI)
Van Cutsem 200924
(primary study reference);
Van Cutsem 2011;25
Ciardiello 2014;34 Van
Cutsem 201543
Yes (only data for
the RAS WT
population43)
Van Cutsem 2009:24 no data for the RAS WT
population; Van Cutsem 2011:25 no data for
the RAS WT population; Ciardiello 2014:34
abstract
OPUS
(CET + FOLFOX4 vs.
FOLFOX4)
Bokemeyer 200923
(primary study reference);
Tejpar 201498
Yes (only data for
the RAS WT
population65)
Bokemeyer 2009:23 no data for the RAS WT
population
FIRE-3
(CET +mFOLFOX6 vs.
BEV +mFOLFOX6)
Heinemann 201399
(primary study reference);
Stintzing 2014;100
Heinemann 201428
Yes (only data for
the RAS WT
population28)
Heinemann 2013:99 abstract of Heinemann
2014;28 Stintzing 2014:100 no data for the RAS
WT population, abstract
CALGB-80405
(CET + CTXa vs.
BEV + CTXa)
Lenz 2014101 No Study not identified in searches (not indexed in
EMBASE or MEDLINE). Participants were
randomised only to CET or BEV and not to the
background CTX. Study published in abstract
format (presented at ESMO 2014) and not
enough information provided to quality
appraise
BEV, bevacizumab; CET, cetuximab; CTX, chemotherapy.
a Chemotherapy was either FOLFOX or FOLFIRI, at the physician’s discretion; randomisation was to cetuximab or bevacizumab.
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Six trials were included in the NMA.28,29,43,44,101 Evidence from these trials enabled one complete
network to be established for the outcomes of OS and PFS. This was possible as the CALGB-80405 trial
compared cetuximab plus FOLFOX or FOLFIRI with bevacizumab plus FOLFOX or FOLFIRI, reporting
separate Kaplan–Meier curves for each of the possible combination therapies.101 Within the global network,
a sensitivity analysis was also conducted with FOLFOX and FOLFIRI grouped as generic chemotherapy. The
complete network approach was not possible for ORR as neither the PEAK trial29 nor the CALGB-80405
trial101 reported ORR and, as a result, only a FOLFIRI network was possible for this outcome. It was also not
possible to include the CALGB-80405 trial101 in any safety outcome network because of lack of reporting.
Therefore, two separate networks, one for FOLFOX and one for FOLFIRI, were created to allow an indirect
treatment comparison for safety outcomes.
The study designs of the included studies were comparable. Although Merck Serono noted that disease
progression was not assessed using the same method in all of the included studies, it was assumed that
this had no impact on the comparative treatment effect for the PFS end point. For the safety outcomes,
in the absence of reported data for the RAS WT population in the PRIME trial,44 Merck Serono used data
reported for the KRAS WT population. Although the company pre specified safety outcomes of interest,
not all could be analysed because of limited reporting in several trials.
Population characteristics were assumed to be the same, although for some trials the baseline
characteristics for the RAS WT population were not reported44 or very little published information was
available101 and data from the KRAS WT population were used as a proxy. Merck Serono highlighted
differences with respect to disease progression (ECOG performance status ≤ 2 in four of the trials28,43,44 vs.
0 or 1 in two of the trials29,101). However, the proportion of participants with an ECOG performance status
of 2 in the OPUS and PRIME44 studies was low and, as such, was not considered to have an impact on the
comparative treatment effect. It was assumed that both FOLFOX regimens (FOLFOX4 and mFOLFOX6) have
a comparable effect.
Network meta-analyses were undertaken using a Bayesian approach with Markov chain Monte Carlo
simulation in WinBUGS. Non-informative prior distributions were used. For the analysis of PFS, OS and ORR,
models with a normal likelihood and identify link were used. In addition, survival data extracted from the
Kaplan–Meier curves were also analysed using a binomial or log-likelihood and log-link using a fractional
polynomial model. Analysis of AEs used a model with a binomial likelihood and logit link. Analyses were run
with an initial burn-in of 10,000 iterations (30,000 for the fractional polynomial models), followed by an
additional 80,000 iterations (30,000 for fractional polynomials) and convergence of the samples was
examined visually. Monte Carlo error was checked to ensure that it was ≤ 5% of the posterior standard
deviation (SD) for the parameters examined. Both fixed- and random-effects models were used. The
deviance information criterion was used to compare the fixed- and random-effects models to determine
goodness of fit (deviance information criterion values were reported for both models); when a difference of
< 5 was observed, a fixed-effects model was reported and the results of the random-effects model were
reported in appendix B (Merck Serono submission). The posterior mean/median and 95% CrI were reported
together with the probability that each treatment was better (more effective) than the others.
Point estimates for relative effectiveness (including the 95% CrI and the probability of each treatment being
the better treatment) were reported in full in the Merck Serono submission (pp. 51–82). Table 59 summarises
the results for OS, PFS and ORR for cetuximab plus FOLFOX and cetuximab plus FOLFIRI compared with
relevant comparators. In terms of AEs (not shown here), cetuximab plus FOLFIRI was associated with more
events than FOLFIRI alone for grade 3–4 venous thromboembolism, skin reactions, acne-like rash, mucositis,
neutropenia, hypokalaemia, hypomagnesaemia and paronychia. Compared with bevacizumab plus FOLFIRI,
cetuximab plus FOLFIRI was worse for skin reactions, acne-like rash, hypokalaemia, hypomagnesaemia and
paronychia. However, cetuximab plus FOLFIRI was better than bevacizumab plus FOLFIRI for nausea (all grades)
and vomiting (all grades). For the FOLFOX network, cetuximab plus FOLFOX was worse than FOLFOX alone for
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grade 3–4 pulmonary embolism and skin reactions. Compared with panitumumab plus FOLFOX, cetuximab
plus FOLFOX was worse for grade 3–4 skin reactions.
The following limitations of the NMA were noted: (1) because of the retrospective nature of the RAS
analysis, for some studies there was a low number of samples available for analysis, reducing the power
of the studies to show statistical significance and (2) limited data were available on safety for the
CALGB-80405 trial,101 resulting in many of the indirect comparison analyses having very wide CIs and
making interpretation of the indirect comparison difficult.
Comparison with the Assessment Group’s network meta-analysis
Of the studies included in the NMA, only the CALGB-80405 trial101 was not included in the NMA
conducted by the Assessment Group. The CALGB-80405 trial compared cetuximab plus FOLFOX or FOLFIRI
with bevacizumab plus FOLFOX or FOLFIRI; however, participants were randomised only to the cetuximab
or bevacizumab component of the treatment, with the background chemotherapy (FOLFOX or FOLFIRI)
chosen at the discretion of physicians. In addition, data from the CALGB-80405 trial are currently available
only in abstract form. For these reasons this study was excluded from the Assessment Group’s systematic
review and NMA. No trials were identified analysing the effectiveness of panitumumab plus FOLFIRI
compared with any of the comparators specified in the NICE scope.14
TABLE 59 Relative effectiveness results for cetuximab plus FOLFIRI and cetuximab plus FOLFOX compared with
relevant comparators:a Merck Serono’s NMA
Comparison
OS,b HR [95% CrI;
Probability(better)]
PFS,b HR [95% CrI;
Probability(better)]
ORR, OR [95% CrI;
Probability(better)]
CET + FOLFIRI vs.
FOLFIRI 0.69 (0.54 to 0.88; > 99%) 0.56 (0.41 to 0.76; > 99%) 3.14 (2.07 to 4.85; > 99%)
BEV + FOLFIRI 0.80 (0.64 to 1.01; 97%) 0.98 (0.81 to 1.19; 58%) 1.29 (0.83 to 2.00; 87%)
FOLFOX 0.96 (0.61 to 1.52; 56%) 0.95 (0.61 to 1.47; 60%) NAc
CET+ FOLFOX 0.98 (0.73 to 1.31; 56%) 1.04 (0.81 to 1.35; 37%) NAc
PAN+ FOLFOX 1.26 (0.80 to 1.99; 16%) 1.39 (0.92 to 2.11; 6%) NAc
BEV + FOLFOX 0.83 (0.60 to 1.13; 88%) 1.08 (0.85 to 1.39; 26%) NAc
CET + FOLFOX vs.
FOLFOX 0.99 (0.67 to 1.45; 53%) 0.91 (0.61 to 1.36; 68%) NAc
PAN+ FOLFOX 1.29 (0.87 to 1.91; 10%) 1.33 (0.91 to 1.95; 7%) NAc
BEV + FOLFOX 0.85 (0.64 to 1.12; 88%) 1.04 (0.84 to 1.259; 37%) NAc
FOLFIRI 0.71 (0.48 to 1.04; 96%) 0.54 (0.36 to 0.80; > 99%) NAc
BEV + FOLFIRI 0.82 (0.61 to 1.11; 90%) 0.94 (0.72 to 1.22; 68%) NAc
CET + chemotherapyd vs.
Chemotherapyd 0.76 (0.62 to 0.94; > 99%) 0.67 (0.53 to 0.85; > 99%) –
PAN+ chemotherapyd 1.02 (0.79 to 1.32; 43%) 1.05 (0.80 to 1.37; 38%) –
BEV + chemotherapyd 0.79 (0.67 to 0.94; > 99%) 0.98 (0.85 to 1.13; 61%) –
BEV, bevacizumab; CET, cetuximab; NA, not applicable; PAN, panitumumab.
a Based on results from fixed-effects meta-analysis.
b HR (mean survival also analysed).
c The complete network approach was not possible for ORR as neither the PEAK trial29 nor the CALGB-80405 trial101
reported this outcome and, as a result, only a FOLFIRI network was possible.
d Chemotherapy = pooled FOLFOX and FOLFIRI, conducted as a sensitivity analysis for the complete network for the
outcomes of OS and PFS only.
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Using the CALGB-80405 trial101 enabled Merck Serono to construct a complete network for the outcomes
of PFS and OS. The company conducted two analyses. One analysis used data from participants in the trial
according to chemotherapy received; however, in this approach randomisation is broken and this could
introduce bias into the analysis. The second analysis was a sensitivity analysis in which the results for
FOLFOX and FOLFIRI were pooled as generic chemotherapy, based on the assumption that there was little
difference between FOLFOX and FOLFIRI in terms of effectiveness, as reported in the study by Colucci
et al.103 The analysis of ORR and safety outcomes required two separate networks (one for FOLFOX and
one for FOLFIRI). The Assessment Group’s NMA used two separate networks (FOLFOX and FOLFIRI) for the
analysis of all outcomes in the RAS WT population, as none of the included studies provided evidence to
link the two networks.
Assumptions regarding the similarity of the trials in terms of study and population characteristics were
considered by the Assessment Group to be appropriate.
The absence of reported data for the PRIME44 and PEAK29 trials meant that analysis of ORR and analysis of
all-grade AEs could not be conducted for the FOLFOX network. The Assessment Group, however, had
access to unpublished data from the PRIME and PEAK trials and was able to analyse safety outcomes for
any grade 3/4 AEs and serious AEs as well as grade 3–4 AEs by type, occurring in ≥ 5% participants in
either treatment arm. The Assessment Group also conducted NMA for the outcome of resection rates and
also for the subgroup of patients with liver metastases at baseline.
The methods used in Merck Serono’s NMA were in line with guidance from the NICE Decision
Support Unit.66
Despite the slight differences in approach between the Merck Serono NMA and the Assessment Group’s
NMA, the overall results were similar, with both analyses subject to significant uncertainty.
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Chapter 4 Assessment of cost-effectiveness
The cost-effectiveness of cetuximab and panitumumab for people with previously untreated RAS WTmCRC was assessed by conducting a systematic review of published research evidence.
Objectives
The objectives of this systematic review were to:
l gain insights into the key drivers of cost-effectiveness in this disease area
l obtain an overview of the alternative modelling approaches that have been adopted in this disease and
treatment area
l provide a summary of the findings of previous relevant cost–utility, cost-effectiveness and cost–benefit
studies generalisable to the UK.
Methods
Study identification
The search strategy for the economic review included the following search methods:
l searching of bibliographic and ongoing trials databases
l searching of conference proceedings
l scrutiny of the bibliographies of retrieved papers and company submissions.
The following databases were searched for economic studies: MEDLINE (Ovid), MEDLINE In-Process &
Other Non-Indexed Citations (Ovid), EMBASE (Ovid), NHS Economic Evaluation Database (NHS EED)
(via The Cochrane Library), EconLit (EBSCOhost) and Web of Science (Thomson Reuters).
A supplementary search for health utilities was run in the following databases: MEDLINE (Ovid), MEDLINE
In-Process & Other Non-Indexed Citations (Ovid), EMBASE (Ovid), PsycINFO (Ovid), Web of Science
(Thomson Reuters) and School of Health and Related Research Health Utilities Database.
The searches were developed and run by an information specialist (SB) in January 2015. Search filters were
used to limit the searches to economic or health utility studies as appropriate, and searches were limited to
English-language studies when possible. No date limits were used. An updated search was carried out on
27 April 2015. No papers or abstracts published after this date were included in the review. Ongoing
trials databases were searched by a reviewer in March 2015. The search strategies for each database are
detailed in Appendix 1.
The database search results were exported to and deduplicated using EndNote X7. Deduplication was also
performed using manual checking. After the reviewer had completed the screening process, the bibliographies
of included papers were scrutinised for further potentially relevant studies. The manufacturers’ submissions
were assessed for unpublished data.
Titles and abstracts returned by the search strategy were examined by one researcher (NH) and screened
for possible inclusion. Full texts of potentially relevant studies were ordered. Full publications were assessed
by the same reviewer (NH) for inclusion or exclusion against prespecified criteria.
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Eligibility criteria
Inclusion and exclusion criteria were identical to those in the clinical effectiveness systematic review
(see Chapter 3, Eligibility criteria), with the following exceptions (as specified in the appraisal protocol):
l non-randomised studies were included (e.g. decision model-based analyses or analyses of patient-level
cost and effectiveness data alongside observational studies)
l full cost-effectiveness analyses, cost–utility analyses, cost–benefit analyses and cost–consequence
analyses were included (economic evaluations that reported only average cost-effectiveness ratios were
included only if the incremental ratios could be easily calculated from the published data)
l studies that measured costs but not health benefits were excluded, except for stand-alone cost analyses
from the perspective of the UK NHS.
Data extraction
Study characteristics and results were abstracted by one reviewer (NH). In addition, parameters that could
be used in the construction of an independent economic model were identified and noted.
The evidence base was assessed using narrative synthesis supported by summary data extraction tables.
Critical appraisal
Selected studies were quality assessed by one reviewer (NH) using the checklist developed by Evers et al.104
Studies were marked as ‘no’ when they did not meet a criterion or when there was insufficient evidence to
assess the criterion.
Studies based on decision models were further quality assessed using the checklist developed by Philips et al.105
Results
Figure 7 shows the study flow diagram for this update review. The electronic database search for
cost-effectiveness evidence identified 1979 records after deduplication. After screening by title and
abstract, 1955 studies were excluded and 24 studies were identified for full-text screening; five of these
were conference abstracts and one full-text article could not be retrieved.106 In total, therefore, 19 full texts
were retrieved and assessed for eligibility. Of the five conference abstracts, one was a duplicate and one
was a duplicate of a full paper.
Of the 19 full texts assessed for eligibility, one was deemed to meet the eligibility criteria.107 This study and
the two abstracts for which posters were available108,109 were assessed in full. The poster for the remaining
abstract could not be identified.110 This study could therefore not be assessed in full, but the summary
information is presented here.
Characteristics of identified cost-effectiveness studies
Details of the included studies are provided in Tables 60 and 61. Theses tables show that none of the
included studies compared both cetuximab and panitumumab. The comparator arms were either
bevacizumab in combination chemotherapy agents or chemotherapy alone. The range of chemotherapies
differed across studies. One study108 was based in the UK but used a perspective of the Scottish NHS.
This study considered only cetuximab in combination with chemotherapy (FOLFOX and FOLFIRI).
All studies used Markov or semi-Markov models and included resection and subsequent lines of treatment
as health states, although the overall number of health states varied.
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Jarrett et al.108 reported the smallest estimate of life-years gained, which may be a consequence of the
shorter time horizon of 10 years used in the model, compared with 20 years in the study by Graham et al.107
and non-specified ‘lifetimes’ in the other studies.
The following sections report the methods and results for the four included studies. As bevacizumab is no
longer available through the CDF, the focus is on those studies that report other comparator treatments.
Jarrett et al.108
In this study the authors based the model population on the RAS WT subset of patients who were
retrospectively identified in the CRYSTAL and OPUS trials of cetuximab in combination with FOLFOX4
(or FOLFIRI) compared with FOLFOX4 (or FOLFIRI) alone. Further details of these studies can be found in
Chapter 3. The authors used a Markov cohort model with five states to conduct a cost–utility analysis of
cetuximab plus FOLFOX4 compared with FOLFOX4 alone and cetuximab plus FOLFIRI compared with
FOLFIRI alone, from the Scottish NHS perspective.
The model included states such as first line (progression free), second- and third-line progressed disease
states, post-curative resection and death. PFS was based on parametric survival curves estimated using
the CRYSTAL trial data, using Weibull distributions. Resection transition probabilities were based on the
Records identified through
database searching, after
deduplication
(n = 1979)
Records screened
(n = 1979)
Eligible publications
(n = 4)
Full-text articles assessed
for eligibility
(n = 24)
Identification
Screening
Eligibility
Records excluded
(n = 1925)
Full-text articles not retrieved
(n = 1)
Full-text articles excluded
with reasons
(n = 19)
• Population, n = 15
• Intervention, n = 0
• Comparator, n = 0
• Outcomes, n = 1
• Study design, n = 1
• No usable data, n = 0
• Language, n = 0
• Duplicate, n = 2
• Other, n = 0
FIGURE 7 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram for
cost-effectiveness studies.
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TABLE 60 Characteristics of the included cost-effectiveness studies
First author,
year
Setting,
perspective Population Study purpose Study approach Comparators
Graham 2014107 French health
collective
perspective
Adults aged
≥ 18 years with
RAS WT mCRC
Cost-effectiveness of
first-line PAN + FOLFOX
compared with
BEV + FOLFOX
Semi-Markov decision
model; lifetime
horizon (≤ 20 years),
2-week cycle length
PAN + FOLFOX;
BEV + FOLFOX
Jarrett 2014108 Scottish NHS RAS WT mCRC
patients
Cost-effectiveness of
first-line CET in
combination with
chemotherapy vs.
currently available
treatments
Markov cohort
decision model;
lifetime horizon
(10 years), 1-month
cycles
CET + FOLFOX/
FOLFIRI; FOLFOX/
FOLFIRI alone
Kourlaba 2014110 Greek health-care
perspective
RAS WT mCRC
patients
Cost-effectiveness of
first-line PAN + FOLFOX
vs. BEV + FOLFOX
Semi-Markov decision
model
PAN + FOLFOX;
BEV + FOLFOX
Ortendahl 2014109 US payer US adults with
previously
untreated RAS
WT mCRC
Cost-effectiveness of
first-line CET + FOLFIRI
vs. BEV + FOLFIRI
Markov cohort
decision model;
lifetime horizon
CET+FOLFIRI;
BEV+FOLFIRI
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
TABLE 61 Results of the included cost-effectiveness studies
First author,
year
Outcomes
measured
Discount
rate Base-case results
Sensitivity
analysis
approach
Main sensitivity
analysis results
Graham 2014107 Costs, LYs, QALYs;
ICERs: €/LYG,
€/QALY gained
4.0%
costs and
benefits
PAN+ FOLFOX: 3.58
LYs, 2.68 QALYs,
€97,203; BEV + FOLFOX:
2.73 LYs, 2.05 QALYs,
€74,440
ICERs vs. BEV + FOLFOX:
€26,918/LYG,
€36,577/QALY gained
Scenario analysis,
one-way sensitivity
analysis and PSA
Most notable scenario:
all patients receive best
supportive care after
first-line treatment (ICER
€50,390/QALY gained).
One-way sensitivity
analysis: model most
sensitive to drug
acquisition costs, best
supportive care costs
and costs of subsequent
treatments. PSA:
PAN + FOLFOX most
likely to be cost-effective
at WTP threshold of
€40,000
Jarrett 2014108 Costs, LYs, QALYs;
ICERs: £/LYG,
£/QALY gained
NR CET+ FOLFIRI: 1.79 LYs,
1.30 QALYs, £41,015;
FOLFIRI: 1.45 LYs, 1.05
QALYs, £28,301
Scenario analysis,
one-way sensitivity
analysis
Scenario analysis: no vial
sharing increased ICERs
to £58,220 (FOLFIRI) and
£56,520 (FOLFOX) per
QALY gained. One-way
sensitivity analysis:
model sensitive to
treatment duration,
body surface area,
progression HR and
proportion referred for
curative resection
ICERs vs. FOLFIRI:
£39,631/LYG,
£52,802/QALY gained
CET+ FOLFOX: 1.81
LYs, 1.32 QALYs,
£39,612; FOLFOX: 1.50
LYs, 1.08 QALYs,
£27,685
ICERs vs. FOLFOX:
£38,936/LYG,
£50,894/QALY gained
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CRYSTAL trial and death post resection was based on trial OS data. Transition probabilities for subsequent
treatment were based on a study by Tournigand et al.111 Transition to death following third-line therapy
was based on a study by Jonker et al.112
Unit cost data were based on Scottish sources or UK national sources when Scottish-specific sources were
not available. Resource use for post resection was taken from Adam et al.113 and validated by a clinical
expert in Scotland. The full reference for the study by Adam et al.113 was not reported is not reported.
Other resource use was based on a systematic literature review.
Utilities were based on a systematic literature review. The sources were identified through the Scottish
Medicines Consortium (SMC) report114 of this study as Bennett et al.,115 Wang et al.116 (both also identified
by our review) and Petrou and Hockley117 [not included in our review as this was a validation study of the
EQ-5D and Short Form questionnaire-6 Dimensions (SF-6D) for the general population].
In this study, cetuximab plus FOLFOX4 resulted in 1.81 life-years [1.32 quality-adjusted life-years (QALYs)],
whereas FOLFOX alone resulted in 1.50 life-years (1.08 QALYs). Similarly, cetuximab plus FOLFIRI resulted
in 1.79 life-years (1.30 QALYs), whereas FOLFIRI alone resulted in 1.45 life-years (1.05 QALYs). Cetuximab
in combination with chemotherapy was approximately £12,000 more expensive than chemotherapy alone.
This led to an incremental cost-effectiveness ratio (ICER) of > £50,000 per QALY gained for cetuximab plus
chemotherapy compared with chemotherapy alone.
A scenario analysis in which full vial wastage was assumed, which may be closer to the situation in general
practice, increased the ICER by > £5000. Sensitivity analyses showed that the model was sensitive to the
cost and effect of treatment with cetuximab; duration of treatment, body surface area, progression HR and
the proportion of the cohort referred for curative resection had large impacts on the ICER.
The poster claims that this analysis shows that cetuximab plus chemotherapy is a cost-effective treatment,
especially in light of meeting the SMC’s end-of-life criteria. According to the SMC report,114 cetuximab
was accepted for this patient population, but only after a Patient Access Scheme (PAS) was applied to
demonstrate cost-effectiveness. A further analysis of cetuximab plus FOLFOX4 compared with CAPOX
(XELOX) was requested by the SMC, assuming that XELOX and FOLFOX had similar efficacy, which resulted
in an ICER of > £70,000 per QALY gained (without the PAS).118
TABLE 61 Results of the included cost-effectiveness studies (continued )
First author,
year
Outcomes
measured
Discount
rate Base-case results
Sensitivity
analysis
approach
Main sensitivity
analysis results
Kourlaba 2014110 Costs, LYs, QALYs;
ICERs: €/QALY
gained
NR PAN+ FOLFOX vs.
BEV + FOLFOX:
incremental LYs 0.87,
QALYs 0.65, costs
€22,464
PSA PSA: PAN+ FOLFOX
81.5% likely to be
cost-effective at WTP
threshold of €51,000
per QALY gained
ICER vs. BEV + FOLFOX:
€34,644/QALY gained
Ortendahl 2014109 Costs, LYs, QALYs;
ICERs: $/LYG,
$/QALY gained
NR CET+ FOLFIRI: 4.04 LYs,
3.11 QALYs, $305,727;
BEV + FOLFIRI: 3.17 LYs,
2.43 QALYs, $238,255
NR for RAS WT
subgroup
NR for RAS WT
subgroup
ICERs vs. BEV + FOLFIRI:
$77,380/LYG, $99,636/
QALY gained
BEV, bevacizumab; CET, cetuximab; ICER, incremental cost-effectiveness ratio; LY, life-year; LYG, life-year gained; NR, not
reported; PAN, panitumumab; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life-year; WTP, willingness to pay.
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This study is the most relevant to our review as it is UK based and compares the intervention with
chemotherapy agents available on the NHS. It does not include bevacizumab as a comparator but, with
bevacizumab no longer available through the CDF for this indication, this analysis may still be relevant.
However, it does not assess panitumumab in a similar context and therefore does not address the entire
scope of our review.
Graham et al.107
In this study the authors based their model population on the RAS WT subset of patients who were
retrospectively identified in the PEAK trial.29 In summary, these were patients aged at least 18 years who
were diagnosed with previously untreated RAS WT mCRC. Further details of the PEAK population can be
found in the clinical effectiveness review (see Chapter 3). The authors used a semi-Markov model with
seven states to conduct a cost–utility analysis of panitumumab plus mFOLFOX6 compared with
bevacizumab plus mFOLFOX6, from the perspective of the French health collective.
The model included states such as progression-free and progressive disease with subsequent therapy or
best supportive care (BSC), as well as separate disease states for attempted resection and post resection.
PFS and OS were based on parametric survival curves estimated using the PEAK trial patient-level data,
using Weibull distributions. These were converted to transition probabilities for disease progression and
death. Resection transition probabilities were based on the PEAK trial and a study by Adam et al.113
Transition probabilities for subsequent treatment were also based on the PEAK trial.
Drug acquisition costs were estimated using French Health National Insurance unit costs, and dose intensity
and frequency were calculated from PEAK trial data. Other costs, including the costs of AEs, RAS mutation
testing, drug administration, chemotherapy, physician visits, diagnostic tests, resection, subsequent
treatment and BSC, were taken from the literature and French health-care cost sources. Costs were
reported in 2013 euros.
Utilities were based on the EQ-5D responses from the RAS WT patients in the PRIME trial. For subsequent
lines of treatment, utilities for the RAS WT population were assumed to be similar to those for the KRAS
WT population. Therefore, EQ-5D responses from trials of KRAS WT mCRC patients on subsequent lines of
treatment were used to estimate utilities for subsequent lines of treatment. The EQ-5D responses were
converted to utilities using the Dolan algorithm,119 which were valued using UK responses.
Costs and benefits were discounted at 4% per annum, the suggested discount rate in France.
In this study panitumumab plus mFOLFOX6 resulted in 3.58 life-years (2.68 QALYs), whereas bevacizumab
plus mFOLFOX6 resulted in 2.73 life-years (2.05 QALYs). Costs were also higher for panitumumab plus
mFOLFOX6 at €97,203, compared with €74,440 for bevacizumab plus mFOLFOX6. This was because of the
higher drug costs associated with panitumumab. This resulted in an ICER of €36,577 per QALY gained for
panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6.
The authors conducted multiple scenario analyses, univariate sensitivity analyses and a probabilistic
sensitivity analysis. The most notable scenario analysis, in which no active subsequent treatments were
assumed (all patients received BSC), raised the ICER to > €50,000 per QALY gained. The probabilistic
sensitivity analysis showed that panitumumab plus mFOLFOX6 was more likely to be cost-effective than
bevacizumab plus mFOLFOX6 at a willingness-to-pay threshold of €40,000.
Kourlaba et al.110
The results of this study were available only as a conference abstract. In this study the authors based their
model population on the RAS WT subset of patients who were retrospectively identified in the PEAK trial29
and used a previously existing model consisting of seven health states. The authors used this Markov
model to conduct a cost–utility analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus
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mFOLFOX6, from the perspective of the Greek health-care setting. Given the description, we believe this
model to be the same as that reported in Graham et al.107
Panitumumab plus mFOLFOX6 led to an increase in QALYs of 0.65 compared with bevacizumab plus
mFOLFOX6, and a cost increase of €22,464. This gave an ICER of €34,644 per QALY gained compared
with bevacizumab plus mFOLFOX6.
Ortendahl et al.109
This study was published as a poster in 2014. In this study the authors based their model population on the
KRAS WT subset of patients who were retrospectively identified in the FIRE-3 trial of cetuximab plus FOLFIRI
compared with bevacizumab plus FOLFIRI.28 However, as a scenario analysis, the RAS WT subset was
identified and assessed. The authors used a Markov cohort model with four states to conduct a cost–utility
analysis of cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI from a US perspective.
The model included states such as first line (progression free), second-line progressed disease states,
post-curative resection and death. OS was based on FIRE-3 trial data, using Weibull distributions. Resection
transition probabilities and transition probabilities for subsequent treatment were also based on FIRE-3
trial data.
Unit costs were reported in 2013 US dollars, but sources were not given. Utilities were based on
published literature.
In this study, cetuximab plus FOLFIRI resulted in 4.04 life-years (3.11 QALYs), whereas bevacizumab plus
FOLFIRI resulted in 3.17 life-years (2.43 QALYs). Cetuximab plus FOLFIRI was calculated to cost > $67,000
more than bevacizumab plus FOLFIRI. This led to an ICER of > $99,000 per QALY gained for cetuximab
plus FOLFIRI compared with bevacizumab plus FOLFIRI.
As this was only a scenario analysis, the sensitivity analyses were applied to the base case and therefore
the exact results are not applicable. However, OS and treatment costs appeared to be the most influential
parameters in the base case and this is likely to carry over into the scenario analysis.
Quality of identified cost–utility studies
The study by Jarrett et al.108 is currently available only as a poster presentation, with further information
available through the SMC report on this assessment.114 As such, it lacks some details, primarily
justification for modelling techniques, which may have been presented in a full paper. It was also funded
by Merck Serono and so was not an independent assessment. The assessment does not include all
comparators relevant to our review and this was a criticism raised by the SMC when it requested an
additional comparison be carried out between cetuximab plus FOLFOX4 and XELOX (referred to as
CAPOX), as this was believed to be in regular use in the Scottish NHS. However, this is the only study that
was conducted in the UK and it does include two relevant comparators, FOLFOX and FOLFIRI.
The study by Graham et al.107 is currently the only study that is published in full that assesses the
cost-effectiveness of panitumumab. However, the only comparator is bevacizumab in combination with
chemotherapy, which has not been recommended by NICE and is no longer available through the CDF for
this indication. Furthermore, it is not a UK-based study, making the results less generalisable to the NHS.
This means that the cost-effectiveness estimates provide limited information for this appraisal. The study
was sponsored by Amgen and so this study was not an independent assessment. However, the model is
generally well reported and relevant to answering the objective set in the study. The level of reporting of
methods for validating the model (e.g. sensitivity analyses) was low, as demonstrated in Tables 62 and 63.
The RAS WT analysis by Ortendahl et al.109 was conducted only as a scenario analysis and so the quality
assessment is based on the reporting of the base-case model. As this study is currently presented only in
poster form, there are limits to the reporting, including cost sources and justification of modelling
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methods. Given this limitation, and the fact that the analysis of interest is reported only as a scenario
analysis, the quality assessment is of limited use.
As the study by Kourlaba et al.110 is currently reported only in abstract form and no further details could be
found, we did not quality assess this study.
All of the studies appeared to feature contributions from or were funded by manufacturers and so they all
have the potential for bias.
Discussion
There is limited knowledge to be gained from the studies identified in this review. None of the studies
included all of the comparators relevant to the NHS and only one is relevant to a UK setting.108 Further
details of this study were identified by accessing the SMC-associated documents,114,118 but this study is still
limited in its reporting and does not include panitumumab as a comparator.
TABLE 62 Quality appraisal of cost–utility studies using the checklist developed by Evers et al.104
Criteria
Study
Graham
2014107
Jarrett
2014108
Ortendahl
2014109
1. Is the study population clearly described? Yes Yes Yes
2. Are competing alternatives clearly described? Yes Yes Yes
3. Is a well-defined research question posed in answerable form? Yes Yes Yes
4. Is the economic study design appropriate to the stated objective? Yes Yes Yes
5. Is the chosen time horizon appropriate to include relevant costs and
consequences?
Yes Yes Yes
6. Is the actual perspective chosen appropriate? Yes Yes Yes
7. Are all important and relevant costs for each alternative identified? Yes No No
8. Are all costs measured appropriately in physical units? Yes Yes Yes
9. Are costs valued appropriately? Yes Unclear Unclear
10. Are all important and relevant outcomes for each alternative identified? Yes Yes Yes
11. Are all outcomes measured appropriately? Yes Yes Yes
12. Are outcomes valued appropriately? Yes Yes Yes
13. Is an incremental analysis of costs and outcomes of alternatives
performed?
Yes Yes Yes
14. Are all future costs and outcomes discounted appropriately? Yes NR NR
15. Are all important variables, whose values are uncertain, appropriately
subjected to sensitivity analysis?
No No No
16. Do the conclusions follow from the data reported? Yes Yes Yes
17. Does the study discuss the generalisability of the results to other settings
and patient/client groups?
No No Yes
18. Does the article indicate that there is no potential conflict of interest of
study researcher(s) and funder(s)?
No No No
19. Are ethical and distributional issues discussed appropriately? No Yes No
Source: Evers et al.104
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The quality of the reporting was mixed, primarily because most studies have been published only in
abstract form and presented at conferences. This also suggests the potential for these results to change
before a full journal publication. Although posters were sought for those abstracts presented at
conferences, it is important to remember that the posters themselves are not subject to peer review and so
they have not been through a level of quality assessment prior to this review. The only study that has been
fully peer reviewed and published is that by Graham et al.,107 which is not a UK-based study and whose
main comparator, bevacizumab in combination with chemotherapy, is no longer funded by the CDF and is
therefore not the focus of our research.
Strengths and limitations
This review was conducted by an independent group using a systematic approach to identify and review
studies. Update searching also allowed for the most recent evidence to be identified. Strict review criteria
TABLE 63 Quality appraisal of cost–utility studies using the checklist developed by Philips et al.105,120
Criteria
Study
Graham 2014107 Jarrett 2014108 Ortendahl 2014109
Structure (S)
S1: Statement of decision problem/objective Yes Yes Yes
S2: Statement of scope/perspective Yes Yes Yes
S3: Rationale for structure Yes No No
S4: Structural assumptions No No No
S5: Strategies/comparators Yes Yes Yes
S6: Model type Yes Yes Yes
S7: Time horizon Yes Yes Yes
S8: Disease states/pathways Yes Yes Yes
S9: Cycle length Yes Yes Yes
Data (D)
D1: Data identification No No No
D2: Pre-model data analysis No No No
D2a: Baseline data No No No
D2b: Treatment effects No No No
D2c: Quality-of-life weights (utilities) Yes No No
D3: Data incorporation No No No
D4: Assessment of uncertainty No No No
D4a: Methodological Yes No No
D4b: Structural Yes No No
D4c: Heterogeneity No No No
D4d: Parameter No No No
Consistency (C)
C1: Internal consistency No No No
C2: External consistency Yes No No
Source: Criteria taken from Philips et al.105,120
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meant that only papers relevant to the decision problem were identified, giving a clear demonstration of
the limited evidence currently available.
The review also identified relevant posters associated with the abstracts identified at the title and abstract
stage, which aided in informing this review in greater detail.
As only one reviewer was involved at both the title and abstract screening stage, there is the potential
for studies to have been missed that may have been identified by a second reviewer. Furthermore, the full
text of one study could not be retrieved and assessed at a full-text level.106 However, given the clear
inclusion/exclusion criteria we do not believe that any relevant studies were missed at the title and abstract
screening stage and comparison with similar reviews, such as that provided in the Merck Serono submission,
do not indicate that any studies were missed, nor that the irretrievable study would have been included at
the full-text stage.
Conclusions
It was not stated in the abstract by Jarrett et al.,108 but the associated SMC documents report that a PAS
was required for cetuximab to be considered a cost-effective treatment in Scotland. However, this may not
be indicative of the NHS in England and Wales and, given the limited reporting of all studies, the evidence
is not conclusive enough at this stage to state whether or not cetuximab and/or panitumumab are cost-
effective first-line treatments for RAS WT mCRC patients. Therefore, we believe that our development of a
de novo model is both justified and necessary to answer the decision problem described in this report.
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Chapter 5 Economic evaluations submitted
by manufacturers
In this chapter we present and critique the economic evidence submitted by Merck Serono(15 June 2015, version 2). No economic evidence was submitted by Amgen.
Economic evaluation submitted by Merck Serono
Merck Serono submitted both a systematic review of economic evidence and an economic model.
Cost-effectiveness review
Merck Serono carried out literature searches for cost-effectiveness evidence in MEDLINE, MEDLINE
In-Process & Other Non-Indexed Citations, EMBASE and EconLit (through Ovid), and NHS EED and Health
Economic Evaluations Database (HEED) (via The Cochrane Library) (Merck Serono submission, section 3.2.1,
p. 16). The searches combined free-text and index terms for relevant cancers, free-text terms for cetuximab
and free-text and index terms for relevant cost-effectiveness measurements and study types (Merck Serono
submission, appendix F, pp. 52–63). No language or date limits were applied.
The literature searches used an appropriate range of databases for the topic. The choice of free-text and
index terms was also appropriate and the searches had an appropriate balance of sensitivity and specificity.
The search strategies were reproduced in the appendices, including the number of hits retrieved per search
(Merck Serono submission, appendix F, pp. 58–63). The dates searched were reported elsewhere in the
submission (Merck Serono submission, section 3.2.1, p. 16).
There is a small discrepancy between the list of databases in section 3.2.1 of the Merck Serono submission
and the search strategies reproduced in appendix F. Section 3.2.1 reports that the databases HEED and
NHS EED were searched, but no HEED search strategy is provided in the appendix; two NHS EED search
strategies are provided, which is probably a typographical error rather than a methodological error. There is
also an error in the EMBASE search strategy: line 8 reads ‘6 AND 7’ but should read ‘5 AND 7’. This error
means that the search terms for cetuximab on line 5 are not included in the final results. However, the
search is not adversely affected as the results consist of records related to mCRC and cost-effectiveness;
this is a broader set of records than would have been retrieved by combining the results with terms for
cetuximab using the AND Boolean operator.
Merck Serono also searched for literature containing HRQoL utility values related to mCRC and cetuximab
(Merck Serono submission, section 3.2.1, pp. 18–19). These searches were carried out in MEDLINE,
MEDLINE In-Process & Other Non-Indexed Citations and EMBASE (through Ovid). The choice of databases
and search terms is appropriate for the topic, as is the balance of sensitivity and specificity. The search
strategies are reproduced in the appendices with appropriate detail and without errors (Merck Serono
submission, appendix G, pp. 64–7).
Merck Serono states that its review had two aims: (1) to identify cost-effectiveness evaluations of
cetuximab in KRAS/RAS WT populations and (2) to identify UK-based costs and resource use. In general,
its PICOS (population, intervention, comparator, outcome, study design) inclusion/exclusion criteria were
appropriate and corresponded to the scope of the project. Detailed comments are presented in Table 64.
Our review had stricter population inclusion criteria, in line with the NICE scope.14 Of the studies included
by Merck Serono, we also identified two.108,109 The remaining studies identified by Merck Serono were
excluded from our review on the basis of population (either not first line or not RAS WT). Merck Serono’s
restriction to cetuximab studies also contradicts the NICE scope, which includes panitumumab plus
chemotherapy as an intervention of interest.
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Although we chose a narrower population for our economic review, we agree with the broader population
criteria that Merck Serono used for the HRQoL search. However, it appears that these wider population
criteria were not necessarily implemented in practice, as 10 studies were excluded as not being ‘not
specific to RAS WT mCRC type patients’ (Merck Serono submission, section 3.4.1, p. 59). The utilities
studies that Merck Serono used to inform its model seem, in general, to be appropriate.
De novo economic evaluation
As well as a review of economic studies, Merck provided an executable economic model. We received
several iterations of this model, which we have summarised below.
TABLE 64 Merck Serono’s cost-effectiveness review: PICOS criteria
Criteria
Review
stage Inclusion Exclusion PenTAG comments
Population Abstract/
full text
Cost-effectiveness evaluations
on cetuximab in (K)RAS WT
mCRC in all countries of
interest; patients with KRAS WT
mCRC receiving first-line
therapy for their metastatic
disease in the UK; patients with
RAS WT mCRC receiving
first-line therapy for their
metastatic disease in the UK;
patients with mCRC in the UK
Studies conducted
outside the UK [except
for cost-effectiveness
studies in (K)RAS WT
mCRC with cetuximab];
non-mCRC studies
These inclusion criteria do not
restrict to first-line treatment,
so cost-effectiveness results and
resource identification will be
of limited use in this scenario.
These inclusion criteria also
excluded panitumumab studies
when panitumumab is not
compared with cetuximab.
This fits Merck Serono’s aims
but not those of the NICE scope.
It is appropriate to limit studies
identified for cost and resource
use to the UK only
Intervention/
treatments
Abstract/
full text
Cetuximab in combination with
FOLFOX or irinotecan-based
chemotherapy; panitumumab
in combination with FOLFOX
All other therapies that
are not relevant to
cetuximab
In line with the NICE scope
Comparator Abstract/
full text
No limitations No limitations This could include comparators
not relevant to the NICE scope
Outcomes Abstract
selection
No selection on outcomes Appropriate
Full-text
selection
Utilities/health states; costs
(UK); resource use (UK);
cost–utility, cost-effectiveness
and budget impact outcomes;
model structure and sources;
cost-effectiveness results
(cost per LY; cost per QALY)
in the target population
cetuximab in (K)RAS WT mCRC
(not limited to UK)
Costs other than UK
costs
Appropriate for the aim of the
review
Study design Abstract/
full text
Economic evaluations
(cost-effectiveness, cost–utility
and budget impact analyses);
HTA submissions and reports
including economic data;
cost-of-illness studies; utility
studies
Pharmacokinetic
studies, genomic
studies, methodology/
protocols, case reports/
studies, editorials/
letters etc., conference
proceedings published
before 2013, studies
lasting for < 2 weeks
Appropriate for the aim of the
review
Source: Merck Serono submission, appendix C (pp. 68–9).
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History of submission
We received Merck Serono’s original submission on 6 May 2015. We requested an explanation of the
discrepancies between the model and the report, as well as how to reproduce the liver metastases
subgroup analysis within the model.
Merck Serono submitted a new executable model and report on 15 June 2015, which had one significant
change. Merck Serono claimed that it had detected another error of its own in the cost of cetuximab and
it adjusted this value accordingly. Some other discrepancies between this model and the previous version
were identified, but checks revealed that these were unlikely to have a big impact on the cost-effectiveness
results: implementing the changes that we could identify into the original model gave very similar results to
the new model (ICERs differed by < £3 per QALY). This also suggested that no major wiring errors had
been introduced into this new model. As such, the model methods and results described in this section
refer to the version of the model that we received on 15 June 2015.
Merck Serono also submitted an additional executable model for the liver metastases subgroup on
16 June 2015. On request, Merck Serono submitted on 26 June 2015 a list of the parameters that had
been altered in the ‘overall population model’ to create this subgroup analysis. The ICERs for this subgroup
had again been updated.
Even with the list of parameters, we were unable to reconcile the overall population model and the
liver-limited disease subgroup model. We also noted that OS had been hard-coded into this subgroup
model, which we believe was in error, as this meant that survival did not alter when different interventions
and comparators were selected.
As we could not reconcile this subgroup model with the model for the overall population, and
as Merck Serono submitted its independent model for the liver metastases subgroup at a late
stage in this HTA assessment, we have not critiqued the liver-limited disease subgroup model.
We therefore present the results for this subgroup without comment.
Description of methods
Comparator treatments
Merck Serono considered the following three independent comparisons in its economic evaluation:
1. cetuximab plus FOLFOX compared with FOLFOX
2. cetuximab plus FOLFIRI compared with FOLFIRI
3. cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI.
Merck Serono stated (section 2.2.2, p. 44) that, ‘As there was significant uncertainty surrounding the
results of the NMA, head-to-head trial data was preferred for use in the health economic model’.
Although we believe that it is possible to perform a three-way comparison between cetuximab plus
FOLFIRI, FOLFIRI and bevacizumab plus FOLFIRI, we believe that Merck Serono’s approach of performing
the three independent comparisons is reasonable because:
l bevacizumab plus FOLFIRI has been delisted from the CDF18 and, hence, is no longer a
main comparator
l we agree that there are no clinical data that allow the comparison of FOLFOX- and FOLFIRI-based
treatments.
However, we note that Merck Serono did not include panitumumab plus FOLFOX as a comparator, even
though the relevant RCT data are publicly available.29,44
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XELOX In its economic model, Merck Serono considered XELOX (also referred to as CAPOX) as a
treatment in a scenario analysis, despite the lack of head-to-head data specific to RAS WT mCRC patients.
Merck Serono assumed:
l that the clinical effectiveness of XELOX, that is, the percentage of patients resected, PFS rates, mortality
from PFS, incidences of AEs, is exactly the same as for FOLFOX
l a higher mean per patient total cost of acquisition of XELOX than of FOLFOX (£8093 vs. £6416)
l a slightly lower mean per patient total cost of administration of XELOX than of FOLFOX (£2296 vs. £2803).
Merck Serono justified the first assumption as follows:
In a Phase III trial by Cassidy et al. (Cassidy et al., 2006,121 Cassidy et al., 2007122) CAPOX was shown to
be non-inferior to FOLFOX-4 as a first-line treatment for mCRC. Therefore the two regimens are
expected to be equivalent in terms of efficacy and can thus be treated as equal in terms of outcomes.
In addition, this assumption was validated by clinical experts (Merck Serono, 2015) who stated that the
combinations of different forms of 5FU (differing infusion regimens and oral analogues) along with
both FOLFIRI and FOLFOX have equivalent efficacy.
Merck Serono submission (section 3.7.3.1, p. 66)
We agree with Merck Serono that there are no trials that directly compare cetuximab-based treatment
with XELOX. Our systematic review of the literature (see Chapter 3) also found no such trials comparing
panitumumab-based treatment with XELOX.
Given the time constraints, we did not perform a full systematic search of the literature for clinical
effectiveness evidence for XELOX compared with any other treatment in our base-case analysis. Instead,
we report the findings of a review of XELOX compared with FOLFOX by Douillard et al.123 This study
found that several RCTs have compared continuous-infusion 5-fluorouracil/oxaliplatin with the oral
fluoropyrimidine capecitabine plus oxaliplatin. In all of these trials, non-inferiority was demonstrated for the
use of oral fluoropyrimidines for the predefined end points such as PFS, OS and response rate. However,
the HRs and median TTP/PFS were almost always in favour of FOLFOX (Table 65).
These data give us an idea of the likely relative clinical effectiveness of CAPOX/XELOX and FOLFOX.
However, it should be noted that these data do not relate specifically to patients with RAS WT mCRC but
rather to both RAS WT and mutant patients.
TABLE 65 Time to progression/PFS results of RCTs of CAPOX/XELOX compared with FOLFOX reported in Douillard et al.123
Trial
Number of
patients
Median TTP/PFS (months)
PFS/TTP HR
Continuous-infusion
5-fluorouracil-based
treatment
Oral
fluoropyrimidine-
based treatment
NO16966 trial121 634 FOLFOX4 7.7 XELOX 7.3 0.96 (97.5% CI 0.8 to 1.16)
TREE-1 trial124 106 mFOLFOX6 6.4 CAPEOX 4.4 NR
Ducreux et al.125 306 FOLFOX6 9.3 XELOX 8.8 1.00 (90% CI 0.82 to 1.22)
Díaz-Rubio et al.126 348 FUOX 9.5 XELOX 8.9 1.18 (95% CI 0.9 to 1.5)
Porschen et al.87 NR FUFOX 8.0 CAPOX 7.1 1.17 (95% CI 0.96 to 1.43)
COFFEE trial127 322 OXAFAFU 6.3 OXXEL 6.2 1.06 (95% CI 0.81 to 1.35)
CAPOX/CAPEOX/OXXEL/XELOX, capecitabine+ oxaliplatin; COFFEE, Capecitabine Or Folinic acid/Fluorouracil i.v. bolus
plus Eloxatin Evaluation; FOLFOX4/FOLFOX6/FUFOX/OXAFAFU, folinic acid + 5-fluorouracil + oxaliplatin; FUOX,
5-fluorouracil + oxaliplatin; NR, not reported; TREE, Three Regimens of Eloxatin Evaluation.
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Of course, there are several other parameters that could differ between CAPOX/XELOX and FOLFOX:
l mean treatment duration
l resection rates; however, it seems plausible that resection rates are correlated with PFS
l incidences of AEs; however, given that we find that incidences of AEs have little impact on
cost-effectiveness, we consider this to be a minor issue.
Given all these uncertainties, we believe that it is reasonable for Merck Serono to model XELOX as a
comparator treatment in a scenario analysis, assuming differences in treatment acquisition and
administration costs but equal clinical effectiveness to that of FOLFOX.
Tegafur/uracil Merck Serono did not include tegafur/uracil as a comparator treatment, even though it is
a comparator in the NICE scope.14 Merck Serono stated that it withdrew this product from the market in
the UK in 2013 and no other equivalent preparations are available in the UK (Merck Serono submission,
p. 19). We agree that tegafur/uracil has been discontinued and our clinical advisor believes that it is
unlikely to be used in the UK.
Capecitabine monotherapy Merck Serono did not include capecitabine monotherapy as a comparator,
even though it is a comparator in the NICE scope,14 as its expert advice indicated that it is typically used in
elderly patients with poor performance status, as these patients would not generally be fit enough to
receive biological agents in combination with chemotherapy (Merck Serono submission, p. 19). It also did
not identify any studies that compare cetuximab plus chemotherapy with capecitabine in a RAS WT
population (Merck Serono submission, section 3.2.3, table 22, p. 52).
Our clinical advisor agreed that capecitabine monotherapy and 5-fluorouracil plus folinic acid are not the
preferred first-line treatments in mCRC patients. In general, single-agent fluoropyrimidine regimens
(capecitabine or 5-fluorouracil plus folinic acid) would be used for patients who were unfit for combination
therapy or who have overlapping comorbidities that make other agents problematic. We also did not
identify any studies comparing cetuximab plus chemotherapy with capecitabine in a RAS WT population
Patient population and liver metastases subgroup
Merck Serono considered two patient populations, with a separate model for each group:
1. all first-line patients with RAS wild-type mCRC
2. a subgroup of these patients with metastases confined to the liver (liver metastases subgroup).
As discussed previously, we did not critique the liver metastases subgroup model.
Merck Serono claimed that the following parameters were unique to the liver metastases subgroup:
l resection rates
l PFS for unresected patients.
All other parameters were stated to be unchanged from those in the total population analysis.
Model structure
In common with us, in the base case Merck Serono did not use OS data from the RCTs of first-line drug
treatments. Instead, the RCTs were used to estimate resection rates and PFS only for first-line treatment.
OS was instead estimated as the sum of times on first-, second- and third-line treatments, allowing for
mortality from each line.
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Merck Serono’s model included five health states: first-line progression free, second-line progressive
disease, third-line progressive disease, post resection and dead. Patients remain in first line until they move
to either post resection or to further lines of treatment. Patients can die in any state.
The model used tunnel states to apply time-dependent transition probabilities to move patients
between states.
Differences in clinical effectiveness between first-line drug treatments were represented by the
differences between:
l first-line PFS
l resection rates
l incidences of AEs.
The model cycle length was 1 month, which is appropriate. A model half-cycle correction was applied.
The model time horizon was 10 years, which we believe is far too short. The model time horizon should
be sufficiently long that the vast majority of deaths are modelled. However, 10 years after resection,
Merck Serono estimate that 12% of patients are still alive. Merck Serono’s model can deal with a time
horizon of up to 20 years, at which time it estimates that 4% of patients are still alive. When we change
the time horizon from 10 to 20 years, the ICERs for cetuximab plus FOLFOX compared with FOLFOX and
cetuximab plus FOLFIRI compared with FOLFIRI both decrease because we now model more QALYs post
resection and more patients receive a resection under the cetuximab plus FOLFOX regime than under the
FOLFOX regime and under the cetuximab plus FOLFIRI regime than under the FOLFIRI regime.
However, as explained later (see Model parameters, Post-liver resection: progression-free survival and
overall survival), we believe that their estimates of PFS and OS post resection are logically impossible after
about 11 years, as they then estimate that PFS is greater than OS.
In our model, we used a time horizon of 30 years.
Future costs and benefits were discounted at 3.5% per annum and the perspective taken was that of the
NHS and personal social services, in accordance with the NICE reference case.128
Overall survival
As in our model, Merck Serono did not use OS data from the RCTs. Instead, life expectancy for all
randomised patients was calculated separately for each treatment arm as:
% patients resected × life expectancy given resected + (100%−% patients resected)
× life expectancy given unresected. (1)
The last quantity, life expectancy for unresected patients for each treatment arm was calculated as the sum
of life expectancy on first, second and third lines of treatment, allowing for mortality from each line.
Model parameters
Resection rates Resection of liver metastases is an important component of both our model and Merck
Serono’s model, as cost-effectiveness is sensitive to it.
Merck Serono used the resection rates from the RCTs to estimate the rates for use in its model (Table 66).
Merck Serono did not discuss the derivation of their estimate of the rate of resection for cetuximab plus
FOLFOX, 7.3%. We assumed that Merck Serono set the resection rate as equal to its rate for cetuximab
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plus FOLFIRI, which we believe is unreasonable. It estimated the rate of resection for FOLFOX (2.1%) from
Tournigand et al.111 This is substantially lower than our estimate (see Chapter 6, Model parameters,
Resection rates). The study by Tournigand et al.111 was of second-line treatment not restricted to RAS WT,
whereas our estimate was taken from the first-line treatment of RAS WT patients; therefore, we prefer
our value.
Time of liver resection Merck Serono simulated liver resection at cycle 3 in its model. Notably, the
timing of liver resection was not clearly stated in the submission. As detailed in table 20 (Merck Serono
submission, section 3.2.2, p. 49), resection was modelled at cycle/month 4; however, in table 21 the
submission states that at 3 months in its model some patients can be referred for curative-intent resection
of liver metastases.
Merck Serono’s assumption regarding the timing of liver resection surgery was based on the study by
Adam et al.,113 as indicated in table 20 of the submission (section 3.2.2, p. 49). This assumption seems
reasonable, based on advice from our clinical experts and the values used in TA176.10
Post liver resection: progression-free survival and overall survival In its submission, Merck Serono
stated that it assumed that all patients who underwent curative liver resection for initially unresectable
colorectal liver metastases, turned resectable by systematic chemotherapy, and who are cured of the
disease ‘remain in a progression free state until death and do not require second-line treatment’
(Merck Serono submission, section 3.2.2, p. 47). However, elsewhere in the submission and in the
executable model there exists a progressive disease state, including treatment, for patients post
liver resection.
Merck Serono model PFS and OS after liver resection surgery according to data from Adam et al.113
We also used these data as we understand that they are the most appropriate data available. Further
discussion of this study can be found in Chapter 6 (see Model parameters, Post liver resection:
progression-free survival and overall survival).
Merck Serono fitted a log-logistic distribution to both PFS and OS post resection (Figure 8). Technically,
these data are taken from rows 95 and 96 of Merck Serono’s worksheet ‘Survival models’. Importantly,
Merck Serono did not explain its choice of distribution, or indeed how it estimated the curve fits.
The fits appear reasonable up to end of study follow-up at 10 years, which is also the time horizon of
Merck Serono’s model. However, after about 11 years, PFS in the Merck Serono model is greater than OS,
which is clearly impossible. We believe that this renders the results from Merck Serono’s model for time
horizons > 11 years incorrect.
TABLE 66 Liver metastases resection rates assumed in the Merck Serono model
Treatment All RAS WT patients
FOLFIRI network
CET+ FOLFIRI 7.3% (Merck Serono data from the CRYSTAL trial129)
FOLFIRI 2.1% (Merck Serono data from the CRYSTAL trial111)
BEV + FOLFIRI 7.3% (no justification given)
FOLFOX network
CET+ FOLFOX 7.3% (derivation explained in accompanying text)
FOLFOX 2.1%111
BEV, bevacizumab; CET, cetuximab.
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In common with us, for those patients who had a successful resection, Merck Serono assumed that PFS
and OS were independent of first-line treatment.
Based on its 10-year time horizon, which we believe is far too short, we calculate that Merck Serono
estimates a mean PFS of 2.8 years and mean OS of 4.1 years.
First-line progression-free survival: unresected patients Merck estimated first-line PFS for unresected
patients directly from the pivotal RCTs: CRYSTAL,24 FIRE-328 and OPUS.23 It compared pairs of treatments
independently and did not perform simultaneous comparisons of multiple treatments. Therefore, unlike us,
it did not perform indirect comparisons for first-line PFS for unresected patients.
Merck Serono estimated PFS for unresected patients from data for all patients (resected and unresected) in
the RCTs. We believe that this is an important mistake. Given that it modelled PFS for resected patients
separately, as described in the previous section, it effectively double counted PFS for resected patients.
It overestimated PFS for unresected patients because PFS for resected patients (our estimate 4.5 years) is
far greater than that for unresected patients (e.g. our estimate for cetuximab plus FOLFIRI 1.0 years).
In our analysis, as explained in the previous section, we also estimated PFS for resected patients from the
study by Adam et al.113 However, we estimated PFS for unresected patients using the RCT data for PFS for
all patients and then subtracting PFS for resected patients (see Chapter 6, Model parameters, First-line
progression-free survival: unresected patients).
Merck Serono’s choices of statistical distributions and estimates for mean PFS for first-line unresected
patients are provided in Table 67.
We believe that the PFS curve fits; however, as already stated, we believe that these are overestimates of
PFS for unresected patients.
All other things being equal, Merck Serono’s approach results in cetuximab plus FOLFOX/FOLFIRI appearing
to be better value for money than we believe, given that a greater proportion of patients in the cetuximab
plus FOLFOX/FOLFIRI arms compared with the FOLFOX/FOLFIRI arms are resected and that PFS for resected
patients is substantially greater than that for unresected patients.
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FIGURE 8 Merck Serono’s PFS and OS post-resection fit to the empirical data. Source: figure produced from data
available in the Merck Serono submission (May 2015).
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Probability of postoperative death Merck Serono states in table 21 of the submission (section 3.2.2,
p. 50) that the rate of postoperative death was set to 0%, based on data from the CRYSTAL trial.
However, in the executable model Merck Serono assumes a probability of postoperative death of 1% for
all treatment regimens. As Merck Serono used data from the study by Adam et al.113 to model the cohort
post resection, we think that it would be more appropriate to use the value of 0.7% reported by Adam
et al.113 for operative mortality within 2 months.
Time on first-line drug treatment The mean times on first-line drug treatment are extremely important
quantities because, in Merck Serono’s model, they affect the total mean cost of drug acquisition and
administration per person. In Merck Serono’s model, the former, in particular, is a critical driver of
cost-effectiveness. Therefore, treatment duration is worthy of close scrutiny.
Despite its importance, Merck Serono mentioned treatment duration only very briefly.
Merck Serono estimated the mean duration of cetuximab use in England as 24–25 weeks, ‘depending on
chemotherapy backbone and disease progression’, citing the source as ‘data on file’ (Merck Serono
submission, table 3, p. 17). The submission stated that ‘The period of treatment with cetuximab plus
chemotherapy used in the model were obtained from the relevant clinical trials. As stated in the clinical
evidence section, the period of treatment in the clinical trial represents clinical practice as Merck Serono
research indicates that the period of cetuximab treatment is 25 weeks on average’ (section 3.7.2, p. 64).
In its model, Merck Serono assumed that all patients take first-line drug treatment while in PFS, up to a
certain cut-off time, which varies slightly by treatment arm. After the cut-off time, patients take no
first-line drug. The cut-off times were:
l cetuximab plus FOLFOX – 5.5 months
l FOLFOX – 5.5 months
l cetuximab plus FOLFIRI (vs. FOLFIRI) – 5.8 months
l cetuximab plus FOLFIRI (vs. bevacizumab plus FOLFIRI) – 4.8 months
l FOLFIRI – 5.9 months
l bevacizumab plus FOLFIRI – 5.3 months.
Under its method of modelling treatment duration, we calculate that Merck Serono estimates the
following mean treatment durations:
l cetuximab plus FOLFOX – 4.9 months
l FOLFOX – 4.6 months
TABLE 67 Merck Serono-modelled PFS rates for unresected patients
Treatment Distribution Mean PFS (months)a
CET+ FOLFOX Log-normal 13.4
FOLFOX Log-normal 9.0
CET+ FOLFIRI (vs. FOLFIRI) Weibull 12.5
CET+ FOLFIRI (vs. BEV+ FOLFIRI) Weibull 12.8
FOLFIRI Weibull 8.9
BEV + FOLFIRI Weibull 10.8
BEV, bevacizumab; CET, cetuximab.
a We estimated mean PFS in the Merck Serono model from the ‘Results’ worksheet, setting the discount rate to 0% and
the resection rates in the ‘Setup’ worksheet to 0%.
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l cetuximab plus FOLFIRI (vs. FOLFIRI) – 5.3 months
l cetuximab plus FOLFIRI (vs. bevacizumab plus FOLFIRI) – 4.5 months
l FOLFIRI – 5.2 months
l bevacizumab plus FOLFIRI – 5.1 months.
Below, we argue that these are underestimates (see Critique of the Merck Serono model, Model
parameters, Time on treatment).
Second-line progression-free survival: unresected patients Both we and Merck Serono assumed that
all patients have second-line FOLFIRI after first-line FOLFOX-based treatment and second-line FOLFOX after
first-line FOLFIRI-based treatment.
Merck Serono modelled second-line PFS using data from the study by Tournigand et al.111 Inspection of its
model revealed that it assumed a log-logistic distribution, and we calculated a mean of 0.31 years in
second-line PFS for patients who start on second-line treatment. Merck Serono assumed that this value
was independent of first-line treatment (whether FOLFOX or FOLFIRI based).
Given the lack of data to the contrary, we also assume that PFS on second-line FOLFOX or FOLFIRI is
independent of first-line treatment.
Although not stated in its report, and in common with us, inspection of its model revealed that
Merck Serono assumed that patients take FOLFOX or FOLFIRI for the entire duration of second-line PFS.
Third-line survival: unresected patients In common with us, Merck Serono modelled third-line survival
using data from the study by Jonker et al.112 Inspection of its model revealed that it assumed a Weibull
distribution, and we calculated a mean of 0.74 years’ survival for patients who start on third-line
treatment. Merck Serono also assumed that this value was independent of first- or second-line treatment.
Merck Serono assumed that most patients receive BSC in third line, with 17% receiving capecitabine or
cetuximab. It further assumed that patients would not be retreated with cetuximab.
Utilities The utilities used in Merck Serono’s model are reported in Table 68. We noted that there were
differences between the utilities in the main report and those reported in appendix B. The values in the
appendix correspond to those used in the model.
No RAS WT utility data were identified by Merck Serono or reported by the included trials. Merck Serono
used the study by Bennett et al.115 to obtain estimates of utilities in first- and second-line treatment.
TABLE 68 Health state utilities reported by Merck Serono
Health state
Merck Serono
main report
Merck Serono model
(and appendix B) Source
First line 0.77 0.778 Bennett et al.115
Second line 0.73 0.769 Bennett et al.115
Third line 0.68 0.663 Wang et al.116
PFS post resection NR 0.789 Petrou and Hockley 2005117
Progressive disease
post resection
NR 0.682 Average of second- and third-line utilities, weighted
by time spent in second and third line
NR, not reported.
Source: Merck Serono submission, table 20, pp.50–1; appendix B, table 1, p. 1.
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Bennett et al.115 report utilities for first- and second-line KRAS WT mCRC populations. Further discussion of
this source can be found in Chapter 6 (see Model parameters, Utilities). For first-line utility, Merck Serono
used the estimate of first-line utility reported at baseline for the panitumumab plus FOLFOX population
(0.778). For second-line utility, Merck Serono used the second-line baseline results for panitumumab plus
FOLFIRI (0.769).
Merck Serono used an estimate of 0.663 from Wang et al.116 for third-line treatment. This utility was for a
previously treated KRAS WT mCRC population who were receiving BSC. This source is also discussed
further in Chapter 6 (see Model parameters, Utilities).
Merck Serono used a general population estimate for the utility of PFS post resection. The source of this
value was the study by Petrou and Hockley,117 which used Health Survey for England data from 1996.
More recent data and approaches for using these data are available.130,131
For post-resection progressive disease states, the utility was assumed to be a weighted average of
second-line and third-line health states, adjusted for time in each state.
Costs
RAS mutation testing Merck Serono reported a cost of £200 for RAS mutation testing from the All
Wales Genetic Laboratory (Merck Serono submission, appendix B, table 2), which was applied to all arms
of the model, regardless of treatment.
Drug acquisition Merck Serono assumed costs for drug acquisition per month as shown in Table 69.
These monthly costs were calculated based on the pharmaceutical costs shown in Table 70, all of which
are list prices and do not include any discounts that may be obtained by the NHS.
For each agent in each regimen, the target dosage was calculated based on an assumed constant body
surface area or body mass (Table 71) and then wastage was considered by using the minimum number of
vials to achieve the minimum wastage; for example, for a target cetuximab dose of 895 mg, two 500-mg
vials would lead to wastage of 105 mg, whereas one 500-mg vial and four 100-mg vials would lead to
wastage of 5 mg (in which case the latter was assumed). Wastage was not minimised based on cost, but if
the average cost per milligram was the same across vial sizes (or very similar), this method will minimise
cost. It was assumed that for all regimens there would be 2.17 cycles per month, which is accurate for
14-day cycles.
TABLE 69 Drug acquisition costs per month in Merck Serono’s model
Regimen Cost per month of drug acquisition (£)
CET+ FOLFOX4 5083
FOLFOX4 1546
FOLFOX6 (second line only) 1616
XELOX 1950
CET+ FOLFIRI 4876
BEV + FOLFIRI 3345
FOLFIRI 1339
BEV, bevacizumab; CET, cetuximab.
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TABLE 70 Costs of pharmaceuticals in Merck Serono’s model
Agent Cost (£) Source
Cetuximab 20-ml vial (5 mg/ml): 178.10 Merck Serono
100-ml vial (5 mg/ml): 890.50
Bevacizumab 4-ml vial (25 mg/ml): 242.66 BNF132
16-ml vial (25 mg/ml): 924.40
Oxaliplatin 10-ml vial (5 mg/ml): 155.00 BNF132
40-ml vial (5 mg/ml): 622.38
Fluorouracil 10-ml vial (50 mg/ml): 6.40 BNF132
50-ml vial (50 mg/ml): 32.00
Leucovorin 10-tablet (15-mg) pack: 19.41 BNF132
Irinotecan 2-ml vial: 46.50 BNF132
5-ml vial: 114.00
25-ml vial: 601.25
Capecitabine 60-tablet (150-mg) pack: 40.00 BNF132
120-tablet (500-mg) pack: 295.65
Doxycycline 8-tablet (100-mg) pack: 1.11 BNFa
Ondansetron 30-tablet (4-mg) pack: 5.37 BNFa
Dexamethasone 50-tablet (2-mg) pack: 7.05 BNFa
BNF, British National Formulary.
a Version of BNF used not stated.
Source: Merck Serono executable model.
TABLE 71 Methodology used by Merck Serono to calculate the monthly costs of regimens
Regimen Agent Cycles per month Dosage per cycle Cost per cycle (£) Monthly cost (£)
CET+ FOLFOX4 CET 2.17 500mg/m2 1616.37 3507.52
FOLFOX4 See below 1546.45
Doxycycline 2.17 200mg 1.11 2.41
Ondansetron 2.17 8mg 7.05 15.30
Dexamethasone 2.17 8mg 5.37 11.65
Total 5083.33
FOLFOX4 Oxaliplatin 2.17 85mg/m2 622.38 1350.56
Leucovorin 2.17 200mg/m2 58.23 126.36
5-fluorouracil 2.17 1600 mg/m2 32.04 69.53
Total 1546.45
FOLFOX6 Oxaliplatin 2.17 100mg/m2 622.38 1350.56
Leucovorin 2.17 200mg/m2 58.23 126.36
5-fluorouracil 2.17 2800 mg/m2 64.02 138.92
Total 1615.85
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Merck Serono’s model allowed for both weekly and fortnightly administration of cetuximab, but we
present only the parameter values for fortnightly administration because we believe that this is a more
appropriate base case as it reflects current clinical practice more closely.
Merck Serono assumed premedication with doxycycline, ondansetron and dexamethasone prior to
cetuximab administration, but these did not significantly contribute to overall costs.
Merck Serono did not include any adjustments for mean dose intensity; in practice, some patients would
likely require reductions in their target dose (often because of side effects).
Drug administration The drug administration unit costs used in Merck Serono’s economic model are
provided in Table 72. The report differed from the model in that appendix B appeared to report inpatient
and outpatient costs the other way around.
TABLE 71 Methodology used by Merck Serono to calculate the monthly costs of regimens (continued )
Regimen Agent Cycles per month Dosage per cycle Cost per cycle (£) Monthly cost (£)
XELOX Capecitabine 2.17 28,000 mg/m2 245.94 533.69
Oxaliplatin 2.17 130mg/m2 652.90 1416.79
Total 1950.50
CET+ FOLFIRI CET 2.17 500mg/m2 1616.37 3507.52
FOLFIRI See below 1339.04
Doxycycline 2.17 200mg 1.11 2.41
Ondansetron 2.17 8mg 7.05 15.30
Dexamethasone 2.17 8mg 5.37 11.65
Total 4875.92
BEV + FOLFIRI BEV 2.17 5mg/kg 924.40 2005.95
FOLFIRI See below 1339.04
Total 3344.99
FOLFIRI Irinotecan 2.17 180mg/m2 456.00 989.52
Leucovorin 2.17 400mg/m2 97.05 210.60
5-fluorouracil 2.17 2800mg/m2 64.02 138.92
Total 1339.04
CET, cetuximab; BEV, bevacizumab.
TABLE 72 Merck Serono’s drug administration unit costs
Administration setting Visit number Unit cost (£) Source
Inpatient chemotherapy
administration
First visit 287 NHS Reference Costs 2012–2013:133 SB14Z [OP]
Subsequent visits 255 NHS Reference Costs 2012–2013:133 SB15Z [OP]
Outpatient chemotherapy
administration
First visit 226 NHS Reference Costs 2013–2014:133 SB14Z [OP]
Subsequent visits 314 NHS Reference Costs 2013–2014:133 SB15Z [OP]
OP, outpatient.
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It was not stated in Merck Serono’s report how these unit costs were used and so it was necessary to
determine this from the executable model.
Merck Serono assumed that the ‘first visit’ cost applied to the whole of the first cycle and that the
‘subsequent visits’ cost applied to all subsequent cycles, that is, even if a patient had multiple attendances
per cycle, only one attendance was costed. Drug administration costs were consistent across all regimens
per cycle and all regimens were assumed to have 2.17 treatment cycles per month (including XELOX).
Merck Serono also assumed that drug administration for first-line treatment was carried out 100% of the
time in the outpatient setting and for second-line treatment was carried out 100% of the time in the
inpatient/day-case setting.
In summary, total drug administration costs per month in Merck Serono’s model were £633.38
(first month) or £681.38 (subsequent months) for first-line treatments, and £585.35 (first month, except
XELOX) or £553.35 (subsequent months, all months for XELOX) for second-line treatments.
Medical management The executable model submitted by Merck Serono used resource use and unit
costs for medical management as shown in Table 73. As can be seen, Merck Serono assumed no medical
management costs in three health states (first-line progression free, second-line and post-resection
progression free), a cost of £315 per month for post-resection progressive disease and a cost of £1040
per month for third-line treatment (mainly BSC).
TABLE 73 Medical management costs in the model submitted by Merck Serono
Health state Item Unit cost (£)
Resource use
(per month)
Monthly
cost (£)
First-line progression free 0
Second line 0
Third line BSC costs 997
Capecitabine monotherapy Per month per patient
receiving: 246
17.5% of
patients
43
Total 1040
Post-resection progression free 0
Post-resection progressive
disease
Evaluation of tumour markers:
CEA
60 1a 60
Evaluation of tumour markers:
CA 19–9
60 1a 60
Liver function tests 28 1a 28
Hepatic ultrasonography 51 1a 51
Oncology outpatient attendance 333 0.25a 83
Abdominal CT scan 90 0.125a 11
Lung CT scan 90 0.125a 11
Large bowel CT scan 90 0.125a 11
Total 315
CEA, carcinoembryonic antigen; CA 19–9, carbohydrate antigen 19–9; CT, computerised tomography.
a Merck Serono stated that these were intended to be the resource use values for the first month only, but they were
applied throughout in the executable model submitted.
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Resection cost Merck Serono specified in the submission (appendix B, table 2) that the average cost of
liver resection surgery assumed in the model was £2707. Merck Serono stated that this cost was derived
from NHS reference costs 2013/14134 [Healthcare Resource Group (HRG) unit costs for hepatobiliary and
pancreatic surgery in malignant gastrointestinal disorders]. It represents the average of the HRG unit costs
weighted by the number of finished consulting episodes (Merck Serono submission, appendix B, table 2).
The relevant HRG unit costs are detailed in table 3 of appendix B.
Notably, national average unit costs for the HRGs used to estimate the average cost of liver resection in
Merck Serono’s model (Merck Serono submission, appendix B, table 3) are not consistent with the NHS
reference costs 2013/2014.134 The average cost of liver resection based on the actual average unit costs
reported for these HRG codes is £2467.
Costs post resection
Follow-up consultations Merck Serono assumed a cost of £333 per oncological outpatient attendance. In
the executable model it reported the source of this cost as NHS Reference Costs 2012–2013,133 but we
could not confirm this cost.
The frequency of follow-up consultations in Merck Serono’s model was one visit per 4 months, as in the
study by Adam et al.113 We agree that this is appropriate.
Blood tests Merck Serono modelled the following blood tests in patients post resection: liver function test
and the tests for the tumour markers carcinoembryonic antigen and carbohydrate antigen 19–9 (appendix B,
table 2).
The submission states that the cost of the liver function test was £28.76 (in 2013 UK pounds). However,
in the executable model Merck Serono used a cost of £27.60 per test (in 2013 UK pounds). This cost was
based on the TA17610 (appendix B, table 2) and we believe that this source is appropriate.
Merck Serono assumed that each tumour marker test cost £59.87, based on information from the
Information Services Division (ISD) Scotland. We were unable to identify this source and so cannot
comment on its relevance.
In the manufacturer’s model, the blood tests are conducted during the first month after resection and then
every 4 months, based on the study by Adam et al.113 Based on advice from our clinical expert (Dr Mark Napier,
2015, personal communication), we believe that this cost should be incurred every 3 months.
Despite the difference in cost and frequency of blood tests between our estimates and those of Merck
Serono, we found that using our values in place of Merck Serono’s resulted in a minimal change to the
cost-effectiveness results.
Imaging tests Merck Serono modelled hepatic ultrasonography and computerised tomography (CT) scans in
patients post resection. The cost of the hepatic ultrasonography test was assumed to be £51 (Merck Serono
submission, table 2, appendix B) and it was assumed that this test was conducted during the first month
after the surgery and then every 8 months. Merck Serono modelled abdominal, lung and large bowel CT
scans separately, at a cost of £90 per test (Merck Serono submission, table 2, appendix B). The tests were
assumed to be performed every 8 months.
Merck Serono stated that the above cost estimates were based on NHS reference costs 2012/13;133
however, we could not confirm these estimates.
DOI: 10.3310/hta21380 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 38
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
97
We note that, although Merck Serono calculated different costs for the first month after resection and for
subsequent months, based on changes in resource use, it did not implement these correctly in the model
and instead use the first month costs throughout.
Adverse events Merck Serono modelled costs and disutilities of grade 3/4 AEs. The probability of an AE
was taken directly from each of the relevant trials and for some AEs these came from a KRAS WT rather
than a RAS WT population. Merck Serono assumed that all AEs lasted for 1 month.
The costs and disutilities associated with each AE are reported in Table 74. Periphery sensory neuropathy
and vomiting have disutilities but no costs.
The cost sources for AEs were poorly reported. We were unable to confirm the source of the costs for
hypertension, arterial thromboembolism, venous thromboembolism, neutropenia or neurological toxicities.
The disutility estimates for AEs were better reported and came from a range of published literature.135–138
All of these sources were UK-based studies, using EQ-5D vignettes, but none was conducted on a CRC
population, and some studies reported on the EQ-5D visual analogue scale and some reported on the
EQ-5D time trade-off scale.
TABLE 74 Adverse event utilities and unit costs used in the Merck Serono model
AE
Cost
(£) Source provided
Utility
decrement Source
Hypertension 622 NHS Reference Costs 2013–2014:134 non-elective
inpatient stay – EB04Z – hypertension
–0.069 Doyle et al.135
Gastrointestinal
perforation
2693 NHS Reference Costs 2013–2014:134 FZ38K –
gastrointestinal bleed with single intervention with
a CC of score 5–7
–0.195 Tolley et al.136
Arterial
thromboembolism
777 NHS Reference Costs 2013–2014:134 deep-vein
thrombosis with a CC score of 3–5 – QZ20D
–0.195 Tolley et al.136
Venous
thromboembolism
777 NHS Reference Costs 2013–2014:134 deep-vein
thrombosis with a CC score of 3–5 – QZ20D
–0.195 Tolley et al.136
Skin reactions 13.09 BNF132 –0.03248 Nafees et al.137
Neutropenia 877 NHS Reference Costs 2013–2014:134 non-elective
inpatient stay – PA45Z – medical oncology
–0.09 Nafees et al.137
Diarrhoea 153 NHS Reference Costs 2013–2014:134 general
medicine outpatient visit – service code 300
–0.103 Lloyd et al.138
Leukopenia 153 NHS Reference Costs 2013–2014:134 general
medicine outpatient visit – service code 300
–0.03248 Assumption: equal to
disutility for neutropenia
Periphery sensory
neuropathy
–0.116 Lloyd et al.138
Fatigue 153 NHS Reference Costs 2013–2014:134 general
medicine outpatient visit – service code 300
–0.115 Lloyd et al.138
Vomiting –0.103 Lloyd et al.138
Neurological
toxicities
1400 NHS Reference Costs 2013–2014:134 WA17A
medical oncology neoplasm-related admission with
a CC score of 3+
–0.116 Assumption: equal to
disutility for peripheral
sensory neuropathy
Hypokalaemia 153 NHS Reference Costs 2013–2014:134 general
medicine outpatient visit – service code 300
–0.115 Assumption: equal to
disutility for fatigue
BNF, British National Formulary; CC, complications and comorbidities.
Source: Merck Serono submission, appendix B, table 1, p. 1, and table 4, p. 5.
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Merck Serono results
Base case
Merck Serono reported six base cases, three pairwise comparisons based on cetuximab provided in a
weekly dose and three pairwise comparisons in which cetuximab was given fortnightly. The three pairwise
comparisons were:
1. cetuximab plus FOLFOX compared with FOLFOX alone
2. cetuximab plus FOLFIRI compared with FOLFIRI alone
3. cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI (bevacizumab and FOLFIRI)
It is unclear whether weekly or fortnightly administration of cetuximab is Merck Serono’s preferred base
case (Merck submission, section 3.5, p. 59 vs. section 3.9, p. 68). However, we believe that the results
of fortnightly dosing are most relevant and these are the results that we focus on here. We also focus on
the results for the pairwise comparisons between cetuximab plus FOLFOX and FOLFOX, and between
cetuximab plus FOLFIRI and FOLFIRI, and present only summary results for cetuximab plus FOLFIRI compared
with bevacizumab plus FOLFIRI. These base-case deterministic results are presented in Tables 75–79.
Cetuximab plus FOLFOX has an ICER of £46,503 per QALY gained compared with FOLFOX alone and
cetuximab plus FOLFIRI has an ICER of £55,971 per QALY gained compared with FOLFIRI alone.
For all comparisons the health state with the highest costs and QALYs is first-line PFS. This is because of
the length of time spent in this state, the cost of treatment and the higher utilities of this state.
The cetuximab plus FOLFIRI results differ for the two different pairwise comparisons (vs. FOLFIRI or vs.
bevacizumab plus FOLFIRI) because they are based on different trials (CRYSTAL24 for the FOLFIRI
comparison; FIRE-399 for the bevacizumab plus FOLFIRI comparison). The difference between these results
seems to be primarily driven by costs: the cetuximab plus FOLFIRI arm has similar QALYs for both
comparisons (1.61 for CRYSTAL and 1.60 for FIRE-3).
Probabilistic sensitivity analysis
Merck Serono performed a probabilistic sensitivity analysis for all of its base-case comparisons. According
to the results, cetuximab plus FOLFOX was the most likely cost-effective treatment compared with FOLFOX
at a willingness-to-pay threshold of >£50,000 per QALY and cetuximab plus FOLFIRI was the most likely
cost-effective treatment compared with FOLFIRI at a willingness-to-pay threshold of ≈£60,000 per QALY.
The results of the cetuximab plus FOLFOX compared with FOLFOX probabilistic sensitivity analysis
demonstrated the highest uncertainty in terms of QALYs and, in a small proportion of simulations,
cetuximab plus FOLFOX was dominated by FOLFOX, having larger costs and fewer QALYs. In neither
probabilistic sensitivity analysis did cetuximab plus chemotherapy dominate chemotherapy alone.
TABLE 75 Deterministic base-case results: cetuximab plus FOLFOX compared with FOLFOX, fortnightly
cetuximab dose
Treatment Costs (£) LYs QALYs ICER (£ per LY) ICER (£ per QALY)
CET+ FOLFOX 41,301 2.22 1.64
FOLFOX 26,408 1.81 1.32
Increment (CET + FOLFOX vs. FOLFOX) 14,894 0.41 0.32 36,048 46,503
CET, cetuximab; LY, life-year.
Source: Merck submission, section 3.6.1.1, table 28, p. 61.
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Univariate sensitivity analysis
Merck Serono also conducted univariate sensitivity analyses to find the most influential parameters in the
model. For both the FOLFOX and the FOLFIRI comparisons, the parameters used to estimate the costs of
treatment (number of months of treatment, average body surface area), time in PFS, utility in PFS and the
proportion of patients who underwent liver resection were the parameters that had the largest effects on
the ICERs.
TABLE 76 Disaggregated results: cetuximab plus FOLFOX compared with FOLFOX, fortnightly cetuximab dose
Outcomes CET+ FOLFOX FOLFOX Increment (CET+ FOLFOX vs. FOLFOX)
Costs (£)
PF (first line) 25,741 9888 15,853
Post resection (PD) 364 153 211
Post resection (PF) 0.00 0.00 0.00
PD (second line) 7289 7968 –679
PD (third line) 7907 8398 –491
Total 41,302 26,408 14,894
LYs
PF (first line) 1.02 0.73 0.29
Post resection (PD) 0.08 0.02 0.06
Post resection (PF) 0.19 0.05 0.13
PD (second line) 0.30 0.33 –0.03
PD (third line) 0.63 0.67 –0.04
Total 2.22 1.81 0.41
QALYs
PF (first line) 0.79 0.56 0.22
Post resection (PD) 0.06 0.02 0.04
Post resection (PF) 0.15 0.04 0.10
PD (second line) 0.23 0.25 –0.02
PD (third line) 0.42 0.45 –0.03
Total 1.64 1.32 0.32
CET, cetuximab; LY, life-year; PF, progression free; PD, progressive disease.
Source: Merck Serono executable model.
TABLE 77 Deterministic base-case results: cetuximab plus FOLFIRI compared with FOLFIRI, fortnightly
cetuximab dose
Treatment Costs (£) LYs QALYs ICER (£ per LY) ICER (£ per QALY)
CET+ FOLFIRI 43,592 2.19 1.61
FOLFIRI 27,139 1.81 1.32
Increment (CET + FOLFIRI vs. FOLFIRI) 16,453 0.38 0.29 42,990 55,971
CET, cetuximab; LY, life-year.
Source: Merck submission, section 3.6.1.1, table 28, p. 61.
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Scenario analysis
Merck Serono conducted a scenario analysis in which cetuximab plus FOLFOX was compared with an
alternative chemotherapy strategy, XELOX (also referred to as CAPOX). It assumed the same effectiveness
of XELOX as FOLFOX but a higher cost. As the cost of XELOX was calculated to be higher than that of
FOLFOX, the ICER for cetuximab plus FOLFOX compared with XELOX was slightly lower than the ICER for
cetuximab plus FOLFOX compared with FOLFOX (£42,853 per QALY gained vs. £46,503 per QALY gained).
The results are presented in Table 80.
TABLE 78 Disaggregated results: cetuximab plus FOLFIRI compared with FOLFIRI, fortnightly cetuximab dose
Outcomes CET+ FOLFIRI FOLFIRI Increment (CET+ FOLFIRI vs. FOLFIRI)
Costs (£)
PF (first line) 27,193 10,000 17,193
Post resection (PD) 385 160 224
Post resection (PF) 0.00 0.00 0.00
PD (second line) 7927 8492 –565
PD (third line) 8087 8487 –400
Total 43,592 27,139 16,453
LYs
PF (first line) 0.97 0.73 0.25
Post resection (PD) 0.08 0.02 0.06
Post resection (PF) 0.19 0.05 0.13
PD (second line) 0.30 0.33 –0.02
PD (third line) 0.65 0.68 –0.03
Total 2.19 1.81 0.38
QALYs
PF (first line) 0.75 0.56 0.19
Post resection (PD) 0.06 0.02 0.04
Post resection (PF) 0.15 0.04 0.10
PD (second line) 0.23 0.25 –0.02
PD (third line) 0.43 0.45 –0.02
Total 1.61 1.32 0.29
CET, cetuximab; LY, life-year, PF, progression free, PD, progressive disease.
Source: Merck Serono executable model.
TABLE 79 Deterministic base-case results: cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI,
fortnightly cetuximab dose
Treatment Costs (£) LYs QALYs ICER (£ per LY) ICER (£ per QALY)
CET+ FOLFIRI 37,978 2.16 1.60
BEV + FOLFIRI 34,605 2.03 1.49
Increment (CET + FOLFIRI vs. BEV+ FOLFIRI) 3373 0.14 0.10 24,191 32,726
BEV, bevacizumab, CET, cetuximab, LY, life-year.
Source: Merck submission, section 3.6.1.1, table 28, p. 61.
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Subgroup analysis
Merck Serono conducted a subgroup analysis for a population with metastases confined to the liver. As we
were unable to reconcile this analysis against the overall population model, we present the results here
without comment (Table 81).
Critique of the Merck Serono model
In this section we use our critique of the executable model provided by Merck Serono to assess the impact
of parameters that we believe to be inappropriate on the cost-effectiveness results. These help form the
basis of the comparison between Merck Serono’s results and our cost-effectiveness results.
Model structure
No major wiring errors were discovered in the Merck Serono model. Several small errors and inconsistencies
were discovered in the Markov trace sheets, but these had a minimal impact on the ICERs, for example the
ICER for cetuximab plus FOLFOX compared with FOLFOX changed from £46,503 per QALY gained to
£47,185 per QALY gained once these errors were resolved.
Model parameters
Time on treatment. As stated earlier, Merck Serono assumed that no first-line drugs were given after a
certain cut-off time, which varied slightly by treatment arm. It provided no justification for the cut-off
times. In NICE TA242,139 which considered the cost-effectiveness of cetuximab for post-first-line treatment
of mCRC, Merck Serono assumed cut-off times for cetuximab that were comparable to those in the
current analysis: 13 weeks for cetuximab plus BSC and 24 weeks for cetuximab plus irinotecan plus BSC.
As the Assessment Group, we, PenTAG, disagreed with the use of a cut-off time and argued for far longer
treatment durations. We estimated a mean treatment duration of 4.8 months for cetuximab compared
TABLE 80 Deterministic results: cetuximab plus FOLFOX compared with XELOX
Treatment Costs (£) LYs QALYs ICER (£ per LY) ICER (£ per QALY)
CET+ FOLFOX 41,302 2.22 1.64
XELOX 27,577 1.81 1.32
Increment (CET + FOLFOX vs. XELOX) 13,725 0.41 0.32 33,219 42,853
CET, cetuximab; LY, life-year.
Source: Merck submission, section 3.7.3.1, table 31, p. 67.
TABLE 81 Deterministic results: liver metastases subgroup
Treatment Costs (£) LYs QALYs ICER (£ per LY) ICER (£ per QALY)
CET + FOLFIRI vs. FOLFIRI
CET+ FOLFIRI 45,422 2.76 2.04
FOLFIRI 27,790 2.18 1.60
Increment (CET + FOLFIRI vs. FOLFIRI) 17,632 0.59 0.45 29,955 39,545
CET + FOLFOX vs. FOLFOX
CET+ FOLFOX 43,692 2.30 1.69
FOLFOX 26,199 1.49 1.07
Increment (CET + FOLFOX vs. FOLFOX) 17,494 0.81 0.62 21,465 28,230
CET, cetuximab; LY, life-year.
Source: Merck submission, ‘List of changes’ document, received 26 June 2015.
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with 2.6 months estimated by Merck Serono (section 4.3.13139) and 8.8 months for cetuximab plus
irinotecan compared with 4.4 months estimated by Merck Serono (section 4.3.14139).
The NICE committee preferred our estimates of treatment duration, as detailed below:
The Committee therefore concluded that it did not accept the assumption in the manufacturer’s model
that a fixed treatment period for cetuximab represented UK clinical practice
Reproduced with permission from National Institute for Health and Clinical Excellence (2012).139
Section 4.4.11. Available from www.nice.org.uk/guidance/ta242 (accessed 13 March 2017).
Content accurate at time of going to press
The Committee also noted that because the manufacturer did not provide an estimate of the average
length of cetuximab treatment in the CO.17 trial, the Assessment Group contacted Dr Mittman to
obtain this estimate after the assessment report had been submitted to the Committee. This estimate
was provided to the Committee as an addendum, and is not given in this document because it is
considered academic-in-confidence. The Committee agreed that this estimate of time on treatment
was more appropriate because it was derived from trial data rather than from an assumption.
Reproduced with permission from National Institute for Health and Clinical Excellence (2012).139
Section 4.4.14. Available from www.nice.org.uk/guidance/ta242 (accessed 13 March 2017).
Content accurate at time of going to press
In the course of this appraisal, Merck Serono provided us with mean treatment durations (CiC) [24 August
2015, personal communication (via NICE)]. We have used these to produce our estimates of treatment duration
and they are discussed in Chapter 6 (seeModel parameters, First line time on treatment). Importantly, we did
not apply a cut-off time and the estimates of treatment duration are greater than those used in the Merck
Serono model. We adjusted these values to ensure that we did not model first-line drug treatment after
progression, as both we and Merck Serono assumed no clinical benefit of any first-line treatment after
progression (as our models use only PFS, not OS, from the first-line RCTs) (see Chapter 6, Structure of the
Peninsula Technology Assessment Group model).
The result is that we assumed far longer treatment durations than Merck Serono. This has the important
effect that we estimated higher drug acquisition and drug administration costs.
Utilities In general, we agree with the sources and approach used by Merck Serono to identify and
implement utilities.
Merck Serono used the study by Bennett et al.115 to obtain estimates of utilities for first- and second-line
treatment. As no RAS WT utility data have been identified, we agree that this is the most relevant source
currently available. We also agree that there is no significant evidence of a difference between treatment
arms (or over time) based on published results of quality of life for first- and second-line KRAS WT mCRC
populations (Table 82).
TABLE 82 Comparison of base-case health-state utilities in the Merck Serono and PenTAG models
Health state Merck Serono PenTAG
First line 0.778 0.767
Second line 0.769 0.762
Third line 0.663 0.641
PFS post resection 0.789 < 0.831 (age related)
Disutility PD post resection 0.107 0.142
PD, progressive disease.
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Merck Serono used an estimate of utility from the study by Wang et al.116 for third-line treatment. Again,
this source is appropriate as it is for a previously treated KRAS WT mCRC population who are receiving
BSC (see Table 82).
Although we agree with these sources, the PenTAG base case used alternative values based on these
sources (see Table 82). Further information on the values and the sources themselves can be found in
Chapter 6 (see Model parameters, Utilities).
Merck Serono used the higher estimates of utility reported at baseline for the panitumumab plus chemotherapy
populations.115 We believe that a better estimate for first-line treatment would be to take a weighted average of
the treatment arms (0.767), under the assumption that any difference in utility between them is the result of
random chance. This is discussed in detail in Chapter 6 (seeModel parameters, Utilities). Applying this value
results in only a slight increase in the ICERs.
In second line, as patients are expected to receive only chemotherapy alone in practice, we believe that it
would be more appropriate to use the utility estimate for the FOLFIRI-only population (0.762). Again,
Merck Serono’s ICERs change only very slightly when this value is applied.
Merck Serono’s estimate of utility in third-line BSC is for patients without symptoms of disease or toxicity.
We believe that it would be more appropriate to use an utility estimate for those in the progressive disease
state (reduced utility of 0.641). This leads to a marginal increase in the ICERs compared with
Merck Serono’s base case.
As the utilities for Merck Serono’s base case and our base case are quite similar, the impact of altering
these values is minimal. Even altering first-, second- and third-line utilities to be in line with those in the
PenTAG model results in ICER changes of < £1000.
Merck used general population estimates for utility for PFS post resection, which is the same approach
used in the PenTAG model. However, we recommend using the approach of Ara and Brazier130 to calculate
this utility, adjusted for more recent Health Survey for England data.131 The value used in the PenTAG
submission was also adjusted for age throughout the model and therefore has a maximum value of 0.831
for the starting age of 63 years in the base case. For post-resection progressive disease states in the Merck
Serono model, the utility was assumed to be a weighted average of the second- and third-line health
states, adjusted for time in each state. Again, this seems a reasonable assumption and is an approach that
we also used; however, as our post-resection PFS utility altered according to age, we instead calculated a
disutility to apply in this state (0.142).
Once again, adjusting for these parameters resulted in very little change to the ICERs in the Merck
Serono model.
Costs
RAS mutation testing The cost of RAS mutation testing used in Merck Serono’s model (£200) seems
appropriate and information from other genetics laboratories in the UK (discussed in Chapter 6, see Costs,
Cost of RAS testing) has reinforced the suitability of this cost. However, in the model, this cost is applied to
both arms with cetuximab and arms without cetuximab. If all patients were treated with FOLFOX or
FOLFIRI alone, a test for RAS mutation status would not be performed. RAS mutation testing can be used
as a prognostic tool, but this does not occur in UK practice and for some hospitals RAS mutation testing is
available only through the CDF as a prerequisite for cetuximab or panitumumab treatment (Dr Mark Napier,
2015, personal communication). Removing this cost from the FOLFOX and FOLFIRI arms has a minimal
impact on cost-effectiveness.
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Drug acquisition After allowing for drug wastage, but not dose intensity, similar acquisition costs per
month for cetuximab and bevacizumab were estimated by Merck Serono and us. However, Merck Serono
estimated far higher costs for FOLFOX and FOLFIRI (Figure 9). This is because it used list prices, whereas we
obtained discounted drug acquisition costs from the Commercial Medicines Unit Electronic Market
Information Tool (CMU eMit) database140 in our base case. Merck Serono did not consider panitumumab.
Merck Serono estimated the mean total cost of drug acquisition as the product of the mean time on
first-line treatment and the cost of treatment per unit time, with no allowance for dose intensity. We also
estimated the mean total cost of drug acquisition as the product of the mean time on first-line treatment
and the cost of treatment per unit time, but we also allowed for dose intensity.
Although we used a similar method of calculation and although our estimate of the mean cost per unit
time for cetuximab is similar, Merck Serono’s estimates of the mean total cost of drug acquisition are far
lower than ours for cetuximab plus FOLFOX and cetuximab plus FOLFIRI. This is because we assumed a
greater time on treatment than Merck Serono, as discussed earlier.
Although we estimated longer treatment durations than Merck Serono for FOLFOX and FOLFIRI, we
estimated lower mean total costs for these treatments. This is because we estimated lower costs per unit
time than Merck Serono for FOLFOX and FOLFIRI, as discussed earlier. However, this large difference in the
mean total cost of acquisition of FOLFOX and FOLFIRI between us and Merck Serono had little impact on
cost-effectiveness, as FOLFOX and FOLFIRI are used in both treatment arms in any comparison.
Our estimate of the total cost of acquisition of bevacizumab plus FOLFIRI is coincidentally similar to that of
Merck Serono. One the one hand, we estimate a far greater treatment duration, whereas on the other
hand we estimate a far lower cost per unit time. These two effects cancel each other out to a large extent.
In the rest of this section we critique Merck Serono’s estimates of drug prices.
We believe that some of the drug acquisition costs used by Merck Serono were not appropriate for the
following reasons:
l the costs of certain agents, and particularly those for oxaliplatin, irinotecan and capecitabine, did not
include very significant discounts that are reliably obtained by the NHS
l the drug acquisition costs for XELOX were overestimated because a 14-day cycle was assumed instead
of the actual 21-day cycle
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FIGURE 9 Mean first-line drug acquisition costs: PenTAG vs. Merck Serono. BEV, bevacizumab; CET, cetuximab.
DOI: 10.3310/hta21380 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 38
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105
l the dosages for some agents in some regimens appear to be incorrect
l leucovorin tablets were assumed instead of leucovorin vials for infusion
l the premedication assumed for cetuximab does not appear to match the premedication recommended
in the SPC.35
The combined effect of replacing the drug acquisition costs used by Merck Serono with values preferred by
PenTAG is to reduce the total discounted costs of all regimens, but most significantly the cost of XELOX.
Cetuximab becomes slightly less cost-effective than comparators.
The NICE Guide to the Methods of Technology Appraisal128 states that ‘When there are nationally available
price reductions . . ., the reduced price should be used in the reference-case analysis to best reflect the
price relevant to the NHS’ and makes reference to the CMU eMit database for medicines in the National
Generics Programme Framework for England [reproduced with permission from National Institute for
Health and Care Excellence (2013). Guide to the Methods of Technology Appraisal. Available from
www.nice.org.uk/process/pmg9 (accessed 13 March 2017)]. The CMU eMit database140 includes average
acquisition costs for oxaliplatin, irinotecan, capecitabine, 5-fluorouracil, leucovorin and suitable
premedications for cetuximab. Table 83 indicates that substantial price reductions are achieved of, on
average, 87–98% of the list price.
The drug acquisition costs for XELOX were further overestimated because the model submitted by
Merck Serono assumed a 14-day cycle, whereas XELOX is administered on a 21-day cycle (with 7 rest days).
Merck Serono assumed that, for FOLFOX4, the dosages for each cycle are as follows: oxaliplatin 85 mg/m2,
leucovorin 200 mg/m2 and 5-fluorouracil 1600 mg/m2. We believe that the correct dosage for leucovorin is
400 mg/m2 (200 mg/m2 infusions on days 1 and 2) and for 5-fluorouracil is 2000 mg/m2 (400 mg/m2 bolus
and 600 mg/m2 prolonged infusion on days 1 and 2).23,27 Merck Serono assumed that, for FOLFOX6, the
dosages for each cycle are as follows: oxaliplatin 100 mg/m2, leucovorin 200 mg/m2 and 5-fluorouracil
2800 mg/m2. We believe that the correct dosage for leucovorin is 400 mg/m2 (or 200 mg/m2 levoleucovorin,
which is equivalent).24,28 When the price for leucovorin is estimated based on the average acquisition cost in
the NHS (see Table 83), this does not have a significant impact on overall costs or cost-effectiveness.
It was assumed that leucovorin tablets were used for infusion instead of vials. Leucovorin is administered
intravenously over 1 hour in all regimens (except for XELOX), so tablets are not appropriate. The NHS, on
average, acquires leucovorin tablets at a cost of £0.083 per mg, whereas vials cost £0.0276 per mg.140
The SPC for cetuximab states that premedication with an antihistamine and a corticosteroid is mandatory
prior to the first cetuximab infusion and is recommended prior to subsequent infusions.35 Merck Serono
assumed that doxycycline (an antibiotic), ondansetron (an antiemetic) and dexamethasone (a corticosteroid)
TABLE 83 Nationally available price reductions for drugs used in chemotherapy regimens
Agent
Unit cost based on
list price (BNF16)
(£ per mg)
Unit cost based on
average acquisition cost
(CMU eMit140) (£ per mg) Average discount (%)
Oxaliplatin 3.10 0.0630 98
Irinotecan 1.14 0.0742 93
Fluorouracil 0.0128 0.0012 91
Leucovorin 0.2249 0.0276 88
Capecitabine 0.0047 0.0006 87
BNF, British National Formulary.
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[Auden Mckenzie (Pharma Division) Ltd, Ruislip, UK] would be used as premedication and therefore seems
to have included an antibiotic and an antiemetic that are not indicated in the SPC (although they may be
used in practice, they may also be used in practice across regimens) and has not included an antihistamine.
PenTAG estimated that the overall impact of this is small as all of these premedication drugs are
inexpensive, particularly considering the reliably obtained discounts.
Finally, Merck Serono calculated wastage based on average patient characteristics, including an average
patient body surface area of 1.79 m2 and body mass of 80 kg. We believe more appropriate values are
1.84 m2 and 74.7 kg, respectively, which in the absence of drug wastage would increase the acquisition
costs of all drugs except bevacizumab, which uses weight-based dosing. However, these increases are
unlikely to have a significant impact given wastage. We are also satisfied that calculating wastage based
on mean patient characteristics (rather than calculating average wastage based on a distribution of patient
characteristics) is unlikely to significantly impact on cost-effectiveness in this case. This is because, as the
Assessment Group, we found this to be the case for the NICE HTA of cetuximab, panitumumab and
bevacizumab for subsequent lines of treatment for mCRC in 2011.141 We note that accounting for the
distribution of patient characteristics can, in general, impact on cost-effectiveness in other situations.142
The combined effect of replacing the drug acquisition costs used by Merck Serono with values preferred by
PenTAG is that the total discounted costs of all regimens are reduced, with the costs of XELOX reduced
the most. The ICER for cetuximab plus FOLFOX compared with FOLFOX increases slightly, from approximately
£46,500 to £51,900 per QALY, and the ICER for cetuximab plus FOLFIRI compared with FOLFIRI increases
from £56,000 to £62,900 per QALY, which is likely to be because of the reduced costs of second-line
treatment (meaning that extending the time before second-line treatment has less of a beneficial impact on
cost-effectiveness).
Drug administration We believe that the drug administration costs used by Merck Serono were not
appropriate for the following reasons.
l NHS reference costs were used inappropriately for all regimens.
l The drug administration costs for XELOX were particularly poorly estimated.
l Drug administration activity on the second day each cycle for FOLFOX4 was not costed.
l An outpatient setting was assumed for all patients in first-line treatment.
l Other cost items were not included.
The combined effect of replacing the drug administration costs used in Merck Serono’s model with values
preferred by PenTAG is to increase the total discounted costs for all regimens, with the costs of regimens
containing FOLFOX4 increasing the most and the costs of regimens including XELOX increasing the least.
NHS reference costs were used inappropriately in the following ways.
1. Inpatient drug administration costs were estimated using outpatient drug administration reference costs
from 2012/13133 (with no justification provided). The NHS reference costs do not include the costs of
chemotherapy delivery in an inpatient setting, but, given that inpatient and ‘day case’ seem to have
been used interchangeably, the more appropriate costs to use are those in the ‘Daycase and Regular
Day/Night’ setting, and from the most recent reference costs (2013/14134).
2. The HRG code SB15Z (Deliver Subsequent Elements of a Chemotherapy Cycle) was used inappropriately
for administration costs for complete cycles after the first chemotherapy cycle rather than for activity
not on the first day of a chemotherapy cycle. The first attendance in every cycle should use the HRG
code SB14Z (or another delivery code except for SB15Z) and then any subsequent attendances within
each cycle should use SB15Z.
The drug administration costs for XELOX were poorly estimated because Merck Serono did not account for
the longer duration of XELOX cycles (3 weeks rather than 2 weeks), which results in a 33% reduction in
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administration costs, and because Merck Serono continued to use HRG code SB14Z (Deliver Complex
Chemotherapy, including Prolonged Infusional Treatment, at First Attendance) for XELOX even though the
duration of infusion is significantly shorter. We believe that SB13Z (Deliver More Complex Parenteral
Chemotherapy at First Attendance) is more appropriate and also results in a cost reduction.
The drug administration costs for FOLFOX4 were poorly estimated because no account was taken of the
necessity for an attendance or health-care professional visit to deliver the bolus and prolonged infusion on
the second day of each cycle. We believe that this should generate an additional cost estimated by HRG
code SB15Z each cycle.
Merck Serono also assumed that first-line chemotherapy is always delivered in the outpatient setting,
whereas second-line chemotherapy is always delivered in an inpatient/day-case setting. The NHS reference
costs and clinical expert opinion suggest that, in fact, the day-case setting is more common overall. This
has a significant impact as the costs in the day-case setting are often more expensive.
When we used our unit costs of drug administration in place of Merck Serono’s unit costs, Merck Serono’s
base-case ICERs for cetuximab plus chemotherapy compared with chemotherapy only altered marginally.
Medical management We believe that some of the medical management costs used by Merck Serono
are inappropriate for the following reasons.
l No medical management was assumed in the progression-free health states or in the second-line
progressive disease state.
l The cost of oncology outpatient attendances was estimated from an inappropriate NHS reference cost
and should be roughly half the price.
Merck Serono assumed no medical management in the progression-free health states or in the second-line
progressive disease state. This is not appropriate because patients in these states will receive medical
management in the form of regular consultant outpatient appointments and imaging (CT) to monitor
response to treatment.
The cost of oncology outpatient attendances was estimated from HRG code SB01Z (Procure Chemotherapy
Drugs for Regimens in Band 1) in the outpatient setting, which is incorrect. Instead, the cost of outpatient
attendances should have been estimated from service code 370 (medical oncology), which would have
resulted in a cost of £144 (consultant led; 2012/13 prices) as opposed to £333 (2012/13 prices).
The executable model submitted by Merck Serono did not allow for medical management costs to be
added to the states in which they are not currently modelled, but it is not considered likely that
incorporating values preferred by PenTAG would significantly affect cost-effectiveness as medical
management costs are significantly smaller than the costs associated with chemotherapy and do not vary
between regimens. Indeed, using our model, we find that cost-effectiveness is insensitive to these costs.
However, we estimate a higher cost per unit time for treatment post progression for resected patients.
We assumed a cost of £1254 per month, whereas Merck Serono assumed a cost of £315 per month.
When we used our estimate, Merck Serono’s base-case ICERs increased slightly:
l cetuximab plus FOLFOX compared with FOLFOX – from £47,000 to £49,000 per QALY
l cetuximab plus FOLFIRI compared with FOLFIRI – from £56,000 to £59,000 per QALY.
Liver resection We believe that Merck Serono’s estimate of the cost of liver resection (£2707) is too low.
In TA176,10 the NICE committee agreed that an average cost of £8900 for liver resection was an accurate
reflection of current UK clinical practice. Furthermore, the HRG codes selected by Merck Serono refer to
malignant gastrointestinal tract disorder, which, although relevant to CRC, do not appear to be entirely
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relevant for liver surgery. More appropriate codes are those associated with very complex liver resection
surgery, which we use in our base case.
Using our estimate of liver surgery (£17,582), which includes repeat operations and the chance of
operation failure, Merck’s base-case ICERs increase slightly:
l cetuximab plus FOLFOX vs. FOLFOX – from £47,000 to £49,000 per QALY
l cetuximab plus FOLFIRI vs. FOLFIRI – from £56,000 to £59,000 per QALY.
Adverse events In Merck Serono’s executable model, the disutility for leukopenia was reported to be the
same as that for neutropenia, but the value used was for the disutility for skin reactions. However,
correcting this does not alter the ICERs.
The length of time that the AEs occur for in Merck Serono’s model (a 1-month cycle) seems quite long.
Previous estimates of the duration of AEs suggest that this should be much shorter, as described in study
by Freeman et al.143 Reducing the length of time that AEs occur for primarily reduces the disutility of these
AEs, but also affects some costs. Reducing the duration of AEs to 7 days, as in the PenTAG model,
changes the ICERs only marginally.
The main driver for the costs and QALYs associated with the AEs is the type and incidence of each AE.
The Merck Serono model appears to use AE data for the KRAS WT population rather than the RAS WT
population, as the incidences reported for the CRYSTAL trial24,43 are different in Merck Serono’s model
from what is reported in our clinical effectiveness results. As the PenTAG and Merck Serono models
include very different sets of AEs and PenTAG includes comparisons of more than two technologies, it is
difficult to adjust individual parameters in the Merck Serono model to values that we believe are more
accurate. Instead, we present the total costs and QALYs associated with AEs in the PenTAG and
Merck Serono base cases (Table 84). Despite these being different, the AE costs and QALYs have little
impact on the overall results, increasing the ICERs by < £1500 when the PenTAG values are used.
Conclusions
As no economic evaluation was submitted by Amgen, and Merck Serono did not report results for
panitumumab, we are unable to draw conclusions about panitumumab based on the industry submissions.
The cost-effectiveness review submitted by Merck Serono did not raise any additional analyses relevant
to the decision problem. The model structure seems to be generally appropriate and fit for purpose.
Merck Serono concluded that its de novo analysis demonstrated that cetuximab was cost-effective, but
we believe that important parameter estimates such as treatment duration have been underestimated.
TABLE 84 Total AE costs and QALYs for the Merck Serono and PenTAG models
Arm of model
Total AE costs (£) Total AE QALYs
Merck Serono PenTAG Merck Serono PenTAG
CET+ FOLFOX 458 1472 –0.0075 –0.0018
FOLFOX 469 1039 –0.0058 –0.0012
CET+ FOLFIRI 567 803 –0.0111 –0.0009
FOLFIRI 418 780 –0.0077 –0.0005
CET, cetuximab.
Source: Merck Serono executable model.
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Chapter 6 Independent economic assessment
Methods
Comparator treatments
In our base-case analysis we simultaneously compared treatments separately within the following two
groups. All treatments were in the NICE scope.14
1. FOLFOX network:
¢ cetuximab plus FOLFOX
¢ panitumumab plus FOLFOX
¢ FOLFOX
2. FOLFIRI network:
¢ cetuximab plus FOLFIRI
¢ FOLFIRI.
Two networks were considered as we found no RCT evidence that connects the networks (see Chapter 3,
Results).
These treatments are all widely used on the NHS (Table 85).
Bevacizumab-based treatments
Bevacizumab plus FOLFOX and bevacizumab plus FOLFIRI are both listed as treatments in the NICE scope.14
However, NICE has not recommended these treatments for first-line mCRC. Furthermore, as discussed in
Chapter 1, since the NICE scope was issued, bevacizumab-containing treatment for first-line mCRC has
been delisted from the CDF.18 For this reason, we did not consider this as a comparator in our base-case
analysis.
TABLE 85 Current use of comparator treatments in England and Wales
Scope comparatora Merck Serono PenTAGb
Cetuximab/panitumumab + oxaliplatin- or
irinotecan-based chemotherapy
Important 30% of all patients
Bevacizumab+ oxaliplatin or irinotecan-based
chemotherapy
Not reflected in clinical practice as bevacizumab
is no longer funded by NHS England or the CDF
for the treatment of CRC. Therefore, these
comparisons are not meaningful (Merck Serono
submission, p. 69)
10% of all patients
FOLFOX/XELOX Important 30% of all patients
FOLFIRI/XELIRI Important 10% of all patients
Capecitabine Not comparators 20% of all patients
Tegafur, folinic acid and 5-fluorouracil
a Including those available through the CDF.
b Estimated by our clinical advisor (Dr Mark Napier, 2015, personal communication).
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However, in a sensitivity analysis, we considered bevacizumab plus FOLFOX in the FOLFOX network and
bevacizumab plus FOLFIRI in the FOLFIRI network, as these treatments have recently accounted for
approximately 10% of all eligible patients (see Table 85).
XELOX
In common with Merck Serono we modelled CAPOX/XELOX as a comparator treatment in a scenario
analysis, assuming equal clinical effectiveness for CAPOX/XELOX and FOLFOX. As in the Merck Serono
model, we assumed that the only difference between CAPOX/XELOX and FOLFOX was in the treatment
acquisition and administration costs (see Chapter 5, Comparator treatments, XELOX).
Capecitabine monotherapy and tegafur, folinic acid and 5-fluorouracil
Although our estimates suggest that they account for 20% of all first-line treatments in patients with
metastatic cancer treated on the NHS, capecitabine monotherapy and 5-fluorouracil plus folinic acid are
not included as comparators in our model. On advice from our clinical advisor, we believe that these single
fluoropyrimidine regimens are used only in patients for whom combination therapies are not suitable, for
example when patients have comorbidities such as diabetes or liver dysfunction for which oxaliplatin or
irinotecan would not be appropriate. Merck Serono stated that capecitabine is ‘typically used in elderly
patients with poor performance status’ (Merck Serono submission, table 4, p. 20), which broadly agrees
with our clinical advisor.
If the subgroup of first-line mCRC patients for whom combination chemotherapies are not recommended were
to be modelled, it should be included as a separate subgroup in every treatment arm. As such, this subgroup
would apply to all arms equally and it would therefore have no impact on the cost-effectiveness results.
To model these treatments as a separate arm seems clinically implausible (our estimates suggest that 80%
of patients receive combination chemotherapy in clinical practice and that single fluoropyrimidine regimens
are not the preferred first-line treatment). Furthermore, no evidence of single fluoropyrimidine regimens in
comparison to cetuximab or panitumumab was identified in our clinical effectiveness review. The trials that
inform the treatment effect of panitumumab and cetuximab are restricted to patients who can receive
combination chemotherapies and therefore the patients who receive single fluoropyrimidine regimens are
not accounted for in these effectiveness estimates.
We also did not model tegafur because, as well as being used in single fluoropyrimidine regimens, tegafur/
uracil (the combination most appropriate to this assessment) has been discontinued in the UK and no
relevant alternatives are available (Merck Serono submission, table 4, p. 20).
Patient population and liver metastases subgroup
In common with Merck Serono and the NICE scope,14 we considered two patient populations:
1. all first-line patients with RAS WT mCRC
2. a subgroup of these patients with liver metastases confined to the liver (liver metastases subgroup).
We estimated that the liver metastases subgroup included approximately 26% of all patients, based on the
patients in the five pivotal RCTs [based on data submitted by Amgen and Merck Serono, 19 March 2015,
personal communication (via NICE)].
The following parameters were unique for the liver metastases subgroup:
l resection rates
l PFS for unresected patients
l treatment duration.
All other parameters were unchanged from those in the total population analysis.
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In contrast, Merck Serono claimed that it changed only the resection rates and PFS for unresected patients
for the liver metastases population.
Model structure
Structure of relevant published models
Key aspects of the structure of relevant published models of the cost-effectiveness of drugs for first-line
mCRC are provided in Table 86. This table includes all models that we included in our systematic review,
plus the Merck Serono model from TA176.10 Although the Merck Serono model was included in our
review, as it was based on KRAS WT patients, we have included this model in the table as the current HTA
is a review of TA176. For comparison, we also include our current model in the table.
TABLE 86 Structure of relevant published cost-effectiveness models compared with that of the current
PenTAG model
Model
component
TA176 Merck
Serono model,
ERG report144
and Westwood
et al.45 Graham et al.107
Jarrett et al.108/
SMC 2014
submission118
Ortendahl
et al.109
PenTAG: this
HTA
Patients First-line mCRC
KRAS WT
First-line mCRC
RAS WT
First-line mCRC
RAS WT
First-line mCRC
RAS WT
First-line mCRC
RAS WT
Treatments CET+ FOLFIRI vs.
FOLFIRI;
CET+ FOLFOX vs.
FOLFOX
PAN+ FOLFOX vs.
BEV + FOLFOX
CET+ FOLFIRI vs.
FOLFIRI;
CET+ FOLFOX vs.
FOLFOX
CET+ FOLFIRI vs.
BEV + FOLFIRI
CET+ FOLFIRI vs.
BEV+ FOLFIRI vs.
FOLFIRI;
CET+ FOLFOX vs.
PAN+ FOLFOX vs.
BEV+ FOLFOX
vs. FOLFOX
Health states
PFS and drug
costs
First-line treatment
assumed up to
progression or
until curative
resection
Number of cycles
of treatment from
the PEAK trial29
Not stated Not stated First-line
treatment
assumed up to
progression
PD treatments
second line
FOLFOX or FOLFIRI
(FAD section
3.1810); split
between patients
with no resection
and patients with
unsuccessful
resection. PFS in
second line was
derived from
the PFS curves
published in
Tournigand et al.,111
regardless of the
time of progression
from the first line
Distribution of
treatments from
the PEAK trial:29
anti-EGFR + FOLFIRI
or BEV + FOLFIRI or
BSC. Treatment
duration was
estimated from
published PFS rates
in second-line
treatment145,146 (see
table 1 in Graham
et al.107), as this
was not collected
in the PEAK trial.
Transition
probabilities to
third-line
treatment were
calculated from
the weighted PFS
for each second-
line treatment
FOLFOX or
FOLFIRI. PFS in
second-line
treatment was
derived from the
PFS curves
published in
Tournigand
et al.,111 regardless
of the time of
progression from
the first line
Based on
treatments in the
FIRE-3 trial28
FOLFOX or
FOLFIRI,
independent of
treatment arm
continued
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TABLE 86 Structure of relevant published cost-effectiveness models compared with that of the current
PenTAG model (continued )
Model
component
TA176 Merck
Serono model,
ERG report144
and Westwood
et al.45 Graham et al.107
Jarrett et al.108/
SMC 2014
submission118
Ortendahl
et al.109
PenTAG: this
HTA
Treatments
third line
BSC (FAD section
3.1810). The
probability of
death was derived
from the study by
Jonker et al.,112
which compared
CET+ BSC with
BSC alone. Similar
to second-line
therapy, the risk
of death was
independent of the
treatment arm
BSC BSC. The
probability of
death was
derived from the
study by Jonker
et al.,112 which
compared
CET + BSC with
BSC alone
Not stated BSC. The
probability of
death was
derived from the
study by Jonker
et al.,112 with the
risk of death
independent of
treatment arm
After
successful
curative
resection
One health state
only; CET not
given
Two health states:
PFS and PD
One health state
only
One health state
only
Two health states:
PFS and PD
After
unsuccessful
curative
resection
As if no resection
attempted
As if no resection
attempted
Not stated Not stated As if no resection
attempted
Method of
estimating OS
Not clear but
appears to be a
combination of
survival in the
first-, second- and
third-line trials and
survival post
resection. It
appears that
survival from the
first-line trials was
not extrapolated
because of the
immaturity of the
data
From extrapolation
of OS data from
the PEAK trial29
Not clear but
stated that ‘the
PFS benefit
translates into a
direct overall
survival benefit’
(p. 9)118
Not stated Base case:
combination of
survival in the
first-, second-
and third-line
trials and survival
post resection.
Sensitivity analysis:
as Graham et al.107
(i.e. extrapolation
of OS from the
PEAK trial29)
Model basic variables
Patient age at
model entry
(years)
60 Not stated Not stated 63
Cycle length
(weeks)
1 2 4.3 (1 month) 2 4.3 (1 month)
Time horizon
(years)
23 20 10 30
BEV, bevacizumab; CET, cetuximab; ERG, Evidence Review Group; FAD, Final Appraisal Determination; PAN, panitumumab;
PD, progressive disease.
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
The model for the cost-effectiveness of KRAS testing by Westwood et al.45 was based on the Merck Serono
model for TA176.10 Indeed, the key model structures are identical (see Table 86).
Structure of the Peninsula Technology Assessment Group model
We identified two candidate model structures: structure 1 and structure 2 (Table 87). Ordinarily, we would
choose structure 2 because of the consistency between the costs and health outcomes. However, this is
arguably inappropriate because the RCTs of the first-line drugs included second-line drugs that are not
commonly used in the NHS (Table 88). Also, subsequent lines, for example second-line treatment, may
have a very strong effect on OS. For example, in the FIRE-3 trial28 there was no significant difference in
median PFS, but there was a significant difference in median OS (see Chapter 3, Results, Cetuximab) and
very different subsequent treatments between treatment arms (see Table 88).
TABLE 87 Candidate cost-effectiveness model structures
Model component Structure 1: PenTAG base case Structure 2: scenario analysis
Summary of clinical data Based on RCTs of first-line drugs up to
first-line progression;43,44,65 time on
second-line treatment based on second-line
trial of FOLFOX and FOLFIRI;111 time in
third-line BSC based on published data112
Based completely on RCTs of first-line
drugs43,44,65
Similarity to previous included
economic evaluations
Appears to be similar to the Merck Serono
TA17610 model
Graham et al.107
OS For unresected patients, the sum of times
on first, second and third lines of treatment,
allowing for mortality from each line, and
affected by survival for resected patients
(see end of this section for details)
Estimated by extrapolation from RCTs of
first-line drugs43,44,65
Subsequent treatments Second-line FOLFOX for patients on first-line
FOLFIRI-based treatments; second-line
FOLFIRI for patients on first-line FOLFOX-
based treatments
Percentage of patients taking each
subsequent treatment, as in the first-line
RCTs43,44,65
Advantages and disadvantages of methods
Simplicity Less complex More complex
Consistency between costs and
outcomes in RCTs
Mostly consistent, except we do not have
access to IPD for mortality on first-line
treatment only from the first-line RCTs.
Also, assumed that progression and survival
on second-line treatment do not depend on
first-line treatment
Consistent
Use of first-line RCT data Uses data up to progression only Uses all relevant data, including OS data
Effect of first-line treatment
post progression
Assumed either no effect or assumed equal
for all treatment arms
Captured (but confounded with effect of
subsequent lines of treatment)
Consistency with subsequent
lines of treatments on the NHS
Consistent, as FOLFOX and FOLFIRI are most
likely second-line treatments on NHS
Less consistent, as not all treatments
(e.g. cetuximab, panitumumab,
bevacizumab) after progression are
available on the NHS
Suitability for indirect
comparisons between multiple
treatment arms
Suitable Less suitable because the relative
numbers of patients taking the various
second-line treatments vary between
treatments in the evidence networks
IPD, individual patient data.
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Structure 1 assumed that the PFS benefits of the first-line drugs translate into OS benefits if the
subsequent lines of treatment are balanced between treatment arms. Expressed differently, we assumed
that survival after first-line progression was independent of first-line treatment, which seems plausible,
given a lack of evidence to the contrary. We used structure 1 in our base-case analysis.
Conversely, structure 2 assumed that OS is a product of responses to both first and subsequent lines of
treatment, as experienced in the RCTs. We considered structure 2 in a scenario analysis. Given the limited
data on subsequent treatments, we were forced to make approximations for the costs of these.
In our experience, both structures have been used in many previous NICE appraisals. For example, structure
1 was used in the recent NICE assessment of obinutuzumab in combination with chlorambucil for
previously untreated chronic lymphocytic leukaemia (TA343147) and was endorsed by the NICE committee.
Furthermore, we are not aware of any guidance concerning which structure is the most appropriate. We
note that Merck Serono also used structure 1 in its analysis (see Chapter 5, De novo economic evaluation).
The PenTAG cost-effectiveness model, implemented in Microsoft Excel® (2010; Microsoft Corporation,
Redmond, WA, USA), simulated a cohort of people with RAS WT mCRC starting on first-line line
treatment. The structure of the model was informed by a review of the literature (see Structure of relevant
TABLE 88 Second-line treatments in first-line mCRC RCTs
RCT
Treatment
strategy Population n
Anti-EGFR
(CET/PAN) (%)
Anti-VEGF
(BEV)
Oxaliplatin or
irinotecan Reference
FOLFOX network
PRIME44 PAN+ FOLFOX KRAS WT 325 13 NR 59%
chemotherapy
Douillard et al.26
(p. 1350)
FOLFOX 331 25 NR 65%
chemotherapy
PEAK29 PAN+ FOLFOX RAS WT 88 22
(presumably CET)
40% Irinotecan based
50%, oxaliplatin
based 13%
Schwarzberg
et al.29 (table 3
and appendix A2)
BEV+ FOLFOX 82 37
(presumably
mixture of
CET/PAN)
33% Irinotecan based
51%, oxaliplatin
based 23%
OPUS65 FOLFOX KRAS WT 97 18 19% Irinotecan based
48%, oxaliplatin
based 9%
Bokemeyer et al.22
(table 2)
CET+ FOLFOX 82 10 16% Irinotecan based
45%, oxaliplatin
based 18%
FOLFIRI network
FIRE-328 CET+ FOLFIRI KRAS WT 260 13 46% Oxaliplatin
based 34.3%a
Ortendahl et al.109
cost-effectiveness
analysis
BEV+ FOLFIRI 250 39 17% Oxaliplatin
based 38.3%a
CRYSTAL43 CET+ FOLFIRI KRAS WT 316 NR NR NR Van Cutsem
et al.25
FOLFIRI 350 NR NR NR
BEV, bevacizumab; CET, cetuximab; NR, not reported; PAN, panitumumab; VEGF, vascular endothelial growth factor.
a Numbers of living patients receiving second-line therapy extracted from Heinemann et al.;28 proportions for treatment
type extracted from Ortendahl et al.109
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published models) and the opinions of our clinical expert, Dr Mark Napier (2015, personal communication)
(Figure 10). The structure of our model is very similar to that of Merck Serono’s model (see Chapter 5,
De novo economic evaluation).
In Figure 10, straight arrows represent the possible transitions between health states. Circular arrows
denote that patients can remain in a state at the end of each model cycle. During each cycle, a patient is
assumed to be in one of the states. Patients are assumed to move between states once at the end of each
cycle. Patients can die while in any state.
As with Merck Serono’s model, differences in clinical effectiveness between first-line drug treatments are
represented by the differences between:
l first-line PFS
l resection rates
l incidences of AEs.
Estimates of cost and utility per cycle were assigned to each health state. These were aggregated over the
modelled time horizon to estimate the total per-patient costs and QALYs for each treatment. The main
economic outcome was the ICER, the incremental cost per QALY gained.
The model cycle length was 1 month and the model time horizon was 30 years, after which time virtually
all people in all cohorts have died. This is substantially longer than the 10-year time horizon assumed by
Merck Serono [we have criticised their assumption in Chapter 5 (see De novo economic evaluation)]. A
model half-cycle correction was applied.
Future costs and benefits were discounted at 3.5% per annum and the perspective was that of the NHS
and personal social services, in accordance with the NICE reference case.128
We assumed that all patients were aged 63 years at the start of first-line treatment and that 66% were
male, to be consistent with the clinical effectiveness data from the RCTs. In the model, this affects only the
age-related utilities and background mortality.
Death
PFS post successful
resectionPFS no drug
a
PD post successful
resection
PFS,
first-line drug
Second-line
FOLFOX/FOLFIRI
Third-line
BSC
FIGURE 10 Structure of the PenTAG cost-effectiveness model. PD, progressive disease. a, For cetuximab plus FOLFIRI
and FOLFIRI only.
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Baseline randomised controlled trials
For the FOLFIRI network, the CRYSTAL RCT43 was chosen as the baseline trial because this contains the
only two treatments in our base-case analysis, CET plus FOLFIRI and FOLFIRI. The other RCT, FIRE-3,28
includes BEV plus FOLFIRI, which we consider only in a sensitivity analysis.
For the FOLFOX network, the PRIME RCT44 was selected as the baseline trial as it included two of the three
treatments, PAN plus FOLFOX and FOLFOX, in our base-case analysis. The PEAK trial29 was not selected as
it included one treatment, BEV plus FOLFOX, not in our base case. Although the OPUS trial65 also included
two of the three treatments in our base-case analysis (CET plus FOLFOX and FOLFOX), we did not select
this trial as it was far smaller than the PRIME trial (87 vs. 512 RAS WT patients).
However, we used the OPUS trial as the baseline RCT for the FOLFOX network in a scenario analysis
(see Scenario analyses, OPUS trial as the baseline randomised controlled trial in the FOLFOX network).
In this case, the following parameters change in the FOLFOX network:
l resection rates
l PFS for unresected patients
l treatment durations (see Model parameters).
Modelled patients resected
Drug treatment can reduce the sizes of tumours to allow resection surgery to remove metastases. Our
clinical advisor, Dr Mark Napier, suggested that, generally, resection is offered only to patients with
metastases confined to the liver.
As in the Merck Serono model, and in all other previous models of treatments in this indication, we
assumed that a proportion of patients randomised to each treatment arm have liver metastases resected
(see Figure 10). This proportion varies by treatment arm and according to whether the cohort represents all
patients or only patients with liver metastases confined to the liver (liver metastases subgroup).
Life expectancy after successful resection is substantially greater than for patients without successful resection.
Survival after resection was split into PFS and progressive disease (see Figure 10, ‘PFS post successful resection’
and ‘PD post successful resection’), and patients could die from PFS and progressive disease.
Modelled first-line progression-free survival: unresected patients
In the RCTs relevant to this HTA, the mean time on first-line treatment was less than the mean time in PFS
for the CET + FOLFIRI and FOLFIRI treatments. Given that we also assumed that patients start second-line
treatment at the time of progression, for these two treatments there is therefore a period in first-line PFS
during which patients are on no active drug treatment (see Figure 10, ‘PFS, no drug’ state). In this way, for
unresected patients, first-line PFS was split into two states: on drug and not on drug. Merck Serono also
made this assumption, although it was not stated in its report. For all other treatments, patients were
assumed to receive first-line treatment for the complete duration of first-line PFS.
Time in the ‘PFS, no drug’ state was calculated as the difference between time in PFS first line and first-line
treatment duration, using the simple area under the curve method, that is, transition probabilities from
‘PFS, first-line drug’ to ‘PFS, no drug’ were not calculated explicitly.
As explained in Model parameters (see First-line progression-free survival: unresected patients), first-line PFS
for unresected patients was calculated using PFS from the five pivotal RCTs,28,29,43,44,65 with an adjustment
for indirect comparisons and an adjustment to subtract PFS for resected patients. First-line PFS for
unresected patients was calculated separately for all patients and for the liver metastases subgroup.
Patients could die from first-line PFS, that is, before progressing (see Figure 10).
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Modelled second-line treatments: unresected patients
We assumed that all unresected patients have second-line FOLFIRI after first-line FOLFOX-based treatment
and second-line FOLFOX after first-line FOLFIRI-based treatment (see Figure 10).
Merck Serono also made these assumptions (see Chapter 5, De novo economic evaluation).
Our clinical expert, Dr Mark Napier, advised us that this is the standard treatment for UK patients. In
addition, our assumptions are consistent with NICE clinical guideline 131,1 which recommends second-line
FOLFIRI or irinotecan treatment after first-line FOLFOX. After first-line FOLFIRI, there is no recommendation
for second-line treatment.
Even though second-line panitumumab, cetuximab and bevacizumab were used extensively in the relevant
RCTs (see Table 88), we did not model these because:
l NICE has recommended none of these treatments (Table 89)
l the CDF has recommended only second-line bevacizumab plus FOLFOX; it has recommended neither
panitumumab nor cetuximab
l our clinical expert, Dr Mark Napier, advised us that these treatments are used little in UK practice.
Modelled third-line treatment: unresected patients
Based on clinical advice, we assumed that all unresected patients have third-line BSC after progression on
second-line treatment. This consists of palliative care, with no active drug treatment.
Merck Serono assumed similarly that most patients (83%) receive third-line BSC, with only 17% receiving
capecitabine or cetuximab (see Chapter 5, De novo economic evaluation).
Overall survival
In our base-case analysis, we modelled only PFS from the RCTs. Life expectancy for all randomised patients
was calculated separately for each treatment arm as:
% patients resected × life expectancy given resected + (100%−% patients resected)
× life expectancy given unresected. (2)
The last quantity, life expectancy for unresected patients for each treatment arm, was calculated as the
sum of expected survival times on first, second and third lines of treatment, allowing for mortality from
each line (see Model parameters, Overall survival: unresected patients).
Model parameters
Most parameter values in the model are the same as or very similar to those assumed by Merck Serono.
The parameters that differ and that strongly affect cost-effectiveness are described in Comparison of the
results with those in the Merck Serono submission.
TABLE 89 Recommendations of NICE and the CDF for possible second-line drugs
Source
Second-line drug
Panitumumab Cetuximab Bevacizumab
NICE recommendations Monotherapy not
recommended139
Monotherapy or with
chemotherapy not
recommended139
Bevacizumab in combination with
fluoropyrimidine-based chemotherapy
not recommended139
CDF50 Not recommended Not recommended Bevacizumab+ FOLFIRI not recommended;
bevacizumab+ FOLFOX recommended
Patients could die from second-line PFS (see Figure 10).
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Resection rates
Resection of liver metastases is an important component of both our model and Merck Serono’s model
(see Figure 10) as we find that cost-effectiveness is sensitive to the rates of resection.
In TA176 (Final Appraisal Determination, p. 12),10 Merck Serono judged the rates of resection from the RCTs
to be low compared with clinical practice. Therefore, it considered a resection rate of 43% for the KRAS WT
population for CET plus FOLFIRI and CET plus FOLFOX, taken from the CELIM (Cetuximab in Neoadjuvant
Treatment of Non-Resectable Colorectal Liver Metastases) trial (cited as Folprecht et al.148 by Merck Serono).
This value is substantially greater than the resection rates in the RCTs. The NICE clinical experts and
committee instead preferred a lower value of 35% (Final Appraisal Determination, p. 20, p. 22),10 still
greater than in the RCTs.
Conversely, our clinical expert, Dr Mark Napier, believes that the rates of liver resection in normal practice
will be similar to or lower than those rates seen in the PEAK and CRYSTAL trials [2–13% for all patients,
Table 90; data on file from Amgen and Merck, 19 March 2015, personal communication (via NICE)].
TABLE 90 Liver metastases resection rates in RCTs
RCT Type of resection Treatment
Liver-limited subgroup,
% (n/N) All patients, % (n/N)
RAS WT KRAS WT RAS WT KRAS WT
FOLFIRI network
CRYSTAL Surgical resection –
attempted resection
CET + FOLFIRI 16.3 (7/43)
(Merck Serono)
NR 7.3 (13/178)
(Merck Serono)
NR
FOLFIRI 6.5 (3/46)
(Merck Serono)
2.1 (4/189)
(Merck Serono)
FIRE-3 Secondary resection of
liver metastases with
curative intent
CET + FOLFIRI Not reported NR NR 12.1
(36/297)28
BEV + FOLFIRI 13.6
(40/295)28
FOLFOX network
OPUS Rate of curative
metastatic surgery
(complete resection to
R0)
CET + FOLFOX 13.3 (2/15)
(Merck Serono)
NR NR 9.8
(6/61)23
FOLFOX 0 (0/12)
(Merck Serono)
4.1
(3/73)23
PEAK Rate of curative
metastatic surgery
(complete resection to
R0)
PAN + FOLFOX (Confidential
information has
been removeda)
(Amgen)
NR 12.5 (11/88)
(Amgen)
9.9
(14/142)29
BEV + FOLFOX (Confidential
information has
been removeda)
(Amgen)
11.0 (9/82)
(Amgen)
8.4
(12/143)29
PRIME Results reported in the
KRAS trials as complete
resection (R0) but
end-point definition was
‘reported as complete or
partial [status of surgical
margins not required to
be captured]’ (p. 1347)26
PAN + FOLFOX 31 (15/48)
(Amgen)
27.9
(17/61)26
(Confidential
information has
been removeda)
(Amgen)
9.5
(31/325)26
FOLFOX 17 (7/41)
(Amgen)
17.5
(10/57)26
(Confidential
information has
been removeda)
(Amgen)
7.6
(25/331)26
BEV, bevacizumab; CET, cetuximab; NR, not reported; PAN, panitumumab.
a AiC information.
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He believes that the CELIM trial data are not comparable as these represented carefully selected patients
with liver-only low-volume metastases and ‘nearly’ operable patients.
Given this, and in common with Merck Serono’s model, we used the resection rates from the RCTs
(see Table 90) to estimate the rates for use in our model (Table 91).
FOLFIRI network
In the FOLFIRI network, resection rates for cetuximab plus FOLFIRI and FOLFIRI were taken directly from the
CRYSTAL trial (Figure 11 and see Table 91). This was also the approach taken by Merck Serono.
For bevacizumab plus FOLFIRI, some assumptions were necessary. The ‘all patients’ resection rate for
bevacizumab plus FOLFIRI in the FIRE-3 trial28 for RAS WT patients was estimated as 17.7% [13.6% ×
(11.0%/8.4%); value for KRAS WT patients was 13.6% (see Table 90) and we adjust from the KRAS WT
population to the RAS WT population using a ratio of 11.0% : 8.4%, as in the PEAK trial29 for bevacizumab
plus FOLFOX].
Next, the ‘all patients’ value in the FIRE-3 trial28 for RAS WT patients for cetuximab plus FOLFIRI was
estimated as 14.6% [12.1%/83%; value for KRAS WT patients was 12.1% (see Table 90) and we assume
that 83% of KRAS WT patients are also RAS WT]. It was also assumed that only participants with RAS WT
tumours were resected, given that cetuximab plus FOLFIRI has been shown to be more effective, and is
licensed, for this population.
TABLE 91 Resection rates assumed in the PenTAG and Merck Serono models
Treatment
Liver-limited metastases RASWT subgroup (%) All RAS WT patients (%)
PenTAG Merck Serono PenTAG Merck Serono
FOLFIRI network
CET+ FOLFIRI 16.3a 16.3a 7.3a 7.3a
FOLFIRI 6.5a 6.5a 2.1a 2.1a
BEV + FOLFIRI 20.9 (derivation explained
in text)
9.0 (derivation explained
in text)
7.3 (no justification
given)
FOLFOX network
CET+ FOLFOX (Confidential information
has been removedb)c
(derivation explained
in text)
13.3d 20.7 (derivation explained
in text)
7.3 (derivation
explained in text)
FOLFOX 17.1c 0d (Confidential information
has been removedb)c
2.1111
PAN+ FOLFOX 31.3c NA, as not modelled (Confidential information
has been removedb)c
NA, as not modelled
BEV + FOLFOX (Confidential information
has been removedb)c
(derivation explained
in text)
NA, as not modelled (Confidential information
has been removedb)c
(derivation explained
in text)
NA, as not modelled
BEV, bevacizumab; CET, cetuximab; NA, not applicable; PAN, panitumumab.
a Merck Serono submission version 2, 15 June 2015.
b AiC information.
c PRIME trial data from Amgen, 19 March 2015, personal communication (via NICE).
d OPUS trial data from Merck Serono submission version 2, 15 June 2015.
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Finally, the logit of the value of 9.0% for bevacizumab plus FOLFIRI (see Table 91) was calculated on the
logit scale as logit(7.3%) + (logit(17.7%) – logit(14.6%)), in the manner of an adjusted indirect comparison,
in which 7.3% is the chosen value for cetuximab plus FOLFIRI and 17.7% and 14.6% are derived as
explained above. We worked on the logit transformation, as this ensured that the resulting resection rates
would lie between 0% and 100%.
This is slightly different from the value of 7.3% estimated by Merck Serono. Merck Serono did not justify
its value for the resection rate for bevacizumab plus FOLFIRI (7.3%), but it appears that this was set equal
to the resection rate for cetuximab plus FOLFIRI (7.3%).
In the liver metastases subgroup, the resection rates for cetuximab plus FOLFIRI and FOLFIRI were taken
directly from the CRYSTAL trial (see Table 91 and Figure 11). This was also the approach taken by
Merck Serono.
For bevacizumab plus FOLFIRI in the liver metastases subgroup, some assumptions were necessary. First,
we estimated the resection rate for the RAS WT population in the FIRE-3 trial28 for cetuximab plus FOLFIRI
as 32.6% [14.6% × (16.3%/7.3%), in which 14.6% is the estimated resection rate for all patients and
16.3% and 7.3% are the values reported for the RAS WT population for cetuximab plus FOLFIRI in the
subgroup and all patients populations, respectively (see Table 90)].
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Next, we estimated the resection rate for the RAS WT population in the FIRE-3 trial28 for bevacizumab plus
FOLFIRI as 39.6% [17.7% × (16.3%/7.3%), in which 17.7% is the estimated resection rate for all patients
and 16.3% and 7.3% are as described in the previous paragraph].
Finally, the value of 19.8% for bevacizumab plus FOLFIRI (see Table 91) was calculated as
16.3% × (39.6%/32.6%), in the manner of an adjusted indirect comparison, in which 16.3% is the chosen
value for cetuximab plus FOLFIRI and 39.6% and 32.6% are derived as explained above.
Finally, the value of the logit of 20.9% for bevacizumab plus FOLFIRI (see Table 91) was calculated as logit
(16.3%) + (logit(39.6%) – logit (32.6%)), in the manner of an adjusted indirect comparison, in which 16.3%
is the chosen value for cetuximab plus FOLFIRI and 39.6% and 32.6% are derived as explained above.
FOLFOX network
In the FOLFOX network, resection rates for all patients for panitumumab plus FOLFOX and FOLFOX were
taken directly from the PRIME trial (see Table 91), as this is the baseline RCT in our model for the FOLFOX
network. Merck Serono did not consider panitumumab plus FOLFOX. It estimated the resection rate for
FOLFOX as 2.1%, which it reports was taken from the study by Tournigand et al.111 This is substantially
lower than our estimate. The study by Tournigand et al.111 concerns second-line treatment not restricted to
RAS WT patients, whereas our estimate is taken from first-line treatment for RAS WT patients. Therefore,
we prefer our value.
The value for bevacizumab plus FOLFOX was calculated as an adjusted indirect comparison, using the
chosen value for panitumumab plus FOLFOX and 11.0% and 12.5% as the resection rates for
bevacizumab plus FOLFOX and panitumumab plus FOLFOX from the PEAK trial29 (see Table 90). Merck
Serono did not model this treatment.
The value of the logit of 20.7% for cetuximab plus FOLFOX (see Table 91) was calculated by first
estimating the resection rates for cetuximab plus FOLFOX and FOLFOX for RAS WT patients using the
corresponding values for KRAS WT patients from the OPUS and PRIME trials, respectively. Specifically, the
estimated rate for RAS WT patients for cetuximab plus FOLFOX = 9.8%/83% = 11.9% (as for the FOLFIRI
network, we assumed that 83% of KRAS WT patients are also RAS WT). The estimated rates for RAS and
KRAS patients for FOLFOX were taken directly from the PRIME trial.
Finally, the value of the logit of 20.7% for cetuximab plus FOLFOX was calculated as an adjusted indirect
comparison, using the 11.9% rate for RAS patients for cetuximab plus FOLFOX in the OPUS trial and the
rate for FOLFOX in the PRIME trial and the estimated rate for FOLFOX just calculated.
By comparison, Merck Serono estimated the resection rate for cetuximab plus FOLFOX as 7.3%,
substantially lower than our value of 20.7%. Merck Serono did not discuss the derivation of its estimate.
However, we assume that it was set equal to their rate for cetuximab plus FOLFIRI. If so, we believe that
our estimate, although apparently high, is methodologically more sound, as Merck Serono’s assumption
seems unreasonable.
Now, we turn to the derivation of the resection rates for the liver metastases subgroup.
The rates of 17.1% and 31.3% for FOLFOX and panitumumab plus FOLFOX, respectively, were taken
directly from the PRIME trial, the base-case RCT in the FOLFOX network.
The rate for bevacizumab plus FOLFOX was estimated using an indirect comparison, using the estimated
rate of 31.3% for panitumumab plus FOLFOX and the rates for bevacizumab plus FOLFOX and
panitumumab plus FOLFOX from the PEAK trial.29
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Finally, the rate for cetuximab plus FOLFOX was estimated as follows. Ordinarily, we would estimate the
rate as logit(17.1%) × (logit(13.3%)/logit(0%)), in which 17.1% is the chosen rate for FOLFOX and 13.3%
and 0% are the rates for cetuximab plus FOLFOX and FOLFOX in the OPUS trial. However, estimating the
rate in this way gives an estimate of infinity, which is clearly impossible. The extreme value of 0% in the
OPUS trial is partly a result of the very small sample size of 12 patients (see Table 90), the result of
considering a small subgroup in a small RCT.
Instead, we estimated the rate for cetuximab plus FOLFOX using 17.1% for FOLFOX, as before, and the
other estimated rates for all patients in the OPUS trial.
For the probabilistic sensitivity analysis, the resection rates were assumed to follow gamma distributions,
with means from the RCTs and variances of the mean calculated by p(1 – p)/n, in which p is the
deterministic resection rate and n is the number of patients (see Table 90).
In a scenario analysis we considered the OPUS trial rather than the PRIME trial as the baseline RCT for the
FOLFOX network (see Structure of the Peninsula Technology Assessment Group model). As many of the
resulting resection rates are based on data we received as AiC, we do not report them here.
Time of resection
In the previous assessment TA176,10 Merck Serono assumed in its revised analysis that the time point at
which patients were assessed for curative resection was 16 weeks after the start of treatment (Table 92).
In its submission for the current HTA, Merck Serono’s assumption on the timing of liver resection surgery
was based on the study by Adam et al.,113 as indicated in table 20 (section 3.2.2, p. 49) of the submission,
and was 3 months after the start of treatment.
We believe that it is reasonable to assume that liver resection is performed approximately 12 weeks after
the start of treatment. This is based on expert opinion (Dr Mark Napier, 2015, personal communication)
and TA176,10 and also agrees with the value of 3 months used in the submission from Merck Serono.
Given that this is so soon after randomisation, in our model, in common with Merck Serono, and for
TABLE 92 Time of liver resection surgery
Time to resection Source
Normally assess after 8 weeks, but others might assess at 16 weeks Dr Mark Napier (clinical advisor to PenTAG,
2015, personal communication)
Of people whose disease responds sufficiently to cetuximab to enable
resection of liver metastases, approximately 90% would do so within
12 weeks of treatment with cetuximab
NICE TA176,10 clinical specialists’ opinion
All patients would normally stop receiving treatment with cetuximab
at the time of the assessment for possible liver resection (i.e. after
approximately 12–16 weeks)
NICE TA176,10 clinical specialists’ opinion
16 weeks after the start of treatment Merck Serono’s revised analysis in TA17610
(section 3.31)
Unresected patients were routinely reassessed every four courses of
chemotherapy. Surgery was reconsidered every time a documented
response to chemotherapy was observed
Adam et al.113
At cycle/month 4 based on Adam et al.,113 who found that most
resections occur before 4 months
Merck Serono’s submission, current HTA
(section 3.2.2, table 20, p. 49)
At 3 months in the model some patients can be referred for
curative-intent resection of liver metastases
Merck Serono’s submission, current HTA
(section 3.2.2, table 21, p. 50)
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simplicity, we assume that resection occurs at time zero. The only loss of accuracy is due to a slight
overestimation of discounted costs and QALYs for resected patients of just 1%.
Post liver resection: progression-free survival and overall survival
We found that the cost-effectiveness of cetuximab plus FOLFOX/FOLFIRI and panitumumab plus FOLFOX/
FOLFIRI was sensitive to mean PFS and OS post resection. Therefore, estimation of these quantities is
worthy of close scrutiny.
In the previous assessment TA176,10 OS after liver resection with curative intent was based on the study by
Adam et al.113 This was also the source used by Merck Serono in its submission.
Given sufficient time, we would have performed a systematic review of the literature for PFS and OS after
resection. However, because of time constraints, we searched the literature as follows. We performed a
forward reference search on Adam et al.113 in PubMed to identify all relevant studies relating to survival
after liver resection for mCRC. This yielded two other candidate studies:
1. Adam et al.149
2. Adam et al.150
A comparative analysis of these publications is provided in Table 93.
Key information concerning the patient population (such as age and sex composition) was reported in
Adam et al.113 but not in the other two studies.149,150 OS was reported in all three studies113,149,150 and PFS
was detailed in two of the studies.113,149 Frequencies of surgeries were provided only in Adam et al.113
Therefore, in common with Merck Serono, we estimated PFS and OS post resection from the study by
Adam et al.113
However, the choice of study had little impact on cost-effectiveness, as OS was similar across the three
studies and PFS was similar in the studies by Adam et al.113,149 (see Table 93).
Modelled progression-free survival post resection
Given the lack of data to the contrary, and in common with Merck Serono, for those patients who had a
successful resection we assumed that PFS and OS were independent of first-line treatment.
TABLE 93 Comparison of the study populations, types and frequencies of liver resections and outcomes reported in
Adam et al.113,149,150
Variable Adam et al. 2004113 Adam et al. 2009149 Adam et al. 2012150
Patient characteristics and treatment
Patients from Centre Hepato-Biliaire and
INSERM E0354 ‘Cancer
Chronotherapeutics’, Hôpital
Paul-Brousse, Assistance
Publique–Hopitaux de Paris
Université Paris, Sud Villejuif,
France
The AP-HP Hôpital Paul-Brousse,
Centre Hepato-Biliaire and
Department of Medical
Oncology; INSERM, Unité 785;
INSERM, Laboratoire ‘Rythmes
biologiques et cancers’, Unité
776; Université Paris-Sud,
Villejuif, France; and Department
of Surgery, University Medical
Center Utrecht, Utrecht, the
Netherlands
330 centres in 58 countries,
including the UK, with the
majority from Western
Europe. Data from
LiverMetSurvey (www.
livermetsurgery.org),
accessed 23 November 2011
continued
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TABLE 93 Comparison of the study populations, types and frequencies of liver resections and outcomes reported in
Adam et al.113,149,150 (continued )
Variable Adam et al. 2004113 Adam et al. 2009149 Adam et al. 2012150
Patient population Patients whose metastases
were significantly downstaged
by chemotherapy
Patients with unresectable
colorectal liver metastases at the
time of diagnosis who
underwent rescue surgery after
downsizing chemotherapy and
had a minimum follow-up of
5 years from surgery
Patients who underwent
conversion chemotherapy
and resection for colorectal
liver metastases
Number of patients
initially unresectable
138 184 1999
Lines of treatment One line, 77%; two
lines,14%; three lines, 9%
One line, 74%; more lines, 26% Not reported
Stage of disease Patients with initially
unresectable colorectal liver
metastases
Patients with initially
unresectable colorectal liver
metastases
Patients with initially
unresectable colorectal liver
metastases
Site of metastases 62% of patients with
metastases confined to the
liver
73% of patients with metastases
confined to the liver
Not reported
RAS status Not determined Not determined Not determined
Year 1988–99 1988–2002 2004–11
Mean age (years) 57 56.9 Not reported
Sex 56% male, 44% female 58% male, 42% female Not reported
Total number of
resections, including
repeat resections
223 [i.e. 223/138 = 1.6 per
patient (p. 650)]
Not reported Not reported
Treatment after
resection
Systemic chemotherapy
continued for six to eight
courses after resection
because of the high risk of
recurrence (p. 646)
Postoperative chemotherapy in
93% of patients for six to eight
cycles
Type of resection 93% first hepatectomies;
75% major, 25% limited
hepatectomies (p. 647)
Major resections in 48% of
patients; 26% anatomical, 25%
non-anatomical, 49% both
Outcomes
Postoperative
mortality (%)
0.7 0 Not reported
Postoperative
morbidity (%)
28 25 Not reported
5-year disease-free
survival, % (number
of patients exposed)
22 (28) 19 (31) Not reported
10-year disease-free
survival, % (number
of patients exposed)
17 (12) 15 (12) Not reported
5-year survival, %
(number of patients
exposed)
33 (37) 33 (41) 33 (131)
10-year survival, %
(number of patients
exposed)
23 (12) 27 (14) 20 (23)
INSERM, i’Institut National de la Santé et de la Recherche Médicale.
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Progression-free survival was modelled as follows. A progression event is assumed to occur if either a
patient dies as a result of general background non-CRC mortality or there is progression because of any
other cause. General background non-CRC mortality was modelled explicitly because the PFS tail in Adam
et al.113 is long. Two functional forms were chosen for progression from any other cause: Weibull and
log-logistic (Figure 12). The choice of parameters for these distributions was assessed pragmatically by
minimising the sums of squares of differences between Kaplan–Meier PFS and modelled PFS. Under this
method, the Akaike information criterion and Bayesian information criterion are not obtained. We
acknowledge that it would have been preferable to estimate the underlying individual patient data by
using the method of Hoyle and Henley151 [as we did for first-line PFS (see Model parameters, First-line
progression-free survival: unresected patients)] or the method of Guyot et al.152 However, given the time
constraints, we did not do this, in part because the adjustment for background mortality would have
required additional analysis.
Given a 30-year time horizon, mean PFS was estimated as 4.5 years assuming the Weibull distribution and
4.8 years assuming the log-logistic distribution, substantially greater than the mean PFS for unresected
patients (see Model parameters, First-line progression-free survival: unresected patients).
For our base-case analysis we chose the Weibull distribution as it is possible that the long tail in the study
by Adam et al.113 is heavily influenced by the small numbers of patients at risk in the tail (e.g. 17 patients
at 8 years) and the tail of the log-logistic distribution is longer than the tail of the Weibull distribution
(Figure 13).
For the probabilistic sensitivity analysis, parameter gamma (shape) of the Weibull distribution was held
constant and parameter lambda (scale) was varied in such a way to give the required mean PFS. Mean PFS
was modelled as a gamma distribution with the mean equal to the deterministic mean and the standard
error (SE) of the mean given by the SD of the Weibull distribution divided by the square root of the
number of patients in Adam et al.113 (n = 138).
Modelled overall survival post resection
Overall survival post resection was modelled as for PFS (Figure 14).
Given a 30-year time horizon, mean OS was estimated as 5.6 years assuming the Weibull distribution and
6.2 years assuming the log-logistic distribution.
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et al.113 (Figure 5).
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We rejected the Weibull distribution as, for time periods of > 13 years, OS was predicted to be lower than
PFS. For our base-case analysis we chose the log-logistic distribution as OS was predicted always to be
greater than PFS (see Figure 13).
Based on their overly short time horizon of 10 years, Merck Serono predicted substantially shorter mean
PFS and OS than us:
l PFS – 4.5 years in our model compared with 2.8 years in Merck Serono’s model
l OS – 6.2 years in our model compared with 4.1 years in Merck Serono’s model.
This difference in itself acts to improve the cost-effectiveness of cetuximab plus FOLFOX/FOLFIRI and
panitumumab plus FOLFOX/FOLFIRI in our model compared with Merck Serono’s model, given that these
treatments have relatively high resection rates.
For the probabilistic sensitivity analysis of OS, similar to the calculations for PFS, one parameter of the
log-logistic distribution was held constant and the other parameter was varied in such a way to give the
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FIGURE 13 Peninsula Technology Assessment Group-modelled PFS and OS post resection.
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required mean OS. Mean OS was modelled as a gamma distribution, with the mean equal to the
deterministic mean and the SE of the mean given by the SD of the log-logistic distribution divided by the
square root of the number of patients in Adam et al.113 (n = 138).
First-line progression-free survival: unresected patients
In common with Merck Serono, we based our estimates of first-line PFS for unresected patients on the
data from the pivotal RCTs.
However, Merck Serono (see Chapter 5, De novo economic evaluation) and, as far as we are aware, all
previous economic analyses of first-line treatments for mCRC, estimated PFS for unresected patients
directly from the RCTs of all patients (resected and unresected). We believe that this overestimates PFS for
unresected patients, given that some patients in the RCTs are resected and that PFS for these patients
is substantially longer than that for unresected patients (see Model parameters, Post liver resection:
progression-free survival and overall survival).
In summary, we estimated PFS for unresected patients as follows.
1. Extrapolate PFS for all patients (resected and unresected) separately for each treatment arm from the
five RCTs28,29,43,44,65 relevant to the current HTA. We found that the Weibull distribution was most
appropriate in all cases.
2. Calculate the mean PFS and SE of the mean from each extrapolated PFS curve.
3. Perform a mixed-treatment comparison of the mean PFS.
4. Estimate the mean PFS for patients post resection based on data from Adam et al.,113 which are likely to
be available at the maximum follow-up time of 3 years in the RCTs. This was assumed to apply in all
modelled treatment arms.
5. Estimate PFS for unresected patients. The mean PFS for unresected patients was estimated from the
mean PFS for all patients (step 3), the mean PFS for resected patients (step 4) and the proportion of
patients in each treatment arm who undergo resection (see Chapter 1, Measurement of disease). It was
assumed that PFS for unresected patients follows the same type of distribution as for all patients (step 1)
(Weibull in all cases). The shape parameter for the Weibull distribution was estimated from step 2
and the scale parameter was estimated from the mean PFS for unresected patients (step 2) and the
shape parameter.
These steps are provided in more detail in the following sections.
1. Extrapolate progression-free survival for all patients (resected and unresected)
First, the Kaplan–Meier data were extracted from the RCTs28,29,43,44,65 using DigitizeIt software [see
www.digitizeit.de/ (accessed 14 March 2017)]. The published numbers of patients at risk at each of several
time points were recorded. Next, the underlying individual patient data were estimated using these data
and the method of Hoyle and Henley,151 using the online spreadsheet.151 This method has been shown to
be accurate.153
The fits of the exponential, Weibull, log-logistic, log-normal and logistic distributions were estimated using
the maximum likelihood method, using the R code (The R Foundation for Statistical Computing, Vienna,
Austria) in the spreadsheet of Hoyle and Henley (version 1.2).151 In every case, we chose the Weibull
distribution because:
l The Weibull usually gave the lowest Akaike information criterion and Bayesian information criterion
values. If it did not, the values were nearly the lowest of all distributions.
l It seemed desirable to choose the same type of distribution for each treatment within the FOLFOX
network and, separately, for each treatment within the FOLFIRI network, because the choice of
distribution affects mean PFS and we believe that substantial evidence would be required to choose
different distributions.
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We note that Merck Serono chose the Weibull distribution for all treatments in the FOLFIRI network and
the log-logistic distribution for both treatments in the FOLFOX network.
Our chosen curve fits are provided in Figure 15. In each case, the mean and variance–covariance matrix of
the parameters of the Weibull distribution were recorded.
2. Calculate mean progression-free survival and standard error of the mean
The means and SEs of the mean were then calculated from the mean and variance–covariance matrices of
the Weibull parameters (Table 94).
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
(a)
0 5 10 15 20 25 30
Time (months)
Pr
o
b
ab
ili
ty
 o
f 
PF
S
1.0
CET + FOLFOX
FOLFOX
CET + FOLFOX fit
FOLFOX fit
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
(b)
0 5 10 15 20 25 30
Time (months)
Pr
o
b
ab
ili
ty
 o
f 
PF
S
1.0
PAN + FOLFOX
FOLFOX
PAN + FOLFOX fit
FOLFOX fit
FIGURE 15 First-line PFS (unresected patients) in the PenTAG model: (a) CET + FOLFOX vs. FOLFOX from the
OPUS trial;65 (b) PAN+ FOLFOX vs. FOLFOX from the PRIME trial;44 (c) PAN + FOLFOX vs. BEV + FOLFOX from
the PEAK trial;29 (d) CET + FOLFIRI vs. FOLFIRI from the CRYSTAL trial;43 and (e) CET + FOLFIRI vs. BEV+ FOLFIRI
from the FIRE-3 trial.28 BEV, bevacizumab; CET, cetuximab; PAN, panitumumab. (continued )
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3. Mixed-treatment comparison of mean progression-free survival
The CRYSTAL trial43 was chosen as the baseline trial for the FOLFIRI network and the PRIME trial44 was
chosen as the baseline trial for the FOLFOX network (see Structure of the Peninsula Technology
Assessment Group model).
For the purposes of the economic model, we performed a mixed-treatment comparison for PFS on mean
survival, not the HR. Indeed, this was our approach in our role as the Assessment Group in 2011 for the
NICE MTA of cetuximab, panitumumab and bevacizumab for subsequent lines of treatment for CRC.141
Our approach was endorsed by the NICE appraisal committee.
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FIGURE 15 First-line PFS (unresected patients) in the PenTAG model: (a) CET + FOLFOX vs. FOLFOX from the
OPUS trial;65 (b) PAN+ FOLFOX vs. FOLFOX from the PRIME trial;44 (c) PAN + FOLFOX vs. BEV + FOLFOX from
the PEAK trial;29 (d) CET+ FOLFIRI vs. FOLFIRI from the CRYSTAL trial;43 and (e) CET + FOLFIRI vs. BEV+ FOLFIRI
from the FIRE-3 trial.28 BEV, bevacizumab; CET, cetuximab; PAN, panitumumab. (continued )
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FIGURE 15 First-line PFS (unresected patients) in the PenTAG model: (a) CET + FOLFOX vs. FOLFOX from the
OPUS trial;65 (b) PAN+ FOLFOX vs. FOLFOX from the PRIME trial;44 (c) PAN + FOLFOX vs. BEV + FOLFOX from
the PEAK trial;29 (d) CET + FOLFIRI vs. FOLFIRI from the CRYSTAL trial;43 and (e) CET + FOLFIRI vs. BEV+ FOLFIRI
from the FIRE-3 trial.28 BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
TABLE 94 Estimated mean PFS and SEs (months) for all patients (resected and unresected) from RCTs
RCT Analysis CET+ FOLFIRI FOLFIRI BEV+ FOLFIRI
FOLFIRI network
CRYSTAL (baseline)43 Mean 13.68 9.67
SE 1.09 0.59
Gamma of Weibull 1.69 1.74
FIRE-328 Mean 13.53 11.88
SE 0.8 0.58
Gamma of Weibull 1.45 1.74
RCT PFS CET+ FOLFOX FOLFOX PAN+ FOLFOX
FOLFOX network
PRIME (baseline)44 Mean 9.46 11.55
SE 0.45 0.57
Gamma of Weibull 1.67 1.68
OPUS65 Mean 9.38 6.72
SE 1.63 0.64
Gamma of Weibull 1.7 1.74
PEAK29 Mean 15.14
SE 1.28
Gamma of Weibull 1.59
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
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Furthermore, there is growing awareness that the HR cannot be recommended as a general measure of
the treatment effect in RCTs.154 It has recently been argued that, for a HR to make scientific sense, we
must assume that the proportional hazards of the treatment effect holds, at least approximately, and that
when the proportional hazards assumption fails it is misleading to report the treatment effect through
the estimated HR, as it depends on follow-up time.154 Instead, the ‘restricted mean’ has recently been
advocated as a superior method of assessment of the treatment effect in trials, with the restricted mean
for a trial arm defined as survival up to some agreed time point.154 For our purposes, as in the previous
assessment of cetuximab, panitumumab and bevacizumab for subsequent lines of treatment for CRC,141
we performed a mixed-treatment comparison of mean survival, which is in the spirit of the ‘restricted
mean’, but with the time point set to infinity and survival extrapolated to infinity. We argue that the full,
not restricted, life expectancy is a preferable clinical outcome as (1) cost-effectiveness is driven by the
overall mean and (2) for the purposes of the mixed-treatment comparison it would be difficult to choose a
time point relevant to all trials.
The NMAs were undertaken within a Bayesian framework using WinBUGS. Prior distributions, when used,
were defined as vaguely as possible.
The FOLFOX and FOLFIRI networks were analysed independently. FOLFOX was the baseline treatment
in the FOLFOX network and FOLFIRI was the baseline treatment in the FOLFIRI network. The absolute
treatment effects were obtained from the NMA models, with the FOLFOX analysis based on the PRIME trial
and the FOLFIRI analysis based on the CRYSTAL trial.
Models with a normal likelihood and identity link were used.66 Analyses were run with three chains and an
initial burn-in of 50,000 iterations, followed by an additional 20,000 iterations on which the results were
based. Further implementation in WinBUGS was as described in Chapter 3 (see Network meta-analysis).
Because of the small number of RCTs contributing to each network, only fixed-effects models were used.
4. Estimate mean progression-free survival for patients post resection
We estimated mean PFS for patients post resection using data from the study by Adam et al.,113 which are
likely to be available at the maximum follow-up times in the RCTs. Expressed differently, we estimated the
likely PFS from data for resected patients in the RCTs.
We judge that it is reasonable to assume that PFS from Adam et al.113 up to 3 years is likely to be fully
reflected in PFS from the RCTs, as this appears to be the latest time at which there are few censorships in
the OS data from the RCTs in our base-case analysis: CRYSTAL,43 PRIME44 and OPUS.65
Specifically, for the CRYSTAL trial, inspection of figure 3B in the study by Van Cutsem et al.43 reveals that
there were very few censorships for OS for follow-up up to 3 years. In detail, in the chemotherapy arm, at
3 years the probability of OS is approximately 0.23, which, given that 189 patients were randomised to
this arm, gives an estimated 43 patients at risk at 3 years if there are no censorships. Given that this is
close to the 38 patients at risk, this implies that follow-up is largely complete up to 3 years. By 4 years, at
3 years the probability of OS is approx. 0.18, which, given that 189 patients are randomised to this arm,
gives an estimated 34 patients at risk at 3 years if there are no censorships. Given that this is substantially
greater than the actual 10 patients at risk, follow-up is incomplete up to 4 years.
Similarly, inspection of the OS Kaplan–Meier graphs from the PRIME and OPUS trials revealed a similar
follow-up time.
Given that the probability of PFS for resected patients at 3 years is 0.30 from Adam et al.,113 we estimated
the mean PFS for resected patients given data up to 3 years as 2.5 years, assuming a constant hazard.
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5. Estimate progression-free survival for unresected patients
Next, we estimated mean PFS for unresected patients using the following equation:
Mean PFS (resected + unresected) =% patients resected × mean PFS (resected)
+% patients unresected × mean PFS (unresected). (3)
We assumed that PFS for unresected patients follows the same distribution as for all patients (Weibull in all
cases). The shape parameter for the Weibull distribution was estimated from step 1 and the scale parameter
was estimated from the mean PFS for unresected patients and the shape parameter.
Modelled PFS for all patients from the RCTs, resected patients and unresected patients is provided in
Figure 16 for the FOLFOX network and in Figure 17 for the FOLFIRI network.
Notice that PFS for unresected patients is shorter than that for all patients, as PFS for resected patients is
substantially greater than that for unresected patients (noting the difference in the scale of the time axis).
Comparison with the Merck Serono model
For the FOLFOX network, our estimates of mean PFS for resected and unresected patients are very similar
to those of Merck Serono (see Chapter 5, De novo economic evaluation) for unresected patients only
(Figure 18a). However, our estimates of mean PFS for unresected patients only are substantially lower than
those of Merck Serono as we subtracted PFS for resected patients, as described earlier.
For the FOLFIRI network, our estimates of mean PFS for resected and unresected patients are slightly
higher than those of Merck Serono for unresected patients only (see Figure 18b). Coincidently, even
though we subtracted PFS for resected patients, our estimates of mean PFS for unresected patients only
are very similar to those of Merck Serono.
OPUS trial as the baseline randomised controlled trial in the FOLFOX network
In a scenario analysis we used the OPUS trial65 rather than the PRIME trial44 as the baseline RCT for the
FOLFOX network (see Structure of the Peninsula Technology Assessment Group model).
In this case, we estimated the following mean PFS for unresected patients with and without liver-limited
disease (‘all patients’):
l cetuximab plus FOLFOX – 9.4 months (OPUS trial;65 see Table 94).
l panitumumab plus FOLFOX – 8.2 months {estimated as 6.7 months FOLFOX [OPUS trial65] ×
[11.55 months panitumumab plus FOLFOX (PRIME trial44)/9.46 months FOLFOX (PRIME trial44)]}
l bevacizumab plus FOLFOX – 5.5 months {estimated as 8.2 months panitumumab plus FOLFOX
[estimate] × [10.12 months bevacizumab plus FOLFOX (PEAK trial29)/15.14 panitumumab plus FOLFOX
(PEAK trial29)]}
l FOLFOX – 6.7 months (OPUS trial;65 see Table 94).
First-line progression-free survival liver metastases subgroup: unresected patients
Data on first-line PFS for the liver metastases subgroup of the RAS WT population are rather limited
(Table 95).
Progression-free survival for the liver metastases subgroup for resected and unresected patients combined
was estimated as follows. When the median PFS for a particular treatment A for the subgroup was
available, the mean PFS for the subgroup was estimated as:
Mean PFS treatment A (all patients) × ½median PFS treatment A (subgroup)
/median PFS treatment A (all patients). (4)
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
134
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 5 10 15 20 25 30
Months
Pr
o
b
ab
ili
ty
 o
f 
PF
S
(a)
CET + FOLFOX
PAN + FOLFOX
BEV + FOLFOX
FOLFOX
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 5 10 15 20
Years
Pr
o
b
ab
ili
ty
 o
f 
PF
S
(b)
0.0
0.1
0.2
0.3
0.4
0.5
Pr
o
b
ab
ili
ty
 o
f 
PF
S
0.6
0.7
0.8
0.9
1.0
(c)
0 5 10 15 20 25 30
Months
CET + FOLFOX
PAN + FOLFOX
BEV + FOLFOX
FOLFOX
FIGURE 16 First-line PFS for the FOLFOX network in the PenTAG model: (a) all patients; (b) resected patientsa;
and (c) unresected patients. a, PFS post resection is assumed to be the same for all arms. BEV, bevacizumab;
CET, cetuximab; PAN, panitumumab.
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FIGURE 17 First-line PFS for the FOLFIRI network in the PenTAG model: (a) all patients; (b) resected patients; and
(c) unresected patients. PFS post resection is assumed to be the same for all arms. BEV, bevacizumab;
CET, cetuximab; PAN, panitumumab.
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The assumption is that, for each treatment, the shape of the PFS curve for the subgroup is the same as the
shape of the PFS curve for all patients.
For cetuximab plus FOLFOX, no estimates of median PFS for the liver metastases subgroup were available.
Instead, we estimated the ratio in Equation 4 for cetuximab plus FOLFOX as equal to the corresponding
ratio for cetuximab plus FOLFIRI.
Similarly, for bevacizumab plus FOLFIRI, no estimates of median PFS for the liver metastases subgroup were
available. Instead, we estimated the ratio in Equation 4 for bevacizumab plus FOLFIRI as equal to the
corresponding ratio for bevacizumab plus FOLFOX.
This approach yielded the estimates of mean PFS for all patients (resected and unresected) for the liver
metastases subgroup in Figure 19.
Next, mean PFS for the unresected patients in the liver metastases subgroup was first estimated using step 1,
as described earlier for all patients, by subtracting the mean PFS for resected patients and using the resection
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FIGURE 18 First-line mean PFS in the PenTAG model and the Merck Serono model: (a) FOLFOX network; and
(b) FOLFIRI network. BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
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TABLE 95 First-line PFS for the liver metastases subgroup of the RAS WT population from RCTsa
RCT Treatment HR (95% CI) Median PFS (months) (95% CI)
FOLFIRI network
CRYSTAL CET+ FOLFIRI 0.21 (0.09 to 0.49) 14 (NR)
FOLFIRI 8.1 (NR)
FIRE-3 CET+ FOLFIRI NR (Merck Serono) NR (Merck Serono)
BEV + FOLFIRI
FOLFOX network
OPUS CET+ FOLFOX 0.35 (0.06 to 1.91) NR
FOLFOX 7.4 (NR)
PEAK PAN+ FOLFOX (Confidential information has
been removeda)
(Confidential information has
been removedb)
BEV + FOLFOX (Confidential information has
been removedb)
PRIME PAN+ FOLFOX 0.75 (0.48 to 1.19)
FOLFOX
BEV, bevacizumab; CET, cetuximab; NR, not reported; PAN, panitumumab.
a All data from Merck Serono and Amgen, 19 March 2015, personal communication (via NICE).
b AiC information.
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rates specific to the subgroup. This yielded the estimates of mean PFS for unresected patients in the liver
metastases subgroup in Figure 19.
However, this method is clearly inappropriate because it yields a negative estimated mean PFS for
unresected patients for bevacizumab plus FOLFOX (see Figure 19a).
We stress that the mean PFS for unresected patients for the liver metastases subgroup is highly uncertain
for all treatments given the number of assumptions. Given that cost-effectiveness is sensitive to PFS, then
cost-effectiveness is also highly uncertain for all treatments for the liver metastases subgroup.
For the probabilistic sensitivity analysis, PFS for unresected patients was calculated as for the deterministic
analysis, but, in addition, we allowed for uncertainty in the following variables as these variables are all
used to calculate PFS for unresected patients:
l PFS (resected and unresected patients) (discussed below)
l resection rates (see Model parameters, Resection rates)
l post resection PFS (see Model parameters, Post liver resection: progression-free survival and
overall survival).
Mean PFS for resected and unresected patients was calculated using a mixed-treatment comparison, as
described in step 3 (see Mixed-treatment comparison of mean progression-free survival). For the FOLFOX
network, this yielded the following covariance matrix on the log scale, with columns and rows
corresponding to FOLFOX, cetuximab plus FOLFOX and panitumumab plus FOLFOX, in that order:
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FIGURE 19 First-line mean PFS for the liver metastases subgroup: (a) FOLFOX network; and (b) FOLFIRI network.
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The log of the mean PFS for resected and unresected patients was then estimated as a multivariate normal
distribution with deterministic means and the covariance matrix given above.
The covariance matrix for the FOLFIRI network, with columns and rows corresponding to FOLFIRI and
cetuximab plus FOLFIRI, in that order, is:
0:0063
0 0:0058
 
. (6)
Similarly, the log of the mean PFS for resected and unresected patients was then estimated as a
multivariate normal distribution with deterministic means and the covariance matrix given above.
Mortality from first-line progression-free survival
Some of the progression events will be related to deaths. Unfortunately, we could find no information on
the number of deaths in the first-line PFS health state in either the RAS or the KRAS populations in the five
pivotal RCTs.28,29,43,44,65 However, Merck Serono provided some useful data in its model. We estimated
mortality in the first-line PFS health state as follows.
Merck Serono provided the survival curve for progressions not related to death for the treatment arms in
Table 96. We calculated the means in Table 96.
First:
l mean progression not related to death was set equal to 1/(rate of progression not related to death).
l mean progression all causes was set equal to 1/(rate of progression not related to death + rate of
progression related to death).
From these simultaneous equations, we can calculate each component rate.
Then, the proportion of all progressions relating to death was estimated as:
Rate of progression related to death/(rate of progression related to death
+ rate of progression not related to death). (See Table 96.) (7)
Because of the paucity of data, we pragmatically estimated the proportion of all progressions related to
death as the average of the proportions in Table 96 (6%).
This figure was used for all seven treatment arms of our model to calculate the number of deaths in each
model cycle from the first-line PFS health state.
Furthermore, given the lack of alternative data, the same proportion was used to calculate the number of
deaths in each model cycle from the second-line health state.
TABLE 96 Estimation of the proportion of progressions relating to death
Progression parameter CET+ FOLFOX FOLFOX CET+ FOLFIRI FOLFIRI
Mean progression (years) not related to death 1.15 0.77 1.07 0.76
Mean PFS in unresected patients (years) (Merck Serono model) 1.04 0.74 0.98 0.73
Estimated number of deaths as a percentage of all progressions 10 4 8 4
CET, cetuximab.
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In the results section, we show that cost-effectiveness is very insensitive to the proportion used.
First-line time on treatment
The mean times on first-line drug treatment are extremely important quantities because they affect the
total mean costs of drug acquisition and administration per person, which are critical drivers of
cost-effectiveness.
We estimated the mean treatment duration for each first-line treatment as follows.
1. We either used the actual mean first-line treatment duration in each of the pivotal RCTs provided by
the relevant company or estimated this quantity based on the median treatment duration in each RCT
(Tables 97 and 98).
2. We estimated the mean treatment duration for each first-line treatment by simple indirect comparison.
Given that the CRYSTAL and PRIME trials were baseline RCTs, the modelled mean treatment durations
for FOLFIRI and cetuximab plus FOLFIRI were taken directly from the CRYSTAL trial and for FOLFOX and
cetuximab plus FOLFOX were taken directly from the PRIME trial (see Table 97).
3. For each treatment, we compared the estimated mean treatment duration with the estimated mean
first-line PFS for unresected patients (see Model parameters, First-line progression-free survival:
unresected patients). We would expect the mean treatment duration to be lower, because in all RCTs
treatment was supposed to stop on progression. However, we show below that this was generally not
the case; usually, mean treatment duration was greater than mean first-line PFS for unresected patients.
TABLE 97 All patients: steps 1 and 2 in the estimation of mean treatment duration
Treatment
From RCTs:
median treatment
duration (months)
Step 1: estimated or actual mean
treatment duration (months)
Step 2: modelled mean
treatment duration (months)
FOLFOX network
CET+ FOLFOX 5.6 (OPUS65) (Confidential information has been
removeda)b (OPUS65)
(Confidential information has been
removeda) (indirect comparison)
FOLFOX 4.6 (OPUS65),
6.2 (PRIME44)
(Confidential information has been
removeda)b (OPUS65), 7.2b (PRIME44)
7.2 (PRIME44)
PAN+ FOLFOX 6.5 (PRIME44),
7.5 (PEAK29)
8.2b (PRIME44), 10.7c (PEAK29) 8.2 (PRIME44)
BEV + FOLFOX 5.9 (PEAK29) 8.5c (PEAK29) 6.4 (indirect comparison)
FOLFIRI network
CET+ FOLFIRI 7.4 (CRYSTAL43),
4.8 (FIRE-328)
(Confidential information has been
removeda)b (CRYSTAL43), 6.9c (FIRE-328)
(Confidential information has been
removeda) (CRYSTAL43)
FOLFIRI 5.8 (CRYSTAL43) (Confidential information has been
removeda)b (CRYSTAL43)
(Confidential information has been
removeda) (CRYSTAL43)
BEV + FOLFIRI 5.3 (FIRE-328) 7.6c (FIRE-328) (Confidential information has been
removeda) (indirect comparison)
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a CiC information.
b Actual mean.
c Estimated mean.
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Given that we used only PFS and not OS data from the RCTs, we assumed no or equal treatment effects
across treatment arms post progression. Therefore, we should not model first-line treatment after first-line
PFS for unresected patients. If we did, we would incur the costs of first-line drug treatment after
progression, but gain no clinical benefit from this, which is clearly inappropriate. Therefore:
l if mean treatment duration was estimated to be less than mean first-line PFS for unresected patients,
our estimate of mean treatment duration was left unaltered
l otherwise, mean treatment duration was capped at mean first-line PFS for unresected patients.
In our base case we used the resulting mean treatment durations for the calculation of drug administration
and drug acquisition costs. In particular, the mean total cost of drug acquisition per patient was estimated
as the product of the drug price per unit time, the mean treatment duration and the mean dose intensity
(see Model parameters, Drug acquisition costs).
For the purposes of discounting of costs only, we assumed that treatment duration follows an exponential
distribution. Cost-effectiveness was almost completely independent of this assumption.
In a sensitivity analysis we used OS data in addition to PFS data from the RCTs. In this case we used the
mean treatment duration in step 3 above, but without the cap for mean first-line PFS, because any first-
line treatment after progression could affect OS.
Data were available for treatment duration from the five RCTs for all patients only; there were no data for
the liver metastases subgroup.
For the probabilistic sensitivity analysis, uncertainty in treatment duration was reflected in the uncertainty
in PFS for unresected patients and the uncertainty in treatment duration from the RCTs. The treatment
durations from the trials were estimated as gamma distributions (hence the minimum value is zero), with
TABLE 98 Liver metastases subgroup: steps 1 and 2 in the estimation of mean treatment duration
Treatment
Step 1: estimated or actual mean t
reatment duration (months)
Step 2: modelled mean treatment
duration (months)
FOLFOX network
CET+ FOLFOX (Confidential information has been removeda)b
(OPUS65)
(Confidential information has been removeda)
(indirect comparison)
FOLFOX (Confidential information has been removeda)b
(OPUS6), 8.6b (PRIME44)
8.6 (PRIME44)
PAN+ FOLFOX 9.3b (PRIME44), NR (PEAK29) 9.3 (PRIME44)
BEV + FOLFOX NR (PEAK29) 7.1c
FOLFIRI network
CET+ FOLFIRI (Confidential information has been removeda)b
(CRYSTAL43), NR (FIRE-328)
(Confidential information has been removeda)
(CRYSTAL43)
FOLFIRI (Confidential information has been removeda)b
(CRYSTAL43)
(Confidential information has been removeda)
(CRYSTAL43)
BEV + FOLFIRI NR (FIRE-328) 11.1c
BEV, bevacizumab; CET, cetuximab; NR, not reported; PAN, panitumumab.
a AiC information.
b Actual mean.
c Estimated as the mean treatment duration for all patients from the RCTs multiplied by the following ratio: mean PFS
(resected and unresected) liver metastases subgroup/mean PFS (resected and unresected) all patients.
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the same deterministic mean and the SE given by the SD from the trial divided by the square root of the
number of patients.
OPUS trial as the baseline randomised controlled trial for the FOLFOX network
In a scenario analysis we used the OPUS trial65 not the PRIME trial44 as the baseline RCT for the FOLFOX
network (see Structure of the Peninsula Technology Assessment Group model).
In this case we estimated the following mean treatment durations for unresected patients (considering all
patients), using the same methodology as discussed for the base case, in which we used the PRIME trial44
as the baseline RCT:
l cetuximab plus FOLFOX – 6.6 months
l panitumumab plus FOLFOX – 5.2 months
l bevacizumab plus FOLFOX – 3.9 months
l FOLFOX – 5.0 months.
Overall survival: unresected patients
In our base-case analysis, we modelled only PFS from the RCTs. As mentioned in Structure of the Peninsula
Technology Assessment Group model, in a sensitivity analysis we modelled OS for unresected patients
from the RCTs in addition to PFS for unresected patients. In particular, our method of estimating OS for
unresected patients was the same as that for estimating PFS for unresected patients, using steps 1–5 (see
Model parameters, First-line progression-free survival: unresected patients).
For the same reasons as for PFS, we found the Weibull distribution to be the most appropriate distribution.
Our chosen curve fits are provided in Figure 20.
As for PFS, OS data from the RCTs were adjusted using data from Adam et al.113 to allow for the fact that
these data reflected some patients after resection (Figure 21).
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FIGURE 20 First-line OS (unresected patients) in the PenTAG model: (a) CET + FOLFOX vs. FOLFOX from the OPUS
trial; (b) PAN+ FOLFOX vs. FOLFOX from the PRIME trial; (c) PAN+ FOLFOX vs. BEV+ FOLFOX from the PEAK trial;
(d) CET+ FOLFIRI vs. FOLFIRI from the CRYSTAL trial; and (e) CET + FOLFIRI vs. BEV + FOLFIRI from the FIRE-3 trial.
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab. (continued )
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The mean OS for unresected patients when estimated directly from the RCTs of first-line drugs was
substantially greater than the mean OS estimated in our base case (Figure 22). Differences are to be
expected as the subsequent treatments in the RCTs (see Table 88) were different from those assumed in
our model. Indeed, this is the key reason that we chose our model structure (see Structure of the Peninsula
Technology Assessment Group model).
Second-line progression-free survival: unresected patients
Both we and Merck Serono assumed that all patients have second-line FOLFIRI after first-line FOLFOX-
based treatment and second-line FOLFOX after first-line FOLFIRI-based treatment (see Structure of the
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 20 40 60 80 100
Time (months)
Pr
o
b
ab
ili
ty
 o
f 
O
S
(b)
PAN + FOLFOX
FOLFOX
PAN + FOLFOX fit
FOLFOX fit
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 20 40 60 80 100
Time (months)
Pr
o
b
ab
ili
ty
 o
f 
O
S
(c)
PAN + FOLFOX
BEV + FOLFOX
PAN + FOLFOX fit
BEV + FOLFOX fit
FIGURE 20 First-line OS (unresected patients) in the PenTAG model: (a) CET + FOLFOX vs. FOLFOX from the OPUS
trial; (b) PAN + FOLFOX vs. FOLFOX from the PRIME trial; (c) PAN+ FOLFOX vs. BEV + FOLFOX from the PEAK trial;
(d) CET+ FOLFIRI vs. FOLFIRI from the CRYSTAL trial; and (e) CET + FOLFIRI vs. BEV+ FOLFIRI from the FIRE-3 trial.
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab. (continued )
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Peninsula Technology Assessment Group model and Chapter 5, De novo economic evaluation, Description
of methods).
We found that the cost-effectiveness of cetuximab and panitumumab was insensitive to our assumption
about the duration of second-line PFS, because we also assumed that this is equal in all treatment arms.
Therefore, this parameter does not merit close scrutiny.
In common with Merck Serono, we also modelled second-line PFS from Tournigand et al.111 In particular,
we modelled separately PFS on second-line FOLFOX and PFS on second-line FOLFIRI.
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FIGURE 20 First-line OS (unresected patients) in the PenTAG model: (a) CET + FOLFOX vs. FOLFOX from the OPUS
trial; (b) PAN+ FOLFOX vs. FOLFOX from the PRIME trial; (c) PAN+ FOLFOX vs. BEV+ FOLFOX from the PEAK trial;
(d) CET+ FOLFIRI vs. FOLFIRI from the CRYSTAL trial; and (e) CET + FOLFIRI vs. BEV + FOLFIRI from the FIRE-3 trial.
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
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Given the lack of data to the contrary, both we and Merck Serono assumed that PFS on second-line
FOLFOX or second-line FOLFIRI was independent of first-line treatment.
First, we digitised the Kaplan–Meier data from Tournigand et al.111 We then fitted Weibull distributions to
each of the two curves (Figure 23). Given that cost-effectiveness is only weakly affected by second-line PFS,
we used a simple pragmatic fitting method by minimising the weighted sums of squares of differences
between empirical and fitted PFS at each month up to 11 months. The weights pragmatically decreased
linearly over time, from 1 at 0 months to 0 at 11 months, to reflect the reduction in the numbers of
patients at risk over time.
This yielded an estimated mean PFS for FOLFOX of 0.41 years and for FOLFIRI of 0.30 years.
Ideally, we would then model second-line PFS corresponding to the fitted Weibull distributions. However,
this would substantially complicate the model, as it would demand time-in-state specific transition
probabilities. Therefore, we pragmatically assumed that second-line PFS follows an exponential distribution,
with the lambda parameter set to 0.186 and 0.242 (time measured in months) for FOLFOX and FOLFIRI,
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FIGURE 23 Weibull curves fit to PFS data from the study by Tournigand et al.:111 (a) second-line FOLFOX; and
(b) second-line FOLFIRI.
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respectively, giving means equal to those above. This then renders the second-line transition probabilities
independent of time. This assumption affects cost-effectiveness only incrementally.
Mortality from second-line progression-free survival
Given the lack of data to the contrary, we estimated the proportion of progressions from second-line
treatment that were related to death as 6%, the corresponding value for first-line treatment (see Model
parameters, First-line progression-free survival: unresected patients). Cost-effectiveness was almost
completely unaffected by this estimate.
Second-line time on treatment: unresected patients
It is appropriate to base time on second-line treatment on data from Tournigand et al.111 as this study
informs second-line PFS.
In this study there was a median of eight cycles of second-line FOLFOX and six cycles of second-line
FOLFIRI.111 Given that one cycle lasted for 2 weeks in this study, this equates to a median time on
treatment of 16 and 12 weeks for FOLFOX and FOLFIRI, respectively. Given the lack of data to the
contrary, we assumed that treatment duration follows an exponential distribution. Therefore, the mean
time on treatment is 0.44 and 0.33 years for FOLFOX and FOLFIRI, respectively. These values are very
similar to the estimated mean PFS in the previous section for FOLFOX and FOLFIRI (0.41 and 0.30 years,
respectively). Therefore, we pragmatically assumed that second-line treatments are taken for the entire
duration of PFS.
Although not stated in its report, inspection of Merck Serono’s model revealed that it also assumed that
patients take FOLFOX or FOLFIRI for the entire duration of second-line PFS.
Third-line survival: unresected patients
We found that the cost-effectiveness of cetuximab and panitumumab is insensitive to our assumption
about the duration of third-line PFS, because we also assumed that this is equal in all treatment arms.
Therefore, this parameter does not merit close scrutiny.
We estimated the mean time in third-line treatment as 0.51 years, which was our estimated value for
third-line treatments for mCRC in the KRAS WT population in our model from TA242139 and that was
endorsed by the NICE committee. This estimate itself was derived from the study by Jonker et al.,112 which
compared treatment with cetuximab plus BSC with treatment with BSC alone.
Merck Serono also modelled third-line survival using data from Jonker et al.112 Inspection of its model
revealed that Merck Serono assumed a Weibull distribution; we calculated a mean of 0.74 years’ survival
for patients who start on third-line treatment. Merck Serono also assumed that this value was independent
of first- or second-line treatment.
Test accuracy
The Evidence Review Group (ERG) report for TA176 raised concerns that the model did not account for
patients who were incorrectly diagnosed.144 Some time was spent determining the relative accuracy of RAS
testing in clinical practice compared with RAS testing in the trials described in the clinical effectiveness
section. This is described in detail in Appendix 7. This was necessary to assess whether or not some
adjustment was necessary to account for differences in patients being incorrectly diagnosed between the
trials and clinical practice.
However, the relationship between a test’s ability to diagnose mutation status and the test’s ability to
predict the outcome of this diagnosis (which treatment patients receive and how effective this is) is a
complex one. In their assessment of diagnostic tests for detecting KRAS mutations, Westwood et al.45
adjusted the meaning of accuracy from ‘test accuracy’ (as discussed in our previous sections) to include
‘accuracy for predicting response to treatment with cetuximab in combination with standard chemotherapy,
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or variation in clinical outcomes following treatment with cetuximab in combination with standard
chemotherapy depending on which method is used to classify patients as having KRAS wild-type tumours’.
The study by Westwood et al.45 explains that, because of the nature of companion diagnostics, the only
conclusions that could reasonably be drawn regarding the diagnostic tests used in trials were that they
appeared to result in a benefit for patients and that there is no evidence to show that different tests used
in practice would lead to significantly different outcomes. Unfortunately, this was difficult to assess, as not
all tests used in practice have been used in trials of this nature.
Given the paucity of significant accuracy data to say otherwise and the apparent similarity in test accuracy
between KRAS and RAS WT testing, we agree with the conclusion provided in Westwood et al.’s45
assessment that there is no evidence of a difference between testing techniques. As such, the true
proportion of incorrect diagnoses in trials or clinical practice is not considered in our model and we do not
adjust the test accuracy in the trials to reflect what is carried out in practice.
Similarly, our clinical advisors (Dr Mark Napier and Christopher Bowles, based at the Royal Devon and
Exeter Hospital) advised that testing for EGFR expression is rarely, if ever, carried out in practice, as it is not
believed to be indicative of the effectiveness of treatment (2015, personal communication). Therefore, we
did not include EGFR testing in the model in either a cost or effectiveness capacity.
Utilities
In this section we follow the principles for the identification, review and synthesis of health-state utility
values from the literature, as recommended by the NICE DSU in the UK.155 There are no agreed reporting
standards for studies of utilities, but the following information is key to understanding the nature and the
quantity and quality of evidence:155
l the population describing the health state (e.g. age, sex, disease severity)
l the approach used to describe the health state
l utility value elicitation technique, for example time trade-off, standard gamble and visual
analogue scale
l sample size
l respondent selection and recruitment, and inclusion and exclusion criteria
l survey response rates, numbers lost to follow-up (and reasons) and methods of handling missing data.
Clearly, the relevance of the data to the decision model, and to the agency to which the model will be
submitted, is important. In the current project, the NICE reference case was used.128 Modification of utility
values from the literature for use in economic models, and sensitivity analyses using less relevant utility values,
should be considered.155 A systematic search for studies reporting utilities should be undertaken.155 For the
current project, the search method is provided in Appendix 1. The results of this search were combined with
the cost-effectiveness search results and the identified studies were screened simultaneously. We expanded
the population to all cases of mCRC, rather than just RAS WT mCRC, as we believed that little evidence
would be available on the utility of the RAS WT population. In addition, sources of utility values were
obtained from published models on the cost-effectiveness of panitumumab and cetuximab in combination
with chemotherapy. We also considered any sources presented in the manufacturers’ submissions.
We also compare the results of our utility review with the results of studies reported by a recent diagnostic
appraisal report,143 which included a complete mCRC population (both KRAS mutant and WT).
We report the findings of the quality of life search in Table 99 and the utilities from the cost-effectiveness
papers in Table 100. Only sources of KRAS WT utilities were identified as credible. When RAS WT utilities
were reported, the sources were unclear107 or important details were not provided and the values could
not be used.69 However, we believe that the KRAS WT population would not differ greatly from the RAS
WT population in terms of utility.
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TABLE 99 Utility studies identified by the quality-of-life search
Study Study population
Preference
elicitation Results Criticisms of study
First line
Bennett
2011115
PRIME trial: 576 previously
untreated KRAS WT mCRC
patients receiving either
PAN+ FOLFOX or FOLFOX
alone
EQ-5D
questionnaire,
UK value set
Baseline EQ-5D: PAN + FOLFOX
0.778 (SD 0.247), FOLFOX 0.756
(SD 0.244); LSM change from
baseline: PAN + FOLFOX 0.022
(95% CI 0.003 to 0.041), FOLFOX
0.027 (95% CI 0.008 to 0.046),
difference –0.005 (95% CI –0.032
to 0.022)
RAS WT results not
currently published;
reports only on
PAN+ FOLFOX and
FOLFOX
Láng
2013156
CRYSTAL trial: 627
previously untreated KRAS
WT mCRC patients
receiving either
CET+ FOLFIRI or FOLFIRI
alone
EORTC QLQ-C30
questionnaire
Values using EORTC QLQ-C30
global health scale: baseline
≈60 both CET+ FOLFIRI and
FOLFIRI, end of follow-up ≈65
CET+ FOLFIRI, ≈63 FOLFIRI; values
converted to EQ-5D scores all lie
within the range 0.62–0.63
RAS WT results not
currently published;
EQ-5D preferred to
EORTC QLQ-C30
Post first line
Bennett
2011115
NCT00339183 trial: 597
previously treated KRAS
WT mCRC patients
receiving either
PAN+ FOLFIRI or FOLFIRI
alone
EQ-5D
questionnaire,
UK value set
Baseline EQ-5D: PAN + FOLFIRI
0.769 (SD 0.230), FOLFOX 0.762
(SD 0.252); LSM change from
baseline: PAN + FOLFIRI –0.024
(95% CI –0.045 to –0.003),
FOLFIRI 0.000 (95% CI –0.021 to
0.022), difference –0.024
(95% CI –0.054 to 0.006)
RAS WT results not
currently published;
reports only on
PAN+ FOLFIRI and
FOLFIRI
Wang
2011116
Previously treated KRAS
WT mCRC patients
receiving PAN+ BSC or
BSC alone
EQ-5D
questionnairea
BSC only: toxicity 0.4409; without
disease or toxicity (progression
free) 0.6630; relapse/disease
progression 0.6407
KRAS WT not RAS WT
population; small
population size (n= 13
informed toxicity utility)
CET, cetuximab; LSM, least squares mean; PAN, panitumumab.
a As reported by Odom et al.157
TABLE 100 Utility values reported in the cost-effectiveness studies
Study Utility Stated source Notes
Graham 2014107 Progression free
0.821
PRIME trial, RAS WT results Not reported elsewhere; most recent values
from Siena et al.69 appear much lower (≈0.75)
Subsequent
treatment 0.782
Second-line panitumumab
trial, KRAS WT results
This trial is also reported in Bennett et al.,115 in
which second-line utility is reported as
0.762–0.769 depending on the arm
BSC 0.681 Third-line trial, KRAS WT
results
This trial is also reported in Odom et al.,157 in
which post first-line utility is reported as 0.68
Post resection
0.821
Assumed the same as
progression free
Ortendahl 2014109
(KRAS WT)
First line 0.77 Meads et al. (2010)a Source not confirmed, but Ewara et al.159 report
the same value; their source is also unconfirmed
Second line 0.75 Meads et al. (2010),
Mittman et al. (2009)a
Source not confirmed
Post successful
resection 0.84
Fryback et al. (1993)a Source not confirmed; study is > 20 years old
a Full publication details not provided by Ortendahl et al.109 for Meads et al. (2010), Mittman et al. (2009) and Fryback
et al. (1993).
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As well as our included cost-effectiveness studies, we identified the studies by Lawrence et al.158 and Ewara
et al.159 as potential utility sources, as these were cost-effectiveness studies of KRAS WT mCRC populations.
Ewara et al.159 did not highlight any sources of utilities that we had not already found through other sources
and the main utility study used by Lawrence et al.,158 by Petrou and Campbell,160 was irretrievable. However,
this study is nearly 20 years old and was conducted on UK oncology nurses and so we do not believe it to
be relevant.
Sources of progression-free utilities
From the searches we identified two full papers reporting progression-free utilities in KRAS WT populations
from the PRIME115 and CRYSTAL trials.156
The utilities from the CRYSTAL trial were valued using the EORTC QLQ-C30, a cancer-specific quality-of-life
questionnaire, and reported by Láng et al.156 The difference in utilities between cetuximab plus FOLFIRI and
FOLFIRI alone did not appear to be significant and neither was the change in utility over time. This supports
the conclusions of other utility sources.69,115 EQ-5D-based utilities are preferred in the NICE reference case.128
There are methods to convert EORTC QLQ-C30 values to EQ-5D values, including that provided by Kim
et al.161 This transformation was calculated for a population that included multiple cancers, but was
validated on a CRC population and therefore is the most relevant transformation to our results. It includes
several covariates but can be used as a simple linear transformation using the global health score reported
by the EORTC QLQ-C30. We manually extracted data points from the study by Láng et al.156 and used the
Kim et al.161 transformation to calculate utility values between 0.62 and 0.63 for the KRAS WT population
receiving cetuximab plus FOLFIRI, across the follow-up time reported in Láng et al.156 This seems quite low
compared with other utilities reported for the KRAS WT population,69,107,115 which are preferred as they do
not require transformation to EQ-5D scores.
Graham et al.,107 Siena et al.69 and Bennett et al.115 all report utilities from the PRIME trial for either KRAS
WT or RAS WT populations. However, the estimates are quite different across these studies. Bennett
et al.115 is the only full paper that reports utility data collected for the KRAS WT population from the PRIME
trial and it also includes utility results for a second-line panitumumab trial. It includes the results of EQ-5D
questionnaires valued on the UK value set calculated by Dolan.119 Bennett et al.115 also report that the
utility change from baseline until disease progression for both arms is not clinically significant and that the
difference between arms is not statistically or clinically significant. This group included both patients who
completed treatment and those who had to withdraw early. The weighted average of baseline utility from
Bennett et al.115 is 0.767 (to three significant figures). This is similar to the utility used in the study by
Ortendahl et al.109 (0.77), also for a KRAS WT mCRC population.
The publication by Siena et al.69 is an abstract reporting utility values for the RAS WT subpopulation of the
PRIME trial. The abstract does not specify at what time point the reported utilities were measured, but it
does state that the change in utility from baseline and the difference between arms were not found to
be statistically significant for this subgroup. In this abstract, the weighted average of the utility of the
panitumumab plus FOLFOX and FOLFOX arms is 0.750, which is below, but not dissimilar to, the utility of
the KRAS WT population reported in the study by Bennett et al.115
The utility estimate reported by Graham et al.107 is noticeably higher (0.821) than either the baseline or the
end-point utilities reported in Bennett et al.115 and Siena et al.69 It is unclear why this is the case as the
authors report that these are EQ-5D utility data for the RAS WT population, valued from the UK valuation
set, as in Siena et al.69 and Bennett et al.115 Both Graham et al.107 and Siena et al.69 report utilities for a RAS
WT population rather than a KRAS WT population, but are still markedly different, suggesting that the
difference in population between Graham et al.107 and Bennett et al.115 is not responsible for this higher
utility. It is possible that an increase in utility at an earlier time point in the follow-up could result in a
higher overall utility. However, this was not described in any of the PRIME trial reports and the results from
the CRYSTAL trial156 suggest a fairly linear relationship between utility and time.
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Sources of post first-line utilities
The study by Bennett et al.115 also contains information on utilities for a second-line KRAS WT mCRC
population, comparing panitumumab plus FOLFIRI with FOLFIRI. No significant difference between arms
was reported in this study. The most relevant of the reported utilities to a UK setting is that for FOLFIRI,
as chemotherapy alone is recommended as second-line treatment. To be consistent with our approach
to estimating first-line utility, we took the baseline utility for FOLFIRI post first line (0.762). This is not
significantly different from the first-line utility (0.767), but does indicate that progression to second-line
treatment is associated with a reduction in quality of life, which seems clinically plausible.
Graham et al.107 report a higher utility (0.782), but quote the source as the same trial reported in Bennett
et al.115 (NCT00339183). As with the first-line utility, it is unclear why this value is higher than that reported
by Bennett et al.115 Merck Serono also used the study by Bennett et al.115 as the source for second-line utility,
but used the value for the panitumumab plus FOLFIRI arm, which is only marginally higher at 0.769.
Ortendahl et al.109 report a utility value from Meads et al. (2010) and Mittmann et al. (2009) of 0.75
(full details for these two publications were not provided by Ortendahl et al.109). We could not confirm the
source of this value nor how this value was elicited.
The utility of progressive disease on BSC is reported by Graham et al.107 as 0.681. This is based on the trial
reported by Odom et al.,157 in which the KRAS WT population was in a progressive disease state receiving
either panitumumab plus BSC or BSC alone. This trial also forms the basis for the analyses conducted by
Wang et al.,116 which aimed to estimate utilities for patients in a post-first-line health state based on their
disease progression or AE status. Merck Serono used the study by Wang et al.116 to inform third-line utility
in its submitted model, choosing a utility for BSC without symptoms or AEs.
Post-resection progression-free utilities are generally high in the models. Both Graham et al.107 and Ortendahl
et al.109 report utilities of > 0.8 (0.821 and 0.84, respectively). However, the utility reported by Graham et al.107
corresponds to the first-line progression-free state and that reported by Ortendahl et al.109 relates to a study
by Fryback et al. (1993) (full details for this publication details were not provided by Ortendahl et al.109).
Neither of these sources has been confirmed and, furthermore, the Fryback et al. study is > 20 years old.
Merck Serono suggested that the utility of this progression-free post-resection population should be equal
to the population utility for the mean age of the cohort. Although this is likely to be an upper limit for this
utility, it is a reasonable approach to take because of the curative intent of the resection.
The utility of progressive disease post resection was assumed to be an average of the second- and third-
line utility weights in both the study by Graham et al.107 and the Merck Serono submission. These are the
only studies that we identified that reported utility for progressive disease post resection and the approach
seems to be a reasonable compromise to include second- and third-line information while keeping
progressive disease post resection as one health state.
One additional utility source that was identified was the study by Färkkilä et al.,162 which assessed 508 CRC
patients in Finland, with EQ-5D data valued on the UK valuation set. In total, 151 patients had metastatic
disease; the average age of this cohort was 66 years and 58% of the cohort were men. For those with
metastatic disease receiving treatment (n = 108) the utility was 0.820 (95% CI 0.783 to 0.858) and for
those with metastatic disease receiving palliative care (n = 41) the utility was 0.643 (95% CI 0.546 to
0.747). The mean time since diagnosis was 18 months. The utility for metastatic disease with treatment is
higher than that reported in Bennett et al.115 and indeed seems high compared with estimates of general
population utility for this cohort (≈0.0821 using the PenTAG model methods). The utility for those
receiving palliative care is similar to that reported in Wang et al.116 The study by Färkkilä et al.162 included
patients who underwent resection as well as those who were unresectable and may also reflect differences
between different countries’ values of HRQoL. However, in general, this study supports the findings of
Bennett et al.115 and Wang et al.,116 and does not supersede their relevance to this analysis.
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Summaries of the findings of the quality-of-life search and the utilities from the cost-effectiveness papers
are reported in Tables 99 and 100, respectively.
Utilities in the Peninsula Technology Assessment Group model
The health-state utilities used in the PenTAG base case are presented in Table 101.
We concluded that utility in first-line PFS would be the same for all treatments and that the most relevant
results are those reported by Bennett et al.115 Therefore, these form the basis of the PenTAG base case.
We used the value of 0.767, the average of the panitumumab plus FOLFOX and FOLFOX arms of the trial,
weighted by the number of patients.
For consistency, and because it is a recent study in a relevant population and provides EQ-5D data valued
on a UK data set, we also used the study by Bennett et al.115 for the second-line utility estimate.
For third-line utility we concluded that the most sensible value to use is that for people receiving BSC who
are in disease progression.116
For post-resection progression-free utility we used the same approach as Merck Serono. However, instead
of the approach in the study by Petrou and Hockley,117 which uses Health Survey for England data from
1996, we used the well-established methodology published by Ara and Brazier,130 updated with Health
Survey for England data from 2012:131
UHSE(2012) = 0:967981− 0:00181 × age− 0:00001 × age
2 + 0:02329 × male. (8)
As with Graham et al.107 and the Merck Serono submission, we also estimated the utility in disease
progression post successful resection by averaging the second- and third-line utilities. We used the same
approach as Merck Serono and weighted the average utility by the time spent in each line of treatment,
which gives us a disutility value in this health state of 0.142.
In the probabilistic sensitivity analysis, utilities for unresected patients were varied with beta distributions
based on their means and SEs.
The utilities post resection are driven by other parameters (e.g. PFS post resection is driven by the mean
age of the cohort). Although strictly these parameters should have additional uncertainty assigned to
TABLE 101 Peninsula Technology Assessment Group’s base-case utility parameters
Parameter Base case SE Distribution Source
First line (PFS) 0.767 0.0110 Beta Bennett et al.115
Second line 0.762 0.0155 Beta Bennett et al.115
Third line (PD) 0.6407 0.0155 Beta Wang et al.116
PFS post successful
resection
0.831 at age
63 years
NA Age-related general population utility130,131
PD post successful
resection disutility
0.142 NA Average of second- and third-line utilities
weighted by time spent in second or third line
NA, not applicable; PD, progressive disease.
Notes
Post-resection utilities are calculated as required in the model and it is the uncertainty of their input parameters that drives
the uncertainty in these utilities. As such, we did not calculate SEs for these parameters.
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them, the lack of information on this uncertainty would lead to estimates of SEs that would overshadow
the influence of the primary drivers of these parameters. Therefore, to ensure that the impact of these
parameters is recognised in our results, we do not assign additional uncertainty to the post-resection
utilities.
Costs
Inflation to 2015/16 prices
Unit costs were inflated to 2015/16 prices by inflating to 2013/14 prices using the Hospital and
Community Health Services pay and prices index163 and then to 2015/16 prices at a rate of 1.64%
per annum.
The rate of growth of the pay and prices index appears to have slowed in recent years (Figure 24) and so
the inclusion of historical values could lead to an overestimate of the likely inflation between 2013/14 and
2015/16. We therefore adopted the approach of taking the average increase in the index for the previous
3 years (i.e. from 2010/11 to 2013/14), that is, a rate of 1.64% per annum.
Table 102 provides the inflation factor used in the model for each year for inflation to 2015/16 prices.
Conversion to UK pounds
When conversion from other currencies to UK pounds was required, International Monetary Fund
purchasing power parity was used to convert within the year (e.g. from 2010 euros to 2010 UK pounds),
after which inflation was applied. The Campbell and Cochrane Economics Methods Group (CCEMG) –
Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre) Cost Converter version
1.5165 was used for the purchasing power parity conversion.
Cost of RAS testing
As detailed in Appendix 7, personal communication with the All Wales Medical Genetics Service (9 April
2015) and the Genetics Laboratory at Royal Devon and Exeter Hospital (11 March 2015) suggested a cost
of £200 for joint KRAS and NRAS mutation testing. This was despite differences in the number of codons
assessed and possible differences in the type of test used.
0
1
2
3
H
C
H
S 
p
ay
 a
n
d
 p
ri
ce
s 
in
d
ex
 
(c
h
an
g
e 
o
n
 p
re
vi
o
u
s 
ye
ar
) 
(%
)
4
5
6
Financial year
20
01
/2
20
02
/3
20
03
/4
20
04
/5
20
05
/6
20
06
/7
20
07
/8
20
08
/9
20
09
/10
20
10
/11
20
11
/12
20
12
/13
20
13
/14
FIGURE 24 Hospital and Community Health Services (HCHS) pay and prices index: change on previous year. Sources:
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As such, we assumed a unit cost of £200 for RAS mutation testing in our model. We also allowed for the cost
of patients who were tested as RAS mutant. We did this by setting the cost as follows: £200/50% = £400,
in which 50% of patients are assumed to be RAS WT.
Drug acquisition costs
We estimated the mean drug acquisition cost per patient as:
Mean first-line treatment duration × drug acquisition cost per unit time × dose intensity. (9)
As discussed previously (see Model parameters, First-line time on treatment), in the base case we used the
mean treatment duration from the RCTs capped by the mean time in first-line PFS for unresected patients.
Table 103 summarises the cost per month of the chemotherapy regimens in the PenTAG model.
Unit costs for each agent were drawn from the CMU eMit database140 when possible or from the British
National Formulary (BNF)16 when an agent was not present in the CMU eMit database (Table 104). When
the CMU eMit database price was used, the average unit cost was derived using a weighted average
(weighted by the market share in milligrams sold of each preparation). The unit cost for bevacizumab was
calculated assuming usage of 16-mg vials, as this resulted in slightly lower costs and did not increase
wastage, thereby slightly lowering total costs. The company submissions from Merck Serono and Amgen
included details of an alternative pricing strategy for cetuximab and a PAS for panitumumab; we were
advised by NICE to use the list prices in the base case and the PAS prices in scenario analyses. These were
presented to NICE in a confidential appendix and are not presented here.
Target dosages per cycle were drawn from the literature (i.e. from RCTs) (Table 105). Cetuximab was
assumed to be administered on a biweekly schedule to coincide with FOLFOX/FOLFIRI administration, as
TABLE 102 Inflation factor for each year for inflation to 2015/16 prices
From calendar year From financial year Inflation factor
2000 2000/1 1.527
2001 2001/2 1.453
2002 2002/3 1.404
2003 2003/4 1.335
2004 2004/5 1.292
2005 2005/6 1.246
2006 2006/7 1.201
2007 2007/8 1.168
2008 2008/9 1.124
2009 2009/10 1.117
2010 2010/11 1.084
2011 2011/12 1.062
2012 2012/13 1.044
2013 2013/14 1.033
2014 2014/15 1.016
2015 2015/16 1
Source: Curtis.163,164
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TABLE 103 Summary of monthly costs of chemotherapy regimens
Regimen Cost per month of drug acquisition (£)
CET+ FOLFOX4 3955
CET+ FOLFOX6 3961
PAN+ FOLFOX4 4195
PAN+ FOLFOX6 4200
BEV + FOLFOX4 2089
BEV + FOLFOX6 2094
FOLFOX4 86
FOLFOX6 91
XELOX 76
CET+ FOLFIRI 3987
BEV + FOLFIRI 2131
FOLFIRI 128
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
TABLE 104 Unit costs for individual agents
Agent Cost (£) Source
Cetuximab 20-ml vial (5 mg/ml): 178.10 BNF16
100-ml vial (5 mg/ml): 890.50
Panitumumab 5-ml vial (20 mg/ml): 379.29 BNF16
20-ml vial (20 mg/ml): 1517.16
Bevacizumab 4-ml vial (25 mg/ml): 242.66 BNF16
16-ml vial (25 mg/ml): 924.40
Oxaliplatin 20-ml vial (5 mg/ml): 6.14 CMU eMit140
10-ml vial (5 mg/ml): 3.65
Fluorouracil 20-ml vial (50 mg/ml): 1.33 CMU eMit140
100-ml vial (25 mg/ml): 6.14
50-ml vial (50 mg/ml): 2.04
5 × 10-ml vial (25 mg/ml): 17.63
10-ml vial (50 mg/ml): 0.87
10 × 20-ml vial (25 mg/ml): 47.50
100-ml vial (50 mg/ml): 3.71
Leucovorin 10-ml vial (10 mg/ml): 2.41 CMU eMit140
5 × 2-ml vial (7.5 mg/ml): 32.39
30-ml vial (10 mg/ml): 3.98
5 × 10-ml vial (3 mg/ml): 23.42
5 × 1-ml vial (3 mg/ml): 25.33
5-ml vial (10 mg/ml): 1.86
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TABLE 104 Unit costs for individual agents (continued )
Agent Cost (£) Source
Irinotecan 5-ml vial (20 mg/ml): 7.38 CMU eMit140
15-ml vial (20 mg/ml): 20.11
2-ml vial (20 mg/ml): 5.43
25-mg vial (20 mg/ml): 48.53
Capecitabine 60-tablet (150-mg) pack: 5.63 CMU eMit140
120-tablet (500-mg) pack: 39.04
Chlorphenamine 5 × 1-ml vial (10 mg/ml): 14.47 CMU eMit140
Dexamethasone 28-tablet (0.5-mg) pack: 45.10 CMU eMit140
50-tablet (2-mg) pack: 21.50
100-tablet (2-mg) pack: 33.96
150-ml oral solution (60 mg): 19.13
75-ml oral solution (30 mg): 17.00
TABLE 105 Dosages in each regimen and resulting cost per month
Regimen Agent Cycles per month Dosage per cycle Cost per cycle (£) Monthly cost (£)
CET+ FOLFOX4 CET 2.17 500mg/m2 1781 3859
FOLFOX4 See below 86
Chlorphenamine 2.17 10mg 2.89 6
Dexamethasone 2.17 8mg 2.08 5
Total 3955
CET+ FOLFOX6 CET 2.17 500mg/m2 1781 3859
FOLFOX6 See below 91
Chlorphenamine 2.17 10mg 2.89 6
Dexamethasone 2.17 8mg 2.08 5
Total 3961
PAN+ FOLFOX4 PAN 2.17 6mg/kg 1896.45 4109
FOLFOX4 See below 86
Total 4195
PAN+ FOLFOX6 PAN 2.17 6mg/kg 1896.45 4109
FOLFOX6 See below 91
Total 4200
BEV + FOLFOX4 BEV 2.17 5mg/kg 924.40 2003
FOLFOX4 See below 86
Total 2089
continued
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this is common clinical practice within the NHS. In addition, Merck Serono argued, on the basis of an
open-label RCT by Brodowicz et al.166 and a literature review,167 that biweekly administration of 500 mg/m2
of cetuximab is equivalent to induction with 400 mg/m2 followed by weekly administration of 250 mg/m2.
Biweekly administration is not included in the SPC for cetuximab. We consider the RCT by Brodowicz
et al.166 to be of sufficient quality to make this claim and believe the claim of equivalence to be reasonable.
The cost-effectiveness of weekly dosing of cetuximab was evaluated in a scenario analysis. In this analysis
the cost per month of drug acquisition for cetuximab (alone) was £4393 for the first month and
£3859 thereafter.
Target dosages and unit costs were not varied in the probabilistic sensitivity analysis.
TABLE 105 Dosages in each regimen and resulting cost per month (continued )
Regimen Agent Cycles per month Dosage per cycle Cost per cycle (£) Monthly cost (£)
BEV + FOLFOX6 BEV 2.17 5mg/kg 924.40 2003
FOLFOX6 See below 91
Total 2094
FOLFOX4 Oxaliplatin 2.17 85mg/m2 12.59 27
Leucovorin 2.17 400mg/m2 22.07 48
Fluorouracil 2.17 2000 mg/m2 4.92 11
Total 86
FOLFOX6 Oxaliplatin 2.17 100mg/m2 12.59 27
Leucovorin 2.17 400mg/m2 11.03 48
Fluorouracil 2.17 2800 mg/m2 7.38 16
Total 91
XELOX Capecitabine 1.45 28,000 mg/m2 33.55 49
Oxaliplatin 1.45 130mg/m2 18.89 27
Total 76
CET+ FOLFIRI CET 2.17 500mg/m2 1781 3859
FOLFIRI See below 128
Chlorphenamine 2.17 10mg 2.89 6
Dexamethasone 2.17 8mg 2.08 5
Total 3987a
BEV + FOLFIRI BEV 2.17 5mg/kg 924.40 2003
FOLFIRI See below 128
Total 2131
FOLFIRI Irinotecan 2.17 180mg/m2 29.68 64
Leucovorin 2.17 400mg/m2 11.03 48
Fluorouracil 2.17 2800 mg/m2 7.38 16
Total 128
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
a A small error in the model resulted in the costs of antihistamine and steroid not being included in the CET + FOLFIRI arm;
however, this made a negligible difference to the cost-effectiveness results.
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Target dosage and wastage were calculated based on an assumed body surface area of 1.85 m2 and a
body weight of 74.7 kg.
Next, we discuss our estimates of mean dose intensity, the last term in the calculation of mean drug
acquisition costs (see Equation 7). Mean dose intensities were assumed to be equal to the following
median dose intensities from the RCTs, provided to us by Merck Serono and Amgen:
l cetuximab plus FOLFOX – 89% (OPUS trial65)
l FOLFOX – 79% (OPUS trial65)
l panitumumab plus FOLFOX – 80% (PRIME trial27)
l bevacizumab plus FOLFOX – 85% (PEAK trial29)
l cetuximab plus FOLFIRI – 92% (CRYSTAL trial43)
l bevacizumab plus FOLFIRI – 85% (from the PEAK trial29 as not provided in the FIRE-3 trial28)
l FOLFIRI – 91% (CRYSTAL43).
The resulting mean drug acquisition costs per patient are provided in Figure 25.
For the scenario analysis in which we modelled OS from the RCTs, we assumed that some patients in the
FOLFOX network take cetuximab- or panitumumab-based treatments (see Scenario analyses, Overall
survival from randomised controlled trials).
Drug administration costs
Drug administration costs are all costs borne by the NHS and personal social services of administering
chemotherapy to a patient, excluding the direct cost of drug acquisition (i.e. payments to drug
manufacturers or distributors).
Following a similar approach to that in previous NICE appraisals relating to mCRC,143,168 we included the
following cost components in drug administration:
l delivery costs
l pharmacy costs
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bevacizumab; CET, cetuximab; PAN, panitumumab.
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l infusion pump costs
l line maintenance costs.
The greatest of these cost components is delivery costs; this is followed by pharmacy costs.
According to NHS reference costs guidance,169 chemotherapy ‘patients receive a core HRG [relating to
the purpose of their attendance (which is SB97Z if no other significant procedure takes place besides
chemotherapy delivery)] and one or more unbundled chemotherapy HRGs split into two categories’. The
first category is procurement HRGs, one of which is generated per chemotherapy cycle and includes the
cost of the entire procurement service, including pharmacy costs. The procurement HRGs are divided
according to setting and cost bands. The second category is delivery HRGs, which are generated for each
attendance (not just at the start of each cycle). The delivery HRGs are divided according to setting and
complexity (for the first day only, subsequent elements have a single unit cost per day in each setting).
It was not possible to use the procurement HRGs to estimate non-delivery administration costs because
they would include the cost of drug acquisition and because the mapping from chemotherapy regimens to
cost bands is not publicly available.
Evidence from the Department of Health, provided to us by Merck Serono [data on file, personal
communication, 24 August 2015 (via NICE)], shows that pharmacy, infusion pump and line maintenance
costs are already included in the delivery HRGs.
The total drug administration costs for each chemotherapy regimen are given in Table 106.
The interventions (cetuximab and panitumumab) are delivered as intravenous infusions prior to the initiation
of the other component of chemotherapy (FOLFOX or FOLFIRI).35,36 The comparator bevacizumab is
administered similarly. FOLFOX6 and FOLFIRI are provided as a 2-hour infusion of leucovorin plus oxaliplatin
or irinotecan followed by bolus 5-fluorouracil and then prolonged infusional 5-fluorouracil (46 hours).
FOLFOX4 is provided as a 2-hour infusion of leucovorin plus oxaliplatin followed by bolus 5-fluorouracil and
prolonged infusional 5-fluorouracil (22 hours), which is repeated on the subsequent day of the cycle.
TABLE 106 Unit costs of drug administration in the PenTAG model
Regimen Drug administration costs per cycle (£)
CET+ FOLFOX4 721
PAN+ FOLFOX4 721
BEV + FOLFOX4 721
CET+ FOLFOX6 392
PAN+ FOLFOX6 392
BEV + FOLFOX6 392
FOLFOX4 713
FOLFOX6 383
CET+ FOLFIRI 392
BEV + FOLFIRI 392
FOLFIRI 383
XELOX 303
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
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Based on guidance for NHS reference costs for 2013–14169 (Table 107), we believe that the appropriate
unit cost for one cycle of FOLFOX4 will consist of the unit cost of HRG code SB14Z (Deliver Complex
Chemotherapy, including Prolonged Infusional Treatment) for day 1 and the unit cost of HRG code SB15Z
(Deliver Subsequent Elements of a Chemotherapy Cycle) for day 2 of the cycle. FOLFOX6 and FOLFIRI will
incur only the unit cost of HRG code SB14Z. This results in significantly increased costs for FOLFOX4
compared with FOLFOX6 and FOLFIRI, but these are justified by the necessity of removing the infusion
pump, flushing the line, delivering a 2-hour infusion and initiating the next 22-hour infusion, which must
be carried out either in hospital or by a nurse visitor.
The setting of chemotherapy delivery is also important, as the unit costs vary considerably according to
setting (Table 108). It can be seen that, although the day-case and regular day/night settings accounts for
the majority of activity, they also produce the highest unit costs. Delivery in an outpatient or ‘other’ setting
significantly reduces the unit cost of the first attendance in a cycle, and delivery in an ‘other’ setting
significantly reduces the unit cost of delivery of subsequent elements of a chemotherapy cycle. The ‘other’
setting refers to community chemotherapy, in which patients receive their chemotherapy treatment in a
facility nearer to home than their cancer centre (e.g. a GP surgery) or in their own home.
The estimated SE for each unit cost was calculated from the underlying reference cost data, which provide
the unit cost and activity supplied by each submitting organisation.
First, the weighted SD was calculated for each unit cost, with the weight for each organisation equal to
its activity. Then, the SE was estimated by dividing by the square root of the number of organisations
(Table 109).
TABLE 107 Chemotherapy delivery definitions
Definition Explanation
Deliver simple parenteral chemotherapy Overall time of 30 minutes nurse time and 30–60 minutes chair
time for the delivery of a complete cycle
Deliver more complex parenteral chemotherapy Overall time of 60 minutes nurse time and up to 120 minutes
chair time for the delivery of a complete cycle
Deliver complex chemotherapy, including prolonged
infusional treatment
Overall time of 60 minutes nurse time and > 2 hours chair time
for the delivery of a complete cycle
Deliver subsequent elements of a chemotherapy cycle Delivery of any part of an outpatient chemotherapy regimen,
other than the first attendance (i.e. day 8 of a day 1 and
8 regimen, or days 8 and 15 of a day 1, 8 and 15 regimen)
Source: Department of Health, table 10 (p. 41).169 © Crown copyright. Reused under the terms of the Open Government
Licence (www.nationalarchives.gov.uk/doc/open-government-licence/).
TABLE 108 Variation in unit costs of chemotherapy delivery according to setting
Setting
SB14Z (Deliver Complex Chemotherapy,
including Prolonged Infusional Treatment)
SB15Z (Deliver Subsequent Elements
of a Chemotherapy Cycle)
Total activity count Unit cost (£) Total activity count Unit cost (£)
Day case and regular
day/night
151,689 401 167,850 328
Outpatient 37,146 266 40,880 314
Other 8577 284 7313 187
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A gamma distribution was used for each unit cost, with parameters derived using the method of moments.170
The drug delivery cost per cycle of FOLFOX6 and FOLFIRI was therefore £383, whereas the cost per cycle of
FOLFOX4 was £713.
It was further deemed important to reflect on the additional nursing time required to deliver monoclonal
antibody therapy (cetuximab, panitumumab or bevacizumab) at the start of each cycle, even though this
would not result in a different HRG currency being generated for the attendance. It is acknowledged
(e.g. paragraph 5.5.6 of the NICE methods guide128) that in such circumstances other sources of evidence
may be appropriate. As such, it was considered appropriate to estimate the additional nursing time and
cost required. Our clinical expert advised that 15 minutes of additional nursing time would be required to
administer monoclonal antibody therapy, which was costed at £34 (£35.12) per hour in 2013/14 (2015/16)
prices,163 resulting in an additional cost per cycle of £8.78 for chemotherapy regimens including
monoclonal antibodies. A gamma distribution was used for the duration of nursing time (independently
drawn for each monoclonal antibody), with a SE of 20% of the mean. Likewise, a gamma distribution was
used for the cost per hour of nursing time, with a SE of 20% of the mean.
Finally, the drug delivery cost per cycle of XELOX was estimated using HRG code SB13Z (Deliver More
Complex Parenteral Chemotherapy at First Attendance) as £303 per cycle. It was assumed that there
would be no additional cost for the delivery of oral capecitabine.
In the scenario analysis of weekly cetuximab administration (see Scenario analyses, Weekly administration
of cetuximab), the delivery cost per cycle for cetuximab regimens was increased by £303 to reflect the
extra attendance for drug delivery.
Cost of liver resection
Resection of liver metastases failure rate We found the following sources of data for the failure rate
of resection of liver metastases (Table 110).
In Merck Serono’s revised analysis in TA176,10 the failure rate was assumed to be 5%. Higher liver surgery
failure rates of 33% for panitumumab plus FOLFOX and 22% for bevacizumab plus FOLFOX were
observed in the PEAK trial.29
TABLE 109 Estimated unit costs and SEs for chemotherapy delivery
HRG code Setting Number of organisations Total activity count Unit cost (£) SD (£) SE (£)
SB13Z DCRDN 128 132,260 316.95 248.46 21.96
OP 49 25,223 218.60 96.55 13.79
Other 10 5468 189.91 107.72 34.06
SB14Z DCRDN 127 151,689 401.48 307.37 27.27
OP 41 37,146 265.85 113.46 17.72
Other 11 8577 283.81 175.79 53.00
SB15Z DCRDN 117 167,850 327.75 258.29 23.88
OP 36 40,880 313.80 156.91 26.15
Other 11 7313 187.00 106.79 32.20
DCRDN, day case and regular day/night; OP, outpatient.
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In our model we assumed a liver resection failure rate of 5% (based on TA17610 and expert advice from
Dr Mark Napier; see Table 110).
Cost of liver surgery In its current submission, Merck Serono modelled a cost of £2707 per liver
resection operation.
In the study by Graham et al.,107 liver resection surgery and hospitalisation were assumed to cost €14,428
(£11,356 as of 21 May 2015) (Table 111).
In TA176, in its original submission to NICE, Merck Serono estimated a cost of £2271 for liver resection. This
was later revised to £8929 and approved by the NICE committee (NICE Final Appraisal Determination10). In the
revised submission, Merck Serono used a weighted average cost per liver resection surgery calculated from
two liver HRG codes: G02 (Liver – Complex Procedures) and G03 (Liver – Very Major Procedures) (Table 112).
TABLE 110 Liver surgery failure rate
Rate (%) Source
< 10 Dr Mark Napier (clinical advisor to PenTAG, 2015, personal communication)
27.8 NICE TA176,10 manufacturer’s initial submission
5 NICE TA176,10 clinical specialists’ opinion (section 4.7)
5 NICE TA176,10 manufacturer’s revised economic analysis
0 Merck submission, current HTA
33.3 PAN + FOLFOX (PEAK trial29) (used in Graham et al.,107 p. 2795)
22.2 BEV + FOLFOX (PEAK trial29) (used in Graham et al.,107 p. 2795)
TABLE 112 Mapping between the OPCS Classification of Interventions and Procedures, HRG v3.5 codes and
HRG4+ codes
OPCS HRG v3.5 codes Description HRG v4+ codes
J021 G02 Right hemihepatectomy NEC GA03, GA04
J022 G02 Left hemihepatectomy NEC GA03, GA04
J023 G02 Resection of segment of liver GA03, GA04, GA05
J028 G02 Other specified partial excision of liver GA03, GA04, GA05
J029 G02 Unspecified partial excision of liver GA05, GA06, GA07
J024 G03 Wedge excision of liver GA03, GA04, GA05
J031 G03 Excision of lesion of liver NEC GA05, GA06, GA07
J032 G03 Destruction of lesion of liver NEC GA06, GA07, GA13
NEC, not elsewhere classified.
TABLE 111 Average liver resection surgery and hospitalisation cost reported in Graham et al.107
Cost (£, 2015) Source
11,356a Graham et al.107
a The conversion from euros (2012) to UK pounds (2015) was carried out using the CCEMG – EPPI-Centre Cost Converter.165
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We could not map from HRG v3.5171 to HRG v4+,172 so instead we identified which OPCS Classification of
Interventions and Procedures version 4.6 mapped to HRG v3.5 codes G02 and G03. Of these, the codes
shown in Table 112 seem potentially relevant to resection of liver metastases.
Based on clinical advice we understand that all liver resection surgeries for mCRC are very complex: 80%
of them are open operations and the remaining 20% are laparoscopic surgeries. Based on this assumption,
the HRG v4+ code GA03 (Very Complex Open Hepatobiliary or Pancreatic Procedures) is likely to be a
suitable candidate for calculating the cost of liver surgery.
Open liver resection We estimated the unit cost of very complex open liver resection surgery as a
weighted average of the costs for the HRGs GA03C, GA03D and GA03E (Table 113). They were
derived including:
l elective inpatients
l elective inpatient excess bed-days
l non-elective inpatients (long stay)
l non-elective inpatient (long stay) excess bed-days
l non-elective inpatients (short stay).
Laparoscopic liver resection In the previous section we estimated the unit cost of open liver resection as
£10,483 in 2013/14 prices (£10,829 in 2015/16 prices). We were not able to identify appropriate HRGs
in the NHS reference costs for laparoscopic liver resection, but we identified a cost study reported by
Polignano et al.173 in which the costs of elective laparoscopic and open liver segmentectomy, performed
with an intention to treat the disease, were compared (Table 114). Twenty-five laparoscopic liver resections
carried out at Ninewells Hospital and Medical School, Dundee, UK, between 2005 and 2007 were
compared with 25 matching open resections conducted at the same institution between 2004 and 2007.
The two groups were homogeneous by age, sex, coexistent morbidity and magnitude of resection.
Hospital costs were obtained from the Scottish Health Service Costs (ISD Scotland) and average costs were
calculated. Laparoscopic surgery was associated with a reduction in total costs of 18.0%, from which we
estimated the cost of laparoscopic liver resection to be £8598 in 2013/14 prices.
TABLE 114 Overall cost of liver segmentectomy reported by Polignano et al.173
Laparoscopic surgery (£) Open surgery (£)
Total (mean ± SD) 11,727 ± 3288 14,298 ± 3817
Source: hospital costs in this study were obtained from Scottish Health Service Costs (ISD Scotland).
TABLE 113 Average cost per liver resection surgery
Currency Currency description Total activity count Unit cost (£) Total cost, (£)
GA03C Very Complex Open Hepatobiliary or
Pancreatic Procedures, with CC Score 4+
627 13,433 8,422,455
GA03D Very Complex Open Hepatobiliary or
Pancreatic Procedures, with CC Score 2–3
596 10,258 6,113,911
GA03E Very Complex Open Hepatobiliary or
Pancreatic Procedures, with CC Score 0–1
940 8659 8,139,070
Weighted average 2163 10,483 22,675,436
Source: Department of Health.169
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Based on expert opinion that 80% of liver resections for metastases are open and 20% are laparoscopic,
we estimated an average cost for liver resection (weighted for the proportion of resections that are open
and the proportion that are laparoscopic) of £10,106 in 2013/14 prices, which was inflated to £10,440 in
2015/16 prices.
Frequency of liver resection In TA176 (p. 13),10 the cost of liver resection was assumed to occur only
once. This was despite the fact that the NICE appraisal committee believed that some patients may undergo
more than one operation to achieve complete resection of metastases (NICE Final Appraisal Determination,
p. 22).10 In its current submission, Merck Serono also assumed one liver resection per patient.
Adam et al.113 reported that 223 hepatectomies (out of 342 surgical procedures) were performed on
138 patients, that is, 1.6 per patient. The frequencies of repeat hepatectomies for recurring CRC in
patients with initially unresectable metastases, observed between January 1990 and January 2010 in a
French hospital, were reported by Wicherts et al.174 (Table 115). In total, 1.4 operations were carried out
per patient.
In conclusion, we assumed a mean of 1.6 operations per patient, based on the study by Adam et al.,113
as our estimates for OS and PFS post resection were based on this source.
Medical management costs
Resource use In this section we describe medical management costs not covered in other cost categories,
including the costs of:
l oncology outpatient attendances
l blood tests
l imaging tests [magnetic resonance imaging (MRI), CT]
l colonoscopy
l palliative care.
Resource use is different pre and post progression, as well as depending on whether or not liver
metastases have been successfully resected.
Resource use parameters are presented per month unless otherwise stated.
First- and second-line pre progression Individuals receiving first- or second-line chemotherapy who
have not undergone successful liver resection are estimated to have a consultant outpatient appointment
every 2 weeks regardless of their chemotherapy regimen, according to expert opinion (Dr Mark Napier,
2015, personal communication). This assumption was also made in TA242.139 One appointment every 2
weeks corresponds to 2.17 appointments on average per month.
Simple blood tests are performed every 2 weeks, but are low cost and are therefore not included. More
involved blood tests (tumour markers and liver function tests) are estimated to be performed at 1 month
and then every 4 months.113 For simplicity it was assumed that these tests would be performed on average
0.25 times per month.
TABLE 115 Frequency of repeat hepatectomies in patients with initially unresectable colorectal metastases
reported by Wicherts et al.174
Number of hepatectomies Number of patients
2 42/114
3 8/114
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During staging, all patients are offered (and are very likely to receive) contrast-enhanced CT of the chest,
abdomen and pelvis.1 This was not included as it is common to all regimens and occurs before
chemotherapy commences.
Rectal cancer patients are also offered MRI to assess the risk of local recurrence during staging;1 this was
also not included.
Magnetic resonance imaging, contrast-enhanced CT and positron emission tomography-CT may be offered
to patients with metastatic disease to determine the locations of disease and inform multidisciplinary
teams.1 These are not included since they are common to all regimens and are likely to occur before
chemotherapy commences.
It was estimated that CT scans are conducted every 3 months to monitor response to chemotherapy.175
Ultrasound imaging and MRI are not believed to be conducted routinely to monitor response, but it was
considered plausible that patients may receive one or two MRI scans per course (Dr Mark Napier, 2015,
personal communication). Based on mean time on first-line FOLFOX in unresected patients of 0.58 years and
assuming two MRI scans over this period, we estimated that patients would receive 0.288 MRI scans per month.
It was assumed, on the basis of expert opinion, that these patients would not undergo routine surveillance
for local recurrence (i.e. colonoscopy).
Resource use parameters were assumed to follow a gamma distribution in the probabilistic sensitivity
analysis, with SEs of 20% of the mean.
Third-line post progression Post-progression patients are expected to receive BSC, with their
management largely being transferred from secondary care to a palliative care team and/or their GP.
Rather than estimate resource use across a large number of cost components, we instead estimated the
cost of BSC per month (see Best supportive care).
Post-successful resection pre progression Given that patients post-successful resection pre progression
have a good prognosis (compared with patients unsuitable for liver resection or in whom liver resection is
incomplete), less intensive medical management is expected to be required.
Oncology outpatient attendances are expected every 4 months, that is, 0.25 appointments per month on
average.113 Blood tests (tumour markers and liver function) are conducted every 3 months (Dr Mark Napier,
2015, personal communication). It was assumed that CT scans are conducted every 3 months (Dr Mark
Napier, 2015, personal communication). MRI scans may be conducted but, given the limited size of this
population and the low number of tests that would be expected to be conducted, these were not included.
Colonoscopy may be recommended for surveillance of local recurrence in these patients. It is
recommended that the first surveillance colonoscopy be offered at 1 year after initial treatment,1 with
subsequent surveillance dictated by the risk of further malignancy, which may be 1- to 3-yearly if
adenomas are found (Dr Mark Napier, 2015, personal communication) or at 5 years if there are no
abnormal findings. We assumed that there would be one colonoscopy at 12 months, plus one
colonoscopy every 3 years thereafter (giving an average of 0.028 colonoscopies per month).
Resource use parameters were assumed to follow a gamma distribution in the probabilistic sensitivity
analysis, with SEs of 20% of the mean.
Post-successful resection post progression Patients post-successful resection post progression were
assumed to receive the same treatment as third-line post-progression patients who were not resected, that
is, BSC.
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Unit costs Unless otherwise stated, unit costs for medical management were drawn from gamma
distributions in the probabilistic sensitivity analysis, with SEs of 20% of the mean.
Oncology outpatient attendance A cost of £155 (2015/16 prices) was assumed per oncology
outpatient attendance, based on a cost of £150 for consultant-led outpatient attendances in medical
oncology (service code 370) from NHS reference costs 2013–14.134
Blood tests We used the same unit cost for blood tests for medical management as we did for blood
tests post resection, namely £13 per tumour marker test and £27 per liver function test (identified from
NICE 2005 interventional procedures guidance176 and inflated to 2015/16 prices).
Imaging Imaging tests were assumed to be carried out in the outpatient setting and costs were estimated
from NHS reference costs 2013–14.134 CT scans were assumed to be carried out in three areas, with
contrast, with an estimated cost of £132 in 2013/2014 prices (£137 in 2015/16 prices).134 MRI scans were
assumed to be carried out in two to three areas, with contrast, with an estimated cost of £193 in 2013/
2014 prices (£200 in 2015/16 prices).134
Colonoscopy Colonoscopy was assumed to be carried out as either a day-case or an outpatient
procedure (and was weighted according to the activity recorded for each setting). The cost of colonoscopy
was estimated from NHS reference costs 2013–14134 as £519 (2015/16 prices).
Best supportive care In previous assessments the cost of BSC was estimated based on a cost-of-illness
study in stage IV breast cancer by Remák and Brazil.177 The cost per month of BSC was estimated as £675
(£1031) in 2000 (2015/16) prices, whereas the total cost of end-of-life care was estimated as £1316
(£2010) in 2000 (2015/16) prices.
We performed a pragmatic literature search for cost-of-illness studies in mCRC and identified the following
two studies of interest.
1. A Finnish study by Färkkilä et al.178 estimated direct health-care costs per month of €1667 in 2010
prices (£1254 in 2015/16 prices) in the ‘palliative state’, with over half of this accounted for by ‘primary/
hospice care’.
2. A US study by Song et al.179 estimated average medical expenditure per month of US$26,649 in 2008
prices (£17,402 in 2015/16 prices) in the ‘death phase’ (which covered up to 3 months prior to death)
based on commercial and Medicare claims data, although this might include time on active treatment.
Given the significant differences between the US and UK health-care systems, it was decided that the
estimate from Song et al.179 was not generalisable to the NHS.
It was judged that the estimate from Färkkilä et al.178 was more recent than the estimate from Remák and
Brazil,177 and was determined using the correct patient population. In addition, although this study was
carried out in Finland, Finland has ‘fairly comprehensive provision of public health care’ (p. 456).178 On this
basis we used a cost per month of BSC of £1254. This is substantially greater than Merck Serono’s
estimate of £315 per month (see Chapter 5, De novo economic evaluation, Description of methods).
No separate cost for end-of-life care was included, as these costs should be included in the palliative state
in the analysis by Färkkilä et al.178
The 95% CI for direct medical costs ranged from 54.5% to 145.5% of the mean cost. This suggests a SE
of approximately 23.2% of the mean. To further acknowledge the uncertainty resulting from the
generalisation of the BSC cost from a different country, a SE of 40% of the mean was used in the
probabilistic sensitivity analysis.
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Adverse events
The NMAs for AEs reported in Chapter 3 (see Results, Adverse events) provide limited results for types of
grade 3 or 4 AEs. The FOLFOX network reports incidences for all comparators for neutropenia, paraesthesia,
rash and skin conditions, and the FOLFIRI network reports incidences for all comparators for skin conditions
and diarrhoea.
On advice from our clinical expert (Dr Mark Napier, 2015, personal communication) we believe that not all
clinically important AEs are likely to have been picked up by these NMAs.
As such, we used an alternative approach to estimate costs and QALYs associated with AEs that was not
reliant on every trial. Instead, we chose two trials as the bases for our two cost-effectiveness networks,
calculated total AE costs and QALYs for FOLFOX and FOLFIRI for these trials using the incidence of each
type of AE that was reported and then calculated costs and QALYs for the other arms of those trials by
adjusting for the relative risk of any grade 3/4 AE.
The two trials chosen as our bases were the PRIME trial27 for the FOLFOX network and the CRYSTAL trial43
for the FOLFIRI network. These were the largest trials with the most relevant comparators and were chosen
for consistency with the rest of the model.
The relative risk of any grade 3/4 AE was calculated by adjusting the ORs reported in Chapter 3 (see
Network meta-analysis) using the following formula:180
RR =
OR
(1−p (AE in base)) + (p (AE in base) × OR)
. (10)
For the purposes of our analysis, we grouped together different types of AEs that were thought to have
similar costs and utilities.
Disutilities for adverse events
The only cost-effectiveness study to report AE disutility was that by Ortendahl et al.,109 which used a value
of –0.07 from Jonker et al. (2007) (full reference not provided by Ortendahl). This is a simplistic approach
as it assumes the same disutility for all AEs. No studies on disutilities for AEs were identified from our
literature review of quality of life. However, we identified a recent NICE diagnostic appraisal report143 that
included a review on AEs in CRC, including UK data. We also consulted the sources provided by Merck
Serono in its submission as potential sources for our model. Our chosen base-case utilities for AEs are
presented in Table 116.
Freeman et al.143 identified the SCOT (Short Course Oncology Treatment) trial,183 which reported UK-based
EQ-5D data for CRC patients. They also received a personal communication related to this trial, which
included additional information.143 Although the Freeman et al.143 study has not yet been published, it has
been reviewed as part of the NICE process and as such we believe it to be of relevance to our report.
However, the EQ-5D data are limited to a few AEs and, as such, we were required to use the studies
identified by Freeman et al.,143 the Merck Serono submission and some additional searching to find
disutility estimates for all AEs reported in our identified trials.
Many of the utility studies identified by Freeman et al.143 and the Merck Serono submission were not
specific to CRC patients. Neither of these studies reported the disutility associated with anaemia or
thromboembolic events. We used a recent NICE technology assessment of cancer treatment-induced
anaemia (TA323)182 to estimate the utility difference for anaemia. This assessment used estimates from
Harrow et al.,181 scaled from the SF-6D to the EQ-5D, and was based on a cancer population.
We did not identify any UK-based studies that reported disutility for thrombosis or any studies specific to a
CRC population. Instead, we used the value of –0.190 reported by Hogg et al.184 This study was conducted
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with 215 people who underwent treatment for thromboembolic events at the Ottawa Hospital Thrombosis
Clinic in Canada. In total, 23% of patients had cancer-related thrombosis. A standard gamble approach
was used to elicit quality-of-life data from patients, but the measure used was not reported. The value of
–0.190 is similar to the value of –0.195 used by Merck Serono in its model (Merck Serono submission,
appendix B, table 1), although Merck Serono based its value on the disutility associated with infection.
A length of 1 week was applied to disutilities, in line with the approach used in the study by Freeman et al.,143
in which expert opinion indicated durations of a maximum of 7 days for grade 3/4 AEs. Freeman et al.143 state
that this was broadly similar to the length of stay associated with AEs reported in Twelves et al.185 Some AEs
may persist for > 7 days but with reduced severity and, in this analysis, grade 1/2 AEs were assumed to have
no disutility.
It is probable that some of the disutility of AEs is already captured in the first-line utility reported by
Bennett et al.,115 as the PRIME trial also recorded AEs and utilities. However, it is unclear what crossover
there is between the cohort who reported utility estimates and the cohort who reported AE data. To
arbitrarily reduce the disutility of AEs related to the PRIME trial would likely underestimate the impact of
these events. As such, we calculated the disutilities independently from the utility estimates in the base
case and set them equal to 0 in a sensitivity analysis. As the values are small for all arms (ranging from
–0.0018 to –0.0005) and the PRIME health state utilities are applied for all treatment arms, any double
counting is also applied in all arms and therefore does not impact greatly on the results.
Unit costs for adverse events
Unit costs were again based on the submission by Merck Serono and the study by Freeman et al.143 These
are detailed in Table 117; most are NHS reference costs relating to specific events. As these are AE costs,
the duration of the AE is not applied to these values.
TABLE 116 Peninsula Technology Assessment Group’s base-case utilities for AEs
AE Base case SE Source
Anaemia –0.08500 0.17 Harrow et al.,181 scaled to the EQ-5D,
as reported in Crathorne et al.182
Asthenia –0.08000 0.0615 Assumed to be the same as fatigue
Diarrhoea –0.09000 0.0379 Freeman et al.143 (SCOT trial data183)
Fatigue –0.08000 0.0615 Freeman et al.143 (SCOT trial data183)
Hypokalaemia –0.08000 0.0615 Assumed to be the same as fatigue
Infection –0.19500 0.012 Tolley et al.136
Leukopenia –0.06070 0.0457 Assumed to be the same as neutropenia
Mucosal inflammation –0.03750 0.1438 Assumed to be the same as mucositis
Mucositis/stomatitis –0.03750 0.1438 Freeman et al.143 (SCOT trial data183)
Neuropathy –0.19700 0.091 Freeman et al.143 (SCOT trial data183)
Neutropenia –0.06070 0.0457 Freeman et al.143 (SCOT trial data183)
Pain –0.06900 0.012 Doyle et al.135 (chest pain)
Paraesthesia –0.06900 0.012 Assumed to be equal to pain
Skin conditions –0.03248 0.01171 Nafees et al.137
Thrombosis –0.19000 0.038 Hogg et al.184
SCOT, Short Course Oncology Treatment.
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Checking the Peninsula Technology Assessment Group’s model for wiring errors
The PenTAG model was checked for wiring errors in the following ways.
l All model formulae that were written were checked by members of the team who did not build the
model (NH, IT, TS).
l The reasonableness of outputs given extreme input values was checked, for example the model
estimated QALYs were calculated to be equal to estimated life-years when the utility estimates were set
to 1.
l A simplified model was built that did not rely on model cycles and the results were compared with the
results of the full model to quickly identify errors.
l The base-case model results were checked for reasonableness using numerous graphs.
l The model results were checked for reasonableness through numerous univariate sensitivity analyses
and a probabilistic sensitivity analysis.
Peninsula Technology Assessment Group’s results
The base-case results are presented first, followed by the results of the sensitivity analyses.
Base-case results
All patients: base-case results
Our base-case results for the FOLFOX and FOLFIRI networks are provided in Tables 118–121.
TABLE 117 Peninsula Technology Assessment Group’s base-case costs for AEs
AE Base-case cost (£) SE (£) Source
Anaemia 799 159.80 Crathorne et al.182
Asthenia 157 31.40 Same as fatigue
Diarrhoea 157 31.40 General medicine outpatient visit service code 300134
Fatigue 157 31.40 General medicine outpatient visit service code 300134
Hypokalaemia 157 31.40 Same as fatigue
Infection 2160 432.00 Spell-based average inpatient stay134
Leukopenia 157 31.40 General medicine outpatient visit service code 300134
Mucosal inflammation 941 188.20 Assumed to be the same as mucositis
Mucositis/stomatitis 941 188.20 Based on Freeman et al.143: non-malignant, ear, nose,
mouth, throat or neck disorders (CB02A, CB02B, CB02C,
CB02D, CB02E, CB02F)134
Neuropathy 1736 347.20 Based on Merck submission: neoplasm-related admission
(WA17A, WA17B, WA17C, WA17D)134
Neutropenia 2160 432.00 Spell-based average inpatient stay134
Pain 135 27.00 Outpatient pain management code 191134
Paraesthesia 0 – Assumed no cost
Skin conditions 6 1.20 Diprobase® (Bayer plc, Newbury, Berkshire, UK)
500-mg pump16 (as used in Freeman et al.143)
Thrombosis 712 142.40 Deep-vein thrombosis (YQ51A, YQ51B, YQ51C, YQ51D)134
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TABLE 118 Base-case summary cost-effectiveness results: all patients, FOLFOX network
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFOX
vs. FOLFOX
PAN+ FOLFOX
vs. FOLFOX
Life-years (mean, undiscounted) 2.41 2.08 1.86 0.55 0.22
QALYs (mean, discounted) 1.61 1.41 1.26 0.35 0.15
Total costs (mean, discounted) (£) 67,057 61,225 30,585 36,471 30,640
ICER (£ per QALY) vs. FOLFOX (£) 104,205 204,103
ICER (£ per QALY) on efficiency
frontier (£)
104,205 Extendedly
dominated
Reference
CET, cetuximab; PAN, panitumumab.
Note
PAN+ FOLFOX is extendedly dominated as it has lower QALY gains and a higher ICER vs. FOLFOX in comparison
with CET + FOLFOX.
TABLE 119 Base-case detailed results: all patients, FOLFOX network
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+FOLFOX vs.
PAN+ FOLFOX
vs. FOLFOXPAN+ FOLFOX FOLFOX
Life-years (mean, undiscounted)
First-line drug
(resected + unresected)
0.72 0.68 0.58 0.04 0.14 0.10
PFS unresected 0.57 0.64 0.52 –0.07 0.06 0.12
PFS post resection 0.85 0.52 0.44 0.33 0.41 0.08
PFS first line 1.42 1.16 0.96 0.26 0.46 0.2
Second-line FOLFOX or
FOLFIRI (unresected)
0.26 0.28 0.29 –0.03 –0.03 –0.01
Third-line BSC (unresected) 0.38 0.42 0.43 –0.04 –0.05 –0.01
PD post resection 0.35 0.21 0.18 0.14 0.17 0.03
OS (mean) 2.41 2.08 1.86 0.33 0.55 0.22
Cohort split
% starting second-line
FOLFOX/FOLFIRI
(unresected)
93.50 93.50 93.50 0.00 0.00 0.00
% starting third-line BSC
(unresected)
87.50 87.50 87.50 0.00 0.00 0.00
Life-years (mean) (undiscounted for patients who spend at least some time in given health state)
PFS unresected 0.72 0.73 0.58 –0.01 0.14 0.16
PFS post resection 4.09 4.09 4.09 0 0 0
PFS first line 4.81 4.82 4.67 –0.01 0.14 0.16
Second-line FOLFOX or
FOLFIRI (unresected)
0.34 0.34 0.34 0 0 0
Third-line BSC (unresected) 0.55 0.55 0.55 0 0 0
PD post resection 1.69 1.69 1.69 0 0 0
OS unresected 1.53 1.54 1.38 –0.01 0.14 0.16
continued
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TABLE 119 Base-case detailed results: all patients, FOLFOX network (continued )
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+FOLFOX vs.
PAN+ FOLFOX
vs. FOLFOXPAN+ FOLFOX FOLFOX
QALYs (discounted)
PFS unresected 0.43 0.48 0.39 –0.05 0.04 0.09
PFS post resection 0.56 0.34 0.29 0.22 0.27 0.05
AEs first line 0.00 0.00 0.00 0.00 0.00 0.00
PFS first line 0.99 0.82 0.68 0.16 0.31 0.14
Second-line FOLFOX or
FOLFIRI (unresected)
0.19 0.21 0.21 –0.02 –0.02 –0.01
Third-line BSC
(unresected)
0.23 0.26 0.26 –0.02 –0.03 –0.01
PD post resection 0.20 0.12 0.10 0.08 0.10 0.02
Total 1.61 1.41 1.26 0.20 0.35 0.15
Costs (discounted) (£)
RAS test 400 400 0 0 400 400
First-line drug acquisition 29,850 26,969 461 2881 29,389 26,508
First-line drug
administration
13,212 12,508 10,527 704 2685 1981
First-line AEs 1512 1582 1068 –70 444 514
First-line medical
management
(unresected)
3029 3394 2746 –365 283 648
Second-line FOLFOX or
FOLFIRI acquisition
(unresected)
379 417 429 –38 –50 –12
Second-line FOLFOX or
FOLFIRI administration
(unresected)
2456 2704 2778 –247 –322 –75
Second-line FOLFOX
or FOLFIRI medical
management
(unresected)
1325 1458 1499 –133 –174 –40
Third-line BSC
(unresected)
5481 6033 6199 –552 –718 –166
Resection operation 3635 2224 1884 1411 1751 340
PFS post resection 1014 620 526 394 488 95
PD post resection 4763 2914 2469 1849 2294 446
Total 67,057 61,225 30,585 5832 36,471 30,640
ICER (£ per QALY) 29,176 104,205 204,103
CET, cetuximab; PAN, panitumumab; PD, progressive disease.
Note
Percentage of patients resected not reported as information is AiC [Amgen, 19 March 2015, personal communication
(via NICE)].
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TABLE 120 Base-case summary cost-effectiveness results: all patients, FOLFIRI network
Outcome CET+ FOLFIRI FOLFIRI CET+ FOLFIRI vs. FOLFIRI
Life-years (mean, undiscounted) 2.21 1.75 0.46
QALYs (mean, discounted) 1.53 1.23 0.30
Total costs (mean, discounted) (£) 65,380 28,250 37,130
ICER (£ per QALY) (£) 122,554
CET, cetuximab.
TABLE 121 Base-case detailed results: all patients, FOLFIRI network
Outcome CET+ FOLFIRI FOLFIRI
CET+ FOLFIRI
vs. FOLFIRI
Life-years (mean, undiscounted)
First-line drug (resected + unresected) 0.76 0.56 0.20
PFS unresected 0.95 0.75 0.20
PFS post resection 0.30 0.09 0.21
PFS first line 1.25 0.83 0.42
Second-line FOLFOX or FOLFIRI (unresected) 0.39 0.41 –0.02
Third-line BSC (unresected) 0.45 0.47 –0.03
PD post resection 0.12 0.04 0.09
OS (mean) 2.21 1.75 0.46
Cohort split
% unresected 92.7 97.9 –5.2
% starting second-line FOLFOX/FOLFIRI (unresected) 93.5 93.5 0.0
% starting third-line BSC (unresected) 87.5 87.5 0.0
% resected 7.3 2.1 5.2
Life-years (mean) (undiscounted for patients who spend at least some time in given health state)
PFS unresected 1.03 0.76 0.26
PFS post resection 4.09 4.09 0.00
PFS first line 5.12 4.85 0.26
Second-line FOLFOX or FOLFIRI (unresected) 0.45 0.45 0.00
Third-line BSC (unresected) 0.55 0.55 0.00
PD post resection 1.69 1.69 0.00
OS unresected 1.93 1.67 0.26
QALYs (discounted)
PFS unresected 0.71 0.56 0.15
PFS post resection 0.20 0.06 0.14
AEs first line –0.00 –0.00 –0.00
PFS first line 0.91 0.62 0.29
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Survival results
The relative proportions of patients in each health state for each treatment throughout the time horizon of
the model are displayed in Figure 26. The mean duration in each health state for each treatment (see
Tables 119 and 121) is represented in these graphs by the area under each curve. Virtually all patients are
predicted to have died 20 years from start of treatment, which is less than the model time horizon of
30 years.
The graphs show two distinct features. The times on first-, second- and third-line treatment for unresected
patients are short and last in total up to about 4 years. The times in PFS and progressive disease post
resection are much longer. This reflects the substantial improvement in survival that we predict for patients
post resection.
It can be clearly seen that we predict higher rates of resection in the FOLFOX network than in the FOLFIRI
network. However, it is important to note that comparisons between the two networks should be made with
caution, as they represent different cohorts of patients, as the data are not randomised between networks.
Figure 26 demonstrates that we expect slightly longer times in first-line PFS for unresected patients for
cetuximab plus FOLFOX and panitumumab plus FOLFOX compared with FOLFOX, and for cetuximab plus
FOLFIRI compared with FOLFIRI.
TABLE 121 Base-case detailed results: all patients, FOLFIRI network (continued )
Outcome CET+ FOLFIRI FOLFIRI
CET+ FOLFIRI
vs. FOLFIRI
Second-line FOLFOX or FOLFIRI (unresected) 0.28 0.30 –0.02
Third-line BSC (unresected) 0.27 0.29 –0.02
PD post resection 0.07 0.02 0.05
Total 1.53 1.23 0.30
Costs (discounted) (£)
RAS test 400 0 400
First-line drug acquisition 32,742 776 31,965
First-line drug administration 7543 5506 2037
First-line AEs 821 482 339
First-line medical management (unresected) 4993 3948 1045
Second-line FOLFOX or FOLFIRI acquisition (unresected) 382 407 –25
Second-line FOLFOX or FOLFIRI administration (unresected) 6868 7317 –449
Second-line FOLFOX or FOLFIRI medical management (unresected) 1991 2122 –130
Third-line BSC (unresected) 6316 6730 –413
Resection operation 1284 372 912
PFS post resection 358 104 254
PD post resection 1683 488 1195
Total 65,380 28,250 37,130
ICER (£ per QALY) 122,554
CET, cetuximab; PAN, panitumumab; PD, progressive disease.
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We predict similar mean times across the treatment arms in second-line PFS and third-line treatment for
unresected patients. Any differences are the result of the slightly different expected proportions of patients
who reach these lines of treatment (see cohort split data in Tables 119 and 121).
The relative magnitudes of the QALYs are similar to the relative magnitudes of the life-years, as the QALYs
are simply the life-years discounted and then multiplied by the utilities appropriate for each health state.
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FIGURE 26 Cohort composition over time by treatment: (a) cetuximab plus FOLFOX; (b) panitumumab plus
FOLFOX; (c) FOLFOX; (d) cetuximab plus FOLFIRI; and (e) FOLFIRI. PD, progressive disease. (t), time. (continued )
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Reductions in QALYs as a result of AEs are very small in all cases. Incremental QALYs with respect to times
in second- and third-line treatment for unresected patients are small in all cases, because patients are
expected to spend similar times in second- and third-line treatment for all comparator arms.
We predict that, for the comparison between cetuximab plus FOLFOX and FOLFOX, most incremental QALYs
come from PFS post resection (Figure 27a). This is largely because of the high expected resection rate for
cetuximab plus FOLFOX compared with FOLFOX. Total incremental QALYs for panitumumab plus FOLFOX
compared with FOLFOX are far lower than for cetuximab plus FOLFOX compared with FOLFOX. This is mostly
because we predict a lower resection rate for panitumumab plus FOLFOX than for cetuximab plus FOLFOX.
For the comparison between cetuximab plus FOLFIRI and FOLFIRI, most incremental QALYs come from the
PFS unresected and PFS post-resection health states (see Figure 27b). Post-resection QALYs are less
important than for cetuximab plus FOLFOX compared with FOLFOX, as we predict low rates of resection
for cetuximab plus FOLFIRI (7.3%) and FOLFIRI (2.1%).
Cost results
The expected absolute first-line drug acquisition costs and first-line drug administration costs are by far the
largest cost items in the FOLFOX network (see Table 119). In the FOLFIRI network, the largest cost items
are the first-line drug acquisition costs and first-line drug administration costs, but also the second-line
drug administration costs (see Table 121). The second-line drug administration costs are large because we
predict that a larger proportion of patients in the FOLFIRI network are unresected and because we predict
that patients spend longer on second-line FOLFOX than second-line FOLFIRI.
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FIGURE 27 Incremental QALYs: PenTAG’s base case, all patients: (a) FOLFOX network; and (b) FOLFIRI network.
CET, cetuximab; PAN, panitumumab; PD, progressive disease.
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Turning to incremental costs, we predict that first-line drug acquisition costs dominate (Figure 28). The
incremental costs of drug acquisition for cetuximab plus FOLFOX and panitumumab plus FOLFOX are
similar because cetuximab and panitumumab cost a similar amount per month and because we predict
that these two treatments are taken for a similar duration (8.7 and 8.2 months, respectively). First-line drug
administration costs also make an important contribution to total incremental costs.
The incremental costs of RAS testing and treating AEs are very small. As for incremental QALYs,
incremental costs in respect of second- and third-line states are also very small, as we predict that patients
spend very similar times in these states between treatment arms.
Cost-effectiveness results and associated uncertainty
Combining all of the information on expected costs and QALYs per person (Figure 29), we estimate the
following ICERs:
l cetuximab plus FOLFOX compared with FOLFOX – £104,000 per QALY
l panitumumab plus FOLFOX compared with FOLFOX – £204,000 per QALY (extendedly dominated by
cetuximab plus FOLFOX and FOLFOX)
l cetuximab plus FOLFIRI compared with FOLFIRI – £123,000 per QALY.
All ICERs throughout are rounded to the nearest thousand pounds, given the limited confidence in the
accuracy of any further significant figures.
Overall, we believe that these estimates are subject to substantial uncertainty, only some of which is
captured in the probabilistic sensitivity analysis (see Probabilistic sensitivity analysis).
In favour of our approach, the PFS data for first-line treatment is of high quality, as it comes directly from
RCTs. However, we note that the evidence for cetuximab plus FOLFOX is not as strong as that for
panitumumab plus FOLFOX, as the OPUS trial of cetuximab plus FOLFOX compared with FOLFOX had far
fewer RAS WT patients (n = 87)65 than the PRIME trial of panitumumab plus FOLFOX compared with
FOLFOX (n = 512).44
Furthermore, we adjusted the PFS from the RCTs of first-line drugs by subtracting those patients who were
resected (see Model parameters, First-line progression-free survival: unresected patients). Without access to
the underlying individual patient data from the RCTs, we acknowledge that our method is only approximate.
We estimated survival post resection from a study that is now several years old.113 Also, none of the
patients in this study took either cetuximab or panitumumab. It is therefore possible that survival post
resection for patients initially treated with these drugs could differ from that reported in the study by
Adam et al.113
We assumed that any treatment effect from first-line drugs stops on progression. This is because we did
not model OS from the RCTs, but instead only PFS. We explored the use of OS data from the RCTs in a
scenario analysis (see Scenario analyses, Overall survival from randomised controlled trials).
Given the lack of data to suggest otherwise, we assumed the same accuracy of the RAS test in clinical
practice as in the first-line RCTs (see Model parameters, Test accuracy). Any differences are likely to result
in worse estimates of cost-effectiveness for cetuximab and panitumumab.
For FOLFOX, our clinical effectiveness results were based on the PRIME trial.44 This was investigated in
scenario analysis (see Scenario analyses, OPUS trial as the baseline randomised controlled trial in the
FOLFOX network). Also, we assumed that cetuximab was given fortnightly, whereas in the RCTs of
cetuximab it was given weekly.43,65 We therefore assumed that the frequency of administration does not
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FIGURE 28 Incremental costs: PenTAG’s base case, all patients: (a) FOLFOX network; and (b) FOLFIRI network.
CET, cetuximab; PAN, panitumumab; PD, progressive disease.
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affect the effectiveness of cetuximab. We modelled the weekly administration of cetuximab in a scenario
analysis (see Scenario analyses, Weekly administration of cetuximab).
We have confidence in our estimated rates of resection for the FOLFIRI network (cetuximab plus FOLFIRI
7.3%, FOLFIRI 2.1%). Also, our estimated rates of resection for panitumumab plus FOLFOX and FOLFOX in
the FOLFOX network are reliable as they are taken directly from the PRIME trial.44 However, our estimate
for cetuximab plus FOLFOX (20.7%) is subject to a good deal of uncertainty as it was obtained by an
indirect comparison (see Model parameters, Resection rates).
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Liver metastases subgroup: base-case results
Our base-case results for the FOLFOX and FOLFIRI networks for the liver metastases subgroup are provided
in Tables 122–125.
Survival results
Much of the discussion relating to all patients is also relevant to the liver metastases subgroup. In this
section we discuss features that are unique to the liver metastases subgroup.
TABLE 122 Base-case summary cost-effectiveness results: liver metastases subgroup, FOLFOX network
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFOX
vs. FOLFOX
PAN+ FOLFOX
vs. FOLFOX
Life-years (mean, undiscounted) 2.98 2.86 2.21 0.76 0.65
QALYs (mean, discounted) 1.97 1.89 1.49 0.49 0.40
Total costs (mean, discounted) (£) 80,931 69,515 34,598 46,333 34,917
ICER (£ per QALY) vs. FOLFOX (£) 95,514 86,875
ICER (£ per QALY) on efficiency
frontier (£)
137,270
(vs. PAN + FOLFOX)
86,875
(vs. FOLFOX)
Reference
CET, cetuximab; PAN, panitumumab.
TABLE 123 Base-case detailed results: liver metastases subgroup, FOLFOX network
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFOX vs.
PAN+ FOLFOX
vs. FOLFOXPAN+ FOLFOX FOLFOX
Life-years (mean, undiscounted)
First-line drug
(resected + unresected)
0.90 0.73 0.67 0.17 0.23 0.06
PFS unresected 0.63 0.50 0.56 0.13 0.08 –0.05
PFS post resection 1.26 1.28 0.70 –0.01 0.57 0.58
PFS first line 1.90 1.78 1.26 0.12 0.64 0.53
Second-line FOLFOX or
FOLFIRI (unresected)
0.22 0.22 0.27 0 –0.04 –0.05
Third-line BSC (unresected) 0.33 0.33 0.40 0 –0.07 –0.07
PD post resection 0.52 0.53 0.29 –0.01 0.23 0.24
OS (mean) 2.98 2.86 2.21 0.11 0.76 0.65
Cohort split
% starting second-line
FOLFOX/FOLFIRI
(unresected)
93.5 93.5 93.5 0.0 0.0 0.0
% starting third-line BSC
(unresected)
87.5 87.5 87.5 0.0 0.0 0.0
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TABLE 123 Base-case detailed results: liver metastases subgroup, FOLFOX network (continued )
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFOX vs.
PAN+ FOLFOX
vs. FOLFOXPAN+ FOLFOX FOLFOX
Life-years (mean) (undiscounted for patients who spend at least some time in given health state)
PFS unresected 0.92 0.73 0.67 0.19 0.25 0.06
PFS post resection 4.09 4.09 4.09 0 0 0
PFS first line 5.01 4.82 4.76 0.19 0.25 0.06
Second-line FOLFOX or
FOLFIRI (unresected)
0.34 0.34 0.34 0 0 0
Third-line BSC
(unresected)
0.55 0.55 0.55 0 0 0
PD post resection 1.69 1.69 1.69 0 0 0
OS unresected 1.72 1.54 1.48 0.19 0.25 0.06
QALYs (discounted)
PFS unresected 0.48 0.38 0.42 0.10 0.06 –0.04
PFS post resection 0.83 0.84 0.46 –0.01 0.37 0.38
AEs first line 0.00 0.00 0.00 0.00 0.00 0.00
PFS first line 1.31 1.22 0.88 0.09 0.43 0.34
Second-line FOLFOX or
FOLFIRI (unresected)
0.16 0.16 0.20 0.00 –0.03 –0.03
Third-line BSC
(unresected)
0.20 0.20 0.24 0.00 –0.04 –0.04
PD post resection 0.30 0.31 0.17 0.00 0.14 0.14
Total 1.97 1.89 1.49 0.08 0.49 0.40
Costs (discounted) (£)
RAS test 400 400 0 0 400 400
First-line drug acquisition 36,927 28,891 533 8036 36,393 28,357
First-line drug
administration
16,344 13,399 12,175 2945 4169 1224
First-line AEs 1512 1582 1068 –70 444 514
First-line medical
management
(unresected)
3339 2663 2952 676 386 –290
Second-line FOLFOX or
FOLFIRI acquisition
(unresected)
328 329 397 0 –69 –69
Second-line FOLFOX or
FOLFIRI administration
(unresected)
2126 2128 2572 –2 –447 –444
Second-line FOLFOX or
FOLFIRI medical
management
(unresected)
1147 1148 1387 –1 –241 –240
Third-line BSC
(unresected)
4743 4748 5739 –6 –996 –991
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TABLE 123 Base-case detailed results: liver metastases subgroup, FOLFOX network (continued )
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFOX vs.
PAN+ FOLFOX
vs. FOLFOXPAN+ FOLFOX FOLFOX
Resection operation 5432 5495 3002 –62 2430 2493
PFS post resection 1515 1533 837 –17 678 695
PD post resection 7119 7200 3934 –84 3273 3357
Total 80,931 69,515 34,598 11,416 46,333 34,917
ICER (£ per QALY) 137,270 95,514 86,875
CET, cetuximab; PAN, panitumumab; PD, progressive disease.
Note
Resection rates are removed because of AiC information contained in them.
TABLE 124 Base-case summary cost-effectiveness results: liver metastases subgroup, FOLFIRI network
Outcome CET+ FOLFIRI FOLFIRI CET+ FOLFIRI vs. FOLFIRI
Life-years (mean, undiscounted) 2.69 1.83 0.86
QALYs (mean, discounted) 1.83 1.26 0.57
Total costs (mean, discounted) (£) 73,153 29,809 43,345
ICER (£ per QALY) (£) 76,298
CET, cetuximab; PAN, panitumumab.
TABLE 125 Base-case detailed results: liver metastases subgroup, FOLFIRI network
Outcome CET+ FOLFIRI FOLFIRI
CET+ FOLFIRI
vs. FOLFIRI
Life-years (mean, undiscounted)
First-line drug (resected + unresected) 0.86 0.65 0.21
PFS unresected 0.99 0.61 0.38
PFS post resection 0.67 0.27 0.40
PFS first line 1.66 0.88 0.78
Second-line FOLFOX or FOLFIRI (unresected) 0.35 0.39 –0.04
Third-line BSC (unresected) 0.40 0.45 –0.05
PD post resection 0.28 0.11 0.17
OS (mean) 2.69 1.83 0.86
Cohort split
% unresected 83.7 93.5 –9.8
% starting second-line FOLFOX/FOLFIRI (unresected) 93.5 93.5 0.0
% starting third-line BSC (unresected) 87.5 87.5 0.0
% resected 16.3 6.5 9.8
continued
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TABLE 125 Base-case detailed results: liver metastases subgroup, FOLFIRI network (continued )
Outcome CET+ FOLFIRI FOLFIRI
CET+ FOLFIRI
vs. FOLFIRI
Life-years (mean) (undiscounted for patients who spend at least some time in given health state)
PFS unresected 1.18 0.65 0.53
PFS post resection 4.09 4.09 0.00
PFS first line 5.27 4.74 0.53
Second-line FOLFOX or FOLFIRI (unresected) 0.45 0.45 0.00
Third-line BSC (unresected) 0.55 0.55 0.00
PD post resection 1.69 1.69 0.00
OS unresected 2.08 1.56 0.53
QALYs (discounted)
PFS unresected 0.74 0.46 0.28
PFS post resection 0.44 0.17 0.26
AEs first line 0.00 0.00 0.00
PFS first line 1.18 0.64 0.54
Second-line FOLFOX or FOLFIRI (unresected) 0.25 0.29 –0.03
Third-line BSC (unresected) 0.24 0.27 –0.03
PD post resection 0.16 0.06 0.10
Total 1.83 1.26 0.57
Costs (discounted) (£)
RAS test 400 0 400
First-line drug acquisition 36,874 896 35,979
First-line drug administration 8495 6351 2143
First-line AEs 821 482 339
First-line medical management (unresected) 5169 3228 1941
Second-line FOLFOX or FOLFIRI acquisition (unresected) 343 390 –47
Second-line FOLFOX or FOLFIRI administration (unresected) 6169 7016 –847
Second-line FOLFOX or FOLFIRI medical management (unresected) 1789 2034 –246
Third-line BSC (unresected) 5674 6453 –779
Resection operation 2866 1143 1723
PFS post resection 799 319 481
PD post resection 3756 1498 2258
Total 73,153 29,809 43,345
ICER (£ per QALY) 76,298
CET, cetuximab; PAN, panitumumab; PD, progressive disease.
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We predict slightly longer life expectancy for the liver metastases subgroup (1.8–3.0 years) than for all
patients (1.8–2.4 years). This is because we also predict greater resection rates for the liver metastases
subgroup than for all patients and life expectancy is substantially greater for patients after resection than
for patients without resection.
We predict that, for both cetuximab plus FOLFOX compared with FOLFOX and panitumumab plus FOLFOX
compared with FOLFOX, most incremental QALYs come from PFS and progressive disease post resection
(Figure 30a). This is largely because of the high expected resection rates for cetuximab plus FOLFOX and
panitumumab plus FOLFOX (31.3%) compared with FOLFOX (17.1%).
For the comparison between cetuximab plus FOLFIRI and FOLFIRI, most incremental QALYs come from PFS
unresected and PFS post resection (see Figure 30b). Post-resection QALYs are less important than for
cetuximab plus FOLFOX compared with FOLFOX, as we predict low rates of resection for cetuximab plus
FOLFIRI (16.3%) and FOLFIRI (6.5%).
Cost results
The expected incremental first-line drug acquisition costs and, to a lesser extent, the first-line drug
administration costs are the largest items in both networks (Figure 31).
The incremental cost of drug acquisition for cetuximab plus FOLFOX compared with FOLFOX is greater
than that for panitumumab plus FOLFOX compared with FOLFOX, even though the monthly acquisition
costs of cetuximab plus FOLFOX and panitumumab plus FOLFOX are similar. This is because we predict that
patients take cetuximab plus FOLFOX for longer than panitumumab plus FOLFOX (11.0 vs. 8.8 months).
Cost-effectiveness results and associated uncertainty
Combining all of the information on expected costs and QALYs per person (Figure 32), we estimate the
following ICERs for the liver metastases subgroup:
l cetuximab plus FOLFOX compared with FOLFOX – £96,000 per QALY
l panitumumab plus FOLFOX compared with FOLFOX – £87,000 per QALY
l cetuximab plus FOLFIRI compared with FOLFIRI – £76,000 per QALY.
We believe that these estimates are highly uncertain, indeed, more uncertain than for all patients
combined, for the reasons give below. Only some of the uncertainty is captured in the probabilistic
sensitivity analysis (see Probabilistic sensitivity analysis).
l All the uncertainties described for all patients in the previous section still apply.
l PFS for unresected patients is more uncertain than that for all patients for the following two reasons:
1. PFS for resected plus unresected patients, which was used to estimate PFS for unresected patients,
is more uncertain for the liver metastases subgroup than for all patients because it was estimated
from the corresponding PFS for all patients, adjusted by the ratio of the median PFS for the liver
metastases subgroup/median PFS for all patients (see Model parameters, First-line progression-free
survival: unresected patients). Furthermore, given that the median PFS for cetuximab plus FOLFOX
was not reported in the OPUS trial, we based our estimate for this treatment on the ratio
corresponding to cetuximab plus FOLFIRI (see Model parameters, First-line progression-free survival:
unresected patients), thus adding further uncertainty.
2. We were forced to estimate PFS for unresected patients from PFS for resected plus unresected
patients for the liver metastases subgroup using a different, and arguably less rigorous, method
from the method used for all patients (see Model parameters, First-line progression-free survival:
unresected patients).
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FIGURE 30 Incremental QALYs: PenTAG’s base case, liver metastases subgroup: (a) FOLFOX network; and (b) FOLFIRI
network. CET, cetuximab; PAN, panitumumab; PD, progressive disease.
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FIGURE 31 Incremental costs: PenTAG’s base case, liver metastases subgroup: (a) FOLFOX network; and (b) FOLFIRI
network. CET, cetuximab; PAN, panitumumab; PD, progressive disease.
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Probabilistic sensitivity analyses
All patients
The scatterplots shown in Figures 33–35 depict the results for all patients of the 1000 simulations of the
probabilistic sensitivity analysis in terms of the incremental cost–utility of cetuximab plus FOLFOX compared
with FOLFOX, panitumumab plus FOLFOX compared with FOLFOX and cetuximab plus FOLFIRI compared
with FOLFIRI, respectively. The plots show that there is substantial uncertainty in the cost-effectiveness of
cetuximab plus FOLFOX compared with FOLFOX, but less uncertainty for the other two comparisons. This is
not surprising as there were relatively few patients in the OPUS RCT of cetuximab plus FOLFOX compared
with FOLFOX.65
Figures 36 and 37 provide the cost-effectiveness acceptability curves for the treatments in the FOLFOX and
FOLFIRI networks, respectively, showing the probability that each treatment provides the best value for
money given a range of willingness-to-pay thresholds.
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FIGURE 32 Results on the cost-effectiveness plane: PenTAG’s base case, liver metastases subgroup: (a) FOLFOX
network; and (b) FOLFIRI network. CET, cetuximab; PAN, panitumumab. Note: straight lines represent the £20,000
and £30,000 per QALY willingness-to-pay thresholds.
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FIGURE 33 Peninsula Technology Assessment Group’s probabilistic sensitivity analysis results: incremental
cost–utility per person of CET + FOLFOX vs. FOLFOX, all patients. CET, cetuximab. Dashed line, willingness-to-pay
threshold of £20,000 per QALY gained; solid line, willingness-to-pay threshold of £30,000 per QALY.
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FIGURE 34 Peninsula Technology Assessment Group’s probabilistic sensitivity analysis results: incremental
cost–utility per person of PAN + FOLFOX vs. FOLFOX, all patients. PAN, panitumumab. Dashed line, willingness-to-
pay threshold of £20,000 per QALY gained; solid line, willingness-to-pay threshold of £30,000 per QALY.
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FIGURE 35 Peninsula Technology Assessment Group’s probabilistic sensitivity analysis results: incremental
cost–utility per person of CET + FOLFIRI vs. FOLFIRI, all patients. CET, cetuximab. Dashed line, willingness-to-pay
threshold of £20,000 per QALY gained; solid line, willingness-to-pay threshold of £30,000 per QALY.
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FIGURE 36 Peninsula Technology Assessment Group’s probabilistic sensitivity analysis results: cost-effectiveness
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In the FOLFOX network, we predict that the probability is zero that panitumumab plus FOLFOX provides
the best value for money at any willingness-to-pay threshold investigated (£0–150,000 per QALY). The
probability that cetuximab plus FOLFOX provides the best value for money exceeds 50% only at a
willingness to pay of about £90,000 per QALY, which is similar to the deterministic ICER for cetuximab
plus FOLFOX compared with FOLFOX of £104,000 per QALY.
We predict that the probability that cetuximab plus FOLFIRI provides the best value for money exceeds
50% only at a willingness to pay of about £120,000 per QALY, which is consistent with the deterministic
ICER for cetuximab plus FOLFIRI compared with FOLFIRI of £123,000 per QALY.
The probabilities that the following treatments are most cost-effective at a willingness-to-pay threshold of
£30,000 per QALY are:
l cetuximab plus FOLFOX – 20%
l panitumumab plus FOLFOX – 0%
l cetuximab plus FOLFIRI – 0%.
Liver metastases subgroup
In the FOLFOX network, we again predict that the probability is zero that panitumumab plus FOLFOX
provides the best value for money at any willingness-to-pay threshold investigated (£0–150,000 per QALY).
The probability that cetuximab plus FOLFOX provides the best value for money tends to be about 40%
above willingness-to-pay thresholds of £100,000 per QALY, which is consistent with the deterministic ICER
for cetuximab plus FOLFOX compared with FOLFOX of £96,000 per QALY.
We predict that the probability that cetuximab plus FOLFIRI provides the best value for money exceeds
50% only at a willingness to pay of about £80,000 per QALY, which is consistent with the deterministic
ICER for cetuximab plus FOLFIRI compared with FOLFIRI of £76,000 per QALY.
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FIGURE 37 Peninsula Technology Assessment Group’s probabilistic sensitivity analysis results: cost-effectiveness
acceptability curves – FOLFIRI network, all patients. CET, cetuximab.
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The probabilities that the following treatments are most cost-effective at a willingness-to-pay threshold of
£30,000 per QALY are:
l cetuximab plus FOLFOX – 2%
l panitumumab plus FOLFOX – 0%
l cetuximab plus FOLFIRI – 0%.
Scenario analyses
In this section we provide the cost-effectiveness results for the different scenario analyses.
Bevacizumab plus FOLFOX and bevacizumab plus FOLFIRI as comparators
For all patients, in the FOLFOX network we predict that bevacizumab plus FOLFOX is dominated by
FOLFOX (Table 126), partly because the resection rate for bevacizumab plus FOLFOX is similar to that for
FOLFOX (see Model parameters, Resection rates) and because the estimated PFS is rather low (see Model
parameters, First-line progression-free survival: unresected patients). Therefore, it does not affect the
conclusions of the cost-effectiveness analysis of cetuximab plus FOLFOX and panitumumab plus FOLFOX
in the base case, in which bevacizumab plus FOLFOX was not a comparator (see Base-case results,
All patients: base-case results).
In the FOLFIRI network, under our base case, in which we did not include bevacizumab plus FOLFIRI, the ICER
for cetuximab plus FOLFIRI compared with FOLFIRI for all patients was approximately £123,000 (see Base-case
results, All patients: base-case results). When we now include bevacizumab plus FOLFIRI, the ICER for
cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI is £199,000 (Table 127), that is, cetuximab
plus FOLFIRI becomes even worse value for money compared with the most cost-effective comparator.
In the liver metastases subgroup, in the FOLFOX network, we predict an ICER for bevacizumab plus
FOLFOX compared with FOLFOX of £21,000 and that bevacizumab plus FOLFOX dominates both
cetuximab plus FOLFOX and panitumumab plus FOLFOX (Table 128). Although PFS for bevacizumab plus
FOLFOX is the lowest of the four treatments, it is the most cost-effective treatment because it has the
highest estimated resection rate (see Model parameters, Resection rates).
In the FOLFIRI network, under our base case, in which we did not include bevacizumab plus FOLFIRI,
the ICER for cetuximab plus FOLFIRI compared with FOLFIRI for the liver metastases subgroup was
approximately £76,000 (see Base-case results, All patients: base-case results). When we now include
bevacizumab plus FOLFIRI, the ICER for cetuximab plus FOLFIRI compared with bevacizumab plus FOLFIRI is
£399,000 (Table 129), that is, cetuximab plus FOLFIRI becomes even worse value for money compared
with the most cost-effective comparator.
XELOX as a comparator
In this scenario analysis, we used XELOX in place of FOLFOX as a comparator in the FOLFOX network.
Only the drug acquisition and administration costs were changed from the base case; all effectiveness
parameters were unchanged. In particular, we assumed that the drug acquisition costs for both XELOX and
FOLFOX are similar and very low, and that the administration cost of XELOX is clearly lower than for
FOLFOX. This explains why the ICERs compared with XELOX are higher than those compared with FOLFOX:
l the ICER for all patients for cetuximab plus FOLFOX compared with FOLFOX is £104,000 per QALY,
whereas the ICER for cetuximab plus FOLFOX compared with XELOX is £126,000 per QALY
l the ICER for all patients for panitumumab plus FOLFOX compared with FOLFOX is £204,000 per QALY,
whereas the ICER for panitumumab plus FOLFOX compared with XELOX is £255,000 per QALY
l the ICER for liver metastases patients for cetuximab plus FOLFOX compared with FOLFOX is £96,000
per QALY, whereas the ICER for cetuximab plus FOLFOX compared with XELOX is £114,000 per QALY
l the ICER for liver metastases patients for panitumumab plus FOLFOX compared with FOLFOX is £87,000 per
QALY, whereas the ICER for panitumumab plus FOLFOX compared with XELOX is £109,000 per QALY.
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Overall survival from randomised controlled trials
In our base-case analysis, we modelled only PFS from the RCTs. OS was estimated from the times on first-,
second- and third-line treatment for unresected patients and for OS for resected patients. In a sensitivity
analysis, we modelled OS in addition to PFS from the RCTs (see Structure of the Peninsula Technology
Assessment Group model). The two differences in the models were:
1. The modelled mean treatment duration for each treatment arm was set equal to the treatment duration
from the RCTs. Unlike in the base case, we did not cap treatment duration as the mean time in first-line
PFS for unresected patients. The rationale for removing the cap is that OS from the RCTs is likely to be
affected (probably lengthened) by first-line drugs taken post progression.
2. The time on third-line BSC for unresected patients was changed in such a way as to yield the OS curves
from the RCTs (after subtracting patients post resection and after the indirect comparisons). The times
in all other health states were unaltered.
We estimated the proportions of patients taking cetuximab- and panitumumab-based treatments second
line from the limited data from the RCTs (see Table 88) and we estimated the mean treatment durations
of the second-line treatments as the averages of the durations on first-line treatment (from the current
model) and third-line treatment (from our 2011 mCRC model for the relevant NICE HTA139,141). From this,
and the estimated monthly costs of drug acquisition and administration for the current model, we
estimated the total costs of drug acquisition and administration for second-line cetuximab plus FOLFIRI and
panitumumab plus FOLFIRI (Table 130).
Overall survival for unresected patients was greater in this sensitivity analysis for all treatment arms
(Figure 38). This may be because a large proportion of patients in the RCTs took monoclonal antibodies
after progression (see Table 88), whereas we assumed no such treatment in the base-case analysis.
The cost-effectiveness of cetuximab plus FOLFOX compared with FOLFOX is substantially worse in this
analysis so that cetuximab plus FOLFOX is now extendedly dominated by panitumumab plus FOLFOX
compared with FOLFOX (Table 131). This is because, compared with baseline, OS increases less for
cetuximab plus FOLFOX than for FOLFOX (see Figure 38).
The ICER for panitumumab plus FOLFOX compared with FOLFOX reduces substantially, from £204,103 to
£92,585 per QALY, because, compared with baseline, OS increases more for panitumumab plus FOLFOX
than for FOLFOX (see Figure 38) and because mean treatment duration increases less for panitumumab
plus FOLFOX than for FOLFOX (see Model parameters, First-line time on treatment).
TABLE 130 Estimated costs of second-line cetuximab plus FOLFIRI and panitumumab plus FOLFIRI
Second-line treatment
Estimated treatment duration (months)
First-line treatment: estimated % of
patients on second-line treatment
First line Second line Third line CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFIRI (Confidential
information has
been removed)a
8.9 8.8 0 12.9 12.7
PAN+ FOLFIRI 8.2 8.5 8.8 14.1 0 12.7
Estimated total cost of
second-line treatment (£)
7158 6625 12,965
CET, cetuximab; PAN, panitumumab.
a Merck Serono, personal communication, 24 August 2015 (via NICE); CiC information.
DOI: 10.3310/hta21380 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 38
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
195
The ICER for cetuximab plus FOLFIRI compared with FOLFIRI reduces from £122,554 to £84,523 per
QALY because, compared with baseline, OS increases more for cetuximab plus FOLFIRI than for FOLFIRI
(Table 132) and mean treatment durations for both treatments are unchanged (see Figure 29).
Merck Serono also presented a scenario analysis in which OS was taken directly from the RCTs. In this
case, the base-case ICERs changed as follows:
l cetuximab plus FOLFOX compared with FOLFOX – from £47,000 to £133,000 per QALY
(a substantial increase)
l cetuximab plus FOLFIRI compared with FOLFIRI – from £56,000 to £55,000 per QALY
(virtually unchanged).
OPUS trial as the baseline randomised controlled trial in the FOLFOX network
For the FOLFOX network, the PRIME trial44 was selected as the baseline trial as it included two of the three
treatments in our base-case analysis: panitumumab plus FOLFOX and FOLFOX. Although the OPUS trial65
also included two of the three treatments in our base-case analysis, cetuximab plus FOLFOX and FOLFOX,
we did not select this trial as it is far smaller than the PRIME trial (n = 87 vs. 512 RAS WT patients) (see
Structure of the Peninsula Technology Assessment Group model).
0
5
10
15
20
M
ea
n
 O
S 
(m
o
n
th
s) 25
30
35
Base case
OS from RCTs
CE
T +
 FO
LF
OX
PA
N 
+ F
OL
FO
X
BE
V +
 FO
LF
OX
FO
LF
OX
CE
T +
 FO
LF
IR
I
BE
V +
 FO
LF
IR
I
FO
LF
IR
I
FIGURE 38 Overall survival estimated using the base-case method or estimated from RCTs. BEV, bevacizumab;
CET, cetuximab; PAN, panitumumab.
TABLE 131 Peninsula Technology Assessment Group’s cost-effectiveness results for OS estimated from RCTs: all
patients, FOLFOX network
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFOX
vs. FOLFOX
PAN+ FOLFOX
vs. FOLFOX
Life-years (mean, undiscounted) 2.52 2.85 2.35 0.17 0.50
QALYs (mean, discounted) 1.67 1.86 1.55 0.12 0.31
Total costs (mean, discounted) (£) 75,585 77,375 48,803 26,781 28,572
ICER (£ per QALY) vs. FOLFOX (£) 219,952 92,585
ICER (£ per QALY) on the
efficiency frontier (£)
Extendedly
dominated
92,585 Reference
CET, cetuximab; PAN, panitumumab.
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In a scenario analysis we used the OPUS trial as the baseline RCT for the FOLFOX network. In this case, the
following parameters changed in the FOLFOX network:
l resection rates (see Model parameters, Resection rates)
l PFS unresected patients (see Model parameters, First-line progression-free survival: unresected patients)
l treatment durations (see Model parameters, First-line time on treatment).
For all patients (Table 133):
l the ICER for cetuximab plus FOLFOX compared with FOLFOX increased slightly, from £104,000 to
£111,000 per QALY gained
l the ICER for panitumumab plus FOLFOX compared with FOLFOX increased slightly, from £204,000 to
£211,000 per QALY gained.
For liver metastases patients (Table 134):
l the ICER for cetuximab plus FOLFOX compared with FOLFOX reduced slightly, from £96,000 to
£90,000 per QALY gained
l the ICER for panitumumab plus FOLFOX compared with FOLFOX increased slightly, from £87,000
to £89,000.
TABLE 133 Peninsula Technology Assessment Group’s cost-effectiveness results estimated using the OPUS trial as
the baseline RCT: all patients, FOLFOX network
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFOX
vs. FOLFOX
PAN+ FOLFOX
vs. FOLFOX
Life-years (mean,
undiscounted)
1.88 1.66 1.51 0.37 0.15
QALYs (mean, discounted) 1.27 1.14 1.03 0.24 0.10
Total costs (mean, discounted) 52,195 47,507 25,661 26,534 21,846
ICER (£ per QALY) vs. FOLFOX 110,676 210,895
ICER (£ per QALY) on
efficiency frontier
110,676 (vs.
FOLFOX)
Extendedly
dominated
Reference
CET, cetuximab; PAN, panitumumab.
TABLE 132 Peninsula Technology Assessment Group’s cost-effectiveness results for OS estimated from RCTs: all
patients, FOLFIRI network
Outcome CET+ FOLFIRI FOLFIRI CET+ FOLFIRI vs. FOLFIRI
Life-years (mean, undiscounted) 2.90 2.10 0.80
QALYs (mean, discounted) 1.92 1.43 0.49
Total costs (mean, discounted) (£) 74,587 32,973 41,614
ICER (£ per QALY) (£) 84,523
CET, cetuximab.
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Weekly administration of cetuximab
We carried out a scenario analysis in which cetuximab was administered weekly. In all cases, the ICERs for
cetuximab increased, because the monthly cost of administration of cetuximab increased substantially:
l cetuximab plus FOLFOX – £1563 to £1910
l cetuximab plus FOLFIRI – from £849 to £1197.
For all patients:
l the ICER for cetuximab plus FOLFOX compared with FOLFOX increased from £104,000 to £123,000
per QALY
l the ICER for cetuximab plus FOLFIRI compared with FOLFIRI increased from £123,000 to £145,000
per QALY.
For the liver metastases subgroup:
l the ICER for cetuximab plus FOLFOX compared with FOLFOX increased from £96,000 to £112,000
per QALY
l the ICER for cetuximab plus FOLFIRI compared with FOLFIRI increased from £76,000 to £90,000
per QALY.
FOLFOX6
In this scenario analysis we used FOLFOX6 instead of FOLFOX4 as a comparator in the FOLFOX network.
Only the drug acquisition and administration costs for cetuximab plus FOLFOX, panitumumab plus FOLFOX
and FOLFOX were changed in this analysis; all effectiveness parameters were unchanged. We found that
the drug acquisition costs were similar to those in the base case but the administration costs of all
treatments fell substantially and by a similar amount, for example from £2348 to £1634 per month for
FOLFOX. This explains why all of ICERs changed very little:
l the ICER for all patients for cetuximab plus FOLFOX compared with FOLFOX decreased from £104,000
to £101,000 per QALY
l the ICER for all patients for panitumumab plus FOLFOX compared with FOLFOX decreased from
£204,000 to £199,000 per QALY
l the ICER for all patients for cetuximab plus FOLFIRI compared with FOLFIRI increased very slightly, such
that it remained £123,000 per QALY to three significant figures
l the ICER for liver metastases patients for cetuximab plus FOLFOX compared with FOLFOX decreased
from £96,000 to £92,000 per QALY
TABLE 134 Peninsula Technology Assessment Group’s cost-effectiveness results estimated using the OPUS trial as
the baseline RCT: liver metastases subgroup, FOLFOX network
Outcome CET+ FOLFOX PAN+ FOLFOX FOLFOX
CET+ FOLFOX
vs. FOLFOX
PAN+ FOLFOX
vs. FOLFOX
Life-years (mean, undiscounted) 2.30 2.17 1.51 0.80 0.66
QALYs (mean, discounted) 1.57 1.47 1.06 0.51 0.41
Total costs (mean,
discounted)
76,095 66,446 30,198 45,897 36,249
ICER (£ per QALY) vs. FOLFOX 89,856 88,801
ICER (£ per QALY) on the
efficiency frontier
94,053 vs.
PAN+ FOLFOX
88,801 vs.
FOLFOX
Reference
CET, cetuximab; PAN, panitumumab.
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l the ICER for liver metastases patients for panitumumab plus FOLFOX compared with FOLFOX decreased
very slightly from £87,000 to £86,000 per QALY
l the ICER for all patients for cetuximab plus FOLFIRI compared with FOLFIRI increased very slightly from
£76,000 to £77,000 per QALY.
It should be noted that the ICERs for cetuximab plus FOLFIRI compared with FOLFIRI changed very slightly
because of the change in the costs of acquisition and administration of second-line FOLFOX.
List prices for FOLFOX and FOLFIRI
In our base case we assumed that CMU eMit discounted prices were used for FOLFOX and FOLFIRI.
All ICERs increased when we used list prices for FOLFOX and FOLFIRI because the prices of these
treatments increased and because we assumed a longer treatment duration for cetuximab plus FOLFOX
and panitumumab plus FOLFOX than for FOLFOX, and a longer treatment duration for cetuximab plus
FOLFIRI than for FOLFIRI (see Model parameters, First-line time on treatment).
For all patients:
l the ICER for cetuximab plus FOLFOX compared with FOLFOX increased from £104,000 to £116,000
per QALY
l the ICER for panitumumab plus FOLFOX compared with FOLFOX increased from £204,000 to £217,000
per QALY
l the ICER for cetuximab plus FOLFIRI compared with FOLFIRI increased from £123,000 to £133,000
per QALY.
For the liver metastases subgroup:
l the ICER for cetuximab plus FOLFOX compared with FOLFOX increased from £96,000 to £108,000
per QALY
l the ICER for panitumumab plus FOLFOX compared with FOLFOX increased from £87,000 to £89,000
per QALY
l the ICER for cetuximab plus FOLFIRI compared with FOLFIRI increased from £76,000 to £82,000
per QALY.
Deterministic sensitivity analyses
Sensitivity analyses were chosen to demonstrate the drivers of cost-effectiveness by setting parameters to
extreme values, for example setting the price of cetuximab equal to the price of panitumumab = £0.
We do not suggest these parameter values as plausible alternatives to our base-case values. We investigate
the choice of values for key parameters when we compare our model with Merck Serono’s model
(see Comparison of the cost-effectiveness results with those of Merck Serono).
Cetuximab plus FOLFOX compared with FOLFOX
One-way deterministic sensitivity analyses for cetuximab plus FOLFOX compared with FOLFOX are reported
in Figure 39, which shows the impact on the deterministic ICER of various alterations in model parameters.
None of these sensitivity analyses resulted in an ICER below the £20,000 per QALY usual maximum
accepted willingness-to-pay threshold for treatments that do not qualify for end of life.
Cost-effectiveness was very sensitive to the resection rates. In particular, if we set the resection rate for
cetuximab plus FOLFOX equal to that for FOLFOX or if we set both rates equal to 0%, the ICER
increased substantially.
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Cost-effectiveness was sensitive to the assumed PFS and OS post resection. If we set these to zero,
cetuximab plus FOLFOX was dominated by FOLFOX.
Cost-effectiveness was sensitive to the estimated PFS for unresected patients. Setting the PFS for cetuximab
plus FOLFOX equal to that for FOLFOX when holding the treatment duration for cetuximab plus FOLFOX
constant (as this is capped at PFS for unresected patients) resulted in a marked increase in the ICER.
As expected, the ICER fell substantially to £21,000 when we set the price of cetuximab to £0. However,
even then, it was above the £20,000 per QALY threshold.
Cost-effectiveness was sensitive to the treatment durations. When we reduced the treatment duration for
cetuximab plus FOLFOX from 8.7 to 7.0 months, the treatment duration for FOLFOX, the ICER fell substantially.
Cost-effectiveness was quite sensitive to discounting and the cost of administration of first-line drugs. If we
set these independently to zero, the ICER fell noticeably.
Cost-effectiveness was also insensitive to changes in the remaining parameters:
l mean starting age (affecting only utilities and general UK mortality, not treatment effectiveness)
l dose intensity
l PFS (unresected)
l time on second-line treatment
l time on third-line treatment
l proportion of progressions that are deaths, that is, mortality from PFS – first line, second line and third line
l price of FOLFOX
l price of a RAS test
l first-line medical management (unresected) costs
l first-line AE costs
l second-line costs
l third-line costs
l resection operation costs
l PFS and progressive disease post resection costs
l disutilities as a result of AEs
l disutility resulting from health state – all utilities set equal to general UK population (age related).
Panitumumab plus FOLFOX compared with FOLFOX
One-way deterministic sensitivity analyses for panitumumab plus FOLFOX compared with FOLFOX are
reported in Figure 40. Again, none of these sensitivity analyses brought the ICER below usually accepted
willingness-to-pay thresholds. There are many similarities with the cetuximab plus FOLFOX compared with
FOLFOX sensitivity analyses. Here, we discuss the differences.
Cost-effectiveness was less sensitive to changes in resection rates because the rate for panitumumab plus
FOLFOX is only slightly greater than that for FOLFOX, whereas the rate for cetuximab plus FOLFOX (20.7%)
is far greater than that for FOLFOX.
Cost-effectiveness worsened substantially when PFS for unresected patients for panitumumab plus FOLFOX
was set equal to that for FOLFOX when holding the treatment duration for panitumumab plus FOLFOX
constant. At first sight it appears counterintuitive that the ICER changes proportionally far more than for
the cetuximab plus FOLFOX comparison. However, this is explained because incremental QALYs in respect
of PFS for unresected patients account for proportionally more of the total incremental QALYs for
panitumumab plus FOLFOX compared with FOLFOX than for cetuximab plus FOLFOX compared with
FOLFOX. This, in turn, is because we assumed a far lower resection rate for panitumumab plus FOLFOX
than for cetuximab plus FOLFOX.
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As expected, the ICER fell substantially, to £28,000 per QALY, when we set the price of panitumumab to
£0. However, even then, as for cetuximab plus FOLFOX compared with FOLFOX, it lies above the £20,000
per QALY threshold.
Cetuximab plus FOLFIRI compared with FOLFIRI
One-way deterministic sensitivity analyses for cetuximab plus FOLFIRI compared with FOLFIRI are reported
in Figure 41.
Again, there are many similarities with the cetuximab plus FOLFOX compared with FOLFOX sensitivity
analyses. Here, we discuss the differences.
Cost-effectiveness was less sensitive to changes in resection rates because the estimated rate for cetuximab
plus FOLFIRI is only slightly greater than that for FOLFIRI (7.3% vs. 2.1%), whereas the estimate for
cetuximab plus FOLFOX (20.7%) is far greater than that for FOLFOX.
Cost-effectiveness worsened substantially when PFS for unresected patients for cetuximab plus FOLFIRI was
set equal to that for FOLFIRI when holding the treatment duration for cetuximab plus FOLFIRI constant. The
reason for this is the same as that for panitumumab plus FOLFOX.
As expected, the ICER fell substantially, to £18,000, when we set the price of cetuximab to £0, slightly
below the £20,000 per QALY threshold.
Comparison of the cost-effectiveness results with those of Merck Serono
Merck Serono, but not Amgen, performed a cost-effectiveness analysis. Therefore, in this section we compare
our cost-effectiveness results with those of Merck Serono. We have not critiqued the liver metastases model
from Merck Serono for the reasons given in Chapter 5 (see De novo economic evaluation). Therefore, the
comparison of results is confined to the ‘all patients’ group (Tables 135 and 136).
First, there are many similarities between our model and Merck Serono’s model. For example, we assumed:
l The same overall model structure (structure 1; see Structure of the Peninsula Technology Assessment
Group model), that is, we both used only resection rates and PFS data and not OS data from the trials
of first-line drugs. In scenario analyses, we both also modelled OS from the RCTs.
l Similar utilities (see Model parameters, Utilities).
l The same source for estimation of PFS and OS after resection (see Model parameters, Post liver
resection: progression-free survival and overall survival).
l The same prices of cetuximab, panitumumab and bevacizumab (see Model parameters, Costs) (we
assumed far lower prices for FOLFOX and FOLFIRI, but this had little effect on cost-effectiveness).
l Similar treatment durations for second-line FOLFOX and FOLFIRI (see Structure of the Peninsula
Technology Assessment Group model; Model parameters, Second-line time on treatment: unresected
patients; and Chapter 5, Description of methods, Model parameters).
However, there are several important differences between the models, which result in very different
estimates of the cost-effectiveness of cetuximab.
The PenTAG ICERs are much higher than the Merck Serono ICERs (see Tables 135 and 136):
l cetuximab plus FOLFOX compared with FOLFOX – £104,000 per QALY for the PenTAG model and
£47,000 per QALY for the Merck Serono model
l cetuximab plus FOLFIRI compared with FOLFIRI – £123,000 per QALY for the PenTAG model and
£56,000 per QALY for the Merck Serono model.
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TABLE 135 Base-case results for the PenTAG and Merck Serono models: all patients, FOLFOX network
Outcome
PenTAG Merck Serono
CET+ FOLFOX FOLFOX
CET+ FOLFOX
vs. FOLFOX CET+ FOLFOX FOLFOX
CET+ FOLFOX
vs. FOLFOX
Life-years (mean, undiscounted)
First-line drug
(resected + unresected)
0.72 0.58 0.14 0.41 0.39 0.02
PFS unresected 0.57 0.52 0.06 1.04 0.74 0.30
PFS post resection 0.85 0.44 0.41 0.20 0.06 0.14
PFS first line 1.42 0.96 0.46 1.24 0.80 0.44
Second-line FOLFOX or
FOLFIRI (unresected)
0.26 0.29 –0.03 0.31 0.33 –0.02
Third-line BSC (unresected) 0.38 0.43 –0.05 0.67 0.70 –0.03
PD post resection 0.35 0.18 0.17 0.09 0.03 0.06
OS (mean) 2.41 1.86 0.55 2.32 1.86 0.46
QALYs (discounted)
PFS unresected 0.43 0.39 0.04 0.79 0.57 0.22
PFS post resection 0.56 0.29 0.27 0.15 0.04 0.11
AEs first line 0.00 0.00 0.00 0.00 0.00 0.01
PFS first-line 0.99 0.68 0.31 0.94 0.60 0.34
Second-line FOLFOX or
FOLFIRI (unresected)
0.19 0.21 –0.02 0.23 0.25 –0.02
Third-line BSC (unresected) 0.23 0.26 –0.03 0.42 0.45 –0.03
PD post resection 0.20 0.10 0.10 0.06 0.02 0.04
Total 1.61 1.26 0.35 1.65 1.32 0.33
Costs (discounted) (£)
RAS test 400 0 400 200 200 0
First-line drug acquisition 29,850 461 29,389 22,113 6416 15,697
First-line drug
administration
13,212 10,527 2685 2971 2803 168
First-line AEs 1512 1068 444 458 469 –11
First-line medical
management (unresected)
3029 2746 283 0 0 0
Second-line drug
acquisition, drug
administration and
medical management
4161 4706 –545 7289 7968 –679
Third-line BSC (unresected) 5481 6199 –718 7907 8398 –491
Resection operation 3635 1884 1751 196 56 140
PFS post resection 1014 526 488 0 0 0
PD post resection 4763 2469 2294 169 97 72
Total 67,057 30,585 36,471 41,303 26,407 14,896
ICER (£ per QALY) 104,205 46,503
CET, cetuximab; PD, progressive disease.
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TABLE 136 Base-case results for the PenTAG and Merck Serono models: all patients, FOLFIRI network
Outcome
PenTAG Merck Serono
CET+ FOLFIRI FOLFIRI
CET+ FOLFIRI
vs. FOLFIRI CET+ FOLFIRI FOLFIRI
CET+ FOLFIRI
vs. FOLFIRI
Life-years (mean, undiscounted)
First-line drug
(resected + unresected)
0.76 0.56 0.20 0.44 0.43 0.01
PFS unresected 0.95 0.75 0.20 0.98 0.73 0.25
PFS post resection 0.30 0.09 0.21 0.20 0.06 0.14
PFS first line 1.25 0.83 0.42 1.18 0.79 0.39
Second-line FOLFOX or
FOLFIRI (unresected)
0.39 0.41 –0.02 0.31 0.33 –0.02
Third-line BSC (unresected) 0.45 0.47 –0.03 0.68 0.71 –0.03
PD post resection 0.12 0.04 0.09 0.09 0.03 0.06
OS (mean) 2.21 1.75 0.46 2.27 1.86 0.41
QALYs (discounted)
PFS unresected 0.71 0.56 0.15 0.76 0.57 0.19
PFS post resection 0.20 0.06 0.14 0.15 0.04 0.11
AEs first line 0.00 0.00 0.00 –0.01 –0.01 0.00
PFS first line 0.91 0.62 0.29 0.91 0.61 0.30
Second-line FOLFOX or
FOLFIRI (unresected)
0.28 0.30 –0.02 0.23 0.25 –0.02
Third-line BSC (unresected) 0.27 0.29 –0.02 0.43 0.45 –0.02
PD post resection 0.07 0.02 0.05 0.06 0.02 0.04
Total 1.53 1.23 0.30 1.63 1.33 0.30
Costs (discounted) (£)
RAS test 400 0 400 200 200 0
First-line drug acquisition 32,742 776 31,965 23,176 6234 16,942
First-line drug
administration
7543 5506 2037 3250 3148 102
First-line AEs 821 482 339 567 418 149
First-line medical
management (unresected)
4993 3948 1045 0 0 0
Second-line drug
acquisition, drug
administration and medical
management
9241 9845 –604 7927 8492 –565
Third-line BSC (unresected) 6316 6730 –413 8087 8487 –400
Resection operation 1284 372 912 196 56 140
PFS post resection 358 104 254 0 0 0
PD post resection 1683 488 1195 189 104 85
Total 65,380 28,250 37,130
ICER (£ per QALY) 122,554 55,971
CET, cetuximab; PD, progressive disease.
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In total, we identified eight items that differed between our model and Merck Serono’s model that have
an important impact on cost-effectiveness.
For the FOLFOX network, treatment duration and PFS for unresected patients are the most important
items. The ICER from Merck Serono’s model increases substantially when both are independently changed
to our estimate, because we assumed substantially greater treatment durations than Merck Serono (see
Model parameters, First-line time on treatment) and because we assumed a substantially smaller difference
in mean PFS for unresected patients between cetuximab plus FOLFOX and FOLFOX than Merck Serono.
This is because we estimated PFS for unresected patients by subtracting PFS for resected patients from the
PFS data for resected plus unresected patients from the RCTs, whereas Merck Serono did not (see Model
parameters, First-line progression-free survival: unresected patients).
For the FOLFIRI network, treatment duration is clearly the most important item. The ICER from Merck
Serono’s model increases substantially when treatment durations are changed to our estimates. Unlike for
the FOLFOX network, the ICER for cetuximab plus FOLFIRI compared with FOLFIRI increases only slightly
when we use our estimates of PFS for unresected patients, even though we again subtracted PFS for
resected patients from PFS for resected plus unresected patients from the RCTs. This is because we
estimated substantially lower resection rates for the FOLFIRI network than for the FOLFOX network (see
Model parameters, First-line progression-free survival: unresected patients).
Above all, treatment duration is the most critical issue in the current HTA with regard to explaining the
difference in cost-effectiveness between our model and Merck Serono’s model.
We now turn to the two important differences between the models, with cost-effectiveness improving
under our assumptions.
We assumed a far longer duration in PFS and progressive disease post resection than did Merck Serono
(see Model parameters, Post liver resection: progression-free survival and overall survival). This substantially
improves the cost-effectiveness of cetuximab plus FOLFOX compared with FOLFOX, and cetuximab plus
FOLFIRI compared with FOLFIRI.
For the FOLFOX network, we assumed far higher resection rates than Merck Serono (see Model
parameters, Resection rates). This also substantially improves the cost-effectiveness of cetuximab plus
FOLFOX compared with FOLFOX (see Table 135). We assumed the same resection rates as Merck Serono
for cetuximab plus FOLFIRI and FOLFIRI.
We have already described how our treatment duration estimates for both the FOLFOX network and
the FOLFIRI network, and our estimates of PFS for unresected patients for the FOLFOX network both
substantially worsen cost-effectiveness. There are four other differences under which cost-effectiveness
worsens in both networks, although only slightly, under our assumptions:
1. We assumed higher unit costs of drug administration than Merck Serono (see Model parameters,
Costs). Our values yield slightly worse cost-effectiveness results because we assumed that patients take
cetuximab plus FOLFOX for longer than FOLFOX and take longer on cetuximab plus FOLFIRI for longer
than FOLFIRI.
2. We assumed a higher cost for resection than Merck Serono (see Model parameters, Costs, Cost of liver
resection). This acts to worsen cost-effectiveness as the resection rate is higher for cetuximab plus
FOLFOX than FOLFOX and for cetuximab plus FOLFIRI than FOLFIRI (see Table 136).
3. We assumed a higher cost per month for treating patients in progressive disease post resection (see
Model parameters, Costs). This acts to worsen cost-effectiveness, again as the resection rate is higher
for cetuximab plus FOLFOX than FOLFOX and for cetuximab plus FOLFIRI than FOLFIRI.
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4. We assumed different costs of drug acquisition per month (see Model parameters, Costs). We assumed
a slightly higher cost of acquisition of cetuximab per month than Merck Serono (£3859 vs. £3478),
which acts to worsen cost-effectiveness. Our estimates of the monthly cost of acquisition of FOLFOX
and FOLFIRI were much lower than those of Merck Serono. However, cost-effectiveness was insensitive
to these differences because they affect both arms similarly in treatment comparison pairs. We assumed
a higher monthly acquisition cost of cetuximab than Merck Serono because we assumed a slightly
larger body surface area than Merck Serono (1.85 m2 vs. 1.79 m2) and the dose of cetuximab depends
on body surface area. In 2011, Merck Serono also estimated body surface area as 1.79 m2 and we
estimated it as 1.85 m2.141 Merck Serono did not give the source of their estimate in the current model.
Furthermore, as we explained for the previous HTA, we prefer our estimate as it was taken from a
database of people receiving palliative chemotherapy for CRC, with 66% males and 34% females, the
typical sex mix in the RCTs of mCRC.142
When we amended Merck Serono’s model for all eight changes simultaneously, the resulting ICERs were
similar to the base-case ICERs in our model.
Of course, this does not in itself prove that there are no important differences between Merck Serono’s
amended model and our model. However, we found no remaining large differences in incremental mean
life-years, QALYs and costs between Merck Serono’s amended model and our model. We conclude that
there are no further differences between our model and Merck Serono’s model that have a large impact
on cost-effectiveness.
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Chapter 7 Comparison of the current multiple
technology appraisal with previous single
technology appraisals
A lthough this MTA sought to update previous guidance from two STAs (TA17610 and TA24011), thereare some important differences between the scope for the previous STA reviews and the scope for this
current MTA (ID794). The main difference is in the patient population. The current scope specifies people
with RAS WT mCRC, whereas the previous STAs specified people with EGFR-expressing mCRC (TA17610)
and those with KRAS WT mCRC (TA 24011). A summary of all the differences between the scopes for the
reviews alongside a summary of how the product licences have changed is provided in Chapter 1 [see
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (review of TA176 and
partial review of TA240) (ID794)].
The single technology appraisal TA176 (2009) (cetuximab) compared
with the multiple technology appraisal ID794 (2015)
Assessment of clinical effectiveness
The appraisal of cetuximab in combination with chemotherapy for the treatment of mCRC (TA17610)
included two studies, CRYSTAL24 and OPUS,23 whereas this MTA review included three studies. Although
two of the three studies were included in the last HTA (CRYSTAL and OPUS), only data from the subgroup
of people evaluated as RAS WT from these trials were relevant to this review,43 as set out in the final scope
from NICE. The additional study identified by the Assessment Group’s searches for this MTA review was
the FIRE-3 RCT.28
The results from the previous STA of cetuximab (TA176) are summarised and compared with the results
of the current MTA in Table 137. Comparisons can be made between TA176 and the current MTA only
for the OPUS and CRYSTAL trials, as the FIRE-3 trial is new to the current appraisal. In line with research
developments, effect estimates (when reported) for OS, PFS and ORR were either similar or point estimates
were slightly decreased in the RAS WT subgroup compared with the KRAS WT population, suggesting
a reduced risk of progression or death in the RAS WT population. However, these results should be
interpreted with caution as the analyses are based on subgroup analyses and sample sizes (for some
TABLE 137 Comparison of clinical effectiveness: TA176 vs. PenTAG (ID794)
Outcome
TA176 (2009),10
EGFR-expressing mCRCa
TA176 (2009),10 KRAS WT
mCRC
PenTAG (2015), RAS WT
mCRC
OPUS: CET + FOLFOX4 vs. FOLFOX4
n 336 134 87
PFS, HR (95% CI) NR 0.570 (0.358 to 0.907) 0.53 (0.27 to 1.04)
OS, HR (95% CI) NR NR 0.94 (0.56 to 1.56)
ORR, % (95% CI) 45.6 vs. 36.0b 60.7 (47.3 to 72.9) vs. 37.0
(26.0 to 49.1)*b
58 (41 to 74) vs. 29 (17 to 43)b
Resection rate (%) NR 11.5 vs. 4.1b NR
continued
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TABLE 137 Comparison of clinical effectiveness: TA176 vs. PenTAG (ID794) (continued )
Outcome
TA176 (2009),10
EGFR-expressing mCRCa
TA176 (2009),10 KRAS WT
mCRC
PenTAG (2015), RAS WT
mCRC
HRQoL NR NR NR
Safety
Any grade 3/4
events (%)
(Confidential information
has been removedc)
NR 79 vs. 63b
Most commonly
reported grade
3/4 AEsd
NR NR Leukopenia, neutropenia,
paraesthesia, rash, any skin
reactions and acne-like rash
skin reaction
CRYSTAL: CET + FOLFIRI vs. FOLFIRI
n 1198 348 367
PFS, HR (95% CI) 0.85 (0.726 to 0.998) 0.684 (0.501 to 0.934) 0.56 (0.41 to 0.76)
OS, HR (95% CI) 0.93 (0.81 to 1.07) 0.84 (0.64 to 1.11) 0.69 (0.54 to 0.88)
ORR, % (95% CI) 45.6 vs. 36.0e 59.3 (51.6 to 66.7) vs. 43.2
(35.8 to 58.9)**e
66 (59 to 73) vs. 39 (32 to 46)e
Resection rate NR 3.5% vs. 2.3%e OR 3.11 (95% CI 2.03 to 4.78)
HRQoL: EORTC
QLQ-C30; EQ-5D
NR Statistically significant
differences between the two
treatment groups in favour of
the FOLFIRI-only group were
reportedf
NR
Safety
Any grade 3/4
events (%)
(Confidential information
has been removedc)
NR 80.9 vs. 58.2e
Most commonly
reported grade
3/4 AEsd
NR Neutropenia, constipation,
dyspepsia, dyspnoea,
dysgeusia, injection site
reaction, erythema,
hypotension, hypertrichosis
and cheilitis
g
Deep-vein thrombosis,
dermatitis acneiform,
diarrhoea, fatigue, leukopenia,
neutropenia, rash, any skin
reactions and acne-like rash
skin reaction
FIRE-3: CET + FOLFIRI vs. BEV + FOLFIRI
n NA NA 342
PFS, HR (95% CI) NA NA 0.93 (0.74 to 1.17)
OS, HR (95% CI) NA NA 0.7 (0.53 to 0.92)
ORR, % (95% CI) NA NA 65.5 (58 to 73) vs. 60 (52 to 67)h
Resection rate NA NA NR
HRQoL NA NA NR
Safety
Any grade 3/4
events (%)
NA NA 69 vs. 67.3h
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studies) were small, reducing the power of the studies to show statistical significance. No comparison
could be made with respect to HRQoL data as the current MTA did not identify any data for HRQoL
among the RAS WT population. Variability in the reporting of AEs between TA176 and the current MTA,
for example summary AEs, AEs in ≥ 5% of participants or AEs with a > 5% difference between treatment
arms, made it difficult to draw comparisons when data were reported. All results are subject to uncertainty
(see Chapter 8, Strengths and limitations).
Assessment of cost-effectiveness
As TA176 was a STA, only economic evidence submitted by the manufacturer (Merck Serono) was
available, critiqued by an ERG. In this assessment, economic evidence was available both from the
manufacturer and from us, the Assessment Group.
No studies were identified in the cost-effectiveness review carried out for TA176. In its recent submission,
Merck Serono identified 15 studies, which included an economic analysis of cetuximab. Two of these studies
were specific to the RAS WT population and were also identified by the Assessment Group.108,109 Our review
excluded the remaining 13 papers on the basis of population; the two included papers were both abstracts
with associated posters. This indicates that some economic evidence is currently available compared with
when TA176 was completed, but still not enough to adequately answer the decision problem.
Both TA176 and this assessment included a de novo economic analysis submitted by Merck Serono. Merck
Serono appears to have updated its model from TA176, as both Merck Serono models (TA176 and the
2015 submission) appear to be very similar in structure. Furthermore, both Merck Serono models appear
very similar in structure. In particular, the health states were generally similar: three lines of treatment plus
post-resection states. For both models, modelling of first-line treatment was based on trial evidence, and
subsequent lines of treatment and post resection were informed by the literature.111–113 In both TA176 and
the 2015 submission, Merck Serono presented the cost-effectiveness results as head-to-head comparisons
based on trials. The main differences between TA176 and the cost-effectiveness analyses in this
assessment are described in Table 138.
TABLE 137 Comparison of clinical effectiveness: TA176 vs. PenTAG (ID794) (continued )
Outcome
TA176 (2009),10
EGFR-expressing mCRCa
TA176 (2009),10 KRAS WT
mCRC
PenTAG (2015), RAS WT
mCRC
Most commonly
reported grade
3/4 AEd
NA NA Acneiform/exanthema,
desquamation, diarrhoea,
haematotoxicity,
hepatotoxicity, hypertension,
hypokalaemia, infection, nail
changes/paronychia, nausea,
pain, skin reactions,
thromboembolic events and
thrombosis (any)
*p = 0.011; **p= 0.0028.
CET, cetuximab; BEV, bevacizumab; NA, not applicable; NR, not recorded.
a Full analysis set: people with EGFR-expressing mCRC.
b CET+ FOLFOX4 vs. FOLFOX4.
c CiC information.
d Most commonly reported grade 3/4 AEs for which at least one arm had an incidences of ≥ 5%.
e CET+ FOLFIRI vs. FOLFIRI.
f QLQ-C30 measurement reported. EQ-5D measure was also used; however, only 37 patients completed the evaluable
baseline ED-5D questionnaires and therefore no formal statistical analyses were performed.
g With a difference of ≥ 5% between the groups.
h CET+ FOLFIRI vs. BEV + FOLFIRI.
Sources: NICE10 and Meads et al.144
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Given the similarities in the models and the absence of the TA176 executable model, we present only
summary results in Table 139 and narratively compare the results. We focus on the comparisons with
FOLFOX and FOLFIRI, as in our comparison with Merck Serono’s submission (version 2; 15 June 2015).
The life-years and QALYs for the FOLFOX network appear to have increased from TA176 to the Merck
Serono submission (2015), but the life-years and QALYs for the FOLFIRI networks have decreased. These
differences are presumably driven by the changes in population and time horizon. However, the
incremental life-years and QALYs of the two analyses are virtually identical.
The main differences between the models are in the costs. The costs in TA176 and the Merck Serono
submission are broadly similar; however, small changes in the costs are amplified in the cost-effectiveness
results to give quite different ICERs, with reductions in the ICERs of between £13,000 and £17,000 per
QALY depending on the network. These reductions result from higher costs for the FOLFOX/FOLFIRI arms
in the most recent Merck Serono submission than in TA176 and lower costs for the cetuximab plus
FOLFOX/FOLFIRI arms. The PenTAG model reports the highest costs of all.
Table 140 provides the disaggregated costs for the three analyses. The reporting of these costs varies
across analyses, but overall the results suggest that the differences in costs between the PenTAG model
and TA176 are driven by the same differences as those between the PenTAG model and the Merck Serono
submission: costs relating to first-line treatment, including cheaper acquisition costs for FOLFOX and FOLFIRI
(from use of the CMU eMit rather than the BNF), more expensive drug administration costs for FOLFOX and
FOLFIRI and longer treatment durations. Neither the original submission for TA17610 nor the ERG report144
provides disaggregated life-years and so the effects of treatment duration cannot be confirmed, but as
treatment duration is a driver of the cost of administration (and is a major driver of the differences between
the Merck Serono model and the PenTAG model in this assessment) it seems plausible that differences in
treatment duration will impact on costs. Other discrepancies in costs result from higher costs in second-
and third-line treatment, higher costs of resection and the addition of medical management costs to
first-line treatment.
TABLE 138 Comparison of model characteristics: TA176 vs. Merck Serono submission vs. PenTAG economic model
Characteristic TA176 (2009)10 Merck Serono (2015) PenTAG (2015)
Programme used
to build model
TreeAge Pro 2006/7 software
(TreeAge Software, Inc.,
Williamstown, MAUSA)
Microsoft Excel Microsoft Excel
Population EGFR-expressing, KRAS WT
mCRC. Also required good
performance status, suitable
for irinotecan or oxaliplatin
chemotherapy, initially
unresectable liver metastases
RAS WT mCRC, unresectable
metastases at any site
RAS WT mCRC, unresectable
metastases at any site
Intervention(s) CET+ FOLFOX CET+ FOLFIRI CET+ FOLFOX CET+ FOLFIRI CET + FOLFOX,
PAN + FOLFOX
CET+ FOLFIRI
Comparators
including scenario
analysis
FOLFOX FOLFIRI FOLFOX,
XELOX
FOLFIRI,
BEV+ FOLFIRI
FOLFOX,
BEV + FOLFOX,
XELOX
FOLFIRI,
BEV + FOLFIRI
Time horizon Lifetime (mean 23 years in
model)
10 years Lifetime (30 years)
Cycle length 1 week 1 month 1 month
BEV, bevacizumab; CET, cetuximab; PAN, panitumumab.
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The single technology appraisal TA240 (2013) (panitumumab)
compared with the multiple technology appraisal ID794 (2015)
The appraisal of panitumumab in combination with chemotherapy for the treatment of mCRC (TA24011)
was ended because no evidence submission was received from the manufacturer or sponsor of the
technology. Therefore, NICE was unable to make a recommendation about the use in the NHS of
panitumumab in combination with chemotherapy for the treatment of mCRC.11
Two studies of clinical effectiveness were identified in the current MTA review, the PEAK trial29 and the
PRIME trial,44 both of which contained data from the RAS WT population.
Similarly, no economic evidence was submitted in TA240,11 but two published cost-effectiveness
studies107,110 were identified in the current MTA review, which include economic assessments of
panitumumab in combination with FOLFOX compared with relevant comparators. No de novo economic
analysis was submitted by Amgen for either either TA24011 or this current MTA.
COMPARISON OF THE CURRENT MTA WITH PREVIOUS STAS
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Chapter 8 Discussion
Statement of principal findings
Aim
The remit of this report was to review and update the evidence used to inform the current NICE guidance
(TA17610 and TA24011) on the clinical effectiveness and cost-effectiveness of two EGFR inhibitors,
cetuximab and panitumumab, for the treatment of first-line mCRC.
In this section we will not restate the previous evidence, but assume that the discussion will be read in the
context of the previous evidence summaries and the decisions that flowed from them. The conclusions will
focus on the implications of the new effectiveness and cost-effectiveness evidence for service provision.
Clinical effectiveness systematic review
Of 2811 titles/abstracts screened, five RAS WT subgroup analyses from RCTs met the inclusion criteria for
the clinical effectiveness systematic review. Given the differences in the eligible population between this
current MTA review and the previous STA reviews, the evidence included in this submission was all identified
by the Assessment Group’s searches. Three subgroup analyses provided data for the effectiveness of
cetuximab and two provided evidence for the effectiveness of panitumumab. Efficacy and safety outcomes
were tabulated and discussed in a narrative review. All included studies provided evidence for the NMA
when data were available for the outcome of interest. It was not possible to construct a complete network.
Two discrete networks were generated, one evaluating FOLFOX-containing chemotherapy regimens and the
other comparing FOLFIRI-containing chemotherapy regimens.
The risk of bias was generally similar between studies with respect to randomisation, allocation concealment,
blinding, outcome reporting and loss to follow-up. The main consideration with respect to quality was that
currently available data for both cetuximab and panitumumab are taken from only a subgroup of the ITT
population. To set this in context, the rationale for this is based on tumour biology: research has shown a
treatment interaction for RAS and EGFR inhibitors. In response to this, the EMA recently revised the licensed
indications for these products based on the subgroup data from the ITT populations of the trials. Currently,
the only available data demonstrating efficacy in people with RAS WT mCRC is from subgroup analyses; the
Assessment Group did not identify any RCT evidence for which there was an ITT RAS WT population.
Despite this, the limitations associated with the interpretation of subgroup data still apply. Given the use of
subgroup data all comparisons were made without protection by stratification/randomisation. Instead,
allocation to subgroups was based on RAS analysis of tumour samples from the KRAS WT exon 2 trial
participants; the RAS ascertainment rate was 61%, minimising the potential for significant ascertainment
bias (missing data largely resulted from unavailable tumour samples or inconclusive RAS test results). In
addition, although imbalances in baseline characteristics between groups were expected, no major
differences were observed, minimising the potential for selection bias. Because of the retrospective nature
of the RAS analysis, a low number of samples was available for analysis, reducing the power of the studies
to show statistical significance.
Summary of benefits and risks
Individuals respond differently to some drugs.58,59 Genotype is an important determinant of both the
response to treatment and the susceptibility to adverse reactions for a wide range of drugs,60,61 for
example response to EGFR inhibitors has been shown to be dependent on gene expression in colon
cancer, with studies demonstrating a treatment interaction between RAS status and the effectiveness of
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EGFR inhibitors.62–64 In line with research developments evaluating the negative impact of RAS mutations
on the effectiveness of EGFR inhibitors, approval for the use of anti-EGFR antibodies has now been limited
to people with mCRC with RAS WT tumours. Tumour samples from trial populations supporting the
original licensed indications were evaluated retrospectively for RAS status. Importantly, therefore, data
supporting this recent licence change and this NICE assessment are not from the ITT trial population for
any of the included studies but from a subgroup of people contained within the original RCTs and the
results are therefore subject to uncertainty. However, no RCTs with an ITT population by RAS WT status
were identified.
Previously, NICE has appraised cetuximab (TA17610) for the treatment of people with EGFR-expressing
mCRC, in line with the licensed indication at the time. Although two of the identified cetuximab trials in
this review were included in the last appraisal, only data from the subgroup of people evaluated as RAS
WT from those trials are relevant to the scope of this review, as set out in the final scope from NICE
(see Chapter 3, Studies identified). The appraisal of panitumumab in combination with chemotherapy for
the treatment of mCRC (TA24011) was ended because no evidence submission was received from the
manufacturer or sponsor of the technology. As such, NICE was unable to make recommendations relating
to the use of panitumumab in the NHS. All data included in this update review for both cetuximab and
panitumumab have been identified by the PenTAG searches.
Cetuximab
Two trials provided evidence for the effectiveness of cetuximab in combination with chemotherapy
(FOLFOX or FOLFIRI) compared with chemotherapy alone (FOLFOX or FOLFIRI). The evidence consistently
suggested a treatment effect in favour of the addition of cetuximab to chemotherapy (FOLFOX or FOLFIRI)
compared with chemotherapy alone (FOLFOX or FOLFIRI) for the outcomes of interest (PFS, OS, ORR and
complete resection rate). Overall, clinical safety was consistent with the results for the KRAS WT population
in the trials. The most common AEs were diarrhoea, haematotoxicity, neutropenia and skin reactions.
One trial provided evidence for the effectiveness of cetuximab in combination with chemotherapy (FOLFIRI)
compared with bevacizumab in combination with chemotherapy (FOLFIRI). The proportion of people who
achieved an objective response was similar between the cetuximab plus FOLFIRI arm and the bevacizumab
plus FOLFIRI arm. However, the association with longer OS suggests a benefit for cetuximab plus FOLFIRI
(HR 0.70, 95% CI 0.53 to 0.92).
Panitumumab
One trial provided evidence for the effectiveness of panitumumab in combination with chemotherapy
(FOLFOX) compared with chemotherapy alone (FOLFOX). No evidence was identified comparing
panitumumab plus FOLFIRI with FOLFIRI. The evidence consistently suggested a treatment effect in favour
of the addition of cetuximab to FOLFOX compared with FOLFOX. Overall, clinical safety was consistent
with the results for the KRAS WT population in the trial. The most common AEs were diarrhoea,
haematotoxicity, neutropenia and skin reactions.
One trial provided evidence for the effectiveness of panitumumab in combination with chemotherapy
(mFOLFOX6) compared with bevacizumab in combination with chemotherapy (mFOLFOX6). The proportion
of people who achieved an ORR was similar between the panitumumab plus FOLFIRI arm and the
bevacizumab plus FOLFIRI arm. For PFS, the addition of panitumumab to mFOLFOX6 was associated with a
35% reduction in the risk of progression compared with bevacizumab plus FOLFOX. In addition, a trend
towards an OS benefit with panitumumab plus FOLFOX was observed (HR 0.63, 95% CI 0.39 to 1.02).
Network meta-analysis: FOLFOX network
There was no evidence to suggest that cetuximab plus FOLFOX is any more effective than FOLFOX,
bevacizumab plus FOLFOX or panitumumab plus FOLFOX in terms of increasing the time to death or the
TTP or death.
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Direct evidence suggests that panitumumab plus FOLFOX is more effective at increasing the TTP or death
than FOLFOX and bevacizumab plus FOLFOX. Panitumumab plus FOLFOX was also estimated to be more
effective at increasing the time to death than FOLFOX.
There was limited evidence to suggest that cetuximab plus FOLFOX is more effective than panitumumab
plus FOLFOX at improving the ORR.
There was little evidence that cetuximab plus FOLFOX is associated with fewer AEs than panitumumab plus
FOLFOX; however, some of these analyses were limited by the small number of events recorded in the
treatment arms.
Network meta-analysis: FOLFIRI network
The evidence suggests that cetuximab plus FOLFIRI and bevacizumab plus FOLFIRI are more effective than
FOLFIRI at increasing the TTP or death and the ORR.
Direct evidence suggests that cetuximab plus FOLFIRI is more effective than FOLFIRI and bevacizumab plus
FOLFIRI at increasing the time to death.
Cost-effectiveness
Published economic evaluations
Of the 1979 references identified in the searches, four studies were included in the review: one full
paper,107 two conference abstracts with accompanying posters108,109 and one conference abstract in which
the accompanying poster could not be retrieved.110
One study was UK based but compared only cetuximab plus chemotherapy with chemotherapy alone.108
This study was reported only as a conference abstract and poster. As this study was related to a SMC
appraisal, additional details were sought from the SMC report.114
The full paper compared panitumumab in combination with FOLFOX with bevacizumab in combination
with FOLFOX and was conducted in France107 and so the results are of limited generalisability to the UK.
One other conference abstract also looked at this comparison, from the Greek health-care perspective.110
The final abstract with accompanying poster looked at the RAS WT population only as a scenario analysis
and was conducted from a health-care perspective.109
As the majority of included studies were not published as full papers, the quality of the reporting was
limited. One important note relating to the quality assessment was that all studies included at least one
author who was employed by a manufacturer.
No studies completely answered the decision problem and, as such, highlighted the need for a de novo
cost-effectiveness model.
Critique of the company submission
Amgen did not submit an economic evaluation.
Merck Serono conducted a cost-effectiveness review and two executable models: one for the overall RAS
WT population and one for a liver-limited disease subgroup. As Merck Serono sent us their liver subgroup
model very late in the review period, and as we were unable to reconcile the subgroup analysis with the
overall population model, we did not critique this subgroup analysis.
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The model was generally poorly reported. There were several discrepancies between the parameters in the
report and the parameters in the model, and the sources of some parameters could not be identified. A
second iteration of the overall population model and report were received to solve discrepancies in the
results reported in the first submission.
Merck Serono estimated the ICERs for the two key comparisons:
l cetuximab plus FOLFOX compared with FOLFOX – £47,000 per QALY
l cetuximab plus FOLFIRI compared with FOLFIRI – £56,000 per QALY.
The model itself contained some minor errors and inconsistencies, but no major wiring errors
were identified.
We are satisfied with the general structure of and the great majority of the parameter values in Merck
Serono’s model. However, we disagree with several of the parameters used, which is discussed elsewhere.
Independent economic assessment
In the independent economic assessment the ICERs for anti-EGFR therapy compared with chemotherapy
alone were all > £100,000 per QALY gained. In the FOLFOX network, panitumumab plus FOLFOX was
extendedly dominated by cetuximab plus FOLFOX compared with FOLFOX as it had fewer QALY gains
compared with FOLFOX and higher ICERs. In general, there was a survival gain for patients on anti-EGFR
therapy, of 0.46 undiscounted life-years gained in the FOLFIRI arm and ranging from 0.22 to 0.55
undiscounted life-years gained in the FOLFOX arm. This benefit remained in the QALY results: 0.15–0.35
QALYs gained in the FOLFOX network and 0.30 QALYs gained in the FOLFIRI network for anti-EGFR
therapies. However, the additional costs were substantial: >£35,000 for all anti-EGFR therapies compared
with FOLFOX or FOLFIRI.
The probabilistic sensitivity analyses suggested that anti-EGFR therapies are unlikely to be cost-effective at
a willingness-to-pay threshold of £30,000 per QALY gained. In the FOLFOX network, FOLFOX was 78%
likely to be the most cost-effective treatment, cetuximab plus FOLFOX was 22% likely to be the most
cost-effective treatment and panitumumab plus FOLFOX was 0% likely to be the most cost-effective
treatment. Similarly, in the FOLOFIRI network, FOLFIRI was 100% likely to be the most cost-effective
treatment and cetuximab plus FOLFIRI was 0% likely to be the most cost-effective treatment.
Deterministic sensitivity analyses showed that cost-effectiveness was very sensitive to resection rates, PFS
and OS post resection, PFS for unresected patients and treatment duration. Cost-effectiveness was quite
sensitive to discounting and the cost of administering first-line therapies. Other parameters had little
impact on cost-effectiveness.
In subgroup analyses, the ICERs for patients with liver metastases only for anti-EGFR therapies compared
with chemotherapy alone improved to £90,000–£104,000 per QALY gained in the FOLFOX network and
£107,000 per QALY gained in the FOLFIRI network. However, because of the higher uncertainty in this
subgroup (effectiveness estimates based on smaller sample sizes), the probabilistic sensitivity analyses
demonstrated that anti-EGFR therapy is unlikely to be cost-effective at a willingness-to-pay threshold of
£30,000 per QALY gained: in the FOLFOX network, FOLFOX was 98% likely to be the most cost-effective
treatment and in the FOLFIRI network FOLFIRI was 100% likely to be the most cost-effective treatment.
When bevacizumab was considered as a comparator it was found to not be cost-effective at a
willingness-to-pay threshold of £30,000 per QALY: bevacizumab plus FOLFOX was dominated by FOLFOX
(fewer QALYs and higher costs) and the ICER for cetuximab plus FOLFIRI compared with bevacizumab plus
FOLFIRI was much higher than the ICER for cetuximab plus FOLFIRI compared with FOLFIRI.
DISCUSSION
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When XELOX was considered as a comparator, the ICERs for panitumumab plus FOLFOX and cetuximab
plus FOLFOX increased. This was because of the lower cost of XELOX compared with FOLFOX.
Strengths and limitations
Systematic review of effectiveness studies
A strength of this report is that a systematic review of RCTs for cetuximab and panitumumab in people with
mCRC with RAS WT tumours and a NMA were conducted to evaluate relative efficacy. In the absence of
head-to-head RCTs, a NMA was conducted to assess the relative efficacy of panitumumab in combination
with chemotherapy and cetuximab in combination with chemotherapy.
However, there are some important sources of uncertainty that may have an impact on the conclusions.
l Currently available data providing evidence for the effectiveness of cetuximab and panitumumab are
taken from subgroups of protocol-defined trial populations. The rationale for this is based on
developments in tumour biology research [i.e. research demonstrating an interaction between RAS and
EGFR inhibitors (specifically the negative implications of RAS mutations on the effectiveness of EGFR
inhibitors)]. Of note, the recent changes by the EMA to the licensed indications for cetuximab and
panitumumab are based on these same subgroup data, and treatment effect estimates for both
cetuximab and panitumumab are in the expected direction and consistent across trial populations.
l Given the use of subgroup data all comparisons were made without protection by stratification/
randomisation. Instead, allocation to subgroups was based on re-evaluating tumour samples from the
KRAS WT exon 2 population for RAS status. Although this minimised the potential for ascertainment
bias, there were missing data for some of the trials (either tumour samples were not evaluable for RAS
status or the results were inconclusive). No significant imbalances between the trial populations was
observed, minimising the potential for selection bias. Of note, none of the included subgroup analyses
reported the results of a test for treatment interaction. Because of the retrospective nature of the RAS
analysis, for some studies there was a low number of samples available for analysis, reducing the
power of the studies to show statistical significance.
l No evidence was identified to estimate the effectiveness of panitumumab plus FOLFIRI (licence
approved for panitumumab plus FOLFIRI for the first-line treatment of adults with RAS WT mCRC in
quarter 1, 2015).
l The subgroup analyses all contributed to the NMA. However, it was not possible to construct a
complete network and so two discrete networks were generated, one evaluating FOLFOX-containing
chemotherapy regimens and the other comparing FOLFIRI-containing chemotherapy regimens. It was
therefore not possible to make a comparison between FOLFOX-containing regimens and FOLFIRI-
containing regimens.
l Although there were some reporting omissions in the publications of the subgroup analyses, we were
able to confirm estimates through other sources, for example through EMA reports or through
the companies.
l The time point at which the ORR was measured was unclear for all of the trials. The ORR was
measured at either 6- or 8-week intervals (according to methods reported in the primary publications).
Given this uncertainty, the results reported for the RAS WT population for this outcome should be
treated with caution.
l Sample sizes for the subgroup of the RAS WT population with liver metastases at baseline were small,
increasing the level of uncertainty, lack of statistical power and limitations with regard to precision and
validity. However, subgroup data were the only available data for this population. The effect estimates
were consistent across all studies, although one trial, FIRE-3 (which contributed evidence for the
effectiveness of cetuximab plus FOLFIRI compared with FOLFIRI), did not report data for all outcomes
for this subgroup.
l None of the included publications reported HRQoL estimates for the RAS WT population.
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l We are aware of other cetuximab trials, for example the COIN (Phase III trial comparing either
COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy with standard continuous
palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment
of metastatic colorectal cancer) and NORDIC VII [FLOX (5-fluorouracil/folinic acid/oxaliplatin) in
Combination with Cetuximab in First-line Treatment of Colorectal Cancer] trials, for which there are
currently no RAS WT subgroup data available.
l Data comparing cetuximab plus FOLFOX with panitumumab plus FOLFOX were available only from the
NMA. The limitations regarding the data for the RAS WT population (see above) also apply to the NMA
and, as such, the results should also be interpreted with caution.
l The extent to which the results of included trials can provide a reasonable basis for generalisation to
the population of people with mCRC in the UK NHS is unclear.
Economic model (Peninsula Technology Assessment Group)
Strengths
The PenTAG model is an independent model that was not sponsored by any of the manufacturers
producing cetuximab or panitumumab. We used up-to-date clinical effectiveness data to populate the
model, which were acquired through a systemic review of the current evidence.
Drug acquisition costs were obtained, when possible, from the CMU eMit database, which reflects the true
cost to the NHS of acquiring these drugs, as it includes discounts obtained by hospital pharmacies. For
other drugs the list price from the BNF was used, as in the NICE reference case.128
We explored areas of uncertainty through scenario analyses and sensitivity analyses (deterministic and
probabilistic). Although the ICERs for anti-EGFR therapies compared with chemotherapy alone altered quite
substantially in some analyses, none fell below a willingness-to-pay threshold of £20,000 per QALY gained.
Limitations
The model is subject to the same limitations as the clinical effectiveness review as these limitations were
carried through into the modelling
Similarly, when data were unavailable directly from trials, assumptions were made to inform the model,
leading to areas of uncertainty, which are discussed in the following section.
Areas of uncertainty
The evidence was poor for estimating the accuracy (correct diagnoses) and effectiveness (how the
diagnosis influences the treatment effectiveness) of companion diagnostic testing for testing RAS mutation
status, with no trials presenting the effectiveness of treatment following diagnosis for all tests used in
clinical practice. We assumed, from the evidence available, that this is the same in practice as it is in
the trials, but this may not be true and would likely result in lower effectiveness for cetuximab and
panitumumab in practice.
Some drugs (those for which the BNF price was used) may be obtained at lower costs than were assumed
in the model because of locally procured discounts. There is no indication what these costs might be and
the NICE reference case has been adhered to in this regard.
It was assumed that fortnightly cetuximab is used in the NHS as this is believed to be current clinical
practice and is less costly and burdensome for patients. It was assumed that clinical effectiveness would be
unchanged between weekly and fortnightly cetuximab on the basis of a single non-inferiority trial. It
remains possible that there is, in fact, a difference in effectiveness between the schedules, although on the
basis of the current evidence there is unlikely to be a substantial difference. This also adds complexity to
the decision process, as to achieve the ICER reported in the PenTAG base case might require NICE to issue
guidance outside the current marketing authorisation
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The PFS data for first-line treatment are of high quality as they are taken directly from RCTs, but it should
be noted that the evidence for cetuximab plus FOLFOX is not as strong as that for panitumumab plus
FOLFOX, as the OPUS trial of cetuximab plus FOLFOX compared with FOLFOX had far fewer RAS WT
patients (n = 87) than the PRIME trial of panitumumab plus FOLFOX compared with FOLFOX (n = 512).
This is demonstrated in the probabilistic sensitivity analysis, in which the cetuximab plus FOLFOX compared
with FOLFOX results are much more uncertain than the panitumumab plus FOLFOX compared with
FOLFOX results.
As there were two trials on which to base the effectiveness of FOLFOX, one had to be chosen for the base
case. Because of its larger size, we based our effectiveness estimates for FOLFOX on the PRIME trial. In the
scenario analysis, in which the effectiveness estimates for FOLFOX were based on the OPUS trial, the ICERs
for panitumumab plus FOLFOX compared with FOLFOX decreased substantially, particularly for the liver
metastases subgroup.
We adjusted the PFS from the RCTs of first-line drugs by subtracting PFS for patients who were resected
(see Chapter 6, Model parameters, First-line progression-free survival: unresected patients) to calculate PFS
for unresected patients. As the underlying individual patient data from the RCTs were not available, this
method is only approximate.
We estimated survival post resection from a study that is now several years old, in which no patients
received either cetuximab or panitumumab.113 It is therefore possible that survival post resection for
patients initially treated with these drugs could differ from that reported by Adam et al.113
Treatment effect from first-line drugs was assumed to stop following disease progression. This is because
we did not model OS from the RCTs, only PFS. We explored the use of OS data from the RCTs in a
scenario analysis. In this case, the ICER for cetuximab plus FOLFOX compared with FOLFOX significantly
worsened, that for panitumumab plus FOLFOX compared with FOLFOX significantly improved and that for
cetuximab plus FOLFIRI compared with FOLFIRI improved. These changes were driven by the treatment
duration, which was now calculated directly from the RCTs.
For the liver metastases subgroup PFS was even more uncertain, as direct evidence was unavailable and so
adjustments were made to PFS for all patients. Furthermore, we estimated PFS for unresected patients
from PFS for resected plus unresected patients for the liver metastases subgroup using a different, and
arguably less rigorous, method than was used for all patients.
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Chapter 9 Conclusions
The clinical effectiveness evidence in this review suggests that there is some clinical benefit fromanti-EGFR therapies in comparison with standard chemotherapy treatments and mixed clinical benefit
from anti-EGFR therapies in comparison with anti-VEGF therapies. For example, direct evidence suggests
that panitumumab plus FOLFOX is more effective at increasing TTP or death than FOLFOX and
bevacizumab plus FOLFOX. Panitumumab plus FOLFOX is also estimated to be more effective at increasing
time to death than FOLFOX. Evidence suggests that cetuximab plus FOLFIRI and bevacizumab plus FOLFIRI
are more effective than FOLFIRI at increasing TTP or death and the ORR.
There is limited evidence to draw conclusions about which anti-EGFR therapy has most clinical benefit.
There is no evidence to suggest that cetuximab plus FOLFOX is any more effective than panitumumab plus
FOLFOX at increasing the time to death or the TTP or death and there is little evidence to suggest that
cetuximab plus FOLFOX is more effective than panitumumab plus FOLFOX at improving the ORR or
reducing the incidence of AEs.
Estimates of cost-effectiveness currently suggest poor value for money of anti-EGFR therapies at
willingness-to-pay thresholds of £20,000–30,000. Our results indicate that the cost of drug acquisition
and, to a lesser extent, the cost of drug administration drive this poor value for money. Probabilistic
sensitivity analyses further demonstrate that anti-EGFR therapies are unlikely to be cost-effective at a
willingness-to-pay threshold of £30,000 per QALY gained: for the FOLFOX network, FOLFOX has an 80%
likelihood of being the most cost-effective treatment and, for the FOLFIRI network, FOLFIRI has a 100%
likelihood of being the most cost-effective treatment.
In summary, there is the potential for clinical benefit from anti-EGFR therapies, but the cost of
administering these therapies is substantial.
Implications for service provision
During this appraisal, both panitumumab and cetuximab were available on the CDF for first-line mCRC
(correct as of the CDF updates, September 201550,186,187). As RAS WT status is a prerequisite for using
cetuximab and panitumumab in this indication, RAS mutation testing was also funded through the CDF for
many hospitals (Dr Mark Napier, 2015, personal communication). Therefore, both RAS mutation testing
and cetuximab and panitumumab treatment were previously supported by the CDF. Were anti-EGFR
therapies to be approved in NICE guidance, the implications for RAS mutation testing would have to
be considered.
Bevacizumab, one of the named comparators in this analysis, became unavailable on the CDF during this
appraisal and is not recommended by NICE for the first-line treatment of mCRC patients. As this is a
relatively recent change, the proportion of patients who would have previously been considered for
bevacizumab will now receive alternative treatment, which may have some impact on the proportion of
patients tested for cetuximab and panitumumab treatment.
Suggested research priorities
l There is uncertainty associated with drug administration costs for chemotherapy regimens. Given the
significant number of technology appraisals in which parenteral chemotherapy is administered, a study
to identify the most appropriate methods for costing drug administration in chemotherapy, considering
microcosting and the use of NHS reference costs, could be justified.
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l We recommend that the economic analysis should be repeated when the PFS and OS data from the
RCTs are more mature. Given sufficiently mature data, we would no longer need to use PFS and OS
related to patients post resection, with all the associated uncertainty, as we do currently.
l The RCTs of first-line drugs included subsequent treatments that are not widely used in the UK NHS.
Therefore, the economic analysis would benefit from RCTs that use subsequent treatments that are in
line with those widely used in the NHS. However, given the substantial costs of conducting trials,
we appreciate that this is unlikely to happen.
l Given the lack of data to suggest otherwise, we assumed the same accuracy of the RAS test in
clinical practice as in the first-line RCTs. Any differences are likely to result in worse estimates of
cost-effectiveness for cetuximab and panitumumab, as accuracy is more likely to be worse in practice
than in the RCTs. Therefore, we would welcome further research into the relative accuracies of the
tests as used in the trials and in clinical practice.
l Our economic analysis was designed for the NHS in England and Wales; however, it could easily be
adapted for the health-care systems of other countries.
l Cetuximab plus FOLFOX, cetuximab plus FOLFIRI and panitumumab plus FOLFOX are all given
intravenously. Our economic analysis suggests that the administration of these treatments is expensive
and highlights that there is a strong economic incentive to develop oral treatments for mCRC.
However, consideration would have to be given to adherence and safety when transferring the
responsibility of delivering the regimen to the patient population.
l The cost-effectiveness of treatments for the liver metastases subgroup is very uncertain, partly because
of the small numbers of patients in the trials. Therefore, if there is further interest in providing these
treatments to this subgroup of patients, a larger quantity of better-quality evidence is needed.
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Appendix 1 Literature search strategies
Clinical effectiveness review
MEDLINE
Host: Ovid.
Data parameters: 1946 to November Week 3 2014.
Date searched: 5 January 2015.
Searcher: SB.
Hits: 447.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. (panitumumab or vectibix or ‘ABX-EGF’).tw.
3. 1 or 2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intestin*).tw.
5. (CRC or mCRC).tw.
6. exp Colorectal Neoplasms/
7. colon/
8. rectum/
9. or/4-8
10. (random* or rct* or ‘controlled trial*’ or ‘clinical trial*’).tw.
11. randomized controlled trial.pt.
12. 10 or 11
13. 3 and 9 and 12
14. limit 13 to english language
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Data parameters: 31 December 2014.
Date searched: 5 January 2015.
Searcher: SB.
Hits: 66.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. (panitumumab or vectibix or ‘ABX-EGF’).tw.
3. 1 or 2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
5. (CRC or mCRC).tw.
6. 4 or 5
7. (random* or rct* or ‘controlled trial*’ or ‘clinical trial*’).tw.
8. 3 and 6 and 7
DOI: 10.3310/hta21380 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 38
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Huxley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
243
EMBASE
Host: Ovid.
Data parameters: 1974 to 5 January 2015.
Date searched: 6 January 2015.
Searcher: SB.
Hits: 1948.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. cetuximab/
3. (panitumumab or vectibix or ‘ABX-EGF’).tw.
4. panitumumab/
5. or/1-4
6. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
7. (CRC or mCRC).tw.
8. exp colon/
9. exp colon tumor/
10. exp rectum/
11. exp rectum tumor/
12. or/6-11
13. (random* or rct* or ‘controlled trial*’ or ‘clinical trial*’).tw.
14. 5 and 12 and 13
15. limit 14 to english language
Web of Science
Host: Thomson Reuters.
Data parameters: SCI-EXPANDED and Conference Proceedings Citation Index –Science (CPCI-S).
Date searched: 6 January 2015.
Searcher: SB.
Hits: 1093.
Search strategy
1. TITLE: (cetuximab or erbitux or C225 or ‘IMC C225’) OR TOPIC: (cetuximab or erbitux or C225 or
‘IMC C225’)
2. TITLE: (panitumumab or vectibix or ‘ABX-EGF’) OR TOPIC: (panitumumab or vectibix or ‘ABX-EGF’)
3. #1 OR #2
4. TITLE: (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*) OR TOPIC: (colorectal or
colon or colonic or rectal or rectum or bowel or intenstin*)
5. TITLE: (CRC or mCRC) OR TOPIC: (CRC or mCRC)
6. #4 OR #5
7. TITLE: (random* or rct* or ‘controlled trial*’ or ‘clinical trial*’) OR TOPIC: (random* or rct* or
‘controlled trial*’ or ‘clinical trial*’)
8. #7 AND #6 AND #3
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Cochrane Central Register of Controlled Trials (CENTRAL)
Host: The Cochrane Collaboration.
Data parameters: Issue 12 of 12, December 2014.
Date searched: 6 January 2015.
Searcher: SB.
Hits: 255.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’):ti or (cetuximab or erbitux or C225 or ‘IMC C225’):ab
2. (panitumumab or vectibix or ‘ABX-EGF’):ti or (panitumumab or vectibix or ‘ABX-EGF’):ab
3. #1 or #2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*):ti or (colorectal or colon or
colonic or rectal or rectum or bowel or intenstin*):ab
5. (CRC or mCRC):ti or (CRC or mCRC):ab
6. MeSH descriptor: [Colorectal Neoplasms] explode all trees
7. MeSH descriptor: [Colon] explode all trees
8. MeSH descriptor: [Rectum] explode all trees
9. #4 or #5 or #6 or #7 or #8
10. #3 and #9 in Technology Assessments
Cochrane Database of Systematic Reviews (CDSR)
Host: The Cochrane Collaboration.
Data parameters: Issue 1 of 12, January 2015.
Date searched: 6 January 2015.
Searcher: SB.
Hits: none.
Search strategy
See CENTRAL strategy.
Database of Abstracts of Reviews of Effects (DARE)
Host: The Cochrane Collaboration.
Data parameters: Issue 4 of 4, October 2014.
Date searched: 6 January 2015.
Searcher: SB.
Hits: 14.
Search strategy
See CENTRAL strategy.
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Health Techology Assessment database
Host: The Cochrane Collaboration.
Data parameters: Issue 4 of 4, October 2014.
Date searched: 6 January 2015.
Searcher: SB.
Hits: 18.
Search strategy
See CENTRAL strategy.
Summary of results: clinical effectiveness review
Database Hits
MEDLINE 447
MEDLINE In-Process & Other Non-Indexed Citations 66
EMBASE 1948
Web of Science 1093
CENTRAL 255
CDSR 0
DARE 14
HTA database 18
Total 3841
Duplicate records 1205
Total records to screen 2636
Cost-effectiveness review
MEDLINE
Host: Ovid.
Data parameters: 1946 to November Week 3 2014.
Date searched: 8 January 2015.
Searcher: SB.
Hits: 126.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. (panitumumab or vectibix or ‘ABX-EGF’).tw.
3. 1 or 2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
5. (CRC or mCRC).tw.
6. exp Colorectal Neoplasms/
7. colon/
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8. rectum/
9. or/4-8
10. (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or ‘health
utilit*’ or ‘value for money’).tw.
11. (fiscal or funding or financial or finance* or expenditure* or budget*).tw.
12. (‘resource* alloca*’ or ‘resource* use’).tw.
13. exp Economics/
14. exp models, economic/
15. exp ‘Costs and Cost Analysis’/
16. Cost of illness/
17. ec.fs.
18. (decision adj2 (model* or tree* or analy*)).tw.
19. markov.tw.
20. decision trees/
21. or/10-20
22. 3 and 9 and 21
23. limit 22 to english language
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Data parameters: 7 January 2015.
Date searched: 8 January 2015.
Searcher: SB.
Hits: 24.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. (panitumumab or vectibix or ‘ABX-EGF’).tw.
3. 1 or 2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
5. (CRC or mCRC).tw.
6. 4 or 5
7. (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or ‘health
utilit*’ or ‘value for money’).tw.
8. (fiscal or funding or financial or finance* or expenditure* or budget*).tw.
9. (‘resource* alloca*’ or ‘resource* use’).tw.
10. (decision adj2 (model* or tree* or analy*)).tw.
11. markov.tw.
12. or/7-11
13. 3 and 6 and 12
EMBASE
Host: Ovid.
Data parameters: 1974 to 7 January 2015.
Date searched: 8 January 2015.
Searcher: SB.
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Hits: 1314.
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. cetuximab/
3. (panitumumab or vectibix or ‘ABX-EGF’).tw.
4. panitumumab/
5. or/1-4
6. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
7. (CRC or mCRC).tw.
8. exp colon/
9. exp colon tumor/
10. exp rectum/
11. exp rectum tumor/
12. or/6-11
13. (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or ‘health
utilit*’ or ‘value for money’).tw.
14. (fiscal or funding or financial or finance* or expenditure* or budget*).tw.
15. (‘resource* alloca*’ or ‘resource* use’).tw.
16. exp Economics/
17. models, economic/
18. exp health economics/
19. exp ‘Costs and Cost Analysis’/
20. Cost of illness/
21. resource allocation/
22. pe.fs.
23. (decision adj2 (model* or tree* or analy*)).tw.
24. markov.tw.
25. decision trees/
26. or/13-25
27. 5 and 12 and 26
28. limit 27 to english language
Web of Science
Host: Thomson Reuters.
Data parameters: SCI-EXPANDED and CPCI-S.
Date searched: 8 January 2015.
Searcher: SB.
Hits: 231.
Search strategy
1. TITLE: (cetuximab or erbitux or C225 or ‘IMC C225’) OR TOPIC: (cetuximab or erbitux or C225 or
‘IMC C225’)
2. TITLE: (panitumumab or vectibix or ‘ABX-EGF’) OR TOPIC: (panitumumab or vectibix or ‘ABX-EGF’)
3. #2 OR #1
4. TITLE: (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*) OR TOPIC: (colorectal
or colon or colonic or rectal or rectum or bowel or intenstin*)
5. TITLE: (CRC or mCRC) OR TOPIC: (CRC or mCRC)
6. #5 OR #4
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7. TITLE: (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or
‘health utilit*’ or ‘value for money’) OR TOPIC: (pharmacoeconomic* or economic* or price* or
pricing* or cost* or cba or cea or cua or ‘health utilit*’ or ‘value for money’)
8. TITLE: (fiscal or funding or financial or finance* or expenditure* or budget*) OR TOPIC: (fiscal or
funding or financial or finance* or expenditure* or budget*)
9. TITLE: (‘resource* alloca*’ or ‘resource* use’) OR TOPIC: (‘resource* alloca*’ or ‘resource* use’)
10. TITLE: (decision near/1 (model* or tree* or analy*)) OR TOPIC: (decision near/1 (model* or tree* or analy*))
11. TITLE: (markov) OR TOPIC: (markov)
12. #11 OR #10 OR #9 OR #8 OR #7
13. #12 AND #6 AND #3
NHS Economic Evaluation Database (NHS EED)
Host: The Cochrane Collaboration.
Data parameters: Issue 4 of 4, October 2014.
Date searched: 8 January 2015.
Searcher: SB.
Hits: 10.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’):ti or (cetuximab or erbitux or C225 or ‘IMC C225’):ab
2. (panitumumab or vectibix or ‘ABX-EGF’):ti or (panitumumab or vectibix or ‘ABX-EGF’):ab
3. #1 or #2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*):ti or (colorectal or colon or
colonic or rectal or rectum or bowel or intenstin*):ab
5. (CRC or mCRC):ti or (CRC or mCRC):ab
6. MeSH descriptor: [Colorectal Neoplasms] explode all trees
7. MeSH descriptor: [Colon] explode all trees
8. MeSH descriptor: [Rectum] explode all trees
9. #4 or #5 or #6 or #7 or #8
10. #3 and #9 in Economic Evaluations
EconLit
Host: EBSCOhost.
Data parameters: not applicable.
Date searched: 8 January 2015.
Searcher: SB.
Hits: none.
Search strategy
1. TI ( cetuximab or erbitux or C225 or ‘IMC C225’ ) OR AB ( cetuximab or erbitux or C225 or ‘IMC C225’ )
2. TI ( panitumumab or vectibix or ‘ABX-EGF’ ) OR AB ( panitumumab or vectibix or ‘ABX-EGF’ )
3. S1 OR S2
4. TI ( colorectal or colon or colonic or rectal or rectum or bowel or intenstin* ) OR AB ( colorectal or colon
or colonic or rectal or rectum or bowel or intenstin* )
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5. TI ( CRC or mCRC ) OR AB ( CRC or mCRC )
6. S4 OR S5
7. (S3 AND S6)
Summary of cost-effectiveness review
Database Hits
MEDLINE 126
MEDLINE In-Process & Other Non-Indexed Citations 24
EMBASE 1314
Web of Science 231
NHS EED 10
EconLit 0
Total 1705
Quality-of-life review
MEDLINE
Host: Ovid.
Data parameters: 1946 to January Week 1 2015.
Date searched: 13 January 2015.
Searcher: SB.
Hits: 67.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. (panitumumab or vectibix or ‘ABX-EGF’).tw.
3. 1 or 2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
5. (CRC or mCRC).tw.
6. exp Colorectal Neoplasms/
7. colon/
8. rectum/
9. or/4-8
10. (‘quality of life’ or QoL or HRQL or HRQoL or AQoL).tw.
11. quality of life/
12. (‘quality adjusted life year*’ or QALY*).tw.
13. quality-adjusted life years/
14. (‘quality of wellbeing’ or QWB).tw.
15. (‘health* year* equivalent*’ or HYE*).tw.
16. ‘health status’.tw.
17. health status/
18. health status indicators/
19. (‘short form 36’ or ‘shortform 36’ or ‘short form thirty six’ or ‘shortform thirty six’ or ‘SF 36’ or SF36 or
‘SF thirty six’).tw.
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20. (‘short form 20’ or ‘shortform 20’ or ‘short form twenty’ or ‘shortform twenty’ or ‘SF 20’ or SF20 or
‘SF twenty’).tw.
21. (‘short form 16’ or ‘shortform 16’ or ‘short form sixteen’ or ‘shortform sixteen’ or ‘SF 16’ or SF16 or
‘SF sixteen’).tw.
22. (‘short form 12’ or ‘shortform 12’ or ‘short form twelve’ or ‘shortform twelve’ or ‘SF 12’ or ‘SF12 or
‘SF twelve’).tw.
23. (‘short form 10’ or ‘shortform 10’ or ‘short form ten’ or ‘shortform ten’ or SF10 or ‘SF 10’ or
‘SF ten’).tw.
24. (‘short form 6’ or ‘shortform 6’ or ‘short form six’ or ‘shortform six’ or SF6 or ‘SF 6’ or ‘SF six’).tw.
25. (Euroqol or ‘EQ-5D’).tw.
26. Health Surveys/
27. questionnaire*.tw.
28. exp Questionnaires/
29. ‘willingness to pay’.tw.
30. (‘time trade off’ or ‘time tradeoff’ or tto).tw.
31. (‘visual analog* scale’ or VAS).tw.
32. (health adj2 (utilit*3 or value* or preference*)).tw.
33. (‘health utilities index*’ or hui or hui1 or hui2 or hui3 or hui4 or ‘hui 1’ or ‘hui 2’ or ‘hui 3’ or ‘hui 4’).tw.
34. disutil*.tw.
35. ‘standard gamble*’.tw.
36. ‘discrete choice’.tw.
37. or/10-36
38. 3 and 9 and 37
39. limit 38 to english language
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Data parameters: 12 January 2015.
Date searched: 13 January 2015.
Searcher: SB.
Hits: 13.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. (panitumumab or vectibix or ‘ABX-EGF’).tw.
3. 1 or 2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
5. (CRC or mCRC).tw.
6. 4 or 5
7. (‘quality of life’ or QoL or HRQL or HRQoL or AQoL).tw.
8. (‘quality adjusted life year*’ or QALY*).tw.
9. (‘quality of wellbeing’ or QWB).tw.
10. (‘health* year* equivalent*’ or HYE*).tw.
11. ‘health status’.tw.
12. (‘short form 36’ or ‘shortform 36’ or ‘short form thirty six’ or ‘shortform thirty six’ or ‘SF 36’ or SF36 or
‘SF thirty six’).tw.
13. (‘short form 20’ or ‘shortform 20’ or ‘short form twenty’ or ‘shortform twenty’ or ‘SF 20’ or SF20 or
‘SF twenty’).tw.
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14. (‘short form 16’ or ‘shortform 16’ or ‘short form sixteen’ or ‘shortform sixteen’ or ‘SF 16’ or SF16 or
‘SF sixteen’).tw.
15. (‘short form 12’ or ‘shortform 12’ or ‘short form twelve’ or ‘shortform twelve’ or ‘SF 12’ or ‘SF12 or
‘SF twelve’).tw.
16. (‘short form 10’ or ‘shortform 10’ or ‘short form ten’ or ‘shortform ten’ or SF10 or ‘SF 10’ or ‘SF ten’).tw.
17. (‘short form 6’ or ‘shortform 6’ or ‘short form six’ or ‘shortform six’ or SF6 or ‘SF 6’ or ‘SF six’).tw.
18. (Euroqol or ‘EQ-5D’).tw.
19. questionnaire*.tw.
20. ‘willingness to pay’.tw.
21. (‘time trade off’ or ‘time tradeoff’ or tto).tw.
22. (‘visual analog* scale’ or VAS).tw.
23. (health adj2 (utilit*3 or value* or preference*)).tw.
24. (‘health utilities index*’ or hui or hui1 or hui2 or hui3 or hui4 or ‘hui 1’ or ‘hui 2’ or ‘hui 3’ or ‘hui 4’).tw.
25. disutil*.tw.
26. ‘standard gamble*’.tw.
27. ‘discrete choice’.tw.
28. or/7-27
29. 3 and 6 and 28
EMBASE
Host: Ovid.
Data parameters: 1974 to 12 January 2015.
Date searched: 13 January 2015.
Searcher: SB.
Hits: 734.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. cetuximab/
3. (panitumumab or vectibix or ‘ABX-EGF’).tw.
4. panitumumab/
5. or/1-4
6. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
7. (CRC or mCRC).tw.
8. exp colon/
9. exp colon tumor/
10. exp rectum/
11. exp rectum tumor/
12. or/6-11
13. (‘quality of life’ or QoL or HRQL or HRQoL or AQoL).tw.
14. exp quality of life/
15. (‘quality adjusted life year*’ or QALY*).tw.
16. quality-adjusted life years/
17. (‘quality of wellbeing’ or QWB).tw.
18. (‘health* year* equivalent*’ or HYE*).tw.
19. ‘health status’.tw.
20. health status/
21. health status indicators/
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22. (‘short form 36’ or ‘shortform 36’ or ‘short form thirty six’ or ‘shortform thirty six’ or ‘SF 36’ or SF36 or
‘SF thirty six’).tw.
23. (‘short form 20’ or ‘shortform 20’ or ‘short form twenty’ or ‘shortform twenty’ or ‘SF 20’ or SF20 or
‘SF twenty’).tw.
24. (‘short form 16’ or ‘shortform 16’ or ‘short form sixteen’ or ‘shortform sixteen’ or ‘SF 16’ or SF16 or
‘SF sixteen’).tw.
25. (‘short form 12’ or ‘shortform 12’ or ‘short form twelve’ or ‘shortform twelve’ or ‘SF 12’ or ‘SF12 or
‘SF twelve’).tw.
26. (‘short form 10’ or ‘shortform 10’ or ‘short form ten’ or ‘shortform ten’ or SF10 or ‘SF 10’ or
‘SF ten’).tw.
27. (‘short form 6’ or ‘shortform 6’ or ‘short form six’ or ‘shortform six’ or SF6 or ‘SF 6’ or ‘SF six’).tw.
28. (Euroqol or ‘EQ-5D’).tw.
29. health survey/
30. questionnaire*.tw.
31. exp questionnaire/
32. ‘willingness to pay’.tw.
33. (‘time trade off’ or ‘time tradeoff’ or tto).tw.
34. (‘visual analog* scale’ or VAS).tw.
35. (health adj2 (utilit*3 or value* or preference*)).tw.
36. (‘health utilities index*’ or hui or hui1 or hui2 or hui3 or hui4 or ‘hui 1’ or ‘hui 2’ or ‘hui 3’ or
‘hui 4’).tw.
37. disutil*.tw.
38. ‘standard gamble*’.tw.
39. ‘discrete choice’.tw.
40. or/13-39
41. 5 and 12 and 40
42. limit 41 to english language
PsycINFO
Host: Ovid.
Data parameters: 1806 to January Week 1 2015.
Date searched: 13 January 2015.
Searcher: SB.
Hits: two.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’).tw.
2. (panitumumab or vectibix or ‘ABX-EGF’).tw.
3. 1 or 2
4. (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*).tw.
5. (CRC or mCRC).tw.
6. 4 or 5
7. (‘quality of life’ or QoL or HRQL or HRQoL or AQoL).tw.
8. quality of life/
9. (‘quality adjusted life year*’ or QALY*).tw.
10. (‘quality of wellbeing’ or QWB).tw.
11. (‘health* year* equivalent*’ or HYE*).tw.
12. ‘health status’.tw.
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13. (‘short form 36’ or ‘shortform 36’ or ‘short form thirty six’ or ‘shortform thirty six’ or ‘SF 36’ or SF36 or
‘SF thirty six’).tw.
14. (‘short form 20’ or ‘shortform 20’ or ‘short form twenty’ or ‘shortform twenty’ or ‘SF 20’ or SF20 or
‘SF twenty’).tw.
15. (‘short form 16’ or ‘shortform 16’ or ‘short form sixteen’ or ‘shortform sixteen’ or ‘SF 16’ or SF16 or
‘SF sixteen’).tw.
16. (‘short form 12’ or ‘shortform 12’ or ‘short form twelve’ or ‘shortform twelve’ or ‘SF 12’ or ‘SF12 or
‘SF twelve’).tw.
17. (‘short form 10’ or ‘shortform 10’ or ‘short form ten’ or ‘shortform ten’ or SF10 or ‘SF 10’ or ‘SF ten’).tw.
18. (‘short form 6’ or ‘shortform 6’ or ‘short form six’ or ‘shortform six’ or SF6 or ‘SF 6’ or ‘SF six’).tw.
19. (Euroqol or ‘EQ-5D’).tw.
20. questionnaire*.tw.
21. exp Questionnaires/
22. ‘willingness to pay’.tw.
23. (‘time trade off’ or ‘time tradeoff’ or tto).tw.
24. (‘visual analog* scale’ or VAS).tw.
25. (health adj2 (utilit*3 or value* or preference*)).tw.
26. (‘health utilities index*’ or hui or hui1 or hui2 or hui3 or hui4 or ‘hui 1’ or ‘hui 2’ or ‘hui 3’ or ‘hui 4’).tw.
27. disutil*.tw.
28. ‘standard gamble*’.tw.
29. ‘discrete choice’.tw.
30. or/7-29
31. 3 and 6 and 30
32. limit 31 to english language
Web of Science
Host: Thomson Reuters.
Data parameters: SCI-EXPANDED and CPCI-S.
Date searched: 13 January 2015.
Searcher: SB.
Hits: 171.
Search strategy
1. TITLE: (cetuximab or erbitux or C225 or ‘IMC C225’) OR TOPIC: (cetuximab or erbitux or C225 or
‘IMC C225’)
2. TITLE: (panitumumab or vectibix or ‘ABX-EGF’) OR TOPIC: (panitumumab or vectibix or ‘ABX-EGF’)
3. #2 OR #1
4. TITLE: (colorectal or colon or colonic or rectal or rectum or bowel or intenstin*) OR TOPIC: (colorectal
or colon or colonic or rectal or rectum or bowel or intenstin*)
5. TITLE: (CRC or mCRC) OR TOPIC: (CRC or mCRC)
6. #5 OR #4
7. TITLE: (‘quality of life’ or QoL or HRQL or HRQoL or AQoL) OR TOPIC: (‘quality of life’ or QoL or HRQL
or HRQoL or AQoL)
8. TITLE: (‘quality adjusted life year*’ or QALY*) OR TOPIC: (‘quality adjusted life year*’ or QALY*)
9. TITLE: (‘quality of wellbeing’ or QWB) OR TOPIC: (‘quality of wellbeing’ or QWB)
10. TITLE: (‘health* year* equivalent*’ or HYE*) OR TOPIC: (‘health* year* equivalent*’ or HYE*)
11. TITLE: (health status) OR TOPIC: (health status)
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12. TITLE: (‘short form 36’ or ‘shortform 36’ or ‘short form thirty six’ or ‘shortform thirty six’ or ‘SF 36’
or SF36 or ‘SF thirty six’) OR TOPIC: (‘short form 36’ or ‘shortform 36’ or ‘short form thirty six’ or
‘shortform thirty six’ or ‘SF 36’ or SF36 or ‘SF thirty six’)
13. TITLE: (‘short form 20’ or ‘shortform 20’ or ‘short form twenty’ or ‘shortform twenty’ or ‘SF 20’ or
SF20 or ‘SF twenty’) OR TOPIC: (‘short form 20’ or ‘shortform 20’ or ‘short form twenty’ or ‘shortform
twenty’ or ‘SF 20’ or SF20 or ‘SF twenty’)
14. TITLE: (‘short form 16’ or ‘shortform 16’ or ‘short form sixteen’ or ‘shortform sixteen’ or ‘SF 16’ or
SF16 or ‘SF sixteen’) OR TOPIC: (‘short form 16’ or ‘shortform 16’ or ‘short form sixteen’ or ‘shortform
sixteen’ or ‘SF 16’ or SF16 or ‘SF sixteen’)
15. TITLE: (‘short form 12’ or ‘shortform 12’ or ‘short form twelve’ or ‘shortform twelve’ or ‘SF 12’ or
‘SF12 or ‘SF twelve’) OR TOPIC: (‘short form 12’ or ‘shortform 12’ or ‘short form twelve’ or ‘shortform
twelve’ or ‘SF 12’ or ‘SF12 or ‘SF twelve’)
16. TITLE: (‘short form 10’ or ‘shortform 10’ or ‘short form ten’ or ‘shortform ten’ or SF10 or ‘SF 10’ or ‘SF
ten’) OR TOPIC: (‘short form 10’ or ‘shortform 10’ or ‘short form ten’ or ‘shortform ten’ or SF10 or ‘SF
10’ or ‘SF ten’)
17. TITLE: (‘short form 6’ or ‘shortform 6’ or ‘short form six’ or ‘shortform six’ or SF6 or ‘SF 6’ or ‘SF six’)
OR TOPIC: (‘short form 6’ or ‘shortform 6’ or ‘short form six’ or ‘shortform six’ or SF6 or ‘SF 6’ or ‘SF six’)
18. TITLE: (Euroqol or ‘EQ-5D’) OR TOPIC: (Euroqol or ‘EQ-5D’)
19. TITLE: (questionnaire*) OR TOPIC: (questionnaire*)
20. TITLE: (‘willingness to pay’) OR TOPIC: (‘willingness to pay’)
21. TITLE: (‘visual analog* scale’ or VAS) OR TOPIC: (‘visual analog* scale’ or VAS)
22. TITLE: (‘time trade off’ or ‘time tradeoff’ or tto) OR TOPIC: (‘time trade off’ or ‘time tradeoff’ or tto)
23. TITLE: (health near/1 (utilit*3 or value* or preference*)) OR TOPIC: (health near/1 (utilit*3 or value*
or preference*))
24. TITLE: (‘health utilities index*’ or hui or hui1 or hui2 or hui3 or hui4 or ‘hui 1’ or ‘hui 2’ or ‘hui 3’ or
‘hui 4’) OR TOPIC: (‘health utilities index*’ or hui or hui1 or hui2 or hui3 or hui4 or ‘hui 1’ or ‘hui 2’ or
‘hui 3’ or ‘hui 4’)
25. TITLE: (disutil*) OR TOPIC: (disutil*)
26. TITLE: (‘standard gamble*’) OR TOPIC: (‘standard gamble*’)
27. TITLE: (‘discrete choice’) OR TOPIC: (‘discrete choice’)
28. #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR
#15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7
29. #28 AND #6 AND #3
School of Health and Related Research Health Utilities Database (ScHARRHUD)
Host: School of Health and Related Research (ScHARR).
Data parameters: not applicable.
Date searched: 13 January 2015.
Searcher: SB.
Hits: one.
Search strategy
1. (cetuximab or erbitux or C225 or ‘IMC C225’) in Title
2. (cetuximab or erbitux or C225 or ‘IMC C225’) in Abstract
3. (panitumumab or vectibix or ‘ABX-EGF’) in Title
4. (panitumumab or vectibix or ‘ABX-EGF’) in Abstract
5. #1 OR #2 OR #3 OR #4
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Summary of quality-of-life review
Database Hits
MEDLINE 67
MEDLINE In-Process & Other Non-Indexed Citations 13
EMBASE 734
PsycINFO 2
Web of Science 171
ScHARRHUD 1
Total 988
Total number of cost-effectiveness and quality-of-life titles/abstracts identified
Database Hits
Cost-effectiveness 1705
Quality of life 988
Total 2693
Duplicate records 714
Total records to screen 1979
Update searches
Clinical effectiveness review
MEDLINE
Host: Ovid.
Data parameters: 1946 to April Week 3 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 48.
Search strategy
See main strategy (date limited 2014 to current).
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Data parameters: 24 April 2015.
Date searched: 27 April 2015.
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Searcher: SB.
Hits: 66.
Search strategy
See main strategy (no date limit used).
EMBASE
Host: Ovid.
Data parameters: 1974 to 24 April 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 48.
Search strategy
See main strategy (date limited 2015 to current).
Web of Science
Host: Thomson Reuters.
Data parameters: SCI-EXPANDED and CPCI-S.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 42.
Search strategy
See main strategy (date limited 2015 to current).
Cochrane Central Register of Controlled Trials (CENTRAL)
Host: The Cochrane Collaboration.
Data parameters: Issue 3 of 12, March 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: one.
Search strategy
See main strategy (date limited 2015 to current).
Cochrane Database of Systematic Reviews (CDSR)
Host: The Cochrane Collaboration.
Data parameters: Issue 4 of 12, April 2015.
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Date searched: 27 April 2015.
Searcher: SB.
Hits: none.
Search strategy
See main strategy (date limited 2015 to current).
Database of Abstracts of Reviews of Effects (DARE)
Host: The Cochrane Collaboration.
Data parameters: Issue 1 of 4, January 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: none.
Search strategy
See main strategy (date limited 2015 to current).
Notes: funding for DARE ended in March 2015 and no new records have been added since January 2015.
Health Technology Assessment database
Host: The Cochrane Collaboration.
Data parameters: Issue 1 of 4, January 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: none.
Search strategy
See main strategy (date limited 2015 to current).
Summary of clinical effectiveness update searches
Database Hits
MEDLINE 48
MEDLINE In-Process & Other Non-Indexed Citations 66
EMBASE 48
Web of Science 42
CENTRAL 1
CDSR 0
DARE 0
HTA 0
Total 205
Duplicate records 30
Total records to screen 175
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Cost-effectiveness review
MEDLINE
Host: Ovid.
Data parameters: 1946 to April Week 3 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 12.
Search strategy
See main strategy (date limited 2014 to current).
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Data parameters: 24 April 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 20.
Search strategy
See main strategy (no date limit used).
EMBASE
Host: Ovid.
Data parameters: 1974 to 24 April 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 26.
Search strategy
See main strategy (date limited 2015 to current).
Web of Science
Host: Thomson Reuters.
Data parameters: SCI-EXPANDED and CPCI-S.
Date searched: 27 April 2015.
Searcher: SB.
Hits: nine.
Search strategy
See main strategy (date limited 2015 to current).
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NHS Economic Evaluation Database (NHS EED)
Host: The Cochrane Collaboration.
Data parameters: Issue 4 of 4, October 2014.
Date searched: 8 January 2015.
Searcher: SB.
Hits: none.
Search strategy
See main strategy (date limited 2015 to current).
Notes: funding for NHS EED ended in March 2015 and no new records have been added since January 2015.
EconLit
Host: EBSCOhost.
Data parameters: not applicable.
Date searched: 8 January 2015.
Searcher: SB.
Hits: none.
Search strategy
See main strategy (date limited 2015 to current).
Summary of cost-effectiveness update searches
Database Hits
MEDLINE 12
MEDLINE In-Process & Other Non-Indexed Citations 20
EMBASE 26
Web of Science 9
NHS EED 0
EconLit 0
Total 67
Quality of life
MEDLINE
Host: Ovid.
Data parameters: 1946 to April Week 3 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 0.
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Search strategy
See main strategy (date limited 2015 to current).
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Data parameters: 24 April 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 14.
Search strategy
See main strategy (no date limit used).
EMBASE
Host: Ovid.
Data parameters: 1974 to 24 April 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: 14.
Search strategy
See main strategy (date limited 2015 to current).
PsycINFO
Host: Ovid.
Data parameters: 1806 to April Week 3 2015.
Date searched: 27 April 2015.
Searcher: SB.
Hits: none.
Search strategy
See main strategy (date limited 2015 to current).
Web of Science
Host: Thomson Reuters.
Data parameters: SCI-EXPANDED and CPCI-S.
Date searched: 27 April 2015.
Searcher: SB.
Hits: three.
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Search strategy
See main strategy (date limited 2015 to current).
School of Health and Related Research Health Utilities Database (ScHARRHUD)
Host: School of Health and Related Research (ScHARR).
Data parameters:
Date searched: 27 April 2015.
Searcher: SB.
Hits: none.
Search strategy
See main strategy (date limited 2015 to current).
Summary of quality-of-life update searches
Database Hits
MEDLINE 0
MEDLINE In-Process & Other Non-Indexed Citations 14
EMBASE 14
PsycINFO 0
Web of Science 3
ScHARRHUD 0
Total 31
Total number of cost-effectiveness and quality-of-life titles/abstracts
identified in the update searches
Database Hits
Cost-effectiveness 67
Quality of life 31
Total 98
Duplicate records 18
Total records to screen 80
Clinical trials registries
The following terms were used to search the ClinicalTrials.gov register for condition and interventions:
Condition: colorectal OR colon OR colonic OR rectal OR rectum OR bowel or intenstin* OR CRC OR mCRC
Intervention: cetuximab OR erbitux OR C225 OR ‘IMC C225’ OR panitumumab OR vectibix OR ‘ABX-EGF’
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The following terms were used to search the WHO ICTRP for condition and interventions:
Condition: colorectal OR colon OR colonic OR rectal OR rectum OR bowel or intenstin* OR CRC OR mCRC
Intervention: cetuximab OR erbitux OR C225 OR ‘IMC C225’ OR panitumumab OR vectibix OR ‘ABX-EGF’
The following terms were used to search the UKCRN portfolio:
cetuximab erbitux C225 ‘IMC C225’ panitumumab vectibix ‘ABX-EGF’
The following terms were used to search the ISRCTN registry:
cetuximab OR erbitux OR C225 OR ‘IMC C225’ OR panitumumab OR vectibix OR ‘ABX-EGF’
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Appendix 2 List of studies excluded from the
clinical effectiveness review
Study
Reason for
exclusion
Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, et al. Panitumumab with irinotecan/leucovorin/
5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007;6:427–32
Comparator
Douillard JY, Zemelka T, Fountzilas G, Barone C, Schlichting M, Heighway J, et al. FOLFOX4 with
cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: the randomized
phase II FUTURE study. Clin Colorectal Cancer 2014;13:14–26.e1
Comparator
Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous
oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal
cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12:642–53
Population
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin,
fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III
colon cancer: a randomized trial. JAMA 2012;307:1383–93
Population
Blons H, Emile JF, Le Malicot K, Julie C, Zaanan A, Tabernero J, et al. Prognostic value of KRAS mutations
in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol
2014;25:2378–85
Population
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, Braud F, et al. Fluorouracil, leucovorin,
and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin
Oncol 2009;27:663–71
Population
Bokemeyer C, Bondarenko I, Hartmann JT, Braud F, Schuch G, Zubel A, et al. Efficacy according to
biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer:
the OPUS study. Ann Oncol 2011;22:1535–46
Population
Bokemeyer C, Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to
chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of
the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:1466–75
Population
Cervantes-Ruiperez A, Markman B, Siena S, Pericay C, Aprile G, Bridgewater JA, et al. The GAIN-C study
(BP25438): randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus
FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer
(mCRC). J Clin Oncol 2012;30(Suppl.):TPS3637
Population
Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and
chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–17
Population
Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan,
fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of
overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011–19
Population
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of
panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as
first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
J Clin Oncol 2010;28:4697–705
Population
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Final results from PRIME:
randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal
cancer. Ann Oncol 2014;25:1346–55
Population
Lang I, Kohne CH, Folprecht G, Rougier P, Curran D, Hitre E, et al. Quality of life analysis in patients with
KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil
and leucovorin. Eur J Cancer 2013;49:439–48
Population
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to
oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results
of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103–14
Population
Mitchell EP, Lacouture M, Shearer H, Iannotti N, Piperdi B, Pillai M, et al. Final STEPP results of
prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in
patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2009;27:RA4027
Populationa
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Study
Reason for
exclusion
Mitchell EP, Piperdi B, Lacouture ME, Shearer H, Iannotti N, Pillai MV, et al. The efficacy and safety of
panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic
colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab)
by KRAS status. Clin Colorectal Cancer 2011;10:333–9
Population
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Appendix 3 Abstracts
We screened the abstracts identified by the clinical effectiveness searches. A total of 90 abstracts werescreened, of which four met the eligibility criteria for the review. Authors of the abstracts were
contacted, which led to the identification of an additional two full papers.43,65 A further three abstracts
were identified in the update searches conducted on 27 April 2015. The relevant abstracts are summarised
in the following table.
Abstract Summary information
Abstracts identified in the clinical effectiveness review searches
Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V,
Klinkhardt U, et al. Treatment outcome according to tumor
RAS mutation status in OPUS study patients with metastatic
colorectal cancer (mCRC) randomized to FOLFOX4 with/without
cetuximab. J Clin Oncol 2014;32(Suppl. 1):3505
OPUS trial – RAS WT analysis; author provided full
paper65
Ciardiello F, Lenz HJ, Kohne CH, Heinemann V, Tejpar S,
Melezinek I, et al. Treatment outcome according to tumor RAS
mutation status in CRYSTAL study patients with metastatic
colorectal cancer (mCRC) randomized to FOLFIRI with/without
cetuximab. J Clin Oncol 2014;32(Suppl. 1):3506
CRYSTAL trial – RAS WT analysis; author provided full
paper43
Douillard JY, Tabernero J, Siena S, Peeters M, Koukakis R,
Terwey JH, et al. Survival outcomes in patients (pts) with KRAS/
NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC)
and non-liver-limited disease (non-LLD): data from the PRIME
study. J Clin Oncol 2014;32(Suppl. 1):3550
PRIME trial – post hoc subgroup analysis by liver-limited
and non-liver-limited disease (same as following abstract
but reports different outcomes); author approached for
more information on 13 February 2014 but none
received
Peeters M, Tabernero J, Douillard JY, Siena S, Davison C,
Braun S, et al. Resection rates and survival in patients with
wild-type KRAS/NRAS metastatic colorectal cancer and liver
metastases: data from the PRIME study. Eur J Cancer
2013;49(Suppl. 4):S17–18
PRIME trial – post hoc subgroup analysis by liver-limited
and non-liver-limited disease (same as abstract above by
Douillard et al. but reports different outcomes); author
approached for more information on 13 February 2014
but none received
Abstracts identified in the update searches (27 April 2015)
Rivera F, Karthaus M, Hecht JR, Fasola G, Canon J-LR,
Koukakis R, et al. First-line treatment with modified FOLFOX6
(mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in
wild-type (WT) RAS metastatic colorectal carcinoma (mCRC):
tumor response outcomes beyond RECIST. J Clin Oncol
2015;33(Suppl. 3):660
PEAK trial – post hoc subgroup analysis reporting
tumour response outcomes beyond RECIST (e.g. early
tumour shrinkage)
Siena S, Tabernero J, Bodoky G, Cunningham D, Rivera F,
Ruff P, et al. Quality of life (QoL) during first-line treatment
with FOLFOX4 with or without panitumumab (pmab) in RAS
wild-type (WT) metastatic colorectal carcinoma (mCRC).
J Clin Oncol 2015;33(Suppl. 3):693
PRIME trial – post hoc subgroup analysis of quality of
life in the RAS WT population (uses EQ-5D health-state
index and overall health rating)
Wang J, Dong J, Johnson P, Maglinte GA, Rong A, Barber BL,
et al. Quality-adjusted survival in patients with RAS wild-type
(WT) metastatic colorectal cancer (mCRC) receiving first-line
therapy with panitumumab plus FOLFOX versus FOLFOX alone
in the PRIME trial. J Clin Oncol 2015;33(Suppl. 3):537
PRIME trial – post hoc subgroup analysis of
quality-adjusted survival in the RAS WT population
Abstracts identified by Amgen (excluded from the Assessment Group review)
Abad et al. Panitumumab plus FOLFOX4 or panitumumab plus
FOLFIRI in subjects with wild-type KRAS (exon 2) colorectal
cancer and multiple or unresectable liver-limited metastases:
data from the randomized, phase II PLANET study. Annual
Meeting of the American Society of Clinical Oncology, ASCO
Chicago, IL United States. 2014;32(Suppl. 1)a
PLANET trial – results predominantly reported for the
KRAS WT population; RAS analysis reports data for ORR
a Detail provided by Amgen; we were not able to identify the exact study.
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TABLE 143 Efficacy results: KRAS WT – cetuximab trials
Trial
Experimental (n/N), median months/%
(95% CI)
Control (n/N), median months/%
(95% CI)
HR/OR
(95% CI)
PFS
OPUS22 CET+ FOLFOX4 (NR), 8.3 (7.2 to 12.0) FOLFOX4 (NR), 7.2 (5.6 to 7.4) HR 0.567
(0.375 to 0.856)
CRYSTAL25 CET+ FOLFIRI (146/316), 9.9 (9.0 to 11.3) FOLFIRI (189/350), 8.4 (7.4 to 9.2) HR 0.696
(0.558 to 0.867)
FIRE-328 CET+ FOLFIRI (250/297), 10.0
(8.8 to 10.8)
BEV+ FOLFIRI (242/295), 10.3
(9.8 to 11.3)
NR
OS
OPUS22 CET+ FOLFOX4 (NR), 22.8 (19.3 to 25.9) FOLFOX4 (NR), 18.5 (16.4 to 22.6) HR 0.855
(0.599 to 1.219)
CRYSTAL25 CET+ FOLFIRI (242/316), 23.5
(21.2 to 26.3)
FOLFIRI (288/350), 20.0 (17.4 to 21.7) HR 0.796
(0.670 to 0.946)
FIRE-328 CET+ FOLFIRI (158/297), 28.7
(24.0 to 36.6)
BEV+ FOLFIRI (185/295), 25.0
(22.7 to 27.6)
NR
ORR
OPUS22 CET+ FOLFOX4 (43/82), 57%
(46% to 68%)
FOLFOX4 (33/97), 34% (25% to 44%) OR 2.551
(1.380 to 4.717)
CRYSTAL25 CET+ FOLFIRI (181/316), 57.3%
(51.6% to 62.8%)
FOLFIRI (139/350), 39.7%
(34.6% to 45.1%)
OR 2.069
(1.515 to 2.826)
FIRE-328 CET+ FOLFIRI (184/297), 62%
(56.2% to 67.5%)
BEV+ FOLFIRI (171/295), 58%
(52.1% to 63.7%)
NR
Complete resection rate (R0)
OPUS22 NR NR NR
CRYSTAL25 CET+ FOLFIRI (16/316), 5.1% FOLFIRI (7/350), 2.0% OR 2.650
(1.083 to 6.490)
FIRE-328 NR NR NR
BEV, bevacizumab; CET, cetuximab; NR, not reported.
TABLE 144 Efficacy results: KRAS WT – panitumumab trials
Trial
Experimental (n/N), median months/%
(95% CI)
Control (n/N), median months/%
(95% CI)
HR/OR
(95% CI)
PFS
PRIME26 PAN+ FOLFOX4 (270/325), 10.0
(9.3 to 11.4)
FOLFOX4 (280/331), 8.6 (7.5 to 9.5) HR 0.80
(0.67 to 0.95)
PEAK29 PAN+mFOLFOX6 (90/142), 10.9
(9.4 to 13.0)
BEV+mFOLFOX6 (94/143), 10.1
(9.0 to 12.6)
HR 0.87
(0.65 to 1.17)
OS
PRIME26 PAN+ FOLFOX4 (214/325), 23.9
(20.3 to 27.7)
FOLFOX4 (231/331), 19.4
(17.6 to 22.7)
HR 0.88
(0.73 to 1.06)
PEAK29 PAN+mFOLFOX6 (52/142), 34.2
(26.6 to NR)
BEV+mFOLFOX6 (78/143), 24.3
(21.0 to 29.2)
HR 0.62
(0.44 to 0.89)
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TABLE 144 Efficacy results: KRAS WT – panitumumab trials (continued )
Trial
Experimental (n/N), median months/%
(95% CI)
Control (n/N), median months/%
(95% CI)
HR/OR
(95% CI)
ORR
PRIME26 PAN+ FOLFOX4 (181/317), 57%
(51.5% to 62.6%)
FOLFOX4 (154/324), 48%
(42.0% to 53.1%)
NR
PEAK29 PAN+mFOLFOX6 (82/142), 57.8%
(49.2% to 66.0%)
BEV +mFOLFOX6 (75/142), 53.5%
(45.0% to 61.9%)
NR
Complete resection rate (R0)
PRIME26 PAN+ FOLFOX4 (31/325), 10% (NR) FOLFOX4 (25/331), 8% (NR) NR
PEAK29 PAN+mFOLFOX6 (14/142), 10% (NR) BEV +mFOLFOX6 (12/143), 8% NR
BEV, bevacizumab; NR, not reported; PAN, panitumumab.
TABLE 145 Adverse events: KRAS WT – cetuximab trials
AE
OPUS,22 n/N (%) CRYSTAL,25 n/N (%) FIRE-3,28 n/N (%)
CET+ FOLFOX4
(n= 82)
FOLFOX4
(n= 97)
CET+ FOLFIRI
(n= 317)
FOLFIRI
(n= 350)
CET+ FOLFIRI
(n= 297)
BEV+ FOLFIRI
(n= 295)
Any AE NR NR NR NR NR NR
Any grade 1 or
grade 2 event
NR NR NR NR NR NR
Any grade 3 or
grade 4 event
67/82 (82) 62/97 (64) 257/317 (81.1) 211/350 (60.3) 211/297 (71) 188/295 (64)
Any serious AE NR NR NR NR NR NR
BEV, bevacizumab; CET, cetuximab; NR, not reported.
TABLE 146 Adverse events: KRAS WT – panitumumab trials
AE
PRIME,26 n/N (%) PEAK,29 n/N (%)
PAN+ FOLFOX4
(n= 322)
FOLFOX4
(n= 327)
PAN+mFOLFOX6
(n= 139)
BEV+mFOLFOX6
(n= 139)
Any AE NR NR 139/139 (100) 139/139 (100)
Any grade 1 or grade 2 event NR NR NR NR
Any grade 3 or grade 4 event 270/322 (84) 227/327 (69) NR NR
Any serious AE NR NR 61/139 (44) 53/139 (38)
BEV, bevacizumab; NR, not reported; PAN, panitumumab.
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Appendix 5 Clinical effectiveness supplementary
information
Best-available response rate
The best-available response rates for the cetuximab trials are reported in Table 147.
The best-available response rates for the panitumumab trials are reported in Table 148.
TABLE 147 Best-available response rates [RAS WT (all loci)]: cetuximab trials
First author and year (trial) Experimental n N % Control n N %
CR
Bokemeyer 201565 (OPUS)a CET+ FOLFOX4 2 38 5 FOLFOX4 0 49 0
Van Cutsem 201543 (CRYSTAL)a CET+ FOLFIRI 2 178 1.1 FOLFIRI 0 189 0
Heinemann 201428 (FIRE-3)b CET+ FOLFIRI 9 171 5 BEV + FOLFIRI 2 171 1
PR
Bokemeyer 201565 (OPUS)a CET+ FOLFOX4 20 38 53 FOLFOX4 14 49 29
Van Cutsem 201543 (CRYSTAL)a CET+ FOLFIRI 116 178 65.2 FOLFIRI 73 189 38.6
Heinemann 201428 (FIRE-3)b CET+ FOLFIRI 103 171 60 BEV + FOLFIRI 100 171 59
Stable disease
Bokemeyer 201565 (OPUS)a CET+ FOLFOX4 10 38 26 FOLFOX4 21 49 43
Van Cutsem 201543 (CRYSTAL)a CET+ FOLFIRI 48 178 27.0 FOLFIRI 90 189 47.6
Heinemann 201428 (FIRE-3)b CET+ FOLFIRI 26 171 15 BEV + FOLFIRI 50 171 29
Progressive disease
Bokemeyer 201565 (OPUS)a CET+ FOLFOX4 4 38 11 FOLFOX4 8 49 16
Van Cutsem 201543 (CRYSTAL)a CET+ FOLFIRI 7 178 3.9 FOLFIRI 17 189 9.0
Heinemann 201428 (FIRE-3)b CET+ FOLFIRI 10 171 6 BEV + FOLFIRI 8 171 5
Not evaluable
Bokemeyer 201565 (OPUS)a CET+ FOLFOX4 2 38 5 FOLFOX4 6 49 12
Van Cutsem 201543 (CRYSTAL)a CET+ FOLFIRI 5 178 2.8 FOLFIRI 9 189 4.8
Heinemann 201428 (FIRE-3)b CET+ FOLFIRI 23 171 13 BEV + FOLFIRI 11 171 6
BEV, bevacizumab; CET, cetuximab.
a Assessed every 8 weeks, median follow-up not reported.
b Assessed 28 days from last treatment cycle (tumour evaluations had to be performed at least 6 weeks after the first
administration of therapy).
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Safety
The incidence of grade 1 or grade 2 AEs for the cetuximab trial is reported in Table 149 and for the
panitumumab trials is reported in Table 150.
Network meta-analysis: additional analyses (safety FOLFOX network)
For many AEs, the OPUS study did not provide the required information and so no comparison could be
made between cetuximab plus FOLFOX and panitumumab plus FOLFOX for diarrhoea, hypokalaemia,
hypomagnesaemia, mucositis/stomatitis, mucosal inflammation, fatigue, peripheral neuropathy or asthenia.
Instead, analyses are reported here to allow the indirect comparison between bevacizumab plus FOLFOX
and FOLFOX (Tables 151–158). Note that, because of the small numbers of events for hypomagnesaemia,
mucositis/stomatitis and mucosal inflammation, the 95% CrIs are wide.
TABLE 149 Incidence of grade 1 or grade 2 AEs (reported at a frequency of ≥ 5% in either treatment group)
[RAS WT (all loci)]: cetuximab trialsa
AE
FIRE-3,b,c,d n/N (%)
CET+ FOLFIRI (n= 171) BEV+ FOLFIRI (n= 171)
Acneiform exanthema/rash 99/171 (58)e 14/171 (8)e
Desquamation 51/171 (30)e 18/171 (11)e
Diarrhoea 85/171 (50) 89/171 (52)
Haemotoxicity 102/171 (60)e 119/171 (70)e
Hepatotoxicity 105/171 (61) 89/171 (52)
Hypertension 32/171 (19)e 46/171 (27)e
Hypokalaemia 56/171 (33)e 27/171 (16)
Infection 64/171 (37) 69/171 (40)e
Mucositis/stomatitis 61/171 (36) 68/171 (40)
Nail changes/paronychia 47/171 (28)e 17/171 (10)e
Nausea 74/171 (43)e 97/171 (57)e
Pain 75/171 (44)e 87/171 (51)e
Skin reaction 98/171 (57) 72/171 (42)
Thromboembolic event 3/171 (2) 2/171 (1)
Thrombosis (any) 3/171 (2) 7/171 (4)
BEV, bevacizumab; CET, cetuximab.
a Note: grade 1/2 AEs not reported/not available for the OPUS and CRYSTAL trials.
b Participants were observed for safety 30 days after the last study drug administration and approximately 6 months
after randomisation.
c MedDRA version 13.1 preferred terms, with special emphasis on grade 3 and grade 4 toxic effects according to the
NCI-CTC for AEs version 3.0.
d Data on file [Merck, 19 March 2015, personal communication (via NICE)].
e Indicates a difference of > 5% between treatment arms.
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TABLE 150 Incidence of grade 1 or grade 2 AEs (reported at a frequency of ≥ 5% in either treatment group)
[RAS WT (all loci)]: panitumumab trials
AE
Trial
PRIME,a,b,c n/N (%) PEAK,a,b,d n/N (%)
PAN+ FOLFOX4
(n= 250)
FOLFOX4
(n= 249)
PAN+mFOLFOX6
(n= 86)
BEV+mFOLFOX6
(n= 80)
Abdominal pain 67/250 (27) 55/249 (22) 17/86 (20) 18/80 (23)
Abdominal pain (upper) 18/250 (7) 17/249 (7) 7/86 (8) 6/80 (8)
Acne 37/250 (15)e 1/249 (0)e 19/86 (22) 1/80 (1)
Alopecia 42/250 (17)e 22/249 (9)e 16/86 (19) 13/80 (16)
Anaemia 32/250 (13) 32/249 (13) 16/86 (19)e 11/80 (14)e
Anorexia 87/250 (35)e 64/249 (26)e – –
Anxiety 20/250 (8) 20/249 (8) 6/86 (7) 4/80 (5)
Arthralgia – – 7/86 (8) 8/80 (10)
Ascites – – 0/86 (0) 4/80 (5)
Asthenia 54/250 (22) 42/249 (17) 28/86 (33)e 22/80 (28)e
Back pain 26/250 (10) 30/249 (12) 9/86 (10) 9/80 (11)
Blood creatinine increased – – 1/86 (1) 6/80 (8)
Bronchitis – – 4/86 (5) 7/80 (9)
Cheilitis – – 6/86 (7) 0/80 (0)
Chills 13/250 (5) 14/249 (6) 7/86 (8) 9/80 (11)
Confusional state – – 1/86 (1) 4/80 (5)
Conjunctivitis 49/250 (20)e 9/249 (4)e 12/86 (14) 3/80 (4)
Constipation 74/250 (30) 78/249 (31) 31/86 (36) 30/80 (38)
Cough 27/250 (11)e 47/249 (19)e 12/86 (14) 5/80 (6)
Decreased appetite – – 40/86 (47)e 26/80 (33)e
Decreased weight 46/250 (18)e 15/249 (6)e 21/86 (24)e 7/80 (9)e
Dehydration – – 12/86 (14)e 5/80 (6)e
Depression 13/250 (5) 11/249 (4) – –
Dermatitis acneiform 82/250 (33)e 0/249 (0)e 14/86 (16)e 0/80 (0)e
Diarrhoea 159/250 (64)e 127/249 (51)e 54/86 (63)e 46/80 (58)e
Dizziness 15/250 (6) 22/249 (9) 9/86 (10) 9/80 (11)
Dry mouth 13/250 (5) 10/249 (4) – –
Dry skin 56/250 (22)e 13/249 (5)e 31/86 (36)e 6/80 (8)e
Dysaesthesia 15/250 (6) 19/249 (8) 11/86 (13) 12/80 (15)
Dysguesia 38/250 (15) 37/249 (15) 20/86 (23)e 13/80 (16)e
Dyspepsia 32/250 (13) 32/249 (13) 5/86 (6) 8/80 (10)
Dysphagia – – 4/86 (5) 4/80 (5)
Dysphonia – – 3/86 (3) 6/80 (8)
Dyspnoea 20/250 (8) 24/249 (10) 10/86 (12) 11/80 (14)
Dyspnoea exertional – – 5/86 (6) 4/80 (5)
Epistaxis 40/250 (16)e 29/249 (12)e 20/86 (23) 17/80 (21)
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TABLE 150 Incidence of grade 1 or grade 2 AEs (reported at a frequency of ≥ 5% in either treatment group)
[RAS WT (all loci)]: panitumumab trials (continued )
AE
Trial
PRIME,a,b,c n/N (%) PEAK,a,b,d n/N (%)
PAN+ FOLFOX4
(n= 250)
FOLFOX4
(n= 249)
PAN+mFOLFOX6
(n= 86)
BEV+mFOLFOX6
(n= 80)
Erythema 40/250 (916)e 9/249 (4)e 8/86 (9)e 0/80 (0)e
Exfoliative rash – – 9/86 (10)e 2/80 (3)e
Fall – – 1/86 (1) 4/80 (5)
Fatigue 93/250 (37) 85/249 (34) 35/46 (41)e 39/80 (49)e
Flatulence – – 8//86 (9) 5/80 (6)
Haematoma – – 1/86 (1)e 5/80 (6)e
Haemoglobin decreased – – 0/86 (0)e 4/80 (5)e
Headache 17/250 (7)e 32/249 (13)e 10/86 (12) 11/80 (14)
Hypersensitivity 7/250 (3) 17/249 (7) – –
Hypertension 14/250 (6) 9/249 (4) 2/86 (2)e 18/80 (23)e
Hypertrichosis – – 5/86 (6)e 0/80 (0)e
Hypoaesthesia – – 2/86 (2) 5/80 (6)
Hypoalbuminaemia – – 2/86 (2) 5/80 (6)
Hypocalcaemia 15/250 (6) 5/249 (2) 9/86 (10) 4/80 (5)
Hypokalaemia 40/250 (16) 29/249 (12) 21/86 (24)e 6/80 (8)e
Hypomagnesaemia 74/250 (30)e 16/249 (6)e 37/86 (43)e 5/80 (6)e
Hypotension – – 7/86 (8) 2/80 (3)
Influenza 2/250 (1)e 15/249 (6)e – –
Infusion-related reaction – – 5/86 (6) 5/80 (6)
Insomnia 34/250 (14) 37/249 (15) 10/86 (12)e 14/80 (18)e
Lacrimation increased 18/250 (7) 21/249 (8) 5/86 (6) 2/80 (3)
Lethargy 9/250 (4) 15/249 (6) – –
Leukopenia 19/250 (8) 19/249 (8) 6/86 (7) 4/80 (5)
Mucosal inflammation 58/250 (23)e 40/249 (16)e 28/86 (33)e 12/80 (15)e
Muscular weakness – – 2/86 (2) 5/80 (6)
Musculoskeletal chest pain – – 2/86 (2)e 6/80 (8)e
Musculoskeletal pain – – 6/86 (7) 5/80 (6)
Nail disorder 32/250 (13)e 3/249 (1)e 7/86 (8) 3/80 (4)
Nasopharyngitis 17/250 (7) 13/249 (5) – –
Nausea 111/250 (44) 122/249 (49) 50/86 (58)e 50/80 (63)e
Neck pain – – 1/86 (1)e 7/80 (9)e
Neurotoxicity 15/250 (6) 12/249 (5) 7/86 (8) 6/80 (8%)
Neuropathy peripheral 48/250 (19)e 67/249 (27)e 35/86 (41)e 23/80 (29)e
Neutropenia 114/250 (46) 113/249 (45) 23/86 (27) 19/80 (24)
Oedema peripheral 28/250 (11) 26/249 (10) 11/86 (13) 8/80 (10)
continued
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TABLE 150 Incidence of grade 1 or grade 2 AEs (reported at a frequency of ≥ 5% in either treatment group)
[RAS WT (all loci)]: panitumumab trials (continued )
AE
Trial
PRIME,a,b,c n/N (%) PEAK,a,b,d n/N (%)
PAN+ FOLFOX4
(n= 250)
FOLFOX4
(n= 249)
PAN+mFOLFOX6
(n= 86)
BEV+mFOLFOX6
(n= 80)
Oropharyngeal pain NR NR 4/86 (5)e 9/80 (11)e
Pain in extremity 18/250 (7) 17/250 (7) 10/86 (12) 10/80 (13)
Pain in jaw NR NR 2/86 (2) 4/80 (5)
Palmar-plantar erythrodysaesthesia 26/250 (10)e 7/249 (3)e 16/86 (19)e 7/80 (9)e
Paraesthesia 77/250 (31) 75/249 (30) 17/86 (20)e 21/80 (26)e
Paronychia 58/250 (23)e 0/249 (0)e 17/86 (20)e 0/80 (0)e
Peripheral sensory neuropathy 38/250 (15) 44/249 (18) 14/86 (16)e 18/80 (23)e
Platelet count decreased NR NR 6/86 (7) 5/80 (6)
Pollakiuria NR NR 5/86 (6) 0/80 (0)
Polyneuropathy 9/86 (10) 7/80 (9)
Productive cough NR NR 2/86 (2) 4/80 (5)
Proteinuria NR NR 12/86 (14)e 5/80 (6)e
Pruritus 62/250 (25)e 11/249 (4)e 12/86 (14)e 3/80 (4)e
Pyrexia 79/250 (32) 68/249 (27) 13/86 (15)e 18/80 (23)e
Rash 138/250 (55)e 20/249 (8)e 54/86 (63)e 7/80 (9)e
Rectal haemorrhage 13/250 (5) 5/249 (2) 7/86 (8) 3/80 (4)
Rhinitis 7/250 (3) 13/249 (5) 5/86 (6) 2/80 (3)
Rhinorrhea NR NR 1/86 (1)e 7/80 (9)e
Skin disorders NR NR 85/86 (99)e 36/80 (45)e
Skin fissures 42/250 (17) 1/249 (0) 17/86 (20)e 1/80 (1)e
Skin hyperpigmentation NR NR 1/86 (1) 4/80 (5)
Skin toxicity NR NR 5/86 (6)e 0/80 (0)e
Stomatitis 76/250 (30)e 35/249 (14)e 35/86 (41)e 19/80 (24)e
Temperature intolerance NR NR 6/86 (7) 7/80 (9)
Thrombocytopenia 47/250 (19)e 64/249 (26)e 22/86 (26)e 6/80 (8)e
Upper respiratory tract infection 13/250 (5) 12/249 (5) 3/86 (3)e 9/80 (11)e
Urinary tract infection 22/250 (9) 17/249 (7) 7/86 (8) 7/80 (9)
Vision blurred NR NR 8/86 (9)e 1/80 (1)e
Vomiting 75/250 (30) 78/249 (31) 31/86 (36)e 24/80 (30)e
Weight increased NR NR 8/86 (9)e 2/80 (3)e
BEV, bevacizumab; NR, not reported; PAN, panitumumab.
a Participants were observed for safety 30 days after the last study drug administration.
b AEs were coded using MedDRA version 15.0 and severity was graded according to the NCI-CTC for AEs version 3.0,
with modifications for specific skin- and nail-related toxicities. Fatal AEs were classified as grade 5.
c Data on file [Amgen, 19 March 2015, personal communication (via NICE)].
d Data on file [Amgen, 19 March 2015, personal communication (via NICE)].
e Indicates a difference of > 5% between treatment arms.
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TABLE 152 Odds ratioa (95% CrI) for grade 3/4 hypokalaemia calculated from a fixed-effects NMA model
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 84 15 < 1
BEV + FOLFOX 2.02 (0.50 to 8.03) 16 41 43
PAN+ FOLFOX 2.23 (1.11 to 4.70)b 1.10 (0.35 to 3.67)c < 1 44 56
BEV, bevacizumab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.
c Direct evidence from the PEAK trial.
TABLE 153 Odds ratioa (95% CrI) for grade 3/4 hypomagnesaemia calculated from a fixed-effects NMA model
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 65 35 0
BEV + FOLFOX 2.80 (0.01 to 2176) 35 65 < 1
PAN+ FOLFOX 87.93 (7.55 to 50,590)b 33.07 (2.42 to 22,180)c 0 < 1 100
BEV, bevacizumab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.
c Direct evidence from the PEAK trial.
TABLE 151 Odds ratioa (95% CrI) for grade 3/4 diarrhoea calculated from a fixed-effects NMA model
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 96 4 < 1
BEV + FOLFOX 3.04 (0.90 to 10.49) 4 30 66
PAN+ FOLFOX 2.40 (1.41 to 4.19)b 0.79 (0.26 to 2.36)c < 1 66 34
BEV, bevacizumab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.
c Direct evidence from the PEAK trial.
TABLE 154 Odds ratioa (95% CrI) for grade 3/4 mucositis/stomatitis calculated from a fixed-effects NMA model
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 45 55 < 1
BEV + FOLFOX 0.75 (0.01 to 44.47) 55 44 < 1
PAN+ FOLFOX 20.07 (3.14 to 483.4)b 27.01 (2.00 to 13,950)c 0 < 1 100
BEV, bevacizumab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.
c Direct evidence from the PEAK trial.
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TABLE 155 Odds ratioa (95% CrI) for grade 3/4 mucosal inflammation calculated from a fixed-effects NMA model
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 89 11 < 1
BEV + FOLFOX 5.77 (0.36 to 186.4) 11 82 7
PAN+ FOLFOX 18.59 (3.11 to 463.5)b 3.32 (0.69 to 27.16)c < 1 7 93
BEV, bevacizumab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.
c Direct evidence from the PEAK trial.
TABLE 156 Odds ratioa (95% CrI) for grade 3/4 fatigue calculated from a fixed-effects NMA model
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 97 3 < 1
BEV + FOLFOX 3.65 (0.98 to 14.15) 3 61 36
PAN+ FOLFOX 4.34 (1.92 to 11.12)b 1.20 (0.44 to 3.35)c < 1 36 64
BEV, bevacizumab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.
c Direct evidence from the PEAK trial.
TABLE 157 Odds ratioa (95% CrI) for grade 3/4 peripheral neuropathy calculated from a fixed-effects NMA model
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 30 32 38
BEV + FOLFOX 1.00 (0.28 to 3.64) 37 19 43
PAN+ FOLFOX 0.93 (0.45 to 1.90)b 0.92 (0.32 to 2.68)c 32 49 19
BEV, bevacizumab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.
c Direct evidence from the PEAK trial.
TABLE 158 Odds ratioa (95% CrI) for grade 3/4 asthenia calculated from a fixed-effects NMA model
Intervention treatment
Comparator treatment Probability (%) ranked
FOLFOX BEV+ FOLFOX First Second Third
FOLFOX 70 22 8
BEV + FOLFOX 2.22 (0.36 to 15.22) 17 16 67
PAN+ FOLFOX 1.47 (0.62 to 3.67)b 0.67 (0.12 to 3.32)c 13 62 25
BEV, bevacizumab; PAN, panitumumab.
a OR < 1 favours ‘intervention’ treatment.
b Direct evidence from the PRIME trial.
c Direct evidence from the PEAK trial.
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Appendix 6 Ongoing trials
Searches of ClinicalTrials.gov, WHO ICTRP, UKCRN and ISRCTN were conducted (see Appendix 1 for thesearch strategies used). All searches were carried out in March 2015. Seven trials were considered as
being relevant to this review (Table 159).
TABLE 159 Ongoing trials
Register/
identifier
number
Sponsor/
collaborators
Trial
name Study location
Established or
anticipated
sample size
Status
(correct as of
June 2017)
Included in
PenTAG
Review
NCT00819780 Amgen PEAK USA, Canada,
Belgium, Germany,
Italy, Spain
285 Completeda Yes
NCT00125034 Merck KGaA OPUS Austria, Belgium,
France, Germany,
Greece, Israel, Italy,
Poland, Portugal,
Romania, Russia,
Spain, Ukraine
344 Completed Yes
NCT01228734 Merck KGaA TAILORb China 481 Completedc No
NCT00364013 Amgen PRIME Multinational 1183 Completed Yes
NCT00154102 Merck KGaA CRYSTAL Multinational 1221 Completed Yes
NCT00433927 Merck KGaA FIRE-3 Germany 568 Ongoing not
recruitingd
Yes
EUCTR2014–
000543–33-BE
Amgen PANIBe Belgium NR Ongoingf No
NR, not reported.
a Primary completion date July 2016; estimated study completion date March 2015.
b A trial to compare oxaliplatin, folinic acid (FA) and 5-fluorouracil (5FU) combination chemotherapy (FOLFOX-4) with or
without cetuximab in the 1st line treatment of metastatic colorectal cancer (mCRC) in Chinese rat sarcoma viral
oncogene homolog (RAS) wild-type patients.
c Primary completion date January 2016; estimated study completion date May 2017 (Last updated January 2017).
d Estimated primary completion date April 2014; estimated study completion date December 2016.
e An open-label, randomized, controlled, multi-center, Phase II trial comparing panitumumab versus bevacizumab in
combination with oxaliplatin – 5 FU (FOLFOX) first-line treatment according Ras wild type status for patients with
metastatic unresectable colorectal cancer (mCRC).
f Primary and study completion date information not available.
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Appendix 7 RAS mutation testing
Panitumumab and cetuximab are licensed only for EGFR-expressing, RAS WT populations, as theirclinical effectiveness is associated with this. We therefore assessed whether or not the identification of
people as having EGFR-expressing RAS WT tumours was significantly different between the trials and
clinical practice, as this could impact on the effectiveness of panitumumab and cetuximab in practice.
Epidermal growth factor receptor expression
The clinical trials included in our review assessed patients for EGFR expression, in line with the
technologies’ licensed indications. Our clinical advisors (Dr Mark Napier and Christopher Bowles, both
based at the Royal Devon and Exeter Hospital) advised that testing for EGFR expression is rarely, if ever,
carried out in practice, as it is believed to not be indicative of the effectiveness of treatment (2015,
personal communication). They believe that not testing for EGFR expression is unlikely to alter the
population included such that the treatment effect changes. Therefore, although this is different from
normal practice in the trials, in which EGFR status was confirmed, it is believed that it is unlikely to affect
the comparison of effectiveness between trials and clinical practice.
As it is not routinely carried out in practice and is not believed to affect the treatment effect, we did not
include EGFR testing in our model.
RAS mutation testing in trials
We compared the testing techniques used across our included trials to see how similar they were to each
other. In our included trials, people with mCRC who were RAS WT were identified retrospectively, using a
range of techniques for testing. This information is summarised in Table 160.
In general, the methods for preparing tissue samples seemed similar across the trials, with PCR methods
used. However, the actual tests used on the samples seemed to differ. For many studies looking at a RAS
WT population, the population was already identified as KRAS WT and the reporting of these methods
was variable, but indicated that, again, several testing techniques were used.
All trials looked at exons 2, 3 and 4 for both NRAS and KRAS testing and nearly all trials looked at the full
range of identified codons for both NRAS and KRAS mutations.
One way that we can compare tests across trials and with tests in clinical practice is to compare the failure
rates of the tests. This is when tests are not completed and therefore are unable to provide a diagnosis,
rather than when they give an incorrect diagnosis. We attempted to ascertain the percentage of
inadequate samples for each test and the failure rate of the tests on samples that were adequate. The
trials were not always specific about why some of the cohort was not tested. In the PEAK trial29 it was
specified that the intended testing cohort was those patients from whom samples were collected, so any
tests that were not run were the result of inadequate samples. For the other trials, the number of patient
samples collected was not reported and so the failure to run a test could have been the result of both
inadequate and unavailable samples. Most trials did not report the reasons why people could not be tested
and so it was not possible to adequately estimate the trial failure rate for sample collection. Even for the
populations for whom a successful KRAS test was conducted, the reasons for samples being unable to be
tested for RAS WT either were not reported or were unclear.
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Similarly, few trials reported the failure rates of the actual tests, that is, tests that were unable to provide a
diagnosis even with an adequate sample. The PEAK29 and PRIME44 trials reported a failure rate of ≈3% for
Sanger sequencing, with the test failing on at least one of the codons.
Given the limited reporting of the testing carried out in the trials, it is difficult to compare them directly,
which in turn makes it difficult to compare them with clinical practice. The one important similarity in
terms of trial testing was that the trials generally looked for mutations in all identified codons for both the
KRAS gene and the NRAS gene.
TABLE 160 RAS mutation testing in the included trials
Variable
Trial
CRYSTAL24,43 FIRE-328 OPUS23,65 PEAK29 PRIME27,44
Initial KRAS exon 2
test
Sample type:
biopsy; testing
technique:
LNA-mediated
qPCR clamping
and melting curve
analysis
Pyrosequencing
(PyroMark Gold
kit, Qiagen)
Melting curve
analysis
NR TheraScreen
KRAS, Qiagen
(Germantown,
MD, USA)
Codons 12, 13 12, 13 12, 13 NR NR
Size of cohort to
test
1198 NR 337 NR 1183
Size of cohort
actually tested
1063 NR 233 NR 1096
% of cohort tested 89 NR 69 NR 93
Reason for tests
not conducted
Sample
inadequate or
unavailable
NR NR NR NR
Failure rate of test NR NR NR NR NR
RAS test OncoBEAM RAS
CRC test by
Sysmex
(Hamburg,
Germany)
Pyrosequencing
(PyroMark Gold
kit, Qiagen)
OncoBEAM
RAS CRC test
by Sysmex
(Hamburg,
Germany)
Sanger
sequencing,
WAVE-based
Surveyor CRC
RAScan™ kit
(Transgenomic,
Omaha, NE, USA)
Sanger
sequencing,
WAVE-based
Surveyor CRC
RAScan™ kit
(Transgenomic,
Omaha, NE, USA)
Additional KRAS
codons
59, 61, 117, 146 61, 146 59, 61, 117, 146 12, 13, 59, 61,
117, 146
61, 117, 146
NRAS codons 12, 13, 59, 61,
117, 146
12, 13, 59, 61,
117, 146
12, 13, 59, 61,
117, 146
12, 13, 59, 61,
117, 146
12, 13, (59a), 61,
117, 146
Size of cohort to
test
666 592 179 285 1183
Size of cohort
actually tested
430 542 118 250 1060
% of cohort tested 65 92 66 88 90
Reason for tests
not being
conducted
NR NR NR Inadequate
samples
NR
Failure rate of test
(%)
NR NR NR 2.60 3.28
LNA, locked nucleic acid; NR, not reported; qPCR, quantitative polymerase chain reaction.
a Codon 59 conducted as an exploratory analysis.
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RAS mutation testing in the UK
A request was sent out for information on RAS mutation tests currently used in the UK through the UK
National External Quality Assessment Service. The data that we received are summarised in Table 161.
For laboratories that reported the cost of testing, this was generally £200 for joint KRAS and NRAS testing,
regardless of the technique used or codons assessed. There is some variability in the tests used, but
pyrosequencing appears to be generally well established. We received little information on the accuracy of
the tests available, although personal communication from Dr Michelle Wood of the Cardiff and Vale
University Health Board (8 April 2015) suggested that NRAS mutation testing may currently be less
sensitive than KRAS mutation testing.
Comparing testing in clinical practice with that carried out in the trials, in general, fewer codons are
assessed. The PRIME trial44 demonstrated that, by adding one additional codon to the tests (codon 59), an
additional seven people who were RAS mutant were discovered. This suggests that in clinical practice there
is the potential for people diagnosed as RAS WT to be diagnosed as RAS mutant if the techniques used
were more similar to those used in the trials.
Published evidence of RASmutation testing in practice
As well as contacting UK genetics laboratories directly and examining their websites, we searched for
literature that described comparisons of tests to ascertain the accuracy data available. There is limited
published evidence on the accuracy of RAS mutation tests. One study, by Blons et al.,189 conducted in
France on KRAS testing, compared several testing techniques; the results for tests used in more than one
laboratory are reproduced in Table 162. The results show that, even with high levels of dilution, the
sensitivity and specificity remain quite high, in accordance with the tests’ limits of detection.
A further study by Tack et al.190 was identified that reported combined false-negative rates of 5.0%
(sensitivity 95%) and false-positive rates of 1.5% (specificity 98.5%) for RAS mutation testing across 131
laboratories (10 samples). This included several different testing techniques in terms of the number of
exons tested and the types of tests used.190 This study summarises part of the work conducted by the
TABLE 161 RAS mutation testing in UK
Variable
Location
Cardiff Exeter Salisbury
Type of test Pyrosequencing; for
tumour samples of < 10%,
COLD-PCR reduces limit of
detection
Next-generation sequencing
KRAS codons tested 12, 13, 61, 146 12, 13, 59, 61, 117, 146 12, 13, 61
NRAS codons tested 12, 13, 59, 61 12, 13, 59, 61 12, 13, 61
Reported accuracy Sensitivity: KRAS 99%,
NRAS 88%
NR NR
Cost KRAS or NRAS £120, KRAS
and NRAS £200
KRAS and NRAS £200 Contact
Notes 20% tumour tissue required
Source Dr Michelle Wood
(8 April 2015, personal
communication)
Christopher Bowles
(18 April 2015, personal
communication)
Wessex Regional Genetics
Laboratory web page188
COLD, coamplification at lower denaturation temperature.
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European Society of Pathology Colon External Quality Assessment scheme and includes data from the UK.
The results were similar to those from Blons et al.,189 suggesting that the accuracy of testing for RAS
mutations may not differ significantly from the accuracy of testing for KRAS mutations. It also suggests
that testing may be fairly consistent, despite the wide range of techniques used.
A recent diagnostic assessment by Westwood et al.45 compared diagnostic tests for detecting KRAS
mutations. They found that the relationship between what the tests predicts (mutation status) and the
outcome of this diagnosis (which treatment patients receive) is a complex one. As such, they adjusted the
meaning of accuracy from ‘test accuracy’ to include ‘accuracy for predicting response to treatment with
cetuximab in combination with standard chemotherapy, or variation in clinical outcomes following
treatment with cetuximab in combination with standard chemotherapy depending on which method is
used to classify patients as having KRAS wild-type tumours’.
The authors concluded that the diagnostic tests used in trials seem to result in a benefit for patients.
Unfortunately, as not all tests used in practice have been used in trials, there is also little evidence to draw
conclusions on the effectiveness of these tests. Westwood et al.45 concluded that there was no significant
evidence to suggest that different tests would result in different outcomes for patients, with the caveat
that lack of evidence to show a difference is not equal to proving that the effectiveness of the tests
is equivalent.
Given the paucity of significant accuracy data to contradict the findings of Westwood et al.,45 and because
it is outside the scope of this review, we currently agree with Westwood et al.’s45 assessment. Therefore, in
our model we assume that the accuracy of the tests in the trials are equal to the accuracy of those used in
practice and make no adjustments for this.
TABLE 162 Published evidence of current RAS mutation testing
Test
Laboratories
(n)
Samples
(n)
Analytical
failures
(n)
Analytical
failures
(%)
Success
rate in
true
negative
(%)
Success rate in true positive (%)
Dilutions
All 100% 50% 25% 5%
Direct
sequencing
15 1260 4 0.32 98.90 76.00 99.00 99.00 87.00 38.00
Taqman 8 672 11 1.64 99.00 92.30 95.80 100.00 99.30 76.40
Snapshot 7 588 4 0.68 98.80 89.70 95.20 100.00 93.70 73.80
Pyrosequencing 5 420 6 1.43 95.00 96.60 100.00 100.00 100.00 89.70
HRM and
sequencing
5 420 0 0.00 100.00 78.00 100.00 98.90 88.90 40.00
HRM, high resolution melt.
Source: table 1, Blons et al.189 Reproduced under the terms of the Creative Commons Attribution (CC BY) license,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source
are credited.
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Appendix 8 WinBUGs code for the network
meta-analyses
Fixed-effects model with normal likelihood and identity link used for
overall survival, progression-free survival and objective response
rate outcomes
model{                               # *** PROGRAM STARTS 
for(i in 1:ns2) {                    # LOOP THROUGH 2-ARM STUDIES 
    y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials 
#Deviance contribution for trial i 
    resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2] 
  } 
 
for(i in 1:(ns2)){                 #   LOOP THROUGH ALL STUDIES 
     for (k in 2:na[i]) {             #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)   # calculate variances 
        prec[i,k] <- 1/var[i,k]      # set precisions 
        delta[i,k] <-  d[t[i,k]] - d[t[i,1]] 
      } 
  }    
totresdev <- sum(resdev[])            #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
for (c in 1:nt-1){ 
 for (k in 2:nt) { 
  IC[c,k] <- d[k] - d[c] 
  exp_IC[c,k] <-exp(IC[c,k]) 
 } 
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 } 
# ranking  
for (k in 1:nt) { 
#    rk[k] <- rank(d[],k)                            
   rk[k] <- nt+1-rank(d[],k)                      # assumes events are ‘good’  
   rank1[k] <- equals(rk[k],1)  
   rank2[k] <- equals(rk[k],2)  
   rank3[k] <- equals(rk[k],3)  
   rank4[k] <- equals(rk[k],4)  
 
 } 
 
}   
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Fixed-effects model with binomial likelihood and logit link
used for adverse event outcomes
model{                          # *** PROGRAM STARTS 
for(i in 1:ns){                 # LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)      # vague priors for all trial baselines 
    for (k in 1:na[i])  {       # LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k])    # binomial likelihood 
# model for linear predictor 
        logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]] 
# expected value of the numerators  
        rhat[i,k] <- p[i,k] * n[i,k] 
#Deviance contribution 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) 
             +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) 
      } 
# summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]]) 
     }    
totresdev <- sum(resdev[])      # Total Residual Deviance 
d[1]<-0    # treatment effect is zero for reference treatment 
# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
for (c in 1:nt-1){ 
 for (k in 2:nt) { 
  IC[c,k] <- d[k] - d[c] 
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  exp_IC[c,k] <-exp(IC[c,k]) 
 } 
 } 
# ranking  
for (k in 1:nt) { 
     rk[k] <- rank(d[],k)                            
   rank1[k] <- equals(rk[k],1)  
   rank2[k] <- equals(rk[k],2)  
   rank3[k] <- equals(rk[k],3)  
   rank4[k] <- equals(rk[k],4)  
  
 }         
} 
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